Paper	Intervention	Outcome	Efficacy	eNNT	GRADE	AMSTAR	k	Design	Age	BD_stage	Comparison	Comparison_type	TE	seTE	Rank	Meta_review	invTE	TE_lo	TE_up	Intervention_acro	Comparison_acro	Outcome_acro
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	fluoxetine	Discontinuation, due to any cause (Acceptability)	"eSMD=0.42 [-0.14, 0.95] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.28	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.42	0.28	III (Low)	Bahji A., 2020 (NMA)	-0.42	-0.14	0.95	fluo	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	carbamazepine	Discontinuation, due to any cause (Acceptability)	"eSMD=0.34 [-0.25, 0.95] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.26	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.34	0.31	III (Low)	Bahji A., 2020 (NMA)	-0.34	-0.25	0.95	cbz	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	escitalopram	Discontinuation, due to any cause (Acceptability)	"eSMD=0.28 [-1.47, 1.93] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.37	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.28	0.87	III (Low)	Bahji A., 2020 (NMA)	-0.28	-1.47	1.93	escit	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	imipramine	Discontinuation, due to any cause (Acceptability)	"eSMD=0.21 [-0.35, 0.76] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.47	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.21	0.28	III (Low)	Bahji A., 2020 (NMA)	-0.21	-0.35	0.76	imp	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	olanzapine+fluoxetine	Discontinuation, due to any cause (Acceptability)	"eSMD=0.17 [-0.03, 0.37] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=10.45	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.17	0.1	III (Low)	Bahji A., 2020 (NMA)	-0.17	-0.03	0.37	ola+fluo	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	ziprasidone	Discontinuation, due to any cause (Acceptability)	"eSMD=0.14 [-0.65, 0.92] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=12.68	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.14	0.4	III (Low)	Bahji A., 2020 (NMA)	-0.14	-0.65	0.92	zip	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	olanzapine	Discontinuation, due to any cause (Acceptability)	"eSMD=0.12 [-0.06, 0.31] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=14.79	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.12	0.09	III (Low)	Bahji A., 2020 (NMA)	-0.12	-0.06	0.31	ola	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	lithium	Discontinuation, due to any cause (Acceptability)	"eSMD=0.08 [-0.23, 0.38] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=22.17	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.08	0.16	III (Low)	Bahji A., 2020 (NMA)	-0.08	-0.23	0.38	lit	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	quetiapine	Discontinuation, due to any cause (Acceptability)	"eSMD=0.07 [-0.04, 0.18] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=25.33	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.07	0.06	III (Low)	Bahji A., 2020 (NMA)	-0.07	-0.04	0.18	que	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	divalproate	Discontinuation, due to any cause (Acceptability)	"eSMD=0.06 [-0.33, 0.45] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=29.55	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.06	0.2	III (Low)	Bahji A., 2020 (NMA)	-0.06	-0.33	0.45	div	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	lamotrigine	Discontinuation, due to any cause (Acceptability)	"eSMD=0.03 [-0.12, 0.18] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=59.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.03	0.08	III (Low)	Bahji A., 2020 (NMA)	-0.03	-0.12	0.18	lam	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	gabapentin	Discontinuation, due to any cause (Acceptability)	"eSMD=0.02 [-1.33, 1.39] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=88.63	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.02	0.69	III (Low)	Bahji A., 2020 (NMA)	-0.02	-1.33	1.39	gaba	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	paroxetine	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.03 [-0.32, 0.27] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=59.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	-0.03	0.15	III (Low)	Bahji A., 2020 (NMA)	0.03	-0.32	0.27	par	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	cariprazine	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.08 [-0.31, 0.15] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=22.17	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	-0.08	0.12	III (Low)	Bahji A., 2020 (NMA)	0.08	-0.31	0.15	car	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	lurasidone	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.08 [-0.34, 0.19] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=22.17	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	-0.08	0.14	III (Low)	Bahji A., 2020 (NMA)	0.08	-0.34	0.19	lur	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	phenelzine	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.24 [-1.39, 0.92] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.42	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	-0.24	0.59	III (Low)	Bahji A., 2020 (NMA)	0.24	-1.39	0.92	phen	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	aripiprazole	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.28 [-0.51, -0.06] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.37	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	-0.28	0.11	II (Moderate)	Bahji A., 2020 (NMA)	0.28	-0.51	-0.06	ari	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	lithium	Discontinuation, due to any cause (Acceptability)	"eSMD=-1.55 [-2.16, -1.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1.38	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	venlafaxine	mono	-1.55	0.28	I (High)	Bahji A., 2020 (NMA)	1.55	-2.16	-1.05	lit	ven	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	imipramine	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.92 [-1.77, -0.14] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.06	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	tranylcypromine	mono	-0.92	0.42	I (High)	Bahji A., 2020 (NMA)	0.92	-1.77	-0.14	imp	tran	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	olanzapine	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.34 [-0.66, -0.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.26	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	olanzapine+fluoxetine	combo	-0.34	0.17	II (Moderate)	Bahji A., 2020 (NMA)	0.34	-0.66	-0.01	ola	ola+fluo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	lithium	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.28 [-0.79, 0.2] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.37	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	sertraline	mono	-0.28	0.25	III (Low)	Bahji A., 2020 (NMA)	0.28	-0.79	0.2	lit	sert	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	paroxetine	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.16 [-0.47, 0.15] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=11.1	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	quetiapine	mono	-0.16	0.16	III (Low)	Bahji A., 2020 (NMA)	0.16	-0.47	0.15	par	que	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	imipramine	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.07 [-1.65, 1.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=25.33	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	moclobemide	mono	-0.07	0.82	III (Low)	Bahji A., 2020 (NMA)	0.07	-1.65	1.55	imp	moc	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	fluoxetine	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.07 [-1.77, 1.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=25.33	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	olanzapine	mono	-0.07	0.85	III (Low)	Bahji A., 2020 (NMA)	0.07	-1.77	1.55	fluo	ola	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	lithium	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.01 [-0.32, 0.31] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=177.25	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	quetiapine	mono	-0.01	0.16	III (Low)	Bahji A., 2020 (NMA)	0.01	-0.32	0.31	lit	que	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	fluoxetine	Discontinuation, due to any cause (Acceptability)	"eSMD=0 [-1.65, 1.65] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	olanzapine+fluoxetine	combo	0	0.84	III (Low)	Bahji A., 2020 (NMA)	0	-1.65	1.65	fluo	ola+fluo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	gabapentin	Discontinuation, due to any cause (Acceptability)	"eSMD=0 [-1.55, 1.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	lamotrigine	mono	0	0.79	III (Low)	Bahji A., 2020 (NMA)	0	-1.55	1.55	gaba	lam	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	lamotrigine	Discontinuation, due to any cause (Acceptability)	"eSMD=0.06 [-0.25, 0.37] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=29.55	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	olanzapine+fluoxetine	combo	0.06	0.16	III (Low)	Bahji A., 2020 (NMA)	-0.06	-0.25	0.37	lam	ola+fluo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	fluoxetine	Discontinuation, due to any cause (Acceptability)	"eSMD=0.22 [-0.37, 0.81] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	imipramine	mono	0.22	0.3	III (Low)	Bahji A., 2020 (NMA)	-0.22	-0.37	0.81	fluo	imp	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	imipramine	Discontinuation, due to any cause (Acceptability)	"eSMD=0.36 [-1.01, 1.77] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.98	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	phenelzine	mono	0.36	0.71	III (Low)	Bahji A., 2020 (NMA)	-0.36	-1.01	1.77	imp	phen	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	n-acetyl cysteine+acetylsalicylic acid	Discontinuation, due to any cause (Acceptability)	"eSMD=0.74 [-0.33, 1.77] <br> <img src=""https://www.linkpicture.com/q/Diapositive19.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.5	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.74	0.54	II (Moderate)	Bahji A., 2021 (NMA)	-0.74	-0.33	1.77	nac+asa	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	citalopram	Discontinuation, due to any cause (Acceptability)	"eSMD=0.48 [-0.24, 1.22] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.76	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.48	0.37	II (Moderate)	Bahji A., 2021 (NMA)	-0.48	-0.24	1.22	cit	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	lisdexamfetamine	Discontinuation, due to any cause (Acceptability)	"eSMD=0.48 [-0.7, 1.65] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.76	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.48	0.6	II (Moderate)	Bahji A., 2021 (NMA)	-0.48	-0.7	1.65	lisdex	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	pramipexole	Discontinuation, due to any cause (Acceptability)	"eSMD=0.35 [-0.35, 1.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.12	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.35	0.36	II (Moderate)	Bahji A., 2021 (NMA)	-0.35	-0.35	1.08	pram	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	paroxetine	Discontinuation, due to any cause (Acceptability)	"eSMD=0.27 [-0.12, 0.66] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.6	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.27	0.2	II (Moderate)	Bahji A., 2021 (NMA)	-0.27	-0.12	0.66	par	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	celecoxib	Discontinuation, due to any cause (Acceptability)	"eSMD=0.25 [-0.16, 0.66] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.13	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.25	0.21	II (Moderate)	Bahji A., 2021 (NMA)	-0.25	-0.16	0.66	cel	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	inositol	Discontinuation, due to any cause (Acceptability)	"eSMD=0.25 [-0.7, 1.17] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.13	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.25	0.48	II (Moderate)	Bahji A., 2021 (NMA)	-0.25	-0.7	1.17	ino	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	aripiprazole	Discontinuation, due to any cause (Acceptability)	"eSMD=0.17 [-0.7, 1.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=10.45	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.17	0.45	II (Moderate)	Bahji A., 2021 (NMA)	-0.17	-0.7	1.05	ari	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	t4 hormone	Discontinuation, due to any cause (Acceptability)	"eSMD=0.17 [-0.35, 0.7] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=10.45	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.17	0.27	II (Moderate)	Bahji A., 2021 (NMA)	-0.17	-0.35	0.7	t4	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	quetiapine	Discontinuation, due to any cause (Acceptability)	"eSMD=0.16 [-0.04, 0.35] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=11.1	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.16	0.1	II (Moderate)	Bahji A., 2021 (NMA)	-0.16	-0.04	0.35	que	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	fluoxetine	Discontinuation, due to any cause (Acceptability)	"eSMD=0.13 [0.02, 0.25] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=13.65	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.13	0.06	II (Moderate)	Bahji A., 2021 (NMA)	-0.13	0.02	0.25	fluo	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	lamotrigine	Discontinuation, due to any cause (Acceptability)	"eSMD=0.08 [-0.07, 0.23] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=22.17	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.08	0.08	II (Moderate)	Bahji A., 2021 (NMA)	-0.08	-0.07	0.23	lam	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	sAME	Discontinuation, due to any cause (Acceptability)	"eSMD=0.06 [-0.89, 1.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=29.55	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.06	0.48	II (Moderate)	Bahji A., 2021 (NMA)	-0.06	-0.89	1.01	sAME	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	imipramine	Discontinuation, due to any cause (Acceptability)	"eSMD=0.06 [-0.12, 0.25] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=29.55	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.06	0.09	II (Moderate)	Bahji A., 2021 (NMA)	-0.06	-0.12	0.25	imp	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	coenzyme Q10	Discontinuation, due to any cause (Acceptability)	"eSMD=0.05 [-1.47, 1.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=35.46	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.05	0.77	II (Moderate)	Bahji A., 2021 (NMA)	-0.05	-1.47	1.55	coQ10	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	n-acetyl cysteine	Discontinuation, due to any cause (Acceptability)	"eSMD=0.01 [-0.19, 0.2] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=177.25	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.01	0.1	II (Moderate)	Bahji A., 2021 (NMA)	-0.01	-0.19	0.2	nac	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	armodafinil	Discontinuation, due to any cause (Acceptability)	"eSMD=0.01 [-0.1, 0.11] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=177.25	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.01	0.05	II (Moderate)	Bahji A., 2021 (NMA)	-0.01	-0.1	0.11	armo	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	creatine	Discontinuation, due to any cause (Acceptability)	"eSMD=0 [-1.47, 1.47] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0	0.75	II (Moderate)	Bahji A., 2021 (NMA)	0	-1.47	1.47	creatine	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	memantine	Discontinuation, due to any cause (Acceptability)	"eSMD=0 [-0.05, 0.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0	0.03	II (Moderate)	Bahji A., 2021 (NMA)	0	-0.05	0.05	mem	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	paroxetine+bupropion	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.01 [-0.17, 0.15] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=177.25	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.01	0.08	II (Moderate)	Bahji A., 2021 (NMA)	0.01	-0.17	0.15	par+bup	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	acetylsalicylic acid	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.02 [-0.52, 0.49] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=88.63	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.02	0.26	II (Moderate)	Bahji A., 2021 (NMA)	0.02	-0.52	0.49	asa	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	minocycline	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.03 [-0.65, 0.59] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=59.09	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.03	0.32	II (Moderate)	Bahji A., 2021 (NMA)	0.03	-0.65	0.59	mino	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	pindolol	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.03 [-0.19, 0.13] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=59.09	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.03	0.08	II (Moderate)	Bahji A., 2021 (NMA)	0.03	-0.19	0.13	pin	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	vitD3	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.03 [-0.7, 0.63] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=59.09	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.03	0.34	II (Moderate)	Bahji A., 2021 (NMA)	0.03	-0.7	0.63	vitD3	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	omega3	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.04 [-0.21, 0.13] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=44.32	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.04	0.09	II (Moderate)	Bahji A., 2021 (NMA)	0.04	-0.21	0.13	omega3	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	agomelatin	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.05 [-0.25, 0.15] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=35.46	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.05	0.1	II (Moderate)	Bahji A., 2021 (NMA)	0.05	-0.25	0.15	ago	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	lurasidone	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.07 [-0.25, 0.1] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=25.33	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.07	0.09	II (Moderate)	Bahji A., 2021 (NMA)	0.07	-0.25	0.1	lur	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	dextromethorphan	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.12 [-0.3, 0.07] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=14.79	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.12	0.09	II (Moderate)	Bahji A., 2021 (NMA)	0.12	-0.3	0.07	dexm	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	ketamine	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.13 [-0.61, 0.35] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=13.65	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.13	0.24	II (Moderate)	Bahji A., 2021 (NMA)	0.13	-0.61	0.35	ket	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	pioglitazone	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.14 [-0.66, 0.38] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=12.68	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.14	0.27	II (Moderate)	Bahji A., 2021 (NMA)	0.14	-0.66	0.38	pio	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	ziprasidone	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.17 [-0.34, 0.02] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=10.45	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.17	0.09	II (Moderate)	Bahji A., 2021 (NMA)	0.17	-0.34	0.02	zip	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	bupropion	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.19 [-1.55, 1.22] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=9.36	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.19	0.71	II (Moderate)	Bahji A., 2021 (NMA)	0.19	-1.55	1.22	bup	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	minocycline+acetylsalicylic acid	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.2 [-0.7, 0.29] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=8.89	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.2	0.25	II (Moderate)	Bahji A., 2021 (NMA)	0.2	-0.7	0.29	mino+asa	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	levetiracetam	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.24 [-0.79, 0.32] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.42	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.24	0.28	II (Moderate)	Bahji A., 2021 (NMA)	0.24	-0.79	0.32	levt	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	pregnenolone	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.29 [-0.76, 0.2] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.15	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.29	0.24	II (Moderate)	Bahji A., 2021 (NMA)	0.29	-0.76	0.2	preg	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	t3 hormone	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.29 [-1.93, 1.39] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.15	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.29	0.85	II (Moderate)	Bahji A., 2021 (NMA)	0.29	-1.93	1.39	t3	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	infliximab	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.3 [-0.83, 0.25] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.95	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.3	0.28	II (Moderate)	Bahji A., 2021 (NMA)	0.3	-0.83	0.25	infx	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	n-acetyl cysteine	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.83 [-1.93, 0.26] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.26	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	n-acetyl cysteine+acetylsalicylic acid	aug	-0.83	0.56	II (Moderate)	Bahji A., 2021 (NMA)	0.83	-1.93	0.26	nac	nac+asa	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	lithium	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.79 [-1.93, 0.31] <br> <img src=""https://www.linkpicture.com/q/Diapositive2.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.36	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	paroxetine	aug	-0.79	0.57	II (Moderate)	Bahji A., 2021 (NMA)	0.79	-1.93	0.31	lit	par	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	lamotrigine	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.43 [-1.17, 0.3] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.19	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	tranylcypromine	aug	-0.43	0.38	II (Moderate)	Bahji A., 2021 (NMA)	0.43	-1.17	0.3	lam	tran	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	amitriptyline	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.38 [-1.65, 0.89] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.72	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	l-sulpride	aug	-0.38	0.65	II (Moderate)	Bahji A., 2021 (NMA)	0.38	-1.65	0.89	amit	l-sulpr	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	acetylsalicylic acid	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.32 [-1.77, 1.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.59	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	n-acetyl cysteine+acetylsalicylic acid	aug	-0.32	0.73	II (Moderate)	Bahji A., 2021 (NMA)	0.32	-1.77	1.08	asa	nac+asa	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	imipramine	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.29 [-0.68, 0.1] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.15	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	paroxetine	aug	-0.29	0.2	II (Moderate)	Bahji A., 2021 (NMA)	0.29	-0.68	0.1	imp	par	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	citalopram	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.28 [-0.92, 0.34] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.37	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	lamotrigine	aug	-0.28	0.32	II (Moderate)	Bahji A., 2021 (NMA)	0.28	-0.92	0.34	cit	lam	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	acetylsalicylic acid	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.12 [-0.76, 0.51] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=14.79	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	minocycline	aug	-0.12	0.32	II (Moderate)	Bahji A., 2021 (NMA)	0.12	-0.76	0.51	asa	mino	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	risperidone	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.12 [-0.66, 0.42] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=14.79	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	risperidone+paroxetine	aug	-0.12	0.28	II (Moderate)	Bahji A., 2021 (NMA)	0.12	-0.66	0.42	risp	risp+par	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	inositol	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.05 [-0.61, 0.52] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=35.46	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	lamotrigine	aug	-0.05	0.29	II (Moderate)	Bahji A., 2021 (NMA)	0.05	-0.61	0.52	ino	lam	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	sertraline	Discontinuation, due to any cause (Acceptability)	"eSMD=0.04 [-0.19, 0.26] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=44.32	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	venlafaxine	aug	0.04	0.11	II (Moderate)	Bahji A., 2021 (NMA)	-0.04	-0.19	0.26	sert	ven	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	acetylsalicylic acid	Discontinuation, due to any cause (Acceptability)	"eSMD=0.05 [-0.47, 0.56] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=35.46	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	minocycline+acetylsalicylic acid	aug	0.05	0.26	II (Moderate)	Bahji A., 2021 (NMA)	-0.05	-0.47	0.56	asa	mino+asa	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	bupropion	Discontinuation, due to any cause (Acceptability)	"eSMD=0.07 [-1.33, 1.47] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=25.33	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	desipramine	aug	0.07	0.71	II (Moderate)	Bahji A., 2021 (NMA)	-0.07	-1.33	1.47	bup	desimp	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	imipramine	Discontinuation, due to any cause (Acceptability)	"eSMD=0.07 [-0.19, 0.33] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=25.33	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	moclobemide	aug	0.07	0.13	II (Moderate)	Bahji A., 2021 (NMA)	-0.07	-0.19	0.33	imp	moc	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	fluoxetine	Discontinuation, due to any cause (Acceptability)	"eSMD=0.1 [-0.04, 0.25] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=17.74	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	lamotrigine	aug	0.1	0.07	II (Moderate)	Bahji A., 2021 (NMA)	-0.1	-0.04	0.25	fluo	lam	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	fluoxetine	Discontinuation, due to any cause (Acceptability)	"eSMD=0.11 [-0.18, 0.4] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=16.13	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	imipramine	aug	0.11	0.15	II (Moderate)	Bahji A., 2021 (NMA)	-0.11	-0.18	0.4	fluo	imp	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	bupropion	Discontinuation, due to any cause (Acceptability)	"eSMD=0.15 [-0.13, 0.43] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=11.84	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	sertraline	aug	0.15	0.14	II (Moderate)	Bahji A., 2021 (NMA)	-0.15	-0.13	0.43	bup	sert	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	paroxetine	Discontinuation, due to any cause (Acceptability)	"eSMD=0.16 [-0.35, 0.66] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=11.1	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	venlafaxine	aug	0.16	0.26	II (Moderate)	Bahji A., 2021 (NMA)	-0.16	-0.35	0.66	par	ven	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	minocycline	Discontinuation, due to any cause (Acceptability)	"eSMD=0.17 [-0.39, 0.74] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=10.45	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	minocycline+acetylsalicylic acid	aug	0.17	0.29	II (Moderate)	Bahji A., 2021 (NMA)	-0.17	-0.39	0.74	mino	mino+asa	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	bupropion	Discontinuation, due to any cause (Acceptability)	"eSMD=0.2 [-0.08, 0.47] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.89	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	venlafaxine	aug	0.2	0.14	II (Moderate)	Bahji A., 2021 (NMA)	-0.2	-0.08	0.47	bup	ven	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	bupropion	Discontinuation, due to any cause (Acceptability)	"eSMD=0.26 [-0.24, 0.76] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.86	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	topiramate	aug	0.26	0.26	II (Moderate)	Bahji A., 2021 (NMA)	-0.26	-0.24	0.76	bup	top	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	amitriptyline	Discontinuation, due to any cause (Acceptability)	"eSMD=0.33 [-0.59, 1.27] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.42	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	paroxetine	aug	0.33	0.47	II (Moderate)	Bahji A., 2021 (NMA)	-0.33	-0.59	1.27	amit	par	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	paroxetine	Discontinuation, due to any cause (Acceptability)	"eSMD=0.38 [-0.42, 1.17] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.72	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	risperidone+paroxetine	aug	0.38	0.41	II (Moderate)	Bahji A., 2021 (NMA)	-0.38	-0.42	1.17	par	risp+par	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	inositol	Discontinuation, due to any cause (Acceptability)	"eSMD=0.48 [0.05, 0.89] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.76	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	risperidone	aug	0.48	0.21	II (Moderate)	Bahji A., 2021 (NMA)	-0.48	0.05	0.89	ino	risp	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	acetylsalicylic acid	Discontinuation, due to any cause (Acceptability)	"eSMD=0.51 [-0.53, 1.54] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.55	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	n-acetyl cysteine	aug	0.51	0.53	II (Moderate)	Bahji A., 2021 (NMA)	-0.51	-0.53	1.54	asa	nac	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	paroxetine	Discontinuation, due to any cause (Acceptability)	"eSMD=0.51 [-0.25, 1.27] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.55	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	risperidone	aug	0.51	0.39	II (Moderate)	Bahji A., 2021 (NMA)	-0.51	-0.25	1.27	par	risp	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	lamotrigine	Discontinuation, due to any cause (Acceptability)	"eSMD=0.53 [0.06, 0.98] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.42	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	risperidone	aug	0.53	0.23	II (Moderate)	Bahji A., 2021 (NMA)	-0.53	0.06	0.98	lam	risp	Acceptability
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2006 (MA)</a>"	haloperidol+lithium/divalproate	Discontinuation, due to any cause (Acceptability)	"eSMD=0.02 [-0.19, 0.22] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=88.63	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo+lithium/divalproate	combo	0.02	0.1	II (Moderate)	Cipriani A., 2006 (MA)	-0.02	-0.19	0.22	hal+lit/div	pbo+lit/div	Acceptability
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2011 (NMA)</a>"	gabapentin	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.31 [-0.89, 0.27] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.76	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	65	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.31	0.3	III (Low)	Cipriani A., 2011 (NMA)	0.31	-0.89	0.27	gaba	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2011 (NMA)</a>"	haloperidol	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.04 [-0.29, 0.22] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=44.32	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	65	Network meta-analysis	Adults	Mania/Mixed	ziprasidone	mono	-0.04	0.13	III (Low)	Cipriani A., 2011 (NMA)	0.04	-0.29	0.22	hal	zip	Acceptability
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2011 (NMA)</a>"	carbamazapine	Discontinuation, due to any cause (Acceptability)	"eSMD=0.08 [-0.25, 0.42] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=22.17	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	65	Network meta-analysis	Adults	Mania/Mixed	haloperidol	mono	0.08	0.17	III (Low)	Cipriani A., 2011 (NMA)	-0.08	-0.25	0.42	cbz	hal	Acceptability
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2011 (NMA)</a>"	olanzapine	Discontinuation, due to any cause (Acceptability)	"eSMD=0.26 [0, 0.51] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.86	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	65	Network meta-analysis	Adults	Mania/Mixed	ziprasidone	mono	0.26	0.13	III (Low)	Cipriani A., 2011 (NMA)	-0.26	0	0.51	ola	zip	Acceptability
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2013 (MA)</a>"	divalproate	Discontinuation, due to any cause (Acceptability)	"eSMD=0.08 [0.01, 0.14] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=22.17	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Low	4	Pairwise meta-analysis	Mixed (Children-Adults)	Maintenance	lithium	mono	0.08	0.03	I (High)	Cipriani A., 2013 (MA)	-0.08	0.01	0.14	div	lit	Acceptability
"<a href='https://doi.org/' target=""_blank"">Bartoli F., 2017 (MA)</a>"	allopurinol	Discontinuation, due to any cause (Acceptability)	"eSMD=0.05 [-0.13, 0.23] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=35.46	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	aug	0.05	0.09	IV (Very Low)	Bartoli F., 2017 (MA)	-0.05	-0.13	0.23	allopur	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Jochim J., 2019 (MA)</a>"	divalproate	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.32 [-0.74, 0.1] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.59	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Children & Adolescents	Mania/Mixed	placebo	mono	-0.32	0.21	III (Low)	Jochim J., 2019 (MA)	0.32	-0.74	0.1	div	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Jochim J., 2019 (MA)</a>"	divalproate	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.37 [-0.74, 0] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.85	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Children & Adolescents	Mania/Mixed	risperidone	mono	-0.37	0.19	III (Low)	Jochim J., 2019 (MA)	0.37	-0.74	0	div	risp	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	cariprazine	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.03 [-0.19, 0.14] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=59.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	18	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.03	0.08	III (Low)	Kadakia A., 2021 (NMA)	0.03	-0.19	0.14	car	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (MA)</a>"	omega3	Discontinuation, due to any cause (Acceptability)	"eSMD=0.38 [0.1, 0.66] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.72	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Pairwise meta-analysis	Adults	Maintenance	placebo	aug	0.38	0.14	II (Moderate)	Kishi T., 2021 (MA)	-0.38	0.1	0.66	omega3	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	asenapine	Discontinuation, due to any cause (Acceptability)	"eSMD=0.44 [0.16, 0.72] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.09	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Maintenance	placebo	mono	0.44	0.14	II (Moderate)	Kishi T., 2021 (NMA)	-0.44	0.16	0.72	ase	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Discontinuation, due to any cause (Acceptability)	"eSMD=0.24 [0.15, 0.33] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.42	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	70	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.24	0.05	II (Moderate)	Kishi T., 2021 (NMA)	-0.24	0.15	0.33	ola	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	quetiapine	Discontinuation, due to any cause (Acceptability)	"eSMD=0.23 [0.1, 0.36] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.74	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Maintenance	placebo	mono	0.23	0.07	II (Moderate)	Kishi T., 2021 (NMA)	-0.23	0.1	0.36	que	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Discontinuation, due to any cause (Acceptability)	"eSMD=0.2 [0.1, 0.32] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.89	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Maintenance	placebo	mono	0.2	0.06	II (Moderate)	Kishi T., 2021 (NMA)	-0.2	0.1	0.32	ola	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole LAI	Discontinuation, due to any cause (Acceptability)	"eSMD=0.17 [-0.03, 0.38] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=10.45	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Maintenance	placebo	mono	0.17	0.1	III (Low)	Kishi T., 2021 (NMA)	-0.17	-0.03	0.38	ariLAI	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Discontinuation, due to any cause (Acceptability)	"eSMD=0.15 [-0.02, 0.32] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=11.84	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	70	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.15	0.09	III (Low)	Kishi T., 2021 (NMA)	-0.15	-0.02	0.32	pal	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	quetiapine	Discontinuation, due to any cause (Acceptability)	"eSMD=0.15 [0.02, 0.29] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=11.84	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	70	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.15	0.07	II (Moderate)	Kishi T., 2021 (NMA)	-0.15	0.02	0.29	que	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	tamoxifen	Discontinuation, due to any cause (Acceptability)	"eSMD=0.15 [-0.25, 0.56] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=11.84	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	70	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.15	0.21	III (Low)	Kishi T., 2021 (NMA)	-0.15	-0.25	0.56	tamox	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	risperidone	Discontinuation, due to any cause (Acceptability)	"eSMD=0.14 [0.01, 0.27] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=12.68	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	70	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.14	0.07	II (Moderate)	Kishi T., 2021 (NMA)	-0.14	0.01	0.27	risp	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	risperidone LAI	Discontinuation, due to any cause (Acceptability)	"eSMD=0.13 [0, 0.27] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=13.65	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Maintenance	placebo	mono	0.13	0.07	III (Low)	Kishi T., 2021 (NMA)	-0.13	0	0.27	rispLAI	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Discontinuation, due to any cause (Acceptability)	"eSMD=0.12 [0.01, 0.25] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=14.79	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Maintenance	placebo	mono	0.12	0.06	II (Moderate)	Kishi T., 2021 (NMA)	-0.12	0.01	0.25	div	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	eslicarbazepine	Discontinuation, due to any cause (Acceptability)	"eSMD=0.11 [-0.26, 0.51] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=16.13	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	70	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.11	0.2	III (Low)	Kishi T., 2021 (NMA)	-0.11	-0.26	0.51	eslicbz	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Discontinuation, due to any cause (Acceptability)	"eSMD=0.11 [-0.06, 0.22] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=16.13	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Maintenance	placebo	mono	0.11	0.07	III (Low)	Kishi T., 2021 (NMA)	-0.11	-0.06	0.22	lam	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Discontinuation, due to any cause (Acceptability)	"eSMD=0.1 [0.02, 0.18] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=17.74	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Maintenance	placebo	mono	0.1	0.04	II (Moderate)	Kishi T., 2021 (NMA)	-0.1	0.02	0.18	lit	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Discontinuation, due to any cause (Acceptability)	"eSMD=0.1 [0.01, 0.18] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=17.74	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	70	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.1	0.04	II (Moderate)	Kishi T., 2021 (NMA)	-0.1	0.01	0.18	ari	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	carbamazepine	Discontinuation, due to any cause (Acceptability)	"eSMD=0.09 [-0.06, 0.24] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=19.71	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	70	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.09	0.08	III (Low)	Kishi T., 2021 (NMA)	-0.09	-0.06	0.24	cbz	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Discontinuation, due to any cause (Acceptability)	"eSMD=0.09 [0, 0.18] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=19.71	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	70	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.09	0.05	III (Low)	Kishi T., 2021 (NMA)	-0.09	0	0.18	div	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	ziprasidone	Discontinuation, due to any cause (Acceptability)	"eSMD=0.08 [-0.05, 0.21] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=22.17	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	70	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.08	0.07	III (Low)	Kishi T., 2021 (NMA)	-0.08	-0.05	0.21	zip	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Discontinuation, due to any cause (Acceptability)	"eSMD=0.06 [-0.12, 0.25] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=29.55	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Maintenance	placebo	mono	0.06	0.09	III (Low)	Kishi T., 2021 (NMA)	-0.06	-0.12	0.25	pal	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Discontinuation, due to any cause (Acceptability)	"eSMD=0.06 [-0.03, 0.17] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=29.55	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	70	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.06	0.05	III (Low)	Kishi T., 2021 (NMA)	-0.06	-0.03	0.17	hal	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Discontinuation, due to any cause (Acceptability)	"eSMD=0.02 [-0.16, 0.2] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=88.63	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Maintenance	placebo	mono	0.02	0.09	III (Low)	Kishi T., 2021 (NMA)	-0.02	-0.16	0.2	ari	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	asenapine	Discontinuation, due to any cause (Acceptability)	"eSMD=0 [-0.14, 0.14] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	70	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0	0.07	III (Low)	Kishi T., 2021 (NMA)	0	-0.14	0.14	ase	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	cariprazine	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.01 [-0.15, 0.14] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=177.25	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	70	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.01	0.07	III (Low)	Kishi T., 2021 (NMA)	0.01	-0.15	0.14	car	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.02 [-0.11, 0.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=88.63	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	70	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.02	0.05	III (Low)	Kishi T., 2021 (NMA)	0.02	-0.11	0.08	lit	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.06 [-0.24, 0.11] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=29.55	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	70	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.06	0.09	III (Low)	Kishi T., 2021 (NMA)	0.06	-0.24	0.11	lam	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	brexpiprazole	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.06 [-0.27, 0.15] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=29.55	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	70	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.06	0.11	III (Low)	Kishi T., 2021 (NMA)	0.06	-0.27	0.15	brex	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	licarbazepine	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.09 [-0.33, 0.15] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=19.71	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	70	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.09	0.12	III (Low)	Kishi T., 2021 (NMA)	0.09	-0.33	0.15	licbz	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	topiramate	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.16 [-0.3, -0.02] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=11.1	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	70	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.16	0.07	II (Moderate)	Kishi T., 2021 (NMA)	0.16	-0.3	-0.02	top	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	verapamil	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.24 [-0.58, 0.1] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.42	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	70	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.24	0.17	III (Low)	Kishi T., 2021 (NMA)	0.24	-0.58	0.1	verapamil	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	valnoctamide	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.31 [-0.63, 0.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.76	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	70	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.31	0.16	III (Low)	Kishi T., 2021 (NMA)	0.31	-0.63	0.01	valnoctamide	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	chlorpromazine	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.61 [-2.54, 1.12] <br> <img src=""https://www.linkpicture.com/q/Diapositive4.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	70	Network meta-analysis	Adults	Mania/Mixed	haloperidol	mono	-0.61	0.93	III (Low)	Kishi T., 2021 (NMA)	0.61	-2.54	1.12	chlorp	hal	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.3 [-0.2, -0.1] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.95	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	70	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.3	0.03	II (Moderate)	Kishi T., 2021 (NMA)	0.3	-0.2	-0.1	lam	ola	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.25 [-0.37, -0.14] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.13	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	70	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.25	0.06	II (Moderate)	Kishi T., 2021 (NMA)	0.25	-0.37	-0.14	lit	ola	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	asenapine	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.24 [-0.38, -0.09] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.42	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	70	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.24	0.07	II (Moderate)	Kishi T., 2021 (NMA)	0.24	-0.38	-0.09	ase	ola	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.17 [-0.29, -0.06] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=10.45	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	70	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.17	0.06	II (Moderate)	Kishi T., 2021 (NMA)	0.17	-0.29	-0.06	hal	ola	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.17 [-0.33, -0.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=10.45	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	70	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	-0.17	0.08	II (Moderate)	Kishi T., 2021 (NMA)	0.17	-0.33	-0.01	lit	que	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.15 [-0.31, 0.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=11.84	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	70	Network meta-analysis	Adults	Mania/Mixed	risperidone	mono	-0.15	0.08	III (Low)	Kishi T., 2021 (NMA)	0.15	-0.31	0.01	lit	risp	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.15 [-0.25, -0.04] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=11.84	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	70	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.15	0.05	II (Moderate)	Kishi T., 2021 (NMA)	0.15	-0.25	-0.04	div	ola	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.13 [-0.27, 0.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=13.65	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Maintenance	quetiapine	mono	-0.13	0.07	III (Low)	Kishi T., 2021 (NMA)	0.13	-0.27	0.01	lit	que	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.11 [-0.23, 0.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=16.13	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Maintenance	olanzapine	mono	-0.11	0.06	III (Low)	Kishi T., 2021 (NMA)	0.11	-0.23	0.01	lit	ola	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	cariprazine	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.09 [-0.25, 0.07] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=19.71	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Maintenance	lithium	mono	-0.09	0.08	III (Low)	Kishi T., 2021 (NMA)	0.09	-0.25	0.07	car	lit	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.09 [-0.25, 0.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=19.71	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	70	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	-0.09	0.08	III (Low)	Kishi T., 2021 (NMA)	0.09	-0.25	0.08	hal	que	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.08 [-0.25, 0.09] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=22.17	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Maintenance	lithium+divalproate	combo	-0.08	0.09	III (Low)	Kishi T., 2021 (NMA)	0.08	-0.25	0.09	lit	lit+div	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.07 [-0.23, 0.09] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=25.33	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	70	Network meta-analysis	Adults	Mania/Mixed	risperidone	mono	-0.07	0.08	III (Low)	Kishi T., 2021 (NMA)	0.07	-0.23	0.09	hal	risp	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.05 [-0.22, 0.12] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=35.46	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Maintenance	lithium+divalproate	combo	-0.05	0.09	III (Low)	Kishi T., 2021 (NMA)	0.05	-0.22	0.12	div	lit+div	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.04 [-0.22, 0.14] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=44.32	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	70	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	-0.04	0.09	III (Low)	Kishi T., 2021 (NMA)	0.04	-0.22	0.14	lam	lit	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.04 [-0.2, 0.11] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=44.32	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	70	Network meta-analysis	Adults	Mania/Mixed	risperidone	mono	-0.04	0.08	III (Low)	Kishi T., 2021 (NMA)	0.04	-0.2	0.11	ari	risp	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.01 [-0.16, 0.14] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=177.25	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	70	Network meta-analysis	Adults	Mania/Mixed	ziprasidone	mono	-0.01	0.08	III (Low)	Kishi T., 2021 (NMA)	0.01	-0.16	0.14	hal	zip	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole+divalproate	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.01 [-0.34, 0.32] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=177.25	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Maintenance	divalproate	mono	-0.01	0.17	III (Low)	Kishi T., 2021 (NMA)	0.01	-0.34	0.32	ari+div	div	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	carbamazepine	Discontinuation, due to any cause (Acceptability)	"eSMD=0 [-0.17, 0.17] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	70	Network meta-analysis	Adults	Mania/Mixed	divalproate	mono	0	0.09	III (Low)	Kishi T., 2021 (NMA)	0	-0.17	0.17	cbz	div	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Discontinuation, due to any cause (Acceptability)	"eSMD=0 [-0.2, 0.2] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	70	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	0	0.1	III (Low)	Kishi T., 2021 (NMA)	0	-0.2	0.2	pal	que	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Discontinuation, due to any cause (Acceptability)	"eSMD=0.01 [-0.12, 0.14] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=177.25	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Maintenance	lithium	mono	0.01	0.07	III (Low)	Kishi T., 2021 (NMA)	-0.01	-0.12	0.14	lam	lit	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Discontinuation, due to any cause (Acceptability)	"eSMD=0.03 [-0.3, 0.14] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=59.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	70	Network meta-analysis	Adults	Mania/Mixed	haloperidol	mono	0.03	0.11	III (Low)	Kishi T., 2021 (NMA)	-0.03	-0.3	0.14	ari	hal	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Discontinuation, due to any cause (Acceptability)	"eSMD=0.03 [-0.08, 0.13] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=59.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Maintenance	lithium	mono	0.03	0.05	III (Low)	Kishi T., 2021 (NMA)	-0.03	-0.08	0.13	div	lit	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Discontinuation, due to any cause (Acceptability)	"eSMD=0.03 [-0.21, 0.27] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=59.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Maintenance	lamotrigine+divalproate	combo	0.03	0.12	III (Low)	Kishi T., 2021 (NMA)	-0.03	-0.21	0.27	lam	lam+div	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole+lamotrigine	Discontinuation, due to any cause (Acceptability)	"eSMD=0.05 [-0.14, 0.25] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=35.46	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Maintenance	lamotrigine	mono	0.05	0.1	III (Low)	Kishi T., 2021 (NMA)	-0.05	-0.14	0.25	ari+lam	lam	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Discontinuation, due to any cause (Acceptability)	"eSMD=0.06 [-0.36, 0.48] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=29.55	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Maintenance	lithium+oxcarbazepine	combo	0.06	0.21	III (Low)	Kishi T., 2021 (NMA)	-0.06	-0.36	0.48	lit	lit+oxc	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Discontinuation, due to any cause (Acceptability)	"eSMD=0.08 [-0.09, 0.24] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=22.17	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Maintenance	risperidone LAI	mono	0.08	0.08	III (Low)	Kishi T., 2021 (NMA)	-0.08	-0.09	0.24	ola	rispLAI	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Discontinuation, due to any cause (Acceptability)	"eSMD=0.08 [-0.05, 0.21] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=22.17	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	70	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	0.08	0.07	III (Low)	Kishi T., 2021 (NMA)	-0.08	-0.05	0.21	hal	lit	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Discontinuation, due to any cause (Acceptability)	"eSMD=0.11 [-0.02, 0.23] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=16.13	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	70	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	0.11	0.06	III (Low)	Kishi T., 2021 (NMA)	-0.11	-0.02	0.23	div	lit	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Discontinuation, due to any cause (Acceptability)	"eSMD=0.1 [0.04, 0.26] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=17.74	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	70	Network meta-analysis	Adults	Mania/Mixed	risperidone	mono	0.1	0.06	II (Moderate)	Kishi T., 2021 (NMA)	-0.1	0.04	0.26	ola	risp	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Discontinuation, due to any cause (Acceptability)	"eSMD=0.11 [-0.01, 0.23] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=16.13	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	70	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	0.11	0.06	III (Low)	Kishi T., 2021 (NMA)	-0.11	-0.01	0.23	ari	lit	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole+lithium/divalproate	Discontinuation, due to any cause (Acceptability)	"eSMD=0.11 [-0.18, 0.4] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=16.13	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	6	Network meta-analysis	Adults	Maintenance	placebo+lithium/divalproate	combo	0.11	0.15	IV (Very Low)	Kishi T., 2021 (NMA)	-0.11	-0.18	0.4	ari+lit/div	pbo+lit/div	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	carbamazepine	Discontinuation, due to any cause (Acceptability)	"eSMD=0.11 [-0.06, 0.27] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=16.13	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	70	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	0.11	0.08	III (Low)	Kishi T., 2021 (NMA)	-0.11	-0.06	0.27	cbz	lit	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Discontinuation, due to any cause (Acceptability)	"eSMD=0.14 [-0.01, 0.3] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=12.68	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	70	Network meta-analysis	Adults	Mania/Mixed	topiramate	mono	0.14	0.08	III (Low)	Kishi T., 2021 (NMA)	-0.14	-0.01	0.3	lit	top	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine+lithium/divalproate	Discontinuation, due to any cause (Acceptability)	"eSMD=0.14 [-0.14, 0.43] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=12.68	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	6	Network meta-analysis	Adults	Maintenance	placebo+lithium/divalproate	combo	0.14	0.15	IV (Very Low)	Kishi T., 2021 (NMA)	-0.14	-0.14	0.43	ola+lit/div	pbo+lit/div	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	quetiapine+lithium/divalproate	Discontinuation, due to any cause (Acceptability)	"eSMD=0.2 [0.02, 0.39] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.89	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	6	Network meta-analysis	Adults	Maintenance	placebo+lithium/divalproate	combo	0.2	0.09	III (Low)	Kishi T., 2021 (NMA)	-0.2	0.02	0.39	que+lit/div	pbo+lit/div	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	ziprasidone+lithium/divalproate	Discontinuation, due to any cause (Acceptability)	"eSMD=0.23 [-0.08, 0.53] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.74	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	6	Network meta-analysis	Adults	Maintenance	placebo+lithium/divalproate	combo	0.23	0.16	IV (Very Low)	Kishi T., 2021 (NMA)	-0.23	-0.08	0.53	zip+lit/div	pbo+lit/div	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lurasidone+lithium/divalproate	Discontinuation, due to any cause (Acceptability)	"eSMD=0.39 [0.11, 0.68] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.6	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	6	Network meta-analysis	Adults	Maintenance	placebo+lithium/divalproate	combo	0.39	0.15	III (Low)	Kishi T., 2021 (NMA)	-0.39	0.11	0.68	lur+lit/div	pbo+lit/div	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	risperidone	Discontinuation, due to any cause (Acceptability)	"eSMD=0.44 [0.11, 0.76] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.09	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	70	Network meta-analysis	Adults	Mania/Mixed	valnoctamide	mono	0.44	0.17	II (Moderate)	Kishi T., 2021 (NMA)	-0.44	0.11	0.76	risp	valnoctamide	Acceptability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Discontinuation, due to any cause (Acceptability)	"eSMD=0.59 [-0.68, 1.85] <br> <img src=""https://www.linkpicture.com/q/Diapositive17.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	70	Network meta-analysis	Adults	Mania/Mixed	endoxifen	mono	0.59	0.65	III (Low)	Kishi T., 2021 (NMA)	-0.59	-0.68	1.85	div	end	Acceptability
"<a href='https://doi.org/' target=""_blank"">Lam R.W., 2020 (MA)</a>"	bright light therapy	Discontinuation, due to any cause (Acceptability)	"eSMD=0.34 [-0.07, 0.76] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.26	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	6	Pairwise meta-analysis	Adults	Bipolar Depression	TAU/sham	mono	0.34	0.21	IV (Very Low)	Lam R.W., 2020 (MA)	-0.34	-0.07	0.76	BLT	tau/sham	Acceptability
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	lithium	Discontinuation, due to any cause (Acceptability)	"eSMD=0.15 [-0.12, 0.43] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=11.84	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	7	Pairwise meta-analysis	Mixed (Children-Adults)	Mania/Mixed	placebo	mono	0.15	0.14	III (Low)	McKnight R.F., 2019 (MA)	-0.15	-0.12	0.43	lit	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	lithium	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.34 [-0.66, -0.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.26	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Mixed (Children-Adults)	Mania/Mixed	risperidone	mono	-0.34	0.17	I (High)	McKnight R.F., 2019 (MA)	0.34	-0.66	-0.01	lit	risp	Acceptability
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	divalproate	Discontinuation, due to any cause (Acceptability)	"eSMD=0.1 [-0.08, 0.29] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=17.74	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Pairwise meta-analysis	Mixed (Children-Adults)	Mania/Mixed	lithium	mono	0.1	0.09	III (Low)	McKnight R.F., 2019 (MA)	-0.1	-0.08	0.29	div	lit	Acceptability
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	chlorpromazine	Discontinuation, due to any cause (Acceptability)	"eSMD=0.31 [-0.05, 0.66] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.76	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	lithium	mono	0.31	0.18	III (Low)	McKnight R.F., 2019 (MA)	-0.31	-0.05	0.66	chlorp	lit	Acceptability
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	CBT	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.27 [-0.59, 0.06] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.6	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	36	Network meta-analysis	Mixed (Children-Adults)	Maintenance	psychoeducation brief	aug	-0.27	0.17	III (Low)	Miklowitz D.J., 2020 (NMA)	0.27	-0.59	0.06	CBT	PE brief	Acceptability
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	CBT	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.25 [-0.56, 0.06] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.13	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	36	Network meta-analysis	Mixed (Children-Adults)	Maintenance	family/conjoint therapy	aug	-0.25	0.16	III (Low)	Miklowitz D.J., 2020 (NMA)	0.25	-0.56	0.06	CBT	family/conjoint	Acceptability
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	psychoeducation	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.2 [-0.45, 0.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=8.89	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	36	Network meta-analysis	Mixed (Children-Adults)	Maintenance	supportive therapy	aug	-0.2	0.13	III (Low)	Miklowitz D.J., 2020 (NMA)	0.2	-0.45	0.05	PE	supp	Acceptability
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	CBT	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.2 [-0.56, 0.17] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=8.89	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	36	Network meta-analysis	Mixed (Children-Adults)	Maintenance	IPSRT	aug	-0.2	0.19	III (Low)	Miklowitz D.J., 2020 (NMA)	0.2	-0.56	0.17	CBT	IPSRT	Acceptability
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	psychoeducation	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.16 [-0.37, 0.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=11.1	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	36	Network meta-analysis	Mixed (Children-Adults)	Maintenance	TAU	N/A	-0.16	0.11	III (Low)	Miklowitz D.J., 2020 (NMA)	0.16	-0.37	0.05	PE	tau	Acceptability
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	functional remediation	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.15 [-0.58, 0.27] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=11.84	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	36	Network meta-analysis	Mixed (Children-Adults)	Maintenance	TAU	N/A	-0.15	0.22	III (Low)	Miklowitz D.J., 2020 (NMA)	0.15	-0.58	0.27	functional rem	tau	Acceptability
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	IPSRT	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.08 [-0.47, 0.31] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=22.17	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	36	Network meta-analysis	Mixed (Children-Adults)	Maintenance	psychoeducation brief	aug	-0.08	0.2	III (Low)	Miklowitz D.J., 2020 (NMA)	0.08	-0.47	0.31	IPSRT	PE brief	Acceptability
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	CBT	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.02 [-0.33, 0.29] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=88.63	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	36	Network meta-analysis	Mixed (Children-Adults)	Maintenance	supportive therapy	aug	-0.02	0.16	III (Low)	Miklowitz D.J., 2020 (NMA)	0.02	-0.33	0.29	CBT	supp	Acceptability
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	family/conjoint therapy	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.02 [-0.32, 0.28] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=88.63	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	36	Network meta-analysis	Mixed (Children-Adults)	Maintenance	psychoeducation brief	aug	-0.02	0.15	III (Low)	Miklowitz D.J., 2020 (NMA)	0.02	-0.32	0.28	family/conjoint	PE brief	Acceptability
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	functional remediation	Discontinuation, due to any cause (Acceptability)	"eSMD=0.01 [-0.42, 0.43] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=177.25	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	36	Network meta-analysis	Mixed (Children-Adults)	Maintenance	psychoeducation	aug	0.01	0.22	III (Low)	Miklowitz D.J., 2020 (NMA)	-0.01	-0.42	0.43	functional rem	PE	Acceptability
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	CBT	Discontinuation, due to any cause (Acceptability)	"eSMD=0.02 [-0.17, 0.22] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=88.63	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	36	Network meta-analysis	Mixed (Children-Adults)	Maintenance	TAU	N/A	0.02	0.1	III (Low)	Miklowitz D.J., 2020 (NMA)	-0.02	-0.17	0.22	CBT	tau	Acceptability
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	family/conjoint therapy	Discontinuation, due to any cause (Acceptability)	"eSMD=0.05 [-0.34, 0.45] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=35.46	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	36	Network meta-analysis	Mixed (Children-Adults)	Maintenance	IPSRT	aug	0.05	0.2	III (Low)	Miklowitz D.J., 2020 (NMA)	-0.05	-0.34	0.45	family/conjoint	IPSRT	Acceptability
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	IPSRT	Discontinuation, due to any cause (Acceptability)	"eSMD=0.17 [-0.19, 0.53] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=10.45	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	36	Network meta-analysis	Mixed (Children-Adults)	Maintenance	supportive therapy	aug	0.17	0.18	III (Low)	Miklowitz D.J., 2020 (NMA)	-0.17	-0.19	0.53	IPSRT	supp	Acceptability
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	CBT	Discontinuation, due to any cause (Acceptability)	"eSMD=0.18 [-0.07, 0.43] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=9.87	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	36	Network meta-analysis	Mixed (Children-Adults)	Maintenance	psychoeducation	aug	0.18	0.13	III (Low)	Miklowitz D.J., 2020 (NMA)	-0.18	-0.07	0.43	CBT	PE	Acceptability
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	family/conjoint therapy	Discontinuation, due to any cause (Acceptability)	"eSMD=0.23 [-0.14, 0.59] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.74	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	36	Network meta-analysis	Mixed (Children-Adults)	Maintenance	supportive therapy	aug	0.23	0.19	III (Low)	Miklowitz D.J., 2020 (NMA)	-0.23	-0.14	0.59	family/conjoint	supp	Acceptability
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	family/conjoint therapy	Discontinuation, due to any cause (Acceptability)	"eSMD=0.27 [-0.02, 0.56] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.6	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	36	Network meta-analysis	Mixed (Children-Adults)	Maintenance	TAU	N/A	0.27	0.15	III (Low)	Miklowitz D.J., 2020 (NMA)	-0.27	-0.02	0.56	family/conjoint	tau	Acceptability
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	psychoeducation brief	Discontinuation, due to any cause (Acceptability)	"eSMD=0.29 [-0.05, 0.63] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.15	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	36	Network meta-analysis	Mixed (Children-Adults)	Maintenance	TAU	N/A	0.29	0.17	III (Low)	Miklowitz D.J., 2020 (NMA)	-0.29	-0.05	0.63	PE brief	tau	Acceptability
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	family/conjoint therapy	Discontinuation, due to any cause (Acceptability)	"eSMD=0.43 [0.11, 0.74] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.19	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	36	Network meta-analysis	Mixed (Children-Adults)	Maintenance	psychoeducation	aug	0.43	0.16	I (High)	Miklowitz D.J., 2020 (NMA)	-0.43	0.11	0.74	family/conjoint	PE	Acceptability
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	lithium+imipramine	Discontinuation, due to any cause (Acceptability)	"eSMD=0.12 [-0.07, 0.34] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=14.79	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	28	Network meta-analysis	Adults	Maintenance	placebo	mono	0.12	0.1	IV (Very Low)	Miura T., 2014 (NMA)	-0.12	-0.07	0.34	lit+imp	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	paliperidone	Discontinuation, due to any cause (Acceptability)	"eSMD=0.06 [-0.18, 0.3] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=29.55	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	28	Network meta-analysis	Adults	Maintenance	placebo	mono	0.06	0.12	IV (Very Low)	Miura T., 2014 (NMA)	-0.06	-0.18	0.3	pal	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	imipramine	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.27 [-0.52, -0.03] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.6	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	28	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.27	0.12	III (Low)	Miura T., 2014 (NMA)	0.27	-0.52	-0.03	imp	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	imipramine	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.4 [-0.68, -0.14] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.49	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	28	Network meta-analysis	Adults	Maintenance	lithium+imipramine	combo	-0.4	0.14	III (Low)	Miura T., 2014 (NMA)	0.4	-0.68	-0.14	imp	lit+imp	Acceptability
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	imipramine	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.38 [-0.61, -0.14] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.72	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	28	Network meta-analysis	Adults	Maintenance	lithium	mono	-0.38	0.12	III (Low)	Miura T., 2014 (NMA)	0.38	-0.61	-0.14	imp	lit	Acceptability
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	carbamazepine	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.08 [-0.26, 0.1] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=22.17	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	28	Network meta-analysis	Adults	Maintenance	lithium	mono	-0.08	0.09	IV (Very Low)	Miura T., 2014 (NMA)	0.08	-0.26	0.1	cbz	lit	Acceptability
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	lithium	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.02 [-0.22, 0.17] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=88.63	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	28	Network meta-analysis	Adults	Maintenance	lithium+imipramine	combo	-0.02	0.1	IV (Very Low)	Miura T., 2014 (NMA)	0.02	-0.22	0.17	lit	lit+imp	Acceptability
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	fluoxetine	Discontinuation, due to any cause (Acceptability)	"eSMD=0.13 [-0.12, 0.37] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=13.65	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	28	Network meta-analysis	Adults	Maintenance	lithium	mono	0.13	0.12	IV (Very Low)	Miura T., 2014 (NMA)	-0.13	-0.12	0.37	fluo	lit	Acceptability
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	fluoxetine	Discontinuation, due to any cause (Acceptability)	"eSMD=0.23 [-0.01, 0.48] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.74	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	28	Network meta-analysis	Adults	Maintenance	placebo	mono	0.23	0.12	IV (Very Low)	Miura T., 2014 (NMA)	-0.23	-0.01	0.48	fluo	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Ogawa Y., 2014 (MA)</a>"	risperidone	Discontinuation, due to any cause (Acceptability)	"eSMD=0.2 [0.03, 0.37] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.89	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	aug	0.2	0.09	I (High)	Ogawa Y., 2014 (MA)	-0.2	0.03	0.37	risp	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Ogawa Y., 2014 (MA)</a>"	quetiapine	Discontinuation, due to any cause (Acceptability)	"eSMD=0.14 [0.01, 0.27] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=12.68	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	aug	0.14	0.07	I (High)	Ogawa Y., 2014 (MA)	-0.14	0.01	0.27	que	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Ogawa Y., 2014 (MA)</a>"	olanzapine	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.02 [-0.14, 0.1] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=88.63	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	aug	-0.02	0.06	II (Moderate)	Ogawa Y., 2014 (MA)	0.02	-0.14	0.1	ola	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Ogawa Y., 2014 (MA)</a>"	aripiprazole	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.08 [-0.21, 0.06] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=22.17	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	aug	-0.08	0.07	II (Moderate)	Ogawa Y., 2014 (MA)	0.08	-0.21	0.06	ari	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Ogawa Y., 2014 (MA)</a>"	ziprasidone	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.16 [-0.29, -0.02] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=11.1	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	aug	-0.16	0.07	I (High)	Ogawa Y., 2014 (MA)	0.16	-0.29	-0.02	zip	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Palacios J., 2019 (MA)</a>"	tamoxifen	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.01 [-0.06, 0.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=177.25	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	aug	-0.01	0.03	III (Low)	Palacios J., 2019 (MA)	0.01	-0.06	0.05	tamox	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Taylor D.M., 2014 (NMA)</a>"	olanzapine+fluoxetine	Discontinuation, due to any cause (Acceptability)	"eSMD=0.31 [0.02, 0.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.76	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.31	0.14	IV (Very Low)	Taylor D.M., 2014 (NMA)	-0.31	0.02	0.55	ola+fluo	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Taylor D.M., 2014 (NMA)</a>"	ziprasidone	Discontinuation, due to any cause (Acceptability)	"eSMD=0.23 [-0.17, 0.56] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.74	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.23	0.19	IV (Very Low)	Taylor D.M., 2014 (NMA)	-0.23	-0.17	0.56	zip	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Taylor D.M., 2014 (NMA)</a>"	divalproate	Discontinuation, due to any cause (Acceptability)	"eSMD=0.19 [-0.28, 0.58] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=9.36	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.19	0.22	IV (Very Low)	Taylor D.M., 2014 (NMA)	-0.19	-0.28	0.58	div	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Taylor D.M., 2014 (NMA)</a>"	olanzapine	Discontinuation, due to any cause (Acceptability)	"eSMD=0.11 [-0.1, 0.34] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=16.13	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.11	0.11	IV (Very Low)	Taylor D.M., 2014 (NMA)	-0.11	-0.1	0.34	ola	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Taylor D.M., 2014 (NMA)</a>"	quetiapine	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.01 [-0.17, 0.15] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=177.25	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.01	0.08	IV (Very Low)	Taylor D.M., 2014 (NMA)	0.01	-0.17	0.15	que	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Taylor D.M., 2014 (NMA)</a>"	lamotrigine	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.02 [-0.17, 0.16] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=88.63	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.02	0.08	IV (Very Low)	Taylor D.M., 2014 (NMA)	0.02	-0.17	0.16	lam	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Taylor D.M., 2014 (NMA)</a>"	lithium	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.04 [-0.35, 0.33] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=44.32	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.04	0.17	IV (Very Low)	Taylor D.M., 2014 (NMA)	0.04	-0.35	0.33	lit	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Taylor D.M., 2014 (NMA)</a>"	lurasidone	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.11 [-0.36, 0.17] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=16.13	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.11	0.14	IV (Very Low)	Taylor D.M., 2014 (NMA)	0.11	-0.36	0.17	lur	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Taylor D.M., 2014 (NMA)</a>"	aripiprazole	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.27 [-0.52, -0.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.6	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.27	0.13	IV (Very Low)	Taylor D.M., 2014 (NMA)	0.27	-0.52	-0.01	ari	pbo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Taylor D.M., 2014 (NMA)</a>"	lamotrigine	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.31 [-0.56, -0.03] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.76	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Bipolar Depression	olanzapine+fluoxetine	combo	-0.31	0.14	IV (Very Low)	Taylor D.M., 2014 (NMA)	0.31	-0.56	-0.03	lam	ola+fluo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Taylor D.M., 2014 (NMA)</a>"	olanzapine	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.19 [-0.48, 0.12] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=9.36	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Bipolar Depression	olanzapine+fluoxetine	combo	-0.19	0.15	IV (Very Low)	Taylor D.M., 2014 (NMA)	0.19	-0.48	0.12	ola	ola+fluo	Acceptability
"<a href='https://doi.org/' target=""_blank"">Taylor D.M., 2014 (NMA)</a>"	lithium	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.03 [-0.34, 0.33] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=59.09	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Bipolar Depression	quetiapine	mono	-0.03	0.17	IV (Very Low)	Taylor D.M., 2014 (NMA)	0.03	-0.34	0.33	lit	que	Acceptability
"<a href='https://doi.org/' target=""_blank"">Yildiz A., 2015 (NMA)</a>"	divalproate	Discontinuation, due to any cause (Acceptability)	"eSMD=-0.05 [-0.32, 0.21] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=35.46	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	56	Network meta-analysis	Adults	Mania/Mixed	haloperidol	mono	-0.05	0.14	IV (Very Low)	Yildiz A., 2015 (NMA)	0.05	-0.32	0.21	div	hal	Acceptability
"<a href='https://doi.org/' target=""_blank"">Zhang J., 2021 (MA)</a>"	ECT	Discontinuation, due to any cause (Acceptability)	"eSMD=0.14 [-0.4, 0.86] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=12.68	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Mania	TAU	mono	0.14	0.32	IV (Very Low)	Zhang J., 2021 (MA)	-0.14	-0.4	0.86	ECT	tau	Acceptability
"<a href='https://doi.org/' target=""_blank"">Jochim J., 2019 (MA)</a>"	divalproate	Adverse events, Abdominal pain	"eSMD=-0.53 [-0.98, -0.09] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.42	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.53	0.23	I (High)	Jochim J., 2019 (MA)	0.53	-0.98	-0.09	div	pbo	AE, Abdominal pain
"<a href='https://doi.org/' target=""_blank"">Jochim J., 2019 (MA)</a>"	divalproate	Adverse events, Abdominal pain	"eSMD=-0.72 [-1.77, 0.26] <br> <img src=""https://www.linkpicture.com/q/Diapositive2.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.57	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Children & Adolescents	Mania/Mixed	placebo	mono	-0.72	0.52	III (Low)	Jochim J., 2019 (MA)	0.72	-1.77	0.26	div	pbo	AE, Abdominal pain
"<a href='https://doi.org/' target=""_blank"">Jochim J., 2019 (MA)</a>"	divalproate	Adverse events, Abdominal pain	"eSMD=-1.47 [-Inf, 0.34] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1.43	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Children & Adolescents	Mania/Mixed	risperidone	mono	-1.47	Inf	III (Low)	Jochim J., 2019 (MA)	1.47	-Inf	0.34	div	risp	AE, Abdominal pain
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2019 (MA)</a>"	ramelteon	Adverse events, Abnormal dreams	"eSMD=0.22 [-1.55, 1.93] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Maintenance	placebo	mono	0.22	0.89	III (Low)	Kishi T., 2019 (MA)	-0.22	-1.55	1.93	ram	pbo	AE, Abnormal dreams
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	lithium	Adverse events, Accidental injury	"eSMD=-0.08 [-0.68, 0.52] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=22.17	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.08	0.31	III (Low)	McKnight R.F., 2019 (MA)	0.08	-0.68	0.52	lit	pbo	AE, Accidental injury
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	lamotrigine	Adverse events, Accidental injury	"eSMD=0.15 [-0.47, 0.78] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=11.84	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	lithium	mono	0.15	0.32	III (Low)	McKnight R.F., 2019 (MA)	-0.15	-0.47	0.78	lam	lit	AE, Accidental injury
"<a href='https://doi.org/' target=""_blank"">Meduri M., 2016 (MA)</a>"	aripiprazole	Adverse events, Activation	"eSMD=-0.04 [-0.18, 0.09] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=44.32	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.04	0.07	II (Moderate)	Meduri M., 2016 (MA)	0.04	-0.18	0.09	ari	pbo	AE, Activation
"<a href='https://doi.org/' target=""_blank"">Meduri M., 2016 (MA)</a>"	aripiprazole	Adverse events, Activation	"eSMD=-0.17 [-0.52, 0.17] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=10.45	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	aug	-0.17	0.18	II (Moderate)	Meduri M., 2016 (MA)	0.17	-0.52	0.17	ari	pbo	AE, Activation
"<a href='https://doi.org/' target=""_blank"">Meduri M., 2016 (MA)</a>"	aripiprazole	Adverse events, Activation	"eSMD=-0.42 [-0.68, -0.15] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.28	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	haloperidol	mono	-0.42	0.14	I (High)	Meduri M., 2016 (MA)	0.42	-0.68	-0.15	ari	hal	AE, Activation
"<a href='https://doi.org/' target=""_blank"">Rendell J.M., 2010 (MA)</a>"	olanzapine	Adverse events, Agitation	"eSMD=0.29 [-0.01, 0.58] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.15	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	0.29	0.15	II (Moderate)	Rendell J.M., 2010 (MA)	-0.29	-0.01	0.58	ola	pbo	AE, Agitation
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	cariprazine	Adverse events, Akathisia	"eSMD=-0.74 [-1.22, -0.1] <br> <img src=""https://www.linkpicture.com/q/Diapositive2.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.5	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	7	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.74	0.29	II (Moderate)	Kadakia A., 2021 (NMA)	0.74	-1.22	-0.1	car	pbo	AE, Akathisia
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	lurasidone	Adverse events, Akathisia	"eSMD=-1.22 [-1.93, 0.22] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1.63	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	7	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-1.22	0.55	III (Low)	Kadakia A., 2021 (NMA)	1.22	-1.93	0.22	lur	pbo	AE, Akathisia
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	aripiprazole	Adverse events, Akathisia	"eSMD=-1.39 [-1.93, -0.4] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1.48	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	7	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-1.39	0.39	I (High)	Kadakia A., 2021 (NMA)	1.39	-1.93	-0.4	ari	pbo	AE, Akathisia
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2020 (NMA)</a>"	olanzapine	Adverse events, Akathisia	"eSMD=-0.68 [-1.47, 0.12] <br> <img src=""https://www.linkpicture.com/q/Diapositive3.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.71	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.68	0.41	IV (Very Low)	Kishi T., 2020 (NMA)	0.68	-1.47	0.12	ola	pbo	AE, Akathisia
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2020 (NMA)</a>"	quetiapine	Adverse events, Akathisia	"eSMD=-0.72 [-1.33, -0.13] <br> <img src=""https://www.linkpicture.com/q/Diapositive2.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.57	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.72	0.31	II (Moderate)	Kishi T., 2020 (NMA)	0.72	-1.33	-0.13	que	pbo	AE, Akathisia
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	quetiapine	Adverse events, Akathisia	"eSMD=0.08 [-0.29, 0.45] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=22.17	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	25	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.08	0.19	II (Moderate)	Kishi T., 2021 (NMA)	-0.08	-0.29	0.45	que	pbo	AE, Akathisia
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Akathisia	"eSMD=-0.04 [-0.42, 0.34] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=44.32	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	25	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.04	0.19	II (Moderate)	Kishi T., 2021 (NMA)	0.04	-0.42	0.34	lit	pbo	AE, Akathisia
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Adverse events, Akathisia	"eSMD=-0.36 [-1.22, 0.48] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.98	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	25	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.36	0.43	II (Moderate)	Kishi T., 2021 (NMA)	0.36	-1.22	0.48	lam	pbo	AE, Akathisia
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	asenapine	Adverse events, Akathisia	"eSMD=-0.37 [-0.83, 0.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.85	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	25	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.37	0.23	II (Moderate)	Kishi T., 2021 (NMA)	0.37	-0.83	0.08	ase	pbo	AE, Akathisia
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Adverse events, Akathisia	"eSMD=-0.43 [-0.86, 0.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.19	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	25	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.43	0.22	II (Moderate)	Kishi T., 2021 (NMA)	0.43	-0.86	0.01	ola	pbo	AE, Akathisia
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Adverse events, Akathisia	"eSMD=-0.52 [-0.95, -0.1] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.49	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	25	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.52	0.22	I (High)	Kishi T., 2021 (NMA)	0.52	-0.95	-0.1	pal	pbo	AE, Akathisia
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Adverse events, Akathisia	"eSMD=-0.61 [-0.81, -0.44] <br> <img src=""https://www.linkpicture.com/q/Diapositive4.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	25	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.61	0.09	I (High)	Kishi T., 2021 (NMA)	0.61	-0.81	-0.44	ari	pbo	AE, Akathisia
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	brexpiprazole	Adverse events, Akathisia	"eSMD=-0.72 [-1.22, -0.22] <br> <img src=""https://www.linkpicture.com/q/Diapositive2.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.57	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	25	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.72	0.26	I (High)	Kishi T., 2021 (NMA)	0.72	-1.22	-0.22	brex	pbo	AE, Akathisia
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	ziprasidone	Adverse events, Akathisia	"eSMD=-0.79 [-1.05, -0.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive2.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.36	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	25	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.79	0.13	I (High)	Kishi T., 2021 (NMA)	0.79	-1.05	-0.55	zip	pbo	AE, Akathisia
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	cariprazine	Adverse events, Akathisia	"eSMD=-0.81 [-1.05, -0.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.31	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	25	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.81	0.13	I (High)	Kishi T., 2021 (NMA)	0.81	-1.05	-0.55	car	pbo	AE, Akathisia
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Adverse events, Akathisia	"eSMD=-0.95 [-1.12, -0.76] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.01	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	25	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.95	0.09	I (High)	Kishi T., 2021 (NMA)	0.95	-1.12	-0.76	hal	pbo	AE, Akathisia
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Adverse events, Akathisia	"eSMD=-1.01 [-1.39, -0.66] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1.91	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	25	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	-1.01	0.19	I (High)	Kishi T., 2021 (NMA)	1.01	-1.39	-0.66	hal	que	AE, Akathisia
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Adverse events, Akathisia	"eSMD=-0.59 [-1.01, -0.18] <br> <img src=""https://www.linkpicture.com/q/Diapositive4.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.09	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	25	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	-0.59	0.21	I (High)	Kishi T., 2021 (NMA)	0.59	-1.01	-0.18	pal	que	AE, Akathisia
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Adverse events, Akathisia	"eSMD=-0.58 [-0.95, -0.21] <br> <img src=""https://www.linkpicture.com/q/Diapositive4.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.14	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	25	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	-0.58	0.19	I (High)	Kishi T., 2021 (NMA)	0.58	-0.95	-0.21	ari	lit	AE, Akathisia
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Adverse events, Akathisia	"eSMD=-0.52 [-0.98, -0.07] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.49	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	25	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.52	0.23	I (High)	Kishi T., 2021 (NMA)	0.52	-0.98	-0.07	hal	ola	AE, Akathisia
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Adverse events, Akathisia	"eSMD=-0.32 [-1.22, 0.58] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.59	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	25	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	-0.32	0.46	II (Moderate)	Kishi T., 2021 (NMA)	0.32	-1.22	0.58	lam	lit	AE, Akathisia
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Adverse events, Akathisia	"eSMD=-0.15 [-0.37, 0.07] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=11.84	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	25	Network meta-analysis	Adults	Mania/Mixed	ziprasidone	mono	-0.15	0.11	II (Moderate)	Kishi T., 2021 (NMA)	0.15	-0.37	0.07	hal	zip	AE, Akathisia
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Akathisia	"eSMD=-0.12 [-0.63, 0.39] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=14.79	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	25	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	-0.12	0.26	II (Moderate)	Kishi T., 2021 (NMA)	0.12	-0.63	0.39	lit	que	AE, Akathisia
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	asenapine	Adverse events, Akathisia	"eSMD=0.05 [-0.29, 0.4] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=35.46	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	25	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	0.05	0.18	II (Moderate)	Kishi T., 2021 (NMA)	-0.05	-0.29	0.4	ase	ola	AE, Akathisia
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Adverse events, Akathisia	"eSMD=0.33 [0.15, 0.51] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.42	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	25	Network meta-analysis	Adults	Mania/Mixed	haloperidol	mono	0.33	0.09	I (High)	Kishi T., 2021 (NMA)	-0.33	0.15	0.51	ari	hal	AE, Akathisia
"<a href='https://doi.org/' target=""_blank"">Meduri M., 2016 (MA)</a>"	aripiprazole	Adverse events, Akathisia	"eSMD=-0.44 [-1.33, 0.47] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.09	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Children & Adolescents	Mania/Mixed	placebo	mono	-0.44	0.46	II (Moderate)	Meduri M., 2016 (MA)	0.44	-1.33	0.47	ari	pbo	AE, Akathisia
"<a href='https://doi.org/' target=""_blank"">Meduri M., 2016 (MA)</a>"	aripiprazole	Adverse events, Akathisia	"eSMD=-0.76 [-1.08, -0.42] <br> <img src=""https://www.linkpicture.com/q/Diapositive2.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.44	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	aug	-0.76	0.17	I (High)	Meduri M., 2016 (MA)	0.76	-1.08	-0.42	ari	pbo	AE, Akathisia
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2013 (MA)</a>"	divalproate	Adverse events, Alopecia	"eSMD=-0.51 [-0.95, -0.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.55	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Low	2	Pairwise meta-analysis	Adults	Maintenance	placebo	mono	-0.51	0.22	I (High)	Cipriani A., 2013 (MA)	0.51	-0.95	-0.08	div	pbo	AE, Alopecia
"<a href='https://doi.org/' target=""_blank"">Jochim J., 2019 (MA)</a>"	divalproate	Adverse events, Anorexia	"eSMD=-0.81 [-2.16, 0.42] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.31	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.81	0.66	III (Low)	Jochim J., 2019 (MA)	0.81	-2.16	0.42	div	pbo	AE, Anorexia
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	lithium	Adverse events, Anorexia	"eSMD=-0.49 [-1.08, 0.09] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.69	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Mixed (Children-Adults)	Mania/Mixed	placebo	mono	-0.49	0.3	III (Low)	McKnight R.F., 2019 (MA)	0.49	-1.08	0.09	lit	pbo	AE, Anorexia
"<a href='https://doi.org/' target=""_blank"">Rendell J.M., 2010 (MA)</a>"	olanzapine	Adverse events, Anxiety	"eSMD=0.24 [-0.72, 1.22] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.42	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	0.24	0.49	III (Low)	Rendell J.M., 2010 (MA)	-0.24	-0.72	1.22	ola	pbo	AE, Anxiety
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2019 (MA)</a>"	ramelteon	Adverse events, Anxiety/Medication use, anxiolytics use	"eSMD=-0.24 [-1.39, 0.92] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.42	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Maintenance	placebo	mono	-0.24	0.59	III (Low)	Kishi T., 2019 (MA)	0.24	-1.39	0.92	ram	pbo	AE, Anxiety/Anxiolytics use
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	risperidone LAI	Adverse events, Anxiety/Medication use, anxiolytics use	"eSMD=0.29 [-0.03, 0.61] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.15	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Maintenance	placebo	mono	0.29	0.16	IV (Very Low)	Kishi T., 2021 (NMA)	-0.29	-0.03	0.61	rispLAI	pbo	AE, Anxiety/Anxiolytics use
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	asenapine	Adverse events, Anxiety/Medication use, anxiolytics use	"eSMD=0.22 [-0.79, -0.06] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.09	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Maintenance	placebo	mono	0.22	0.19	IV (Very Low)	Kishi T., 2021 (NMA)	-0.22	-0.79	-0.06	ase	pbo	AE, Anxiety/Anxiolytics use
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Adverse events, Anxiety/Medication use, anxiolytics use	"eSMD=0.2 [-0.02, 0.42] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.89	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Maintenance	placebo	mono	0.2	0.11	IV (Very Low)	Kishi T., 2021 (NMA)	-0.2	-0.02	0.42	ola	pbo	AE, Anxiety/Anxiolytics use
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Anxiety/Medication use, anxiolytics use	"eSMD=0.06 [-0.23, 0.35] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=29.55	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Maintenance	placebo	mono	0.06	0.15	IV (Very Low)	Kishi T., 2021 (NMA)	-0.06	-0.23	0.35	lit	pbo	AE, Anxiety/Anxiolytics use
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Adverse events, Anxiety/Medication use, anxiolytics use	"eSMD=0.05 [-0.27, 0.38] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=35.46	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Maintenance	placebo	mono	0.05	0.17	IV (Very Low)	Kishi T., 2021 (NMA)	-0.05	-0.27	0.38	lam	pbo	AE, Anxiety/Anxiolytics use
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Adverse events, Anxiety/Medication use, anxiolytics use	"eSMD=-0.08 [-0.55, 0.39] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=22.17	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.08	0.24	IV (Very Low)	Kishi T., 2021 (NMA)	0.08	-0.55	0.39	ari	pbo	AE, Anxiety/Anxiolytics use
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole LAI	Adverse events, Anxiety/Medication use, anxiolytics use	"eSMD=-0.08 [-0.39, 0.23] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=22.17	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.08	0.16	IV (Very Low)	Kishi T., 2021 (NMA)	0.08	-0.39	0.23	ariLAI	pbo	AE, Anxiety/Anxiolytics use
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Adverse events, Anxiety/Medication use, anxiolytics use	"eSMD=-0.14 [-0.52, 0.23] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=12.68	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.14	0.19	IV (Very Low)	Kishi T., 2021 (NMA)	0.14	-0.52	0.23	pal	pbo	AE, Anxiety/Anxiolytics use
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole+lamotrigine	Adverse events, Anxiety/Medication use, anxiolytics use	"eSMD=-0.39 [-0.95, 0.17] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.6	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Maintenance	lamotrigine	mono	-0.39	0.29	IV (Very Low)	Kishi T., 2021 (NMA)	0.39	-0.95	0.17	ari+lam	lam	AE, Anxiety/Anxiolytics use
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Anxiety/Medication use, anxiolytics use	"eSMD=-0.14 [-0.47, 0.17] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=12.68	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Maintenance	olanzapine	mono	-0.14	0.16	IV (Very Low)	Kishi T., 2021 (NMA)	0.14	-0.47	0.17	lit	ola	AE, Anxiety/Anxiolytics use
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Adverse events, Anxiety/Medication use, anxiolytics use	"eSMD=-0.09 [-0.45, 0.27] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=19.71	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Maintenance	risperidone LAI	mono	-0.09	0.18	IV (Very Low)	Kishi T., 2021 (NMA)	0.09	-0.45	0.27	ola	rispLAI	AE, Anxiety/Anxiolytics use
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Adverse events, Anxiety/Medication use, anxiolytics use	"eSMD=-0.01 [-0.32, 0.31] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=177.25	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Maintenance	lithium	mono	-0.01	0.16	IV (Very Low)	Kishi T., 2021 (NMA)	0.01	-0.32	0.31	lam	lit	AE, Anxiety/Anxiolytics use
"<a href='https://doi.org/' target=""_blank"">Jochim J., 2019 (MA)</a>"	divalproate	Adverse events, any	"eSMD=-0.27 [-0.48, -0.07] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.6	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.27	0.1	II (Moderate)	Jochim J., 2019 (MA)	0.27	-0.48	-0.07	div	pbo	AE, any
"<a href='https://doi.org/' target=""_blank"">Jochim J., 2019 (MA)</a>"	divalproate	Adverse events, any	"eSMD=0.27 [-0.22, 0.76] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.6	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	lithium	mono	0.27	0.25	III (Low)	Jochim J., 2019 (MA)	-0.27	-0.22	0.76	div	lit	AE, any
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2016 (MA)</a>"	risperidone LAI	Adverse events, any	"eSMD=-0.05 [-0.14, 0.03] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=35.46	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Maintenance	placebo	mono	-0.05	0.04	II (Moderate)	Kishi T., 2016 (MA)	0.05	-0.14	0.03	rispLAI	pbo	AE, any
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	lithium	Adverse events, any	"eSMD=-0.07 [-0.44, 0.29] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=25.33	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.07	0.19	III (Low)	McKnight R.F., 2019 (MA)	0.07	-0.44	0.29	lit	pbo	AE, any
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	lamotrigine	Adverse events, any	"eSMD=-0.06 [-0.42, 0.29] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=29.55	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	lithium	mono	-0.06	0.18	III (Low)	McKnight R.F., 2019 (MA)	0.06	-0.42	0.29	lam	lit	AE, any
"<a href='https://doi.org/' target=""_blank"">Meduri M., 2016 (MA)</a>"	aripiprazole	Adverse events, any	"eSMD=-0.1 [-0.19, -0.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=17.74	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	aug	-0.1	0.05	I (High)	Meduri M., 2016 (MA)	0.1	-0.19	-0.01	ari	pbo	AE, any
"<a href='https://doi.org/' target=""_blank"">Pinto J.V., 2020 (MA)</a>"	cariprazine	Adverse events, any	"eSMD=-0.4 [-0.65, -0.17] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.49	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.4	0.12	I (High)	Pinto J.V., 2020 (MA)	0.4	-0.65	-0.17	car	pbo	AE, any
"<a href='https://doi.org/' target=""_blank"">Poolsup N., 2000 (MA)</a>"	lithium	Adverse events, any	"eSMD=-0.86 [-1.77, 0.06] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.19	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Mixed (Children-Adults)	Mania/Mixed	verapamil	mono	-0.86	0.47	IV (Very Low)	Poolsup N., 2000 (MA)	0.86	-1.77	0.06	lit	verapamil	AE, any
"<a href='https://doi.org/' target=""_blank"">Poolsup N., 2000 (MA)</a>"	carbamazepine	Adverse events, any	"eSMD=-0.19 [-0.39, 0.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=9.36	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Mixed (Children-Adults)	Mania/Mixed	lithium	mono	-0.19	0.1	IV (Very Low)	Poolsup N., 2000 (MA)	0.19	-0.39	0.01	cbz	lit	AE, any
"<a href='https://doi.org/' target=""_blank"">Rendell J.M., 2010 (MA)</a>"	risperidone	Adverse events, any	"eSMD=-0.02 [-0.12, 0.07] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=88.63	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	aug	-0.02	0.05	III (Low)	Rendell J.M., 2010 (MA)	0.02	-0.12	0.07	risp	pbo	AE, any
"<a href='https://doi.org/' target=""_blank"">Jochim J., 2019 (MA)</a>"	divalproate	Adverse events, Appetite, increase	"eSMD=-0.24 [-0.83, 0.34] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.42	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.24	0.3	II (Moderate)	Jochim J., 2019 (MA)	0.24	-0.83	0.34	div	pbo	AE, Appetite, increase
"<a href='https://doi.org/' target=""_blank"">Jochim J., 2019 (MA)</a>"	divalproate	Adverse events, Appetite, increase	"eSMD=0.44 [-0.48, 1.39] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	olanzapine	mono	0.44	0.48	III (Low)	Jochim J., 2019 (MA)	-0.44	-0.48	1.39	div	ola	AE, Appetite, increase
"<a href='https://doi.org/' target=""_blank"">Silva M.T., 2013 (MA)</a>"	olanzapine	Adverse events, Appetite, increase	"eSMD=0 [-0.3, 0.3] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Bipolar Depression	olanzapine+fluoxetine	combo	0	0.15	III (Low)	Silva M.T., 2013 (MA)	0	-0.3	0.3	ola	ola+fluo	AE, Appetite, increase
"<a href='https://doi.org/' target=""_blank"">Suttajit S., 2014 (MA)</a>"	quetiapine	Adverse events, Appetite, increase	"eSMD=-0.56 [-0.89, -0.25] <br> <img src=""https://www.linkpicture.com/q/Diapositive4.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.25	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	4	Pairwise meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	-0.56	0.16	II (Moderate)	Suttajit S., 2014 (MA)	0.56	-0.89	-0.25	que	pbo	AE, Appetite, increase
"<a href='https://doi.org/' target=""_blank"">Bartoli F., 2017 (MA)</a>"	allopurinol	Adverse events, Asthenia	"eSMD=-0.05 [-0.4, 0.3] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=35.46	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	aug	-0.05	0.18	IV (Very Low)	Bartoli F., 2017 (MA)	0.05	-0.4	0.3	allopur	pbo	AE, Asthenia
"<a href='https://doi.org/' target=""_blank"">Macritchie K., 2003 (MA)</a>"	divalproate	Adverse events, Asthenia	"eSMD=-0.24 [-0.66, 0.18] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.42	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.24	0.21	II (Moderate)	Macritchie K., 2003 (MA)	0.24	-0.66	0.18	div	pbo	AE, Asthenia
"<a href='https://doi.org/' target=""_blank"">Rendell J.M., 2010 (MA)</a>"	olanzapine	Adverse events, Asthenia	"eSMD=-0.49 [-0.92, -0.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.69	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.49	0.22	I (High)	Rendell J.M., 2010 (MA)	0.49	-0.92	-0.05	ola	pbo	AE, Asthenia
"<a href='https://doi.org/' target=""_blank"">Silva M.T., 2013 (MA)</a>"	olanzapine	Adverse events, Asthenia	"eSMD=0.12 [-0.19, 0.42] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=14.79	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Bipolar Depression	olanzapine+fluoxetine	combo	0.12	0.16	III (Low)	Silva M.T., 2013 (MA)	-0.12	-0.19	0.42	ola	ola+fluo	AE, Asthenia
"<a href='https://doi.org/' target=""_blank"">Suttajit S., 2014 (MA)</a>"	quetiapine	Adverse events, At least one adverse event	"eSMD=-0.09 [-0.12, -0.06] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=19.71	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	4	Pairwise meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	-0.09	0.02	II (Moderate)	Suttajit S., 2014 (MA)	0.09	-0.12	-0.06	que	pbo	AE, At least one
"<a href='https://doi.org/' target=""_blank"">Wang H., 2020 (MA)</a>"	lurasidone	Adverse events, At least one adverse event	"eSMD=-0.06 [-0.13, 0] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=29.55	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.06	0.03	II (Moderate)	Wang H., 2020 (MA)	0.06	-0.13	0	lur	pbo	AE, At least one
"<a href='https://doi.org/' target=""_blank"">Jochim J., 2019 (MA)</a>"	divalproate	Adverse events, Back pain	"eSMD=0.26 [-1.47, 1.93] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.86	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	0.26	0.87	III (Low)	Jochim J., 2019 (MA)	-0.26	-1.47	1.93	div	pbo	AE, Back pain
"<a href='https://doi.org/' target=""_blank"">Vita A., 2013 (MA)</a>"	asenapine	Adverse events, Bradykinesia	"eSMD=-0.33 [-0.95, 0.3] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.42	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.33	0.32	IV (Very Low)	Vita A., 2013 (MA)	0.33	-0.95	0.3	ase	ola	AE, Bradykinesia
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2020 (NMA)</a>"	lurasidone	Adverse events, Constipation	"eSMD=0.03 [-0.79, 0.92] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=59.09	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.03	0.44	IV (Very Low)	Kishi T., 2020 (NMA)	-0.03	-0.79	0.92	lur	pbo	AE, Constipation
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2020 (NMA)</a>"	olanzapine	Adverse events, Constipation	"eSMD=-0.35 [-0.89, 0.18] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.12	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.35	0.27	IV (Very Low)	Kishi T., 2020 (NMA)	0.35	-0.89	0.18	ola	pbo	AE, Constipation
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	brexpiprazole	Adverse events, Constipation	"eSMD=0.14 [-0.42, 0.7] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=12.68	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	27	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.14	0.29	III (Low)	Kishi T., 2021 (NMA)	-0.14	-0.42	0.7	brex	pbo	AE, Constipation
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Adverse events, Constipation	"eSMD=0.09 [-0.25, 0.43] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=19.71	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	27	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.09	0.17	III (Low)	Kishi T., 2021 (NMA)	-0.09	-0.25	0.43	div	pbo	AE, Constipation
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	tamoxifen	Adverse events, Constipation	"eSMD=0 [-1.47, 1.47] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	27	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0	0.75	III (Low)	Kishi T., 2021 (NMA)	0	-1.47	1.47	tamox	pbo	AE, Constipation
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Constipation	"eSMD=-0.14 [-0.43, 0.14] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=12.68	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	27	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.14	0.15	III (Low)	Kishi T., 2021 (NMA)	0.14	-0.43	0.14	lit	pbo	AE, Constipation
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Adverse events, Constipation	"eSMD=-0.3 [-0.7, 0.1] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.95	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	27	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.3	0.2	III (Low)	Kishi T., 2021 (NMA)	0.3	-0.7	0.1	pal	pbo	AE, Constipation
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Adverse events, Constipation	"eSMD=-0.3 [-0.53, -0.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.95	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	27	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.3	0.11	II (Moderate)	Kishi T., 2021 (NMA)	0.3	-0.53	-0.08	ari	pbo	AE, Constipation
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	carbamazepine	Adverse events, Constipation	"eSMD=-0.31 [-0.86, 0.26] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.76	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	27	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.31	0.29	III (Low)	Kishi T., 2021 (NMA)	0.31	-0.86	0.26	cbz	pbo	AE, Constipation
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	cariprazine	Adverse events, Constipation	"eSMD=-0.33 [-0.65, -0.02] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.42	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	27	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.33	0.16	II (Moderate)	Kishi T., 2021 (NMA)	0.33	-0.65	-0.02	car	pbo	AE, Constipation
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Adverse events, Constipation	"eSMD=-0.36 [-0.7, -0.02] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.98	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	27	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.36	0.17	II (Moderate)	Kishi T., 2021 (NMA)	0.36	-0.7	-0.02	ola	pbo	AE, Constipation
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Adverse events, Constipation	"eSMD=-0.38 [-1.27, 0.49] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.72	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	27	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.38	0.45	III (Low)	Kishi T., 2021 (NMA)	0.38	-1.27	0.49	lam	pbo	AE, Constipation
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	quetiapine	Adverse events, Constipation	"eSMD=-0.58 [-0.92, -0.24] <br> <img src=""https://www.linkpicture.com/q/Diapositive4.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.14	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	27	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.58	0.17	I (High)	Kishi T., 2021 (NMA)	0.58	-0.92	-0.24	que	pbo	AE, Constipation
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Adverse events, Constipation	"eSMD=-0.68 [-1.55, 0.22] <br> <img src=""https://www.linkpicture.com/q/Diapositive3.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.71	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	27	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.68	0.45	III (Low)	Kishi T., 2021 (NMA)	0.68	-1.55	0.22	hal	pbo	AE, Constipation
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Adverse events, Constipation	"eSMD=-1.08 [-2.54, 0.56] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1.8	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	27	Network meta-analysis	Adults	Mania/Mixed	oxcarbazepine	mono	-1.08	0.79	III (Low)	Kishi T., 2021 (NMA)	1.08	-2.54	0.56	div	oxc	AE, Constipation
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Adverse events, Constipation	"eSMD=-0.32 [-1.17, 0.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.59	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	27	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.32	0.44	III (Low)	Kishi T., 2021 (NMA)	0.32	-1.17	0.55	hal	ola	AE, Constipation
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Adverse events, Constipation	"eSMD=-0.24 [-1.12, 0.66] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.42	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	27	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	-0.24	0.45	III (Low)	Kishi T., 2021 (NMA)	0.24	-1.12	0.66	lam	lit	AE, Constipation
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Adverse events, Constipation	"eSMD=-0.16 [-0.48, 0.17] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=11.1	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	27	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	-0.16	0.17	III (Low)	Kishi T., 2021 (NMA)	0.16	-0.48	0.17	ari	lit	AE, Constipation
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Constipation	"eSMD=0.22 [-0.17, 0.61] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	27	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	0.22	0.2	III (Low)	Kishi T., 2021 (NMA)	-0.22	-0.17	0.61	lit	ola	AE, Constipation
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Adverse events, Constipation	"eSMD=0.23 [-0.14, 0.62] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.74	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	27	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	0.23	0.19	III (Low)	Kishi T., 2021 (NMA)	-0.23	-0.14	0.62	div	lit	AE, Constipation
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Adverse events, Constipation	"eSMD=0.28 [-0.14, 0.7] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.37	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	27	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	0.28	0.21	III (Low)	Kishi T., 2021 (NMA)	-0.28	-0.14	0.7	pal	que	AE, Constipation
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Constipation	"eSMD=0.44 [0.08, 0.79] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.09	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	27	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	0.44	0.18	I (High)	Kishi T., 2021 (NMA)	-0.44	0.08	0.79	lit	que	AE, Constipation
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Adverse events, Constipation	"eSMD=0.45 [0.13, 0.78] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.01	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	27	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	0.45	0.17	I (High)	Kishi T., 2021 (NMA)	-0.45	0.13	0.78	div	ola	AE, Constipation
"<a href='https://doi.org/' target=""_blank"">Suttajit S., 2014 (MA)</a>"	quetiapine	Adverse events, Constipation	"eSMD=-0.39 [-0.56, -0.22] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.6	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Pairwise meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	-0.39	0.09	II (Moderate)	Suttajit S., 2014 (MA)	0.39	-0.56	-0.22	que	pbo	AE, Constipation
"<a href='https://doi.org/' target=""_blank"">Vita A., 2013 (MA)</a>"	asenapine	Adverse events, Constipation	"eSMD=-0.18 [-0.56, 0.21] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=9.87	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.18	0.2	IV (Very Low)	Vita A., 2013 (MA)	0.18	-0.56	0.21	ase	ola	AE, Constipation
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	ziprasidone	Adverse events, Depression, incidence	"eSMD=0.68 [-0.31, 1.65] <br> <img src=""https://www.linkpicture.com/q/Diapositive18.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.71	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	19	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.68	0.5	III (Low)	Kishi T., 2021 (NMA)	-0.68	-0.31	1.65	zip	pbo	AE, Depression, incidence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	asenapine	Adverse events, Depression, incidence	"eSMD=0.42 [-0.4, 1.22] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.28	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	19	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.42	0.41	III (Low)	Kishi T., 2021 (NMA)	-0.42	-0.4	1.22	ase	pbo	AE, Depression, incidence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	quetiapine	Adverse events, Depression, incidence	"eSMD=0.33 [-0.01, 0.68] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.42	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	19	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.33	0.18	III (Low)	Kishi T., 2021 (NMA)	-0.33	-0.01	0.68	que	pbo	AE, Depression, incidence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Adverse events, Depression, incidence	"eSMD=0.3 [-0.08, 0.68] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.95	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	19	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.3	0.19	III (Low)	Kishi T., 2021 (NMA)	-0.3	-0.08	0.68	ola	pbo	AE, Depression, incidence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Adverse events, Depression, incidence	"eSMD=0.09 [-0.35, 0.53] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=19.71	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	19	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.09	0.22	III (Low)	Kishi T., 2021 (NMA)	-0.09	-0.35	0.53	pal	pbo	AE, Depression, incidence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Depression, incidence	"eSMD=0.09 [-0.33, 0.51] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=19.71	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	19	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.09	0.21	III (Low)	Kishi T., 2021 (NMA)	-0.09	-0.33	0.51	lit	pbo	AE, Depression, incidence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Adverse events, Depression, incidence	"eSMD=0.01 [-0.95, 0.98] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=177.25	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	19	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.01	0.49	III (Low)	Kishi T., 2021 (NMA)	-0.01	-0.95	0.98	lam	pbo	AE, Depression, incidence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Adverse events, Depression, incidence	"eSMD=-0.04 [-0.42, 0.34] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=44.32	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	19	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.04	0.19	III (Low)	Kishi T., 2021 (NMA)	0.04	-0.42	0.34	ari	pbo	AE, Depression, incidence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Adverse events, Depression, incidence	"eSMD=-0.17 [-0.55, 0.21] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=10.45	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	19	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.17	0.19	III (Low)	Kishi T., 2021 (NMA)	0.17	-0.55	0.21	hal	pbo	AE, Depression, incidence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	tamoxifen	Adverse events, Depression, incidence	"eSMD=-0.22 [-1.17, 0.74] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=8.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	19	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.22	0.49	III (Low)	Kishi T., 2021 (NMA)	0.22	-1.17	0.74	tamox	pbo	AE, Depression, incidence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	carbamazepine	Adverse events, Depression, incidence	"eSMD=-0.36 [-1.77, 1.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.98	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	19	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.36	0.72	III (Low)	Kishi T., 2021 (NMA)	0.36	-1.77	1.05	cbz	pbo	AE, Depression, incidence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Adverse events, Depression, incidence	"eSMD=-0.68 [-2.54, 1.12] <br> <img src=""https://www.linkpicture.com/q/Diapositive3.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.71	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	19	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.68	0.93	III (Low)	Kishi T., 2021 (NMA)	0.68	-2.54	1.12	div	pbo	AE, Depression, incidence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Adverse events, Depression, incidence	"eSMD=-0.83 [-1.77, 0.09] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.26	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	19	Network meta-analysis	Adults	Mania/Mixed	ziprasidone	mono	-0.83	0.47	III (Low)	Kishi T., 2021 (NMA)	0.83	-1.77	0.09	hal	zip	AE, Depression, incidence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Adverse events, Depression, incidence	"eSMD=-0.51 [-0.98, -0.02] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.55	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	19	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	-0.51	0.24	II (Moderate)	Kishi T., 2021 (NMA)	0.51	-0.98	-0.02	hal	que	AE, Depression, incidence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Adverse events, Depression, incidence	"eSMD=-0.47 [-0.98, 0.04] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.84	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	19	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.47	0.26	III (Low)	Kishi T., 2021 (NMA)	0.47	-0.98	0.04	hal	ola	AE, Depression, incidence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Depression, incidence	"eSMD=-0.24 [-0.74, 0.26] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.42	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	19	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	-0.24	0.26	III (Low)	Kishi T., 2021 (NMA)	0.24	-0.74	0.26	lit	que	AE, Depression, incidence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Adverse events, Depression, incidence	"eSMD=-0.24 [-0.76, 0.27] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.42	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	19	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	-0.24	0.26	III (Low)	Kishi T., 2021 (NMA)	0.24	-0.76	0.27	pal	que	AE, Depression, incidence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Adverse events, Depression, incidence	"eSMD=-0.13 [-0.61, 0.35] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=13.65	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	19	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	-0.13	0.24	III (Low)	Kishi T., 2021 (NMA)	0.13	-0.61	0.35	ari	lit	AE, Depression, incidence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Adverse events, Depression, incidence	"eSMD=-0.08 [-1.12, 0.95] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=22.17	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	19	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	-0.08	0.53	III (Low)	Kishi T., 2021 (NMA)	0.08	-1.12	0.95	lam	lit	AE, Depression, incidence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	asenapine	Adverse events, Depression, incidence	"eSMD=0.11 [-0.72, 0.95] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=16.13	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	19	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	0.11	0.43	III (Low)	Kishi T., 2021 (NMA)	-0.11	-0.72	0.95	ase	ola	AE, Depression, incidence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Adverse events, Depression, incidence	"eSMD=0.12 [-0.27, 0.52] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=14.79	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	19	Network meta-analysis	Adults	Mania/Mixed	haloperidol	mono	0.12	0.2	III (Low)	Kishi T., 2021 (NMA)	-0.12	-0.27	0.52	ari	hal	AE, Depression, incidence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2016 (MA)</a>"	risperidone LAI	Adverse events, Diabetes	"eSMD=-0.74 [-1.93, 0.47] <br> <img src=""https://www.linkpicture.com/q/Diapositive2.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.5	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Maintenance	placebo	mono	-0.74	0.61	II (Moderate)	Kishi T., 2016 (MA)	0.74	-1.93	0.47	rispLAI	pbo	AE, Diabetes
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2013 (MA)</a>"	divalproate	Adverse events, Diarrhea	"eSMD=0.17 [0.01, 0.33] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=10.45	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Low	2	Pairwise meta-analysis	Mixed (Children-Adults)	Maintenance	lithium	mono	0.17	0.08	I (High)	Cipriani A., 2013 (MA)	-0.17	0.01	0.33	div	lit	AE, Diarrhea
"<a href='https://doi.org/' target=""_blank"">Bartoli F., 2017 (MA)</a>"	allopurinol	Adverse events, Diarrhea	"eSMD=0.06 [-0.28, 0.39] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=29.55	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	aug	0.06	0.17	IV (Very Low)	Bartoli F., 2017 (MA)	-0.06	-0.28	0.39	allopur	pbo	AE, Diarrhea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2019 (MA)</a>"	ramelteon	Adverse events, Diarrhea	"eSMD=0.05 [-0.39, 0.48] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=35.46	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Maintenance	placebo	mono	0.05	0.22	III (Low)	Kishi T., 2019 (MA)	-0.05	-0.39	0.48	ram	pbo	AE, Diarrhea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	tamoxifen	Adverse events, Diarrhea	"eSMD=0.89 [-0.74, 2.54] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.12	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	20	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.89	0.84	III (Low)	Kishi T., 2021 (NMA)	-0.89	-0.74	2.54	tamox	pbo	AE, Diarrhea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Adverse events, Diarrhea	"eSMD=0.65 [-0.26, 1.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive18.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.82	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	20	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.65	0.46	III (Low)	Kishi T., 2021 (NMA)	-0.65	-0.26	1.55	pal	pbo	AE, Diarrhea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Adverse events, Diarrhea	"eSMD=0.59 [-0.66, 1.93] <br> <img src=""https://www.linkpicture.com/q/Diapositive17.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	20	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.59	0.66	III (Low)	Kishi T., 2021 (NMA)	-0.59	-0.66	1.93	lam	pbo	AE, Diarrhea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Adverse events, Diarrhea	"eSMD=0.23 [-0.16, 0.63] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.74	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Network meta-analysis	Adults	Maintenance	placebo	mono	0.23	0.2	IV (Very Low)	Kishi T., 2021 (NMA)	-0.23	-0.16	0.63	lam	pbo	AE, Diarrhea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	quetiapine	Adverse events, Diarrhea	"eSMD=0.07 [-0.3, 0.45] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=25.33	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Network meta-analysis	Adults	Maintenance	placebo	mono	0.07	0.19	IV (Very Low)	Kishi T., 2021 (NMA)	-0.07	-0.3	0.45	que	pbo	AE, Diarrhea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	quetiapine	Adverse events, Diarrhea	"eSMD=0.03 [-0.37, 0.44] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=59.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	20	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.03	0.21	III (Low)	Kishi T., 2021 (NMA)	-0.03	-0.37	0.44	que	pbo	AE, Diarrhea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Adverse events, Diarrhea	"eSMD=0.03 [-0.25, 0.32] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=59.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	20	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.03	0.15	III (Low)	Kishi T., 2021 (NMA)	-0.03	-0.25	0.32	ari	pbo	AE, Diarrhea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Diarrhea	"eSMD=0.03 [-0.35, 0.43] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=59.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	20	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.03	0.2	III (Low)	Kishi T., 2021 (NMA)	-0.03	-0.35	0.43	lit	pbo	AE, Diarrhea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	cariprazine	Adverse events, Diarrhea	"eSMD=0 [-0.38, 0.39] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	20	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0	0.2	III (Low)	Kishi T., 2021 (NMA)	0	-0.38	0.39	car	pbo	AE, Diarrhea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Adverse events, Diarrhea	"eSMD=-0.13 [-0.45, 0.19] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=13.65	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.13	0.16	IV (Very Low)	Kishi T., 2021 (NMA)	0.13	-0.45	0.19	div	pbo	AE, Diarrhea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Adverse events, Diarrhea	"eSMD=-0.2 [-0.52, 0.13] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=8.89	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	20	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.2	0.17	III (Low)	Kishi T., 2021 (NMA)	0.2	-0.52	0.13	div	pbo	AE, Diarrhea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Diarrhea	"eSMD=-0.31 [-0.52, -0.09] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.76	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.31	0.11	III (Low)	Kishi T., 2021 (NMA)	0.31	-0.52	-0.09	lit	pbo	AE, Diarrhea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Adverse events, Diarrhea	"eSMD=-0.89 [-2.54, 0.81] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.12	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	20	Network meta-analysis	Adults	Mania/Mixed	oxcarbazepine	mono	-0.89	0.85	III (Low)	Kishi T., 2021 (NMA)	0.89	-2.54	0.81	div	oxc	AE, Diarrhea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Adverse events, Diarrhea	"eSMD=-0.55 [-0.14, 0.48] <br> <img src=""https://www.linkpicture.com/q/Diapositive4.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.3	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Network meta-analysis	Adults	Maintenance	lithium	mono	-0.55	0.16	IV (Very Low)	Kishi T., 2021 (NMA)	0.55	-0.14	0.48	div	lit	AE, Diarrhea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Diarrhea	"eSMD=-0.38 [-0.76, 0.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.72	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Network meta-analysis	Adults	Maintenance	quetiapine	mono	-0.38	0.2	IV (Very Low)	Kishi T., 2021 (NMA)	0.38	-0.76	0.01	lit	que	AE, Diarrhea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Adverse events, Diarrhea	"eSMD=-0.26 [-0.79, 0.25] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.86	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	20	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.26	0.27	III (Low)	Kishi T., 2021 (NMA)	0.26	-0.79	0.25	div	ola	AE, Diarrhea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Adverse events, Diarrhea	"eSMD=-0.23 [-0.68, 0.21] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.74	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	20	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	-0.23	0.23	III (Low)	Kishi T., 2021 (NMA)	0.23	-0.68	0.21	div	lit	AE, Diarrhea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Diarrhea	"eSMD=-0.03 [-0.63, 0.56] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=59.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	20	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.03	0.3	III (Low)	Kishi T., 2021 (NMA)	0.03	-0.63	0.56	lit	ola	AE, Diarrhea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Diarrhea	"eSMD=0.01 [-0.43, 0.43] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=177.25	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	20	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	0.01	0.22	III (Low)	Kishi T., 2021 (NMA)	-0.01	-0.43	0.43	lit	que	AE, Diarrhea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Adverse events, Diarrhea	"eSMD=0.53 [0.16, 0.92] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.42	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Network meta-analysis	Adults	Maintenance	lithium	mono	0.53	0.19	II (Moderate)	Kishi T., 2021 (NMA)	-0.53	0.16	0.92	lam	lit	AE, Diarrhea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Adverse events, Diarrhea	"eSMD=0.56 [-0.66, 1.77] <br> <img src=""https://www.linkpicture.com/q/Diapositive17.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.25	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	20	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	0.56	0.62	III (Low)	Kishi T., 2021 (NMA)	-0.56	-0.66	1.77	lam	lit	AE, Diarrhea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Adverse events, Diarrhea	"eSMD=0.63 [-0.31, 1.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive18.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.91	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	20	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	0.63	0.47	III (Low)	Kishi T., 2021 (NMA)	-0.63	-0.31	1.55	pal	que	AE, Diarrhea
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	lithium	Adverse events, Diarrhea	"eSMD=-0.47 [-0.68, -0.24] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.84	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	6	Pairwise meta-analysis	Mixed (Children-Adults)	Mania/Mixed	placebo	mono	-0.47	0.11	II (Moderate)	McKnight R.F., 2019 (MA)	0.47	-0.68	-0.24	lit	pbo	AE, Diarrhea
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	lithium	Adverse events, Diarrhea	"eSMD=-0.79 [-1.47, -0.06] <br> <img src=""https://www.linkpicture.com/q/Diapositive2.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.36	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Mixed (Children-Adults)	Mania/Mixed	risperidone	mono	-0.79	0.36	I (High)	McKnight R.F., 2019 (MA)	0.79	-1.47	-0.06	lit	risp	AE, Diarrhea
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	divalproate	Adverse events, Diarrhea	"eSMD=0.05 [-0.29, 0.38] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=35.46	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	4	Pairwise meta-analysis	Mixed (Children-Adults)	Mania/Mixed	lithium	mono	0.05	0.17	III (Low)	McKnight R.F., 2019 (MA)	-0.05	-0.29	0.38	div	lit	AE, Diarrhea
"<a href='https://doi.org/' target=""_blank"">Suttajit S., 2014 (MA)</a>"	quetiapine	Adverse events, Diarrhea	"eSMD=0.25 [-0.01, 0.51] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.13	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.25	0.13	III (Low)	Suttajit S., 2014 (MA)	-0.25	-0.01	0.51	que	pbo	AE, Diarrhea
"<a href='https://doi.org/' target=""_blank"">Chiesa A., 2012 (MA)</a>"	quetiapine	Adverse events, Dizziness	"eSMD=-0.49 [-0.63, -0.35] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.69	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Pairwise meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.49	0.07	II (Moderate)	Chiesa A., 2012 (MA)	0.49	-0.63	-0.35	que	pbo	AE, Dizziness
"<a href='https://doi.org/' target=""_blank"">Bartoli F., 2017 (MA)</a>"	allopurinol	Adverse events, Dizziness	"eSMD=-0.06 [-0.4, 0.28] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=29.55	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	aug	-0.06	0.17	IV (Very Low)	Bartoli F., 2017 (MA)	0.06	-0.4	0.28	allopur	pbo	AE, Dizziness
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2019 (MA)</a>"	ramelteon	Adverse events, Dizziness	"eSMD=-0.04 [-0.72, 0.63] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=44.32	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Maintenance	placebo	mono	-0.04	0.34	III (Low)	Kishi T., 2019 (MA)	0.04	-0.72	0.63	ram	pbo	AE, Dizziness
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2020 (NMA)</a>"	lurasidone	Adverse events, Dizziness	"eSMD=0.35 [-0.32, 1.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.12	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.35	0.34	IV (Very Low)	Kishi T., 2020 (NMA)	-0.35	-0.32	1.01	lur	pbo	AE, Dizziness
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2020 (NMA)</a>"	olanzapine	Adverse events, Dizziness	"eSMD=-0.04 [-0.56, 0.48] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=44.32	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.04	0.27	IV (Very Low)	Kishi T., 2020 (NMA)	0.04	-0.56	0.48	ola	pbo	AE, Dizziness
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Adverse events, Dizziness	"eSMD=-0.03 [-0.25, 0.2] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=59.09	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	33	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.03	0.11	II (Moderate)	Kishi T., 2021 (NMA)	0.03	-0.25	0.2	ari	pbo	AE, Dizziness
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Dizziness	"eSMD=-0.13 [-0.44, 0.17] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=13.65	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	33	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.13	0.16	II (Moderate)	Kishi T., 2021 (NMA)	0.13	-0.44	0.17	lit	pbo	AE, Dizziness
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	risperidone	Adverse events, Dizziness	"eSMD=-0.25 [-0.55, 0.03] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.13	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	33	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.25	0.15	II (Moderate)	Kishi T., 2021 (NMA)	0.25	-0.55	0.03	risp	pbo	AE, Dizziness
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	cariprazine	Adverse events, Dizziness	"eSMD=-0.28 [-0.65, 0.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.37	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	33	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.28	0.19	II (Moderate)	Kishi T., 2021 (NMA)	0.28	-0.65	0.08	car	pbo	AE, Dizziness
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Adverse events, Dizziness	"eSMD=-0.32 [-0.72, 0.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.59	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	33	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.32	0.2	II (Moderate)	Kishi T., 2021 (NMA)	0.32	-0.72	0.08	pal	pbo	AE, Dizziness
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	tamoxifen	Adverse events, Dizziness	"eSMD=-0.38 [-1.55, 0.84] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.72	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	33	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.38	0.61	II (Moderate)	Kishi T., 2021 (NMA)	0.38	-1.55	0.84	tamox	pbo	AE, Dizziness
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Adverse events, Dizziness	"eSMD=-0.39 [-0.63, -0.16] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.6	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	33	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.39	0.12	I (High)	Kishi T., 2021 (NMA)	0.39	-0.63	-0.16	div	pbo	AE, Dizziness
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Adverse events, Dizziness	"eSMD=-0.48 [-0.68, -0.25] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.76	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	33	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.48	0.11	I (High)	Kishi T., 2021 (NMA)	0.48	-0.68	-0.25	ola	pbo	AE, Dizziness
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	ziprasidone	Adverse events, Dizziness	"eSMD=-0.52 [-0.89, -0.15] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.49	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	33	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.52	0.19	I (High)	Kishi T., 2021 (NMA)	0.52	-0.89	-0.15	zip	pbo	AE, Dizziness
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Adverse events, Dizziness	"eSMD=-0.53 [-1.05, -0.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.42	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	33	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.53	0.27	I (High)	Kishi T., 2021 (NMA)	0.53	-1.05	-0.01	hal	pbo	AE, Dizziness
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	asenapine	Adverse events, Dizziness	"eSMD=-0.58 [-0.83, -0.3] <br> <img src=""https://www.linkpicture.com/q/Diapositive4.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.14	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	33	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.58	0.14	I (High)	Kishi T., 2021 (NMA)	0.58	-0.83	-0.3	ase	pbo	AE, Dizziness
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	quetiapine	Adverse events, Dizziness	"eSMD=-0.61 [-0.89, -0.35] <br> <img src=""https://www.linkpicture.com/q/Diapositive4.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	33	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.61	0.14	I (High)	Kishi T., 2021 (NMA)	0.61	-0.89	-0.35	que	pbo	AE, Dizziness
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	carbamazepine	Adverse events, Dizziness	"eSMD=-0.7 [-0.92, -0.48] <br> <img src=""https://www.linkpicture.com/q/Diapositive3.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.64	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	33	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.7	0.11	I (High)	Kishi T., 2021 (NMA)	0.7	-0.92	-0.48	cbz	pbo	AE, Dizziness
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	brexpiprazole	Adverse events, Dizziness	"eSMD=-0.92 [-2.16, 0.27] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.06	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	33	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.92	0.62	II (Moderate)	Kishi T., 2021 (NMA)	0.92	-2.16	0.27	brex	pbo	AE, Dizziness
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Adverse events, Dizziness	"eSMD=-0.47 [-1.17, 0.23] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.84	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	33	Network meta-analysis	Adults	Mania/Mixed	oxcarbazepine	mono	-0.47	0.36	II (Moderate)	Kishi T., 2021 (NMA)	0.47	-1.17	0.23	div	oxc	AE, Dizziness
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Adverse events, Dizziness	"eSMD=-0.26 [-0.61, 0.1] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.86	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	33	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	-0.26	0.18	II (Moderate)	Kishi T., 2021 (NMA)	0.26	-0.61	0.1	div	lit	AE, Dizziness
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Adverse events, Dizziness	"eSMD=-0.21 [-0.49, 0.06] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=8.47	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	33	Network meta-analysis	Adults	Mania/Mixed	risperidone	mono	-0.21	0.14	II (Moderate)	Kishi T., 2021 (NMA)	0.21	-0.49	0.06	ola	risp	AE, Dizziness
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	asenapine	Adverse events, Dizziness	"eSMD=-0.1 [-0.33, 0.14] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=17.74	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	33	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.1	0.12	II (Moderate)	Kishi T., 2021 (NMA)	0.1	-0.33	0.14	ase	ola	AE, Dizziness
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Adverse events, Dizziness	"eSMD=-0.06 [-0.61, 0.51] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=29.55	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	33	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.06	0.29	II (Moderate)	Kishi T., 2021 (NMA)	0.06	-0.61	0.51	hal	ola	AE, Dizziness
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Adverse events, Dizziness	"eSMD=-0.02 [-0.53, 0.49] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=88.63	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	33	Network meta-analysis	Adults	Mania/Mixed	ziprasidone	mono	-0.02	0.26	II (Moderate)	Kishi T., 2021 (NMA)	0.02	-0.53	0.49	hal	zip	AE, Dizziness
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Adverse events, Dizziness	"eSMD=0.08 [-0.47, 0.63] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=22.17	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	33	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	0.08	0.28	II (Moderate)	Kishi T., 2021 (NMA)	-0.08	-0.47	0.63	hal	que	AE, Dizziness
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Adverse events, Dizziness	"eSMD=0.08 [-0.17, 0.33] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=22.17	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	33	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	0.08	0.13	II (Moderate)	Kishi T., 2021 (NMA)	-0.08	-0.17	0.33	div	ola	AE, Dizziness
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Adverse events, Dizziness	"eSMD=0.29 [-0.18, 0.65] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.15	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	33	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	0.29	0.21	II (Moderate)	Kishi T., 2021 (NMA)	-0.29	-0.18	0.65	pal	que	AE, Dizziness
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Dizziness	"eSMD=0.34 [-0.01, 0.68] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.26	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	33	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	0.34	0.18	II (Moderate)	Kishi T., 2021 (NMA)	-0.34	-0.01	0.68	lit	ola	AE, Dizziness
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Dizziness	"eSMD=0.48 [0.18, 0.79] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.76	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	33	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	0.48	0.16	I (High)	Kishi T., 2021 (NMA)	-0.48	0.18	0.79	lit	que	AE, Dizziness
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	lithium	Adverse events, Dizziness	"eSMD=-0.42 [-0.72, -0.1] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.28	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Pairwise meta-analysis	Mixed (Children-Adults)	Mania/Mixed	placebo	mono	-0.42	0.16	I (High)	McKnight R.F., 2019 (MA)	0.42	-0.72	-0.1	lit	pbo	AE, Dizziness
"<a href='https://doi.org/' target=""_blank"">Suttajit S., 2014 (MA)</a>"	quetiapine	Adverse events, Dizziness	"eSMD=-0.43 [-0.56, -0.3] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.19	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	6	Pairwise meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	-0.43	0.07	II (Moderate)	Suttajit S., 2014 (MA)	0.43	-0.56	-0.3	que	pbo	AE, Dizziness
"<a href='https://doi.org/' target=""_blank"">Zhang J., 2021 (MA)</a>"	ECT	Adverse events, Dizziness	"eSMD=-0.36 [-1.22, 0.52] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.98	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania	TAU	mono	-0.36	0.44	III (Low)	Zhang J., 2021 (MA)	0.36	-1.22	0.52	ECT	tau	AE, Dizziness
"<a href='https://doi.org/' target=""_blank"">Chiesa A., 2012 (MA)</a>"	quetiapine	Adverse events, Dry mouth	"eSMD=-0.98 [-1.12, -0.86] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1.95	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Pairwise meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.98	0.07	I (High)	Chiesa A., 2012 (MA)	0.98	-1.12	-0.86	que	pbo	AE, Dry mouth
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2020 (NMA)</a>"	olanzapine	Adverse events, Dry mouth	"eSMD=-0.22 [-0.72, 0.27] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=8.09	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.22	0.25	IV (Very Low)	Kishi T., 2020 (NMA)	0.22	-0.72	0.27	ola	pbo	AE, Dry mouth
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2020 (NMA)</a>"	lurasidone	Adverse events, Dry mouth	"eSMD=-0.35 [-1.65, 0.98] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.12	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.35	0.67	IV (Very Low)	Kishi T., 2020 (NMA)	0.35	-1.65	0.98	lur	pbo	AE, Dry mouth
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Adverse events, Dry mouth	"eSMD=0.39 [-0.92, 1.77] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.6	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	7	Network meta-analysis	Adults	Maintenance	placebo	mono	0.39	0.69	IV (Very Low)	Kishi T., 2021 (NMA)	-0.39	-0.92	1.77	pal	pbo	AE, Dry mouth
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Adverse events, Dry mouth	"eSMD=0.13 [-0.37, 0.63] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=13.65	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	7	Network meta-analysis	Adults	Maintenance	placebo	mono	0.13	0.26	IV (Very Low)	Kishi T., 2021 (NMA)	-0.13	-0.37	0.63	div	pbo	AE, Dry mouth
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Dry mouth	"eSMD=0.01 [-0.53, 0.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=177.25	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	16	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.01	0.28	III (Low)	Kishi T., 2021 (NMA)	-0.01	-0.53	0.55	lit	pbo	AE, Dry mouth
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Adverse events, Dry mouth	"eSMD=0.01 [-0.48, 0.49] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=177.25	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	16	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.01	0.25	III (Low)	Kishi T., 2021 (NMA)	-0.01	-0.48	0.49	pal	pbo	AE, Dry mouth
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	asenapine	Adverse events, Dry mouth	"eSMD=0 [-2.16, 2.16] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	7	Network meta-analysis	Adults	Maintenance	placebo	mono	0	1.1	IV (Very Low)	Kishi T., 2021 (NMA)	0	-2.16	2.16	ase	pbo	AE, Dry mouth
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Adverse events, Dry mouth	"eSMD=-0.02 [-0.45, 0.42] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=88.63	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	16	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.02	0.22	III (Low)	Kishi T., 2021 (NMA)	0.02	-0.45	0.42	div	pbo	AE, Dry mouth
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Adverse events, Dry mouth	"eSMD=-0.25 [-0.83, 0.33] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.13	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	16	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.25	0.3	III (Low)	Kishi T., 2021 (NMA)	0.25	-0.83	0.33	hal	pbo	AE, Dry mouth
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	asenapine	Adverse events, Dry mouth	"eSMD=-0.27 [-0.65, 0.48] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.6	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	16	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.27	0.29	III (Low)	Kishi T., 2021 (NMA)	0.27	-0.65	0.48	ase	pbo	AE, Dry mouth
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Dry mouth	"eSMD=-0.38 [-0.86, 0.1] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.72	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	7	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.38	0.24	IV (Very Low)	Kishi T., 2021 (NMA)	0.38	-0.86	0.1	lit	pbo	AE, Dry mouth
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	tamoxifen	Adverse events, Dry mouth	"eSMD=-0.38 [-1.65, 0.86] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.72	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	16	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.38	0.64	III (Low)	Kishi T., 2021 (NMA)	0.38	-1.65	0.86	tamox	pbo	AE, Dry mouth
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Adverse events, Dry mouth	"eSMD=-0.49 [-1.65, 0.72] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.69	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	7	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.49	0.6	IV (Very Low)	Kishi T., 2021 (NMA)	0.49	-1.65	0.72	ola	pbo	AE, Dry mouth
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	quetiapine	Adverse events, Dry mouth	"eSMD=-0.7 [-1.33, -0.09] <br> <img src=""https://www.linkpicture.com/q/Diapositive3.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.64	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	7	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.7	0.32	III (Low)	Kishi T., 2021 (NMA)	0.7	-1.33	-0.09	que	pbo	AE, Dry mouth
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	quetiapine	Adverse events, Dry mouth	"eSMD=-0.7 [-0.98, -0.44] <br> <img src=""https://www.linkpicture.com/q/Diapositive3.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.64	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	16	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.7	0.14	I (High)	Kishi T., 2021 (NMA)	0.7	-0.98	-0.44	que	pbo	AE, Dry mouth
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Adverse events, Dry mouth	"eSMD=-0.72 [-1.05, -0.42] <br> <img src=""https://www.linkpicture.com/q/Diapositive2.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.57	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	16	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.72	0.16	I (High)	Kishi T., 2021 (NMA)	0.72	-1.05	-0.42	ola	pbo	AE, Dry mouth
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	carbamazepine	Adverse events, Dry mouth	"eSMD=-0.76 [-1.47, -0.06] <br> <img src=""https://www.linkpicture.com/q/Diapositive2.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.44	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	16	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.76	0.36	I (High)	Kishi T., 2021 (NMA)	0.76	-1.47	-0.06	cbz	pbo	AE, Dry mouth
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Adverse events, Dry mouth	"eSMD=-1.05 [-2.16, 0.12] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1.84	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	7	Network meta-analysis	Adults	Maintenance	placebo	mono	-1.05	0.58	IV (Very Low)	Kishi T., 2021 (NMA)	1.05	-2.16	0.12	ari	pbo	AE, Dry mouth
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Adverse events, Dry mouth	"eSMD=-0.39 [-0.72, -0.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.6	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	16	Network meta-analysis	Adults	Mania/Mixed	risperidone	mono	-0.39	0.17	I (High)	Kishi T., 2021 (NMA)	0.39	-0.72	-0.05	ola	risp	AE, Dry mouth
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Adverse events, Dry mouth	"eSMD=-0.38 [-1.65, 0.93] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.72	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	16	Network meta-analysis	Adults	Mania/Mixed	oxcarbazepine	mono	-0.38	0.66	III (Low)	Kishi T., 2021 (NMA)	0.38	-1.65	0.93	div	oxc	AE, Dry mouth
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	cariprazine	Adverse events, Dry mouth	"eSMD=0.34 [-0.02, 0.7] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.26	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	7	Network meta-analysis	Adults	Maintenance	lithium	mono	0.34	0.18	IV (Very Low)	Kishi T., 2021 (NMA)	-0.34	-0.02	0.7	car	lit	AE, Dry mouth
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Adverse events, Dry mouth	"eSMD=0.47 [-0.12, 1.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.84	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	16	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	0.47	0.3	III (Low)	Kishi T., 2021 (NMA)	-0.47	-0.12	1.05	hal	que	AE, Dry mouth
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Adverse events, Dry mouth	"eSMD=0.48 [-0.14, 1.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.76	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	16	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	0.48	0.31	III (Low)	Kishi T., 2021 (NMA)	-0.48	-0.14	1.08	hal	ola	AE, Dry mouth
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Adverse events, Dry mouth	"eSMD=0.51 [0.1, 0.93] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.55	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	7	Network meta-analysis	Adults	Maintenance	lithium	mono	0.51	0.21	III (Low)	Kishi T., 2021 (NMA)	-0.51	0.1	0.93	div	lit	AE, Dry mouth
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	asenapine	Adverse events, Dry mouth	"eSMD=0.65 [0.17, 1.12] <br> <img src=""https://www.linkpicture.com/q/Diapositive18.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.82	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	16	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	0.65	0.24	I (High)	Kishi T., 2021 (NMA)	-0.65	0.17	1.12	ase	ola	AE, Dry mouth
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Adverse events, Dry mouth	"eSMD=0.71 [0.38, 1.04] <br> <img src=""https://www.linkpicture.com/q/Diapositive18.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.6	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	16	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	0.71	0.17	I (High)	Kishi T., 2021 (NMA)	-0.71	0.38	1.04	div	ola	AE, Dry mouth
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Dry mouth	"eSMD=0.72 [0.22, 1.22] <br> <img src=""https://www.linkpicture.com/q/Diapositive19.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.57	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	16	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	0.72	0.26	I (High)	Kishi T., 2021 (NMA)	-0.72	0.22	1.22	lit	que	AE, Dry mouth
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Adverse events, Dry mouth	"eSMD=0.72 [0.27, 1.17] <br> <img src=""https://www.linkpicture.com/q/Diapositive19.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.57	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	16	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	0.72	0.23	I (High)	Kishi T., 2021 (NMA)	-0.72	0.27	1.17	pal	que	AE, Dry mouth
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Dry mouth	"eSMD=0.74 [0.13, 1.33] <br> <img src=""https://www.linkpicture.com/q/Diapositive19.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.5	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	16	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	0.74	0.31	I (High)	Kishi T., 2021 (NMA)	-0.74	0.13	1.33	lit	ola	AE, Dry mouth
"<a href='https://doi.org/' target=""_blank"">Nunez N.A., 2020 (MA)</a>"	armodafinil	Adverse events, Dry mouth	"eSMD=-0.43 [-0.81, -0.06] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.19	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.43	0.19	I (High)	Nunez N.A., 2020 (MA)	0.43	-0.81	-0.06	armo	pbo	AE, Dry mouth
"<a href='https://doi.org/' target=""_blank"">Suttajit S., 2014 (MA)</a>"	quetiapine	Adverse events, Dry mouth	"eSMD=-0.72 [-0.81, -0.61] <br> <img src=""https://www.linkpicture.com/q/Diapositive2.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.57	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	6	Pairwise meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	-0.72	0.05	II (Moderate)	Suttajit S., 2014 (MA)	0.72	-0.81	-0.61	que	pbo	AE, Dry mouth
"<a href='https://doi.org/' target=""_blank"">Zhang J., 2021 (MA)</a>"	ECT	Adverse events, Dry mouth	"eSMD=-0.07 [-0.49, 0.36] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=25.33	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania	TAU	mono	-0.07	0.22	IV (Very Low)	Zhang J., 2021 (MA)	0.07	-0.49	0.36	ECT	tau	AE, Dry mouth
"<a href='https://doi.org/' target=""_blank"">Vita A., 2013 (MA)</a>"	asenapine	Adverse events, Dyskinesia	"eSMD=-0.89 [-2.16, 0.32] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.12	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.89	0.63	IV (Very Low)	Vita A., 2013 (MA)	0.89	-2.16	0.32	ase	ola	AE, Dyskinesia
"<a href='https://doi.org/' target=""_blank"">Jochim J., 2019 (MA)</a>"	divalproate	Adverse events, Dyspepsia	"eSMD=-0.43 [-0.81, -0.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.19	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.43	0.19	I (High)	Jochim J., 2019 (MA)	0.43	-0.81	-0.05	div	pbo	AE, Dyspepsia
"<a href='https://doi.org/' target=""_blank"">Vita A., 2013 (MA)</a>"	asenapine	Adverse events, Dystonia	"eSMD=-0.35 [-0.92, 0.23] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.12	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.35	0.29	IV (Very Low)	Vita A., 2013 (MA)	0.35	-0.92	0.23	ase	ola	AE, Dystonia
"<a href='https://doi.org/' target=""_blank"">Jochim J., 2019 (MA)</a>"	divalproate	Adverse events, Dysuria	"eSMD=-0.09 [-1.77, 1.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=19.71	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.09	0.85	III (Low)	Jochim J., 2019 (MA)	0.09	-1.77	1.55	div	pbo	AE, Dysuria
"<a href='https://doi.org/' target=""_blank"">Zhang J., 2021 (MA)</a>"	ECT	Adverse events, ECG change	"eSMD=0.11 [-0.58, 0.81] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=16.13	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania	TAU	mono	0.11	0.35	IV (Very Low)	Zhang J., 2021 (MA)	-0.11	-0.58	0.81	ECT	tau	AE, ECG change
"<a href='https://doi.org/' target=""_blank"">Jochim J., 2019 (MA)</a>"	divalproate	Adverse events, Enuresis	"eSMD=-0.56 [-Inf, 2.54] <br> <img src=""https://www.linkpicture.com/q/Diapositive4.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.25	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Children & Adolescents	Mania/Mixed	risperidone	mono	-0.56	Inf	IV (Very Low)	Jochim J., 2019 (MA)	0.56	-Inf	2.54	div	risp	AE, Enuresis
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Adverse events, Extrapiramidal symptoms/Medication use, Anticholinergic agents use	"eSMD=-0.01 [-0.58, 0.58] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=177.25	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	14	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.01	0.3	IV (Very Low)	Kishi T., 2021 (NMA)	0.01	-0.58	0.58	ola	pbo	AE, Extrapiramidal sxs/Anticholinergic
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Adverse events, Extrapiramidal symptoms/Medication use, Anticholinergic agents use	"eSMD=-0.04 [-0.51, 0.44] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=44.32	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	14	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.04	0.24	IV (Very Low)	Kishi T., 2021 (NMA)	0.04	-0.51	0.44	lam	pbo	AE, Extrapiramidal sxs/Anticholinergic
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	quetiapine	Adverse events, Extrapiramidal symptoms/Medication use, Anticholinergic agents use	"eSMD=-0.1 [-0.47, 0.26] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=17.74	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	14	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.1	0.19	IV (Very Low)	Kishi T., 2021 (NMA)	0.1	-0.47	0.26	que	pbo	AE, Extrapiramidal sxs/Anticholinergic
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	risperidone LAI	Adverse events, Extrapiramidal symptoms/Medication use, Anticholinergic agents use	"eSMD=-0.26 [-0.58, 0.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.86	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	14	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.26	0.29	IV (Very Low)	Kishi T., 2021 (NMA)	0.26	-0.58	0.55	rispLAI	pbo	AE, Extrapiramidal sxs/Anticholinergic
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole LAI	Adverse events, Extrapiramidal symptoms/Medication use, Anticholinergic agents use	"eSMD=-0.27 [-0.59, 0.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.6	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	14	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.27	0.16	IV (Very Low)	Kishi T., 2021 (NMA)	0.27	-0.59	0.05	ariLAI	pbo	AE, Extrapiramidal sxs/Anticholinergic
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Adverse events, Extrapiramidal symptoms/Medication use, Anticholinergic agents use	"eSMD=-0.37 [-1.65, 0.95] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.85	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	14	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.37	0.66	IV (Very Low)	Kishi T., 2021 (NMA)	0.37	-1.65	0.95	pal	pbo	AE, Extrapiramidal sxs/Anticholinergic
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	asenapine	Adverse events, Extrapiramidal symptoms/Medication use, Anticholinergic agents use	"eSMD=-0.61 [-1.93, 0.65] <br> <img src=""https://www.linkpicture.com/q/Diapositive4.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	14	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.61	0.66	IV (Very Low)	Kishi T., 2021 (NMA)	0.61	-1.93	0.65	ase	pbo	AE, Extrapiramidal sxs/Anticholinergic
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Adverse events, Extrapiramidal symptoms/Medication use, Anticholinergic agents use	"eSMD=-0.61 [-0.92, -0.32] <br> <img src=""https://www.linkpicture.com/q/Diapositive4.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	14	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.61	0.15	II (Moderate)	Kishi T., 2021 (NMA)	0.61	-0.92	-0.32	div	pbo	AE, Extrapiramidal sxs/Anticholinergic
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Extrapiramidal symptoms/Medication use, Anticholinergic agents use	"eSMD=-0.66 [-0.92, -0.42] <br> <img src=""https://www.linkpicture.com/q/Diapositive3.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.78	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	14	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.66	0.13	II (Moderate)	Kishi T., 2021 (NMA)	0.66	-0.92	-0.42	lit	pbo	AE, Extrapiramidal sxs/Anticholinergic
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Adverse events, Extrapiramidal symptoms/Medication use, Anticholinergic agents use	"eSMD=-1.12 [-2.16, 0.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1.75	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	14	Network meta-analysis	Adults	Maintenance	placebo	mono	-1.12	0.56	IV (Very Low)	Kishi T., 2021 (NMA)	1.12	-2.16	0.05	ari	pbo	AE, Extrapiramidal sxs/Anticholinergic
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Extrapiramidal symptoms/Medication use, Anticholinergic agents use	"eSMD=-0.56 [-0.92, -0.21] <br> <img src=""https://www.linkpicture.com/q/Diapositive4.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.25	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	14	Network meta-analysis	Adults	Maintenance	quetiapine	mono	-0.56	0.18	II (Moderate)	Kishi T., 2021 (NMA)	0.56	-0.92	-0.21	lit	que	AE, Extrapiramidal sxs/Anticholinergic
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole+divalproate	Adverse events, Extrapiramidal symptoms/Medication use, Anticholinergic agents use	"eSMD=-0.42 [-1.77, 0.89] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.28	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	14	Network meta-analysis	Adults	Maintenance	divalproate	mono	-0.42	0.68	IV (Very Low)	Kishi T., 2021 (NMA)	0.42	-1.77	0.89	ari+div	div	AE, Extrapiramidal sxs/Anticholinergic
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole+lamotrigine	Adverse events, Extrapiramidal symptoms/Medication use, Anticholinergic agents use	"eSMD=-0.31 [-0.68, 0.07] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.76	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	14	Network meta-analysis	Adults	Maintenance	lamotrigine	mono	-0.31	0.19	IV (Very Low)	Kishi T., 2021 (NMA)	0.31	-0.68	0.07	ari+lam	lam	AE, Extrapiramidal sxs/Anticholinergic
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Adverse events, Extrapiramidal symptoms/Medication use, Anticholinergic agents use	"eSMD=0.04 [-0.2, 0.28] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=44.32	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	14	Network meta-analysis	Adults	Maintenance	lithium	mono	0.04	0.12	IV (Very Low)	Kishi T., 2021 (NMA)	-0.04	-0.2	0.28	div	lit	AE, Extrapiramidal sxs/Anticholinergic
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Adverse events, Extrapiramidal symptoms/Medication use, Anticholinergic agents use	"eSMD=0.63 [0.19, 1.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive18.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.91	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	14	Network meta-analysis	Adults	Maintenance	lithium	mono	0.63	0.23	II (Moderate)	Kishi T., 2021 (NMA)	-0.63	0.19	1.08	lam	lit	AE, Extrapiramidal sxs/Anticholinergic
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	cariprazine	Adverse events, Extrapiramidal symptoms/Medication use, Anticholinergic agents use	"eSMD=1.08 [0.27, 1.93] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.8	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	14	Network meta-analysis	Adults	Maintenance	lithium	mono	1.08	0.42	II (Moderate)	Kishi T., 2021 (NMA)	-1.08	0.27	1.93	car	lit	AE, Extrapiramidal sxs/Anticholinergic
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2006 (MA)</a>"	haloperidol+lithium/divalproate	Adverse events, Extrapyramidal symptoms	"eSMD=-1.05 [-1.65, -0.4] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1.84	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo+lithium/divalproate	combo	-1.05	0.32	I (High)	Cipriani A., 2006 (MA)	1.05	-1.65	-0.4	hal+lit/div	pbo+lit/div	AE, Extrapyramidal symptoms
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	aripiprazole	Adverse events, Extrapyramidal symptoms	"eSMD=-0.37 [-0.72, 0.02] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.85	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.37	0.19	III (Low)	Kadakia A., 2021 (NMA)	0.37	-0.72	0.02	ari	pbo	AE, Extrapyramidal symptoms
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	cariprazine	Adverse events, Extrapyramidal symptoms	"eSMD=-0.45 [-0.74, -0.13] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.01	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.45	0.16	II (Moderate)	Kadakia A., 2021 (NMA)	0.45	-0.74	-0.13	car	pbo	AE, Extrapyramidal symptoms
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	quetiapine	Adverse events, Extrapyramidal symptoms	"eSMD=-0.56 [-0.83, -0.26] <br> <img src=""https://www.linkpicture.com/q/Diapositive4.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.25	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.56	0.15	II (Moderate)	Kadakia A., 2021 (NMA)	0.56	-0.83	-0.26	que	pbo	AE, Extrapyramidal symptoms
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	lurasidone	Adverse events, Extrapyramidal symptoms	"eSMD=-0.79 [-1.39, -0.03] <br> <img src=""https://www.linkpicture.com/q/Diapositive2.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.36	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.79	0.35	II (Moderate)	Kadakia A., 2021 (NMA)	0.79	-1.39	-0.03	lur	pbo	AE, Extrapyramidal symptoms
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2020 (NMA)</a>"	olanzapine	Adverse events, Extrapyramidal symptoms	"eSMD=-0.25 [-0.59, 0.09] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.13	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.25	0.17	IV (Very Low)	Kishi T., 2020 (NMA)	0.25	-0.59	0.09	ola	pbo	AE, Extrapyramidal symptoms
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	quetiapine	Adverse events, Extrapyramidal symptoms	"eSMD=-0.03 [-0.27, 0.22] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=59.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.03	0.12	III (Low)	Kishi T., 2021 (NMA)	0.03	-0.27	0.22	que	pbo	AE, Extrapyramidal symptoms
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Adverse events, Extrapyramidal symptoms	"eSMD=-0.13 [-0.55, 0.28] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=13.65	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.13	0.21	III (Low)	Kishi T., 2021 (NMA)	0.13	-0.55	0.28	pal	pbo	AE, Extrapyramidal symptoms
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Adverse events, Extrapyramidal symptoms	"eSMD=-0.33 [-0.65, -0.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.42	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.33	0.16	II (Moderate)	Kishi T., 2021 (NMA)	0.33	-0.65	-0.01	ola	pbo	AE, Extrapyramidal symptoms
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Extrapyramidal symptoms	"eSMD=-0.39 [-0.61, -0.17] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.6	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.39	0.11	I (High)	Kishi T., 2021 (NMA)	0.39	-0.61	-0.17	lit	pbo	AE, Extrapyramidal symptoms
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Adverse events, Extrapyramidal symptoms	"eSMD=-0.48 [-0.63, -0.32] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.76	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.48	0.08	I (High)	Kishi T., 2021 (NMA)	0.48	-0.63	-0.32	ari	pbo	AE, Extrapyramidal symptoms
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	asenapine	Adverse events, Extrapyramidal symptoms	"eSMD=-0.49 [-0.81, -0.17] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.69	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.49	0.16	I (High)	Kishi T., 2021 (NMA)	0.49	-0.81	-0.17	ase	pbo	AE, Extrapyramidal symptoms
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	cariprazine	Adverse events, Extrapyramidal symptoms	"eSMD=-0.53 [-0.81, -0.25] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.42	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.53	0.14	I (High)	Kishi T., 2021 (NMA)	0.53	-0.81	-0.25	car	pbo	AE, Extrapyramidal symptoms
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	risperidone	Adverse events, Extrapyramidal symptoms	"eSMD=-0.59 [-0.83, -0.34] <br> <img src=""https://www.linkpicture.com/q/Diapositive4.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.09	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.59	0.12	I (High)	Kishi T., 2021 (NMA)	0.59	-0.83	-0.34	risp	pbo	AE, Extrapyramidal symptoms
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Adverse events, Extrapyramidal symptoms	"eSMD=-0.65 [-1.27, 0.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive3.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.82	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.65	0.33	III (Low)	Kishi T., 2021 (NMA)	0.65	-1.27	0.01	lam	pbo	AE, Extrapyramidal symptoms
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	ziprasidone	Adverse events, Extrapyramidal symptoms	"eSMD=-0.66 [-0.95, -0.36] <br> <img src=""https://www.linkpicture.com/q/Diapositive3.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.78	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.66	0.15	I (High)	Kishi T., 2021 (NMA)	0.66	-0.95	-0.36	zip	pbo	AE, Extrapyramidal symptoms
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Adverse events, Extrapyramidal symptoms	"eSMD=-0.92 [-1.08, -0.76] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.06	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.92	0.08	I (High)	Kishi T., 2021 (NMA)	0.92	-1.08	-0.76	hal	pbo	AE, Extrapyramidal symptoms
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Adverse events, Extrapyramidal symptoms	"eSMD=-0.89 [-1.17, -0.65] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.12	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	-0.89	0.13	I (High)	Kishi T., 2021 (NMA)	0.89	-1.17	-0.65	hal	que	AE, Extrapyramidal symptoms
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Adverse events, Extrapyramidal symptoms	"eSMD=-0.59 [-0.95, -0.25] <br> <img src=""https://www.linkpicture.com/q/Diapositive4.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.09	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.59	0.18	I (High)	Kishi T., 2021 (NMA)	0.59	-0.95	-0.25	hal	ola	AE, Extrapyramidal symptoms
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Adverse events, Extrapyramidal symptoms	"eSMD=-0.53 [-0.79, -0.28] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.42	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	-0.53	0.13	I (High)	Kishi T., 2021 (NMA)	0.53	-0.79	-0.28	hal	lit	AE, Extrapyramidal symptoms
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole+lithium/divalproate	Adverse events, Extrapyramidal symptoms	"eSMD=-0.51 [-1.12, 0.12] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.55	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	6	Network meta-analysis	Adults	Maintenance	placebo+lithium/divalproate	combo	-0.51	0.32	IV (Very Low)	Kishi T., 2021 (NMA)	0.51	-1.12	0.12	ari+lit/div	pbo+lit/div	AE, Extrapyramidal symptoms
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Extrapyramidal symptoms	"eSMD=-0.36 [-0.65, -0.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.98	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	-0.36	0.15	II (Moderate)	Kishi T., 2021 (NMA)	0.36	-0.65	-0.08	lit	que	AE, Extrapyramidal symptoms
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Adverse events, Extrapyramidal symptoms	"eSMD=-0.33 [-0.58, -0.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.42	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	risperidone	mono	-0.33	0.13	II (Moderate)	Kishi T., 2021 (NMA)	0.33	-0.58	-0.08	hal	risp	AE, Extrapyramidal symptoms
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	ziprasidone+lithium/divalproate	Adverse events, Extrapyramidal symptoms	"eSMD=-0.31 [-0.95, 0.33] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.76	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	6	Network meta-analysis	Adults	Maintenance	placebo+lithium/divalproate	combo	-0.31	0.33	IV (Very Low)	Kishi T., 2021 (NMA)	0.31	-0.95	0.33	zip+lit/div	pbo+lit/div	AE, Extrapyramidal symptoms
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine+lithium/divalproate	Adverse events, Extrapyramidal symptoms	"eSMD=-0.27 [-0.92, 0.37] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.6	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	6	Network meta-analysis	Adults	Maintenance	placebo+lithium/divalproate	combo	-0.27	0.33	IV (Very Low)	Kishi T., 2021 (NMA)	0.27	-0.92	0.37	ola+lit/div	pbo+lit/div	AE, Extrapyramidal symptoms
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Adverse events, Extrapyramidal symptoms	"eSMD=-0.26 [-0.53, 0.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.86	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	ziprasidone	mono	-0.26	0.14	III (Low)	Kishi T., 2021 (NMA)	0.26	-0.53	0.01	hal	zip	AE, Extrapyramidal symptoms
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Adverse events, Extrapyramidal symptoms	"eSMD=-0.25 [-0.89, 0.39] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.13	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	-0.25	0.33	III (Low)	Kishi T., 2021 (NMA)	0.25	-0.89	0.39	lam	lit	AE, Extrapyramidal symptoms
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lurasidone+lithium/divalproate	Adverse events, Extrapyramidal symptoms	"eSMD=-0.2 [-0.56, 0.16] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=8.89	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	6	Network meta-analysis	Adults	Maintenance	placebo+lithium/divalproate	combo	-0.2	0.18	IV (Very Low)	Kishi T., 2021 (NMA)	0.2	-0.56	0.16	lur+lit/div	pbo+lit/div	AE, Extrapyramidal symptoms
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	asenapine	Adverse events, Extrapyramidal symptoms	"eSMD=-0.16 [-0.44, 0.12] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=11.1	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.16	0.14	III (Low)	Kishi T., 2021 (NMA)	0.16	-0.44	0.12	ase	ola	AE, Extrapyramidal symptoms
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Adverse events, Extrapyramidal symptoms	"eSMD=-0.1 [-0.55, 0.34] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=17.74	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	-0.1	0.23	III (Low)	Kishi T., 2021 (NMA)	0.1	-0.55	0.34	pal	que	AE, Extrapyramidal symptoms
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Adverse events, Extrapyramidal symptoms	"eSMD=-0.08 [-0.32, 0.15] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=22.17	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	-0.08	0.12	III (Low)	Kishi T., 2021 (NMA)	0.08	-0.32	0.15	ari	lit	AE, Extrapyramidal symptoms
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Extrapyramidal symptoms	"eSMD=-0.06 [-0.42, 0.29] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=29.55	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.06	0.18	III (Low)	Kishi T., 2021 (NMA)	0.06	-0.42	0.29	lit	ola	AE, Extrapyramidal symptoms
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	quetiapine+lithium/divalproate	Adverse events, Extrapyramidal symptoms	"eSMD=-0.03 [-0.25, 0.19] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=59.09	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	6	Network meta-analysis	Adults	Maintenance	placebo+lithium/divalproate	combo	-0.03	0.11	IV (Very Low)	Kishi T., 2021 (NMA)	0.03	-0.25	0.19	que+lit/div	pbo+lit/div	AE, Extrapyramidal symptoms
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Adverse events, Extrapyramidal symptoms	"eSMD=0.45 [0.28, 0.63] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.01	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	haloperidol	mono	0.45	0.09	I (High)	Kishi T., 2021 (NMA)	-0.45	0.28	0.63	ari	hal	AE, Extrapyramidal symptoms
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Adverse events, Extrapyramidal symptoms	"eSMD=0.67 [0.07, 1.27] <br> <img src=""https://www.linkpicture.com/q/Diapositive18.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.74	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	0.67	0.31	I (High)	Kishi T., 2021 (NMA)	-0.67	0.07	1.27	div	ola	AE, Extrapyramidal symptoms
"<a href='https://doi.org/' target=""_blank"">Meduri M., 2016 (MA)</a>"	aripiprazole	Adverse events, Extrapyramidal symptoms	"eSMD=-0.55 [-1.65, 0.52] <br> <img src=""https://www.linkpicture.com/q/Diapositive4.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.3	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Children & Adolescents	Mania/Mixed	placebo	mono	-0.55	0.55	II (Moderate)	Meduri M., 2016 (MA)	0.55	-1.65	0.52	ari	pbo	AE, Extrapyramidal symptoms
"<a href='https://doi.org/' target=""_blank"">Meduri M., 2016 (MA)</a>"	aripiprazole	Adverse events, Extrapyramidal symptoms	"eSMD=-0.63 [-0.83, -0.45] <br> <img src=""https://www.linkpicture.com/q/Diapositive3.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.91	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	aug	-0.63	0.1	I (High)	Meduri M., 2016 (MA)	0.63	-0.83	-0.45	ari	pbo	AE, Extrapyramidal symptoms
"<a href='https://doi.org/' target=""_blank"">Rendell J.M., 2010 (MA)</a>"	risperidone	Adverse events, Extrapyramidal symptoms	"eSMD=-0.35 [-1.01, 0.32] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.12	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	aug	-0.35	0.34	III (Low)	Rendell J.M., 2010 (MA)	0.35	-1.01	0.32	risp	pbo	AE, Extrapyramidal symptoms
"<a href='https://doi.org/' target=""_blank"">Suttajit S., 2014 (MA)</a>"	quetiapine	Adverse events, Extrapyramidal symptoms	"eSMD=-0.56 [-0.7, -0.42] <br> <img src=""https://www.linkpicture.com/q/Diapositive4.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.25	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	6	Pairwise meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	-0.56	0.07	II (Moderate)	Suttajit S., 2014 (MA)	0.56	-0.7	-0.42	que	pbo	AE, Extrapyramidal symptoms
"<a href='https://doi.org/' target=""_blank"">De Fruyt , 2012 (MA)</a>"	aripiprazole	Adverse events, Fatigue	"eSMD=-0.36 [-0.63, -0.09] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.98	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.36	0.14	I (High)	De Fruyt , 2012 (MA)	0.36	-0.63	-0.09	ari	pbo	AE, Fatigue
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2019 (MA)</a>"	ramelteon	Adverse events, Fatigue	"eSMD=0.25 [-0.33, 0.81] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.13	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Maintenance	placebo	mono	0.25	0.29	III (Low)	Kishi T., 2019 (MA)	-0.25	-0.33	0.81	ram	pbo	AE, Fatigue
"<a href='https://doi.org/' target=""_blank"">Suttajit S., 2014 (MA)</a>"	quetiapine	Adverse events, Fatigue	"eSMD=-0.25 [-0.42, -0.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.13	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	4	Pairwise meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	-0.25	0.09	II (Moderate)	Suttajit S., 2014 (MA)	0.25	-0.42	-0.08	que	pbo	AE, Fatigue
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	lithium	Adverse events, Fever	"eSMD=-0.27 [-0.7, 0.16] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.6	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.27	0.22	III (Low)	McKnight R.F., 2019 (MA)	0.27	-0.7	0.16	lit	pbo	AE, Fever
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	lithium	Adverse events, Frequent urination	"eSMD=-0.92 [-1.39, -0.42] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.06	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Mixed (Children-Adults)	Mania/Mixed	risperidone	mono	-0.92	0.25	I (High)	McKnight R.F., 2019 (MA)	0.92	-1.39	-0.42	lit	risp	AE, Frequent urination
"<a href='https://doi.org/' target=""_blank"">Vita A., 2013 (MA)</a>"	asenapine	Adverse events, Gait disturbance	"eSMD=-0.4 [-1.33, 0.51] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.49	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.4	0.47	IV (Very Low)	Vita A., 2013 (MA)	0.4	-1.33	0.51	ase	ola	AE, Gait disturbance
"<a href='https://doi.org/' target=""_blank"">Meduri M., 2016 (MA)</a>"	aripiprazole	Adverse events, Gastroenteric disturbance	"eSMD=0.17 [-0.32, 0.65] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=10.45	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	aug	0.17	0.25	II (Moderate)	Meduri M., 2016 (MA)	-0.17	-0.32	0.65	ari	pbo	AE, Gastroenteric disturbance
"<a href='https://doi.org/' target=""_blank"">Meduri M., 2016 (MA)</a>"	aripiprazole	Adverse events, Gastroenteric disturbance	"eSMD=-0.05 [-0.39, 0.3] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=35.46	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Children & Adolescents	Mania/Mixed	placebo	mono	-0.05	0.18	II (Moderate)	Meduri M., 2016 (MA)	0.05	-0.39	0.3	ari	pbo	AE, Gastroenteric disturbance
"<a href='https://doi.org/' target=""_blank"">Chiesa A., 2012 (MA)</a>"	quetiapine	Adverse events, Headache	"eSMD=0.3 [0.17, 0.42] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.95	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Pairwise meta-analysis	Adults	Bipolar Depression	placebo	mono	0.3	0.06	II (Moderate)	Chiesa A., 2012 (MA)	-0.3	0.17	0.42	que	pbo	AE, Headache
"<a href='https://doi.org/' target=""_blank"">Bartoli F., 2017 (MA)</a>"	allopurinol	Adverse events, Headache	"eSMD=0.2 [-0.28, 0.68] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.89	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	aug	0.2	0.24	IV (Very Low)	Bartoli F., 2017 (MA)	-0.2	-0.28	0.68	allopur	pbo	AE, Headache
"<a href='https://doi.org/' target=""_blank"">Jochim J., 2019 (MA)</a>"	divalproate	Adverse events, Headache	"eSMD=-0.04 [-0.53, 0.45] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=44.32	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Children & Adolescents	Mania/Mixed	placebo	mono	-0.04	0.25	III (Low)	Jochim J., 2019 (MA)	0.04	-0.53	0.45	div	pbo	AE, Headache
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2019 (MA)</a>"	ramelteon	Adverse events, Headache	"eSMD=0 [-0.32, 0.32] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Maintenance	placebo	mono	0	0.16	III (Low)	Kishi T., 2019 (MA)	0	-0.32	0.32	ram	pbo	AE, Headache
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	risperidone LAI	Adverse events, Headache	"eSMD=0.92 [0.08, 1.77] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.06	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	13	Network meta-analysis	Adults	Maintenance	placebo	mono	0.92	0.43	II (Moderate)	Kishi T., 2021 (NMA)	-0.92	0.08	1.77	rispLAI	pbo	AE, Headache
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole LAI	Adverse events, Headache	"eSMD=0.45 [-0.21, 1.12] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.01	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	13	Network meta-analysis	Adults	Maintenance	placebo	mono	0.45	0.34	IV (Very Low)	Kishi T., 2021 (NMA)	-0.45	-0.21	1.12	ariLAI	pbo	AE, Headache
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Adverse events, Headache	"eSMD=0.32 [-0.37, 1.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.59	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	13	Network meta-analysis	Adults	Maintenance	placebo	mono	0.32	0.35	IV (Very Low)	Kishi T., 2021 (NMA)	-0.32	-0.37	1.01	pal	pbo	AE, Headache
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	brexpiprazole	Adverse events, Headache	"eSMD=0.31 [-0.02, 0.63] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.76	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.31	0.17	II (Moderate)	Kishi T., 2021 (NMA)	-0.31	-0.02	0.63	brex	pbo	AE, Headache
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	tamoxifen	Adverse events, Headache	"eSMD=0.18 [-0.34, 0.7] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=9.87	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.18	0.27	II (Moderate)	Kishi T., 2021 (NMA)	-0.18	-0.34	0.7	tamox	pbo	AE, Headache
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Adverse events, Headache	"eSMD=0.1 [-0.07, 0.27] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=17.74	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.1	0.09	II (Moderate)	Kishi T., 2021 (NMA)	-0.1	-0.07	0.27	ola	pbo	AE, Headache
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Adverse events, Headache	"eSMD=0.05 [-0.08, 0.19] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=35.46	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.05	0.07	II (Moderate)	Kishi T., 2021 (NMA)	-0.05	-0.08	0.19	div	pbo	AE, Headache
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Adverse events, Headache	"eSMD=0.05 [-0.17, 0.26] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=35.46	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.05	0.11	II (Moderate)	Kishi T., 2021 (NMA)	-0.05	-0.17	0.26	hal	pbo	AE, Headache
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	carbamazepine	Adverse events, Headache	"eSMD=0.03 [-0.24, 0.31] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=59.09	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.03	0.14	II (Moderate)	Kishi T., 2021 (NMA)	-0.03	-0.24	0.31	cbz	pbo	AE, Headache
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	quetiapine	Adverse events, Headache	"eSMD=0.02 [-0.16, 0.21] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=88.63	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.02	0.09	II (Moderate)	Kishi T., 2021 (NMA)	-0.02	-0.16	0.21	que	pbo	AE, Headache
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	asenapine	Adverse events, Headache	"eSMD=-0.03 [-1.22, 0.76] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=59.09	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	13	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.03	0.51	IV (Very Low)	Kishi T., 2021 (NMA)	0.03	-1.22	0.76	ase	pbo	AE, Headache
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	risperidone	Adverse events, Headache	"eSMD=-0.03 [-0.25, 0.2] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=59.09	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.03	0.11	II (Moderate)	Kishi T., 2021 (NMA)	0.03	-0.25	0.2	risp	pbo	AE, Headache
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Adverse events, Headache	"eSMD=-0.03 [-0.12, 0.06] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=59.09	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.03	0.05	II (Moderate)	Kishi T., 2021 (NMA)	0.03	-0.12	0.06	ari	pbo	AE, Headache
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	cariprazine	Adverse events, Headache	"eSMD=-0.03 [-0.21, 0.14] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=59.09	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.03	0.09	II (Moderate)	Kishi T., 2021 (NMA)	0.03	-0.21	0.14	car	pbo	AE, Headache
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Adverse events, Headache	"eSMD=-0.05 [-0.42, 0.31] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=35.46	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	13	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.05	0.19	IV (Very Low)	Kishi T., 2021 (NMA)	0.05	-0.42	0.31	ola	pbo	AE, Headache
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Headache	"eSMD=-0.06 [-0.21, 0.1] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=29.55	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.06	0.08	II (Moderate)	Kishi T., 2021 (NMA)	0.06	-0.21	0.1	lit	pbo	AE, Headache
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	quetiapine	Adverse events, Headache	"eSMD=-0.06 [-0.27, 0.16] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=29.55	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	13	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.06	0.11	IV (Very Low)	Kishi T., 2021 (NMA)	0.06	-0.27	0.16	que	pbo	AE, Headache
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Adverse events, Headache	"eSMD=-0.06 [-0.27, 0.14] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=29.55	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.06	0.1	II (Moderate)	Kishi T., 2021 (NMA)	0.06	-0.27	0.14	pal	pbo	AE, Headache
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Adverse events, Headache	"eSMD=-0.09 [-0.3, 0.11] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=19.71	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	13	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.09	0.1	IV (Very Low)	Kishi T., 2021 (NMA)	0.09	-0.3	0.11	lam	pbo	AE, Headache
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Headache	"eSMD=-0.1 [-0.3, 0.1] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=17.74	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	13	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.1	0.1	IV (Very Low)	Kishi T., 2021 (NMA)	0.1	-0.3	0.1	lit	pbo	AE, Headache
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	ziprasidone	Adverse events, Headache	"eSMD=-0.16 [-0.38, 0.06] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=11.1	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.16	0.11	II (Moderate)	Kishi T., 2021 (NMA)	0.16	-0.38	0.06	zip	pbo	AE, Headache
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Adverse events, Headache	"eSMD=-0.44 [-1.05, 0.17] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.09	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.44	0.31	II (Moderate)	Kishi T., 2021 (NMA)	0.44	-1.05	0.17	lam	pbo	AE, Headache
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Adverse events, Headache	"eSMD=-1.27 [-2.54, 0.31] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1.59	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	13	Network meta-analysis	Adults	Maintenance	lithium	mono	-1.27	0.73	IV (Very Low)	Kishi T., 2021 (NMA)	1.27	-2.54	0.31	div	lit	AE, Headache
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Adverse events, Headache	"eSMD=-0.98 [-1.77, -0.14] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1.95	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	13	Network meta-analysis	Adults	Maintenance	risperidone LAI	mono	-0.98	0.42	II (Moderate)	Kishi T., 2021 (NMA)	0.98	-1.77	-0.14	ola	rispLAI	AE, Headache
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Adverse events, Headache	"eSMD=-0.38 [-1.08, 0.33] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.72	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	oxcarbazepine	mono	-0.38	0.36	II (Moderate)	Kishi T., 2021 (NMA)	0.38	-1.08	0.33	div	oxc	AE, Headache
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Adverse events, Headache	"eSMD=-0.38 [-0.98, 0.22] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.72	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	-0.38	0.31	II (Moderate)	Kishi T., 2021 (NMA)	0.38	-0.98	0.22	lam	lit	AE, Headache
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Headache	"eSMD=-0.16 [-0.38, 0.06] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=11.1	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.16	0.11	II (Moderate)	Kishi T., 2021 (NMA)	0.16	-0.38	0.06	lit	ola	AE, Headache
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Adverse events, Headache	"eSMD=-0.09 [-0.32, 0.14] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=19.71	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	-0.09	0.12	II (Moderate)	Kishi T., 2021 (NMA)	0.09	-0.32	0.14	pal	que	AE, Headache
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Headache	"eSMD=-0.08 [-0.31, 0.15] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=22.17	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	-0.08	0.12	II (Moderate)	Kishi T., 2021 (NMA)	0.08	-0.31	0.15	lit	que	AE, Headache
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Adverse events, Headache	"eSMD=-0.08 [-0.29, 0.14] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=22.17	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	haloperidol	mono	-0.08	0.11	II (Moderate)	Kishi T., 2021 (NMA)	0.08	-0.29	0.14	ari	hal	AE, Headache
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Adverse events, Headache	"eSMD=-0.05 [-0.22, 0.12] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=35.46	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.05	0.09	II (Moderate)	Kishi T., 2021 (NMA)	0.05	-0.22	0.12	div	ola	AE, Headache
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Headache	"eSMD=-0.05 [-0.42, 0.32] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=35.46	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	13	Network meta-analysis	Adults	Maintenance	olanzapine	mono	-0.05	0.19	IV (Very Low)	Kishi T., 2021 (NMA)	0.05	-0.42	0.32	lit	ola	AE, Headache
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Headache	"eSMD=-0.04 [-0.28, 0.2] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=44.32	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	13	Network meta-analysis	Adults	Maintenance	quetiapine	mono	-0.04	0.12	IV (Very Low)	Kishi T., 2021 (NMA)	0.04	-0.28	0.2	lit	que	AE, Headache
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Adverse events, Headache	"eSMD=0.01 [-0.24, 0.26] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=177.25	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	13	Network meta-analysis	Adults	Maintenance	lithium	mono	0.01	0.13	IV (Very Low)	Kishi T., 2021 (NMA)	-0.01	-0.24	0.26	lam	lit	AE, Headache
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Adverse events, Headache	"eSMD=0.02 [-0.25, 0.29] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=88.63	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	0.02	0.14	II (Moderate)	Kishi T., 2021 (NMA)	-0.02	-0.25	0.29	hal	que	AE, Headache
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Adverse events, Headache	"eSMD=0.03 [-0.14, 0.19] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=59.09	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	0.03	0.08	II (Moderate)	Kishi T., 2021 (NMA)	-0.03	-0.14	0.19	ari	lit	AE, Headache
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Adverse events, Headache	"eSMD=0.11 [-0.08, 0.3] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=16.13	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	0.11	0.1	II (Moderate)	Kishi T., 2021 (NMA)	-0.11	-0.08	0.3	div	lit	AE, Headache
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Adverse events, Headache	"eSMD=0.13 [-0.09, 0.36] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=13.65	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	risperidone	mono	0.13	0.11	II (Moderate)	Kishi T., 2021 (NMA)	-0.13	-0.09	0.36	ola	risp	AE, Headache
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Adverse events, Headache	"eSMD=0.21 [-0.08, 0.49] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.47	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	ziprasidone	mono	0.21	0.15	II (Moderate)	Kishi T., 2021 (NMA)	-0.21	-0.08	0.49	hal	zip	AE, Headache
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole+lamotrigine	Adverse events, Headache	"eSMD=0.3 [-0.21, 0.81] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.95	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	13	Network meta-analysis	Adults	Maintenance	lamotrigine	mono	0.3	0.26	IV (Very Low)	Kishi T., 2021 (NMA)	-0.3	-0.21	0.81	ari+lam	lam	AE, Headache
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole+divalproate	Adverse events, Headache	"eSMD=0.86 [-0.33, 2.16] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.19	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	13	Network meta-analysis	Adults	Maintenance	divalproate	mono	0.86	0.64	IV (Very Low)	Kishi T., 2021 (NMA)	-0.86	-0.33	2.16	ari+div	div	AE, Headache
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	divalproate	Adverse events, Headache	"eSMD=0.53 [0.23, 0.84] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.42	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Mixed (Children-Adults)	Mania/Mixed	lithium	mono	0.53	0.16	II (Moderate)	McKnight R.F., 2019 (MA)	-0.53	0.23	0.84	div	lit	AE, Headache
"<a href='https://doi.org/' target=""_blank"">Nunez N.A., 2020 (MA)</a>"	armodafinil	Adverse events, Headache	"eSMD=-0.15 [-0.31, 0.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=11.84	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Pairwise meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.15	0.08	III (Low)	Nunez N.A., 2020 (MA)	0.15	-0.31	0.01	armo	pbo	AE, Headache
"<a href='https://doi.org/' target=""_blank"">Rendell J.M., 2010 (MA)</a>"	risperidone	Adverse events, Headache	"eSMD=0.03 [-0.28, 0.36] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=59.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	aug	0.03	0.16	III (Low)	Rendell J.M., 2010 (MA)	-0.03	-0.28	0.36	risp	pbo	AE, Headache
"<a href='https://doi.org/' target=""_blank"">Suttajit S., 2014 (MA)</a>"	quetiapine	Adverse events, Headache	"eSMD=0.21 [0.08, 0.35] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.47	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	6	Pairwise meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.21	0.07	II (Moderate)	Suttajit S., 2014 (MA)	-0.21	0.08	0.35	que	pbo	AE, Headache
"<a href='https://doi.org/' target=""_blank"">Vita A., 2013 (MA)</a>"	asenapine	Adverse events, Headache	"eSMD=0.1 [-0.14, 0.33] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=17.74	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	olanzapine	mono	0.1	0.12	IV (Very Low)	Vita A., 2013 (MA)	-0.1	-0.14	0.33	ase	ola	AE, Headache
"<a href='https://doi.org/' target=""_blank"">Rendell J.M., 2010 (MA)</a>"	risperidone	Adverse events, Hyperkinisia	"eSMD=-0.08 [-0.36, 0.2] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=22.17	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.08	0.14	III (Low)	Rendell J.M., 2010 (MA)	0.08	-0.36	0.2	risp	pbo	AE, Hyperkinisia
"<a href='https://doi.org/' target=""_blank"">Jochim J., 2019 (MA)</a>"	divalproate	Adverse events, Insomnia	"eSMD=-0.25 [-0.83, 0.34] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.13	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.25	0.3	II (Moderate)	Jochim J., 2019 (MA)	0.25	-0.83	0.34	div	pbo	AE, Insomnia
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2019 (MA)</a>"	ramelteon	Adverse events, Insomnia	"eSMD=0.11 [-0.26, 0.48] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=16.13	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Maintenance	placebo	mono	0.11	0.19	III (Low)	Kishi T., 2019 (MA)	-0.11	-0.26	0.48	ram	pbo	AE, Insomnia
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2020 (NMA)</a>"	olanzapine	Adverse events, Insomnia	"eSMD=0.27 [-0.2, 0.74] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.6	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.27	0.24	IV (Very Low)	Kishi T., 2020 (NMA)	-0.27	-0.2	0.74	ola	pbo	AE, Insomnia
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2020 (NMA)</a>"	lurasidone	Adverse events, Insomnia	"eSMD=0.16 [-0.56, 0.89] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=11.1	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.16	0.37	IV (Very Low)	Kishi T., 2020 (NMA)	-0.16	-0.56	0.89	lur	pbo	AE, Insomnia
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2020 (NMA)</a>"	quetiapine	Adverse events, Insomnia	"eSMD=0.01 [-2.16, 2.16] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=177.25	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.01	1.1	IV (Very Low)	Kishi T., 2020 (NMA)	-0.01	-2.16	2.16	que	pbo	AE, Insomnia
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	asenapine	Adverse events, Insomnia	"eSMD=0.61 [-0.34, 1.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive17.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	12	Network meta-analysis	Adults	Maintenance	placebo	mono	0.61	0.48	IV (Very Low)	Kishi T., 2021 (NMA)	-0.61	-0.34	1.55	ase	pbo	AE, Insomnia
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Adverse events, Insomnia	"eSMD=0.61 [0.29, 0.95] <br> <img src=""https://www.linkpicture.com/q/Diapositive17.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	12	Network meta-analysis	Adults	Maintenance	placebo	mono	0.61	0.17	III (Low)	Kishi T., 2021 (NMA)	-0.61	0.29	0.95	ola	pbo	AE, Insomnia
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	quetiapine	Adverse events, Insomnia	"eSMD=0.58 [0.25, 0.89] <br> <img src=""https://www.linkpicture.com/q/Diapositive17.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.14	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	12	Network meta-analysis	Adults	Maintenance	placebo	mono	0.58	0.16	III (Low)	Kishi T., 2021 (NMA)	-0.58	0.25	0.89	que	pbo	AE, Insomnia
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	risperidone LAI	Adverse events, Insomnia	"eSMD=0.16 [-0.28, 0.59] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=11.1	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	12	Network meta-analysis	Adults	Maintenance	placebo	mono	0.16	0.22	IV (Very Low)	Kishi T., 2021 (NMA)	-0.16	-0.28	0.59	rispLAI	pbo	AE, Insomnia
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Insomnia	"eSMD=0.07 [-0.18, 0.33] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=25.33	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	12	Network meta-analysis	Adults	Maintenance	placebo	mono	0.07	0.13	IV (Very Low)	Kishi T., 2021 (NMA)	-0.07	-0.18	0.33	lit	pbo	AE, Insomnia
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Adverse events, Insomnia	"eSMD=0.05 [-0.49, 0.59] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=35.46	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	12	Network meta-analysis	Adults	Maintenance	placebo	mono	0.05	0.28	IV (Very Low)	Kishi T., 2021 (NMA)	-0.05	-0.49	0.59	pal	pbo	AE, Insomnia
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole LAI	Adverse events, Insomnia	"eSMD=0 [-0.59, 0.59] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	12	Network meta-analysis	Adults	Maintenance	placebo	mono	0	0.3	IV (Very Low)	Kishi T., 2021 (NMA)	0	-0.59	0.59	ariLAI	pbo	AE, Insomnia
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Adverse events, Insomnia	"eSMD=-0.03 [-0.44, 0.38] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=59.09	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	12	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.03	0.21	IV (Very Low)	Kishi T., 2021 (NMA)	0.03	-0.44	0.38	lam	pbo	AE, Insomnia
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Insomnia	"eSMD=-0.55 [-0.89, -0.2] <br> <img src=""https://www.linkpicture.com/q/Diapositive4.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.3	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	12	Network meta-analysis	Adults	Maintenance	olanzapine	mono	-0.55	0.18	III (Low)	Kishi T., 2021 (NMA)	0.55	-0.89	-0.2	lit	ola	AE, Insomnia
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Insomnia	"eSMD=-0.51 [-0.86, -0.14] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.55	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	12	Network meta-analysis	Adults	Maintenance	quetiapine	mono	-0.51	0.18	III (Low)	Kishi T., 2021 (NMA)	0.51	-0.86	-0.14	lit	que	AE, Insomnia
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Adverse events, Insomnia	"eSMD=-0.1 [-0.49, 0.3] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=17.74	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	12	Network meta-analysis	Adults	Maintenance	lithium	mono	-0.1	0.2	IV (Very Low)	Kishi T., 2021 (NMA)	0.1	-0.49	0.3	lam	lit	AE, Insomnia
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole+lamotrigine	Adverse events, Insomnia	"eSMD=0.25 [-0.28, 0.76] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.13	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	12	Network meta-analysis	Adults	Maintenance	lamotrigine	mono	0.25	0.27	IV (Very Low)	Kishi T., 2021 (NMA)	-0.25	-0.28	0.76	ari+lam	lam	AE, Insomnia
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole+lithium/divalproate	Adverse events, Insomnia	"eSMD=0.31 [-0.23, 0.86] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.76	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	6	Network meta-analysis	Adults	Maintenance	placebo+lithium/divalproate	combo	0.31	0.28	IV (Very Low)	Kishi T., 2021 (NMA)	-0.31	-0.23	0.86	ari+lit/div	pbo+lit/div	AE, Insomnia
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lurasidone+lithium/divalproate	Adverse events, Insomnia	"eSMD=0.31 [-0.24, 0.86] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.76	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	6	Network meta-analysis	Adults	Maintenance	placebo+lithium/divalproate	combo	0.31	0.28	IV (Very Low)	Kishi T., 2021 (NMA)	-0.31	-0.24	0.86	lur+lit/div	pbo+lit/div	AE, Insomnia
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	ziprasidone+lithium/divalproate	Adverse events, Insomnia	"eSMD=0.37 [-0.23, 0.95] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.85	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	6	Network meta-analysis	Adults	Maintenance	placebo+lithium/divalproate	combo	0.37	0.3	IV (Very Low)	Kishi T., 2021 (NMA)	-0.37	-0.23	0.95	zip+lit/div	pbo+lit/div	AE, Insomnia
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Adverse events, Insomnia	"eSMD=0.45 [0, 0.92] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.01	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	12	Network meta-analysis	Adults	Maintenance	risperidone LAI	mono	0.45	0.23	IV (Very Low)	Kishi T., 2021 (NMA)	-0.45	0	0.92	ola	rispLAI	AE, Insomnia
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	quetiapine+lithium/divalproate	Adverse events, Insomnia	"eSMD=0.53 [0.24, 0.84] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.42	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	6	Network meta-analysis	Adults	Maintenance	placebo+lithium/divalproate	combo	0.53	0.15	III (Low)	Kishi T., 2021 (NMA)	-0.53	0.24	0.84	que+lit/div	pbo+lit/div	AE, Insomnia
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine+lithium/divalproate	Adverse events, Insomnia	"eSMD=1.08 [0.21, 1.93] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.8	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	6	Network meta-analysis	Adults	Maintenance	placebo+lithium/divalproate	combo	1.08	0.44	II (Moderate)	Kishi T., 2021 (NMA)	-1.08	0.21	1.93	ola+lit/div	pbo+lit/div	AE, Insomnia
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	lithium	Adverse events, Insomnia	"eSMD=0.15 [-0.14, 0.45] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=11.84	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	0.15	0.15	III (Low)	McKnight R.F., 2019 (MA)	-0.15	-0.14	0.45	lit	pbo	AE, Insomnia
"<a href='https://doi.org/' target=""_blank"">Vita A., 2013 (MA)</a>"	asenapine	Adverse events, Insomnia	"eSMD=-0.19 [-0.42, 0.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=9.36	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.19	0.12	IV (Very Low)	Vita A., 2013 (MA)	0.19	-0.42	0.05	ase	ola	AE, Insomnia
"<a href='https://doi.org/' target=""_blank"">Vita A., 2013 (MA)</a>"	asenapine	Adverse events, Masked facies	"eSMD=-0.89 [-2.16, 0.32] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.12	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.89	0.63	IV (Very Low)	Vita A., 2013 (MA)	0.89	-2.16	0.32	ase	ola	AE, Masked facies
"<a href='https://doi.org/' target=""_blank"">Jochim J., 2019 (MA)</a>"	divalproate	Adverse events, Nasal congestion	"eSMD=0.53 [-0.48, 1.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.42	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Children & Adolescents	Mania/Mixed	placebo	mono	0.53	0.52	III (Low)	Jochim J., 2019 (MA)	-0.53	-0.48	1.55	div	pbo	AE, Nasal congestion
"<a href='https://doi.org/' target=""_blank"">Jochim J., 2019 (MA)</a>"	divalproate	Adverse events, Nasal congestion	"eSMD=-0.18 [-0.53, 0.18] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=9.87	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Children & Adolescents	Mania/Mixed	risperidone	mono	-0.18	0.18	III (Low)	Jochim J., 2019 (MA)	0.18	-0.53	0.18	div	risp	AE, Nasal congestion
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2020 (NMA)</a>"	lurasidone	Adverse events, Nasopharyngitis	"eSMD=-0.09 [-0.58, 0.42] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=19.71	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.09	0.26	IV (Very Low)	Kishi T., 2020 (NMA)	0.09	-0.58	0.42	lur	pbo	AE, Nasopharyngitis
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2020 (NMA)</a>"	quetiapine	Adverse events, Nasopharyngitis	"eSMD=-0.17 [-0.47, 0.14] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=10.45	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.17	0.16	IV (Very Low)	Kishi T., 2020 (NMA)	0.17	-0.47	0.14	que	pbo	AE, Nasopharyngitis
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2020 (NMA)</a>"	olanzapine	Adverse events, Nasopharyngitis	"eSMD=-0.38 [-0.86, 0.1] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.72	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.38	0.24	IV (Very Low)	Kishi T., 2020 (NMA)	0.38	-0.86	0.1	ola	pbo	AE, Nasopharyngitis
"<a href='https://doi.org/' target=""_blank"">Chiesa A., 2012 (MA)</a>"	quetiapine	Adverse events, Nausea	"eSMD=0.2 [0.01, 0.38] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.89	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Pairwise meta-analysis	Adults	Bipolar Depression	placebo	mono	0.2	0.09	II (Moderate)	Chiesa A., 2012 (MA)	-0.2	0.01	0.38	que	pbo	AE, Nausea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2019 (MA)</a>"	ramelteon	Adverse events, Nausea	"eSMD=0.26 [-0.47, 0.98] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.86	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Maintenance	placebo	mono	0.26	0.37	III (Low)	Kishi T., 2019 (MA)	-0.26	-0.47	0.98	ram	pbo	AE, Nausea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	quetiapine	Adverse events, Nausea	"eSMD=0.65 [0.15, 1.12] <br> <img src=""https://www.linkpicture.com/q/Diapositive18.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.82	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	29	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.65	0.25	I (High)	Kishi T., 2021 (NMA)	-0.65	0.15	1.12	que	pbo	AE, Nausea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	tamoxifen	Adverse events, Nausea	"eSMD=0.61 [-0.53, 1.77] <br> <img src=""https://www.linkpicture.com/q/Diapositive17.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	29	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.61	0.59	III (Low)	Kishi T., 2021 (NMA)	-0.61	-0.53	1.77	tamox	pbo	AE, Nausea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Adverse events, Nausea	"eSMD=0.39 [-0.92, 1.77] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.6	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	9	Network meta-analysis	Adults	Maintenance	placebo	mono	0.39	0.69	III (Low)	Kishi T., 2021 (NMA)	-0.39	-0.92	1.77	pal	pbo	AE, Nausea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	brexpiprazole	Adverse events, Nausea	"eSMD=0.34 [-0.23, 0.92] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.26	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	29	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.34	0.29	III (Low)	Kishi T., 2021 (NMA)	-0.34	-0.23	0.92	brex	pbo	AE, Nausea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Adverse events, Nausea	"eSMD=0.34 [-0.1, 0.79] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.26	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	29	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.34	0.23	III (Low)	Kishi T., 2021 (NMA)	-0.34	-0.1	0.79	pal	pbo	AE, Nausea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Adverse events, Nausea	"eSMD=0.29 [-0.05, 0.63] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.15	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	29	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.29	0.17	III (Low)	Kishi T., 2021 (NMA)	-0.29	-0.05	0.63	ola	pbo	AE, Nausea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	quetiapine	Adverse events, Nausea	"eSMD=0.2 [-0.03, 0.44] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.89	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	9	Network meta-analysis	Adults	Maintenance	placebo	mono	0.2	0.12	III (Low)	Kishi T., 2021 (NMA)	-0.2	-0.03	0.44	que	pbo	AE, Nausea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Adverse events, Nausea	"eSMD=0.19 [-1.01, 1.39] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=9.36	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	29	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.19	0.61	III (Low)	Kishi T., 2021 (NMA)	-0.19	-1.01	1.39	lam	pbo	AE, Nausea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Adverse events, Nausea	"eSMD=-0.1 [-0.31, 0.11] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=17.74	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	9	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.1	0.11	III (Low)	Kishi T., 2021 (NMA)	0.1	-0.31	0.11	lam	pbo	AE, Nausea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	ziprasidone	Adverse events, Nausea	"eSMD=-0.19 [-0.65, 0.27] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=9.36	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	29	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.19	0.23	III (Low)	Kishi T., 2021 (NMA)	0.19	-0.65	0.27	zip	pbo	AE, Nausea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Adverse events, Nausea	"eSMD=-0.21 [-0.37, -0.06] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=8.47	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	9	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.21	0.08	II (Moderate)	Kishi T., 2021 (NMA)	0.21	-0.37	-0.06	div	pbo	AE, Nausea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Adverse events, Nausea	"eSMD=-0.25 [-0.4, -0.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.13	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	29	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.25	0.08	II (Moderate)	Kishi T., 2021 (NMA)	0.25	-0.4	-0.08	ari	pbo	AE, Nausea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Nausea	"eSMD=-0.25 [-0.38, -0.13] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.13	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	9	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.25	0.06	II (Moderate)	Kishi T., 2021 (NMA)	0.25	-0.38	-0.13	lit	pbo	AE, Nausea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	cariprazine	Adverse events, Nausea	"eSMD=-0.27 [-0.52, -0.02] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.6	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	29	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.27	0.13	II (Moderate)	Kishi T., 2021 (NMA)	0.27	-0.52	-0.02	car	pbo	AE, Nausea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Adverse events, Nausea	"eSMD=-0.28 [-0.48, -0.09] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.37	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	29	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.28	0.1	II (Moderate)	Kishi T., 2021 (NMA)	0.28	-0.48	-0.09	div	pbo	AE, Nausea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Nausea	"eSMD=-0.32 [-0.52, -0.1] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.59	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	29	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.32	0.11	II (Moderate)	Kishi T., 2021 (NMA)	0.32	-0.52	-0.1	lit	pbo	AE, Nausea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	asenapine	Adverse events, Nausea	"eSMD=-0.61 [-2.54, 1.17] <br> <img src=""https://www.linkpicture.com/q/Diapositive4.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	9	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.61	0.95	III (Low)	Kishi T., 2021 (NMA)	0.61	-2.54	1.17	ase	pbo	AE, Nausea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	carbamazepine	Adverse events, Nausea	"eSMD=-0.61 [-0.89, -0.33] <br> <img src=""https://www.linkpicture.com/q/Diapositive4.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	29	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.61	0.14	I (High)	Kishi T., 2021 (NMA)	0.61	-0.89	-0.33	cbz	pbo	AE, Nausea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	risperidone	Adverse events, Nausea	"eSMD=-0.86 [-1.55, -0.15] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.19	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	29	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.86	0.36	I (High)	Kishi T., 2021 (NMA)	0.86	-1.55	-0.15	risp	pbo	AE, Nausea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Nausea	"eSMD=-1.17 [-2.16, -0.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1.69	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	9	Network meta-analysis	Adults	Maintenance	olanzapine	mono	-1.17	0.55	I (High)	Kishi T., 2021 (NMA)	1.17	-2.16	-0.01	lit	ola	AE, Nausea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Nausea	"eSMD=-0.89 [-1.47, -0.44] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.12	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	29	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	-0.89	0.26	I (High)	Kishi T., 2021 (NMA)	0.89	-1.47	-0.44	lit	que	AE, Nausea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Nausea	"eSMD=-0.59 [-0.95, -0.25] <br> <img src=""https://www.linkpicture.com/q/Diapositive4.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.09	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	29	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.59	0.18	I (High)	Kishi T., 2021 (NMA)	0.59	-0.95	-0.25	lit	ola	AE, Nausea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Adverse events, Nausea	"eSMD=-0.58 [-0.86, -0.27] <br> <img src=""https://www.linkpicture.com/q/Diapositive4.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.14	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	29	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.58	0.15	I (High)	Kishi T., 2021 (NMA)	0.58	-0.86	-0.27	div	ola	AE, Nausea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Nausea	"eSMD=-0.47 [-0.7, -0.22] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.84	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	9	Network meta-analysis	Adults	Maintenance	quetiapine	mono	-0.47	0.12	II (Moderate)	Kishi T., 2021 (NMA)	0.47	-0.7	-0.22	lit	que	AE, Nausea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Adverse events, Nausea	"eSMD=-0.3 [-0.92, 0.33] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.95	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	29	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	-0.3	0.32	III (Low)	Kishi T., 2021 (NMA)	0.3	-0.92	0.33	pal	que	AE, Nausea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Adverse events, Nausea	"eSMD=-0.19 [-0.79, 0.41] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=9.36	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	29	Network meta-analysis	Adults	Mania/Mixed	oxcarbazepine	mono	-0.19	0.31	III (Low)	Kishi T., 2021 (NMA)	0.19	-0.79	0.41	div	oxc	AE, Nausea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Adverse events, Nausea	"eSMD=-0.03 [-0.27, 0.22] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=59.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	29	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	-0.03	0.12	III (Low)	Kishi T., 2021 (NMA)	0.03	-0.27	0.22	div	lit	AE, Nausea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Adverse events, Nausea	"eSMD=0.04 [-0.1, 0.19] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=44.32	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	9	Network meta-analysis	Adults	Maintenance	lithium	mono	0.04	0.07	III (Low)	Kishi T., 2021 (NMA)	-0.04	-0.1	0.19	div	lit	AE, Nausea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Adverse events, Nausea	"eSMD=0.07 [-0.16, 0.29] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=25.33	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	29	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	0.07	0.11	III (Low)	Kishi T., 2021 (NMA)	-0.07	-0.16	0.29	ari	lit	AE, Nausea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Adverse events, Nausea	"eSMD=0.16 [-0.05, 0.37] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=11.1	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	9	Network meta-analysis	Adults	Maintenance	lithium	mono	0.16	0.11	III (Low)	Kishi T., 2021 (NMA)	-0.16	-0.05	0.37	lam	lit	AE, Nausea
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Adverse events, Nausea	"eSMD=0.51 [-0.7, 1.77] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.55	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	29	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	0.51	0.63	III (Low)	Kishi T., 2021 (NMA)	-0.51	-0.7	1.77	lam	lit	AE, Nausea
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	lithium	Adverse events, Nausea	"eSMD=-0.47 [-0.68, -0.24] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.84	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	6	Pairwise meta-analysis	Mixed (Children-Adults)	Mania/Mixed	placebo	mono	-0.47	0.11	I (High)	McKnight R.F., 2019 (MA)	0.47	-0.68	-0.24	lit	pbo	AE, Nausea
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	lithium	Adverse events, Nausea	"eSMD=-0.51 [-0.86, -0.15] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.55	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Mixed (Children-Adults)	Mania/Mixed	risperidone	mono	-0.51	0.18	I (High)	McKnight R.F., 2019 (MA)	0.51	-0.86	-0.15	lit	risp	AE, Nausea
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	divalproate	Adverse events, Nausea	"eSMD=0.24 [-0.02, 0.48] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.42	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	4	Pairwise meta-analysis	Mixed (Children-Adults)	Mania/Mixed	lithium	mono	0.24	0.13	III (Low)	McKnight R.F., 2019 (MA)	-0.24	-0.02	0.48	div	lit	AE, Nausea
"<a href='https://doi.org/' target=""_blank"">Nunez N.A., 2020 (MA)</a>"	armodafinil	Adverse events, Nausea	"eSMD=-0.3 [-0.55, -0.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.95	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Pairwise meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.3	0.13	II (Moderate)	Nunez N.A., 2020 (MA)	0.3	-0.55	-0.05	armo	pbo	AE, Nausea
"<a href='https://doi.org/' target=""_blank"">Suttajit S., 2014 (MA)</a>"	quetiapine	Adverse events, Nausea	"eSMD=0.14 [-0.04, 0.32] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=12.68	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Pairwise meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.14	0.09	III (Low)	Suttajit S., 2014 (MA)	-0.14	-0.04	0.32	que	pbo	AE, Nausea
"<a href='https://doi.org/' target=""_blank"">Zheng W., 2018 (MA)</a>"	n-acetyl cysteine	Adverse events, Nausea	"eSMD=-0.04 [-0.44, 0.36] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=44.32	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.04	0.2	III (Low)	Zheng W., 2018 (MA)	0.04	-0.44	0.36	nac	pbo	AE, Nausea
"<a href='https://doi.org/' target=""_blank"">Rendell J.M., 2010 (MA)</a>"	olanzapine	Adverse events, Nervousness	"eSMD=0.34 [-0.04, 0.72] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.26	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	0.34	0.19	II (Moderate)	Rendell J.M., 2010 (MA)	-0.34	-0.04	0.72	ola	pbo	AE, Nervousness
"<a href='https://doi.org/' target=""_blank"">Chang H., 2017 (MA)</a>"	paliperidone	Adverse events, Orthostatic hypothension	"eSMD=0.3 [-0.52, 1.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.95	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	0.3	0.41	IV (Very Low)	Chang H., 2017 (MA)	-0.3	-0.52	1.08	pal	pbo	AE, Orthostatic hypothension
"<a href='https://doi.org/' target=""_blank"">Jochim J., 2019 (MA)</a>"	divalproate	Adverse events, Pain	"eSMD=-0.08 [-0.36, 0.2] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=22.17	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.08	0.14	III (Low)	Jochim J., 2019 (MA)	0.08	-0.36	0.2	div	pbo	AE, Pain
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	lithium	Adverse events, Pain	"eSMD=0.81 [0.13, 1.47] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.31	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	0.81	0.34	II (Moderate)	McKnight R.F., 2019 (MA)	-0.81	0.13	1.47	lit	pbo	AE, Pain
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	lamotrigine	Adverse events, Pain	"eSMD=-0.59 [-1.47, 0.28] <br> <img src=""https://www.linkpicture.com/q/Diapositive4.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	lithium	mono	-0.59	0.45	III (Low)	McKnight R.F., 2019 (MA)	0.59	-1.47	0.28	lam	lit	AE, Pain
"<a href='https://doi.org/' target=""_blank"">Vita A., 2013 (MA)</a>"	asenapine	Adverse events, Parkinsonism	"eSMD=-0.45 [-0.89, -0.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.01	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.45	0.22	III (Low)	Vita A., 2013 (MA)	0.45	-0.89	-0.01	ase	ola	AE, Parkinsonism
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2013 (MA)</a>"	divalproate	Adverse events, Polyuria	"eSMD=0.65 [0.3, 1.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive18.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.82	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Low	2	Pairwise meta-analysis	Adults	Maintenance	lithium	mono	0.65	0.18	I (High)	Cipriani A., 2013 (MA)	-0.65	0.3	1.01	div	lit	AE, Polyuria
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	risperidone LAI	Adverse events, Prolactin-related adverse events	"eSMD=-0.86 [-1.39, -0.35] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.19	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.86	0.27	III (Low)	Kishi T., 2021 (NMA)	0.86	-1.39	-0.35	rispLAI	pbo	AE, Prolactin-related
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Adverse events, Prolactin-related adverse events	"eSMD=-1.12 [-2.16, 0] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1.75	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Network meta-analysis	Adults	Maintenance	placebo	mono	-1.12	0.55	IV (Very Low)	Kishi T., 2021 (NMA)	1.12	-2.16	0	pal	pbo	AE, Prolactin-related
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	lithium	Adverse events, Rash	"eSMD=0.05 [-0.45, 0.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=35.46	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Mixed (Children-Adults)	Mania/Mixed	placebo	mono	0.05	0.26	III (Low)	McKnight R.F., 2019 (MA)	-0.05	-0.45	0.55	lit	pbo	AE, Rash
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	lamotrigine	Adverse events, Rash	"eSMD=-0.3 [-0.98, 0.37] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.95	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	lithium	mono	-0.3	0.34	III (Low)	McKnight R.F., 2019 (MA)	0.3	-0.98	0.37	lam	lit	AE, Rash
"<a href='https://doi.org/' target=""_blank"">Chiesa A., 2012 (MA)</a>"	quetiapine	Adverse events, Sedation	"eSMD=-0.83 [-0.98, -0.7] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.26	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Pairwise meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.83	0.07	II (Moderate)	Chiesa A., 2012 (MA)	0.83	-0.98	-0.7	que	pbo	AE, Sedation
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2013 (MA)</a>"	divalproate	Adverse events, Sedation	"eSMD=0.17 [0.01, 0.33] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=10.45	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Low	2	Pairwise meta-analysis	Adults	Maintenance	lithium	mono	0.17	0.08	I (High)	Cipriani A., 2013 (MA)	-0.17	0.01	0.33	div	lit	AE, Sedation
"<a href='https://doi.org/' target=""_blank"">De Fruyt , 2012 (MA)</a>"	aripiprazole	Adverse events, Sedation	"eSMD=-0.49 [-0.95, -0.04] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.69	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.49	0.23	I (High)	De Fruyt , 2012 (MA)	0.49	-0.95	-0.04	ari	pbo	AE, Sedation
"<a href='https://doi.org/' target=""_blank"">Jochim J., 2019 (MA)</a>"	divalproate	Adverse events, Sedation	"eSMD=-0.31 [-0.68, 0.03] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.76	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.31	0.18	II (Moderate)	Jochim J., 2019 (MA)	0.31	-0.68	0.03	div	pbo	AE, Sedation
"<a href='https://doi.org/' target=""_blank"">Jochim J., 2019 (MA)</a>"	divalproate	Adverse events, Sedation	"eSMD=0.38 [0.05, 0.7] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.72	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	olanzapine	mono	0.38	0.17	I (High)	Jochim J., 2019 (MA)	-0.38	0.05	0.7	div	ola	AE, Sedation
"<a href='https://doi.org/' target=""_blank"">Macritchie K., 2003 (MA)</a>"	divalproate	Adverse events, Sedation	"eSMD=-0.13 [-0.55, 0.29] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=13.65	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Mixed (Children-Adults)	Mania/Mixed	lithium	mono	-0.13	0.21	II (Moderate)	Macritchie K., 2003 (MA)	0.13	-0.55	0.29	div	lit	AE, Sedation
"<a href='https://doi.org/' target=""_blank"">Meduri M., 2016 (MA)</a>"	aripiprazole	Adverse events, Sedation	"eSMD=-0.43 [-1.93, 1.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.19	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Children & Adolescents	Mania/Mixed	placebo	mono	-0.43	0.77	III (Low)	Meduri M., 2016 (MA)	0.43	-1.93	1.08	ari	pbo	AE, Sedation
"<a href='https://doi.org/' target=""_blank"">Meduri M., 2016 (MA)</a>"	aripiprazole	Adverse events, Sedation	"eSMD=-0.52 [-0.74, -0.29] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.49	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.52	0.11	I (High)	Meduri M., 2016 (MA)	0.52	-0.74	-0.29	ari	pbo	AE, Sedation
"<a href='https://doi.org/' target=""_blank"">Suttajit S., 2014 (MA)</a>"	quetiapine	Adverse events, Sedation	"eSMD=-0.66 [-0.76, -0.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive3.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.78	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	6	Pairwise meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	-0.66	0.05	II (Moderate)	Suttajit S., 2014 (MA)	0.66	-0.76	-0.55	que	pbo	AE, Sedation
"<a href='https://doi.org/' target=""_blank"">Vita A., 2013 (MA)</a>"	asenapine	Adverse events, Sedation	"eSMD=-0.68 [-1.08, -0.28] <br> <img src=""https://www.linkpicture.com/q/Diapositive3.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.71	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.68	0.2	III (Low)	Vita A., 2013 (MA)	0.68	-1.08	-0.28	ase	pbo	AE, Sedation
"<a href='https://doi.org/' target=""_blank"">Vita A., 2013 (MA)</a>"	asenapine	Adverse events, Sedation	"eSMD=0.03 [-0.18, 0.25] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=59.09	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	olanzapine	mono	0.03	0.11	IV (Very Low)	Vita A., 2013 (MA)	-0.03	-0.18	0.25	ase	ola	AE, Sedation
"<a href='https://doi.org/' target=""_blank"">Chiesa A., 2012 (MA)</a>"	quetiapine	Adverse events, Serious, any	"eSMD=0.11 [-0.25, 0.49] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=16.13	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Bipolar Depression	placebo	mono	0.11	0.19	III (Low)	Chiesa A., 2012 (MA)	-0.11	-0.25	0.49	que	pbo	AE, Serious, any
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	lithium	Adverse events, Serious, any	"eSMD=0.11 [-0.28, 0.52] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=16.13	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	4	Pairwise meta-analysis	Mixed (Children-Adults)	Mania/Mixed	placebo	mono	0.11	0.2	III (Low)	McKnight R.F., 2019 (MA)	-0.11	-0.28	0.52	lit	pbo	AE, Serious, any
"<a href='https://doi.org/' target=""_blank"">Bartoli F., 2017 (MA)</a>"	allopurinol	Adverse events, Somnolence	"eSMD=-0.13 [-0.61, 0.34] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=13.65	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	aug	-0.13	0.24	IV (Very Low)	Bartoli F., 2017 (MA)	0.13	-0.61	0.34	allopur	pbo	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	lurasidone	Adverse events, Somnolence	"eSMD=-0.24 [-0.72, 0.31] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.42	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	15	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.24	0.26	III (Low)	Kadakia A., 2021 (NMA)	0.24	-0.72	0.31	lur	pbo	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	cariprazine	Adverse events, Somnolence	"eSMD=-0.35 [-0.76, 0.11] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.12	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	15	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.35	0.22	III (Low)	Kadakia A., 2021 (NMA)	0.35	-0.76	0.11	car	pbo	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	aripiprazole	Adverse events, Somnolence	"eSMD=-0.39 [-0.74, 0.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.6	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	15	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.39	0.19	III (Low)	Kadakia A., 2021 (NMA)	0.39	-0.74	0.01	ari	pbo	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	olanzapine	Adverse events, Somnolence	"eSMD=-0.58 [-0.79, -0.37] <br> <img src=""https://www.linkpicture.com/q/Diapositive4.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.14	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	15	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.58	0.11	II (Moderate)	Kadakia A., 2021 (NMA)	0.58	-0.79	-0.37	ola	pbo	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	quetiapine	Adverse events, Somnolence	"eSMD=-0.89 [-1.05, -0.7] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.12	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	15	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.89	0.09	II (Moderate)	Kadakia A., 2021 (NMA)	0.89	-1.05	-0.7	que	pbo	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	ziprasidone	Adverse events, Somnolence	"eSMD=-0.89 [-1.22, -0.53] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.12	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	15	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.89	0.18	I (High)	Kadakia A., 2021 (NMA)	0.89	-1.22	-0.53	zip	pbo	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2019 (MA)</a>"	ramelteon	Adverse events, Somnolence	"eSMD=-0.2 [-0.66, 0.26] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=8.89	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Maintenance	placebo	mono	-0.2	0.23	III (Low)	Kishi T., 2019 (MA)	0.2	-0.66	0.26	ram	pbo	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Adverse events, Somnolence	"eSMD=0.06 [-0.3, 0.43] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=29.55	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Maintenance	placebo	mono	0.06	0.19	IV (Very Low)	Kishi T., 2021 (NMA)	-0.06	-0.3	0.43	lam	pbo	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	asenapine	Adverse events, Somnolence	"eSMD=0 [-1.55, 1.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Maintenance	placebo	mono	0	0.79	IV (Very Low)	Kishi T., 2021 (NMA)	0	-1.55	1.55	ase	pbo	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Somnolence	"eSMD=-0.01 [-0.22, 0.21] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=177.25	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.01	0.11	IV (Very Low)	Kishi T., 2021 (NMA)	0.01	-0.22	0.21	lit	pbo	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Adverse events, Somnolence	"eSMD=-0.15 [-1.08, 0.79] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=11.84	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.15	0.48	II (Moderate)	Kishi T., 2021 (NMA)	0.15	-1.08	0.79	lam	pbo	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Adverse events, Somnolence	"eSMD=-0.16 [-0.44, 0.14] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=11.1	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.16	0.15	IV (Very Low)	Kishi T., 2021 (NMA)	0.16	-0.44	0.14	div	pbo	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Somnolence	"eSMD=-0.26 [-0.49, -0.03] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.86	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.26	0.12	I (High)	Kishi T., 2021 (NMA)	0.26	-0.49	-0.03	lit	pbo	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	risperidone LAI	Adverse events, Somnolence	"eSMD=-0.34 [-0.98, 0.29] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.26	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.34	0.32	IV (Very Low)	Kishi T., 2021 (NMA)	0.34	-0.98	0.29	rispLAI	pbo	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Adverse events, Somnolence	"eSMD=-0.35 [-0.49, -0.21] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.12	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.35	0.07	I (High)	Kishi T., 2021 (NMA)	0.35	-0.49	-0.21	div	pbo	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	quetiapine	Adverse events, Somnolence	"eSMD=-0.36 [-0.74, 0.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.98	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.36	0.19	IV (Very Low)	Kishi T., 2021 (NMA)	0.36	-0.74	0.01	que	pbo	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Adverse events, Somnolence	"eSMD=-0.42 [-0.61, -0.22] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.28	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.42	0.1	I (High)	Kishi T., 2021 (NMA)	0.42	-0.61	-0.22	ari	pbo	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Adverse events, Somnolence	"eSMD=-0.43 [-0.72, -0.14] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.19	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.43	0.15	I (High)	Kishi T., 2021 (NMA)	0.43	-0.72	-0.14	pal	pbo	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	carbamazepine	Adverse events, Somnolence	"eSMD=-0.49 [-0.7, -0.27] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.69	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.49	0.11	I (High)	Kishi T., 2021 (NMA)	0.49	-0.7	-0.27	cbz	pbo	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	ziprasidone	Adverse events, Somnolence	"eSMD=-0.51 [-0.79, -0.21] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.55	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.51	0.15	I (High)	Kishi T., 2021 (NMA)	0.51	-0.79	-0.21	zip	pbo	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	risperidone	Adverse events, Somnolence	"eSMD=-0.63 [-0.81, -0.45] <br> <img src=""https://www.linkpicture.com/q/Diapositive3.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.91	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.63	0.09	I (High)	Kishi T., 2021 (NMA)	0.63	-0.81	-0.45	risp	pbo	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Adverse events, Somnolence	"eSMD=-0.65 [-0.92, -0.37] <br> <img src=""https://www.linkpicture.com/q/Diapositive3.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.82	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.65	0.14	I (High)	Kishi T., 2021 (NMA)	0.65	-0.92	-0.37	hal	pbo	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Adverse events, Somnolence	"eSMD=-0.68 [-0.81, -0.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive3.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.71	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.68	0.07	I (High)	Kishi T., 2021 (NMA)	0.68	-0.81	-0.55	ola	pbo	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Adverse events, Somnolence	"eSMD=-0.7 [-1.22, -0.2] <br> <img src=""https://www.linkpicture.com/q/Diapositive3.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.64	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.7	0.26	II (Moderate)	Kishi T., 2021 (NMA)	0.7	-1.22	-0.2	ola	pbo	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	quetiapine	Adverse events, Somnolence	"eSMD=-0.76 [-0.98, -0.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive2.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.44	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.76	0.11	I (High)	Kishi T., 2021 (NMA)	0.76	-0.98	-0.55	que	pbo	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	asenapine	Adverse events, Somnolence	"eSMD=-0.79 [-1.01, -0.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive2.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.36	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.79	0.12	I (High)	Kishi T., 2021 (NMA)	0.79	-1.01	-0.55	ase	pbo	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Adverse events, Somnolence	"eSMD=-0.89 [-2.16, 0.33] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.12	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.89	0.64	IV (Very Low)	Kishi T., 2021 (NMA)	0.89	-2.16	0.33	pal	pbo	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	cariprazine	Adverse events, Somnolence	"eSMD=-0.92 [-1.55, -0.23] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.06	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.92	0.34	I (High)	Kishi T., 2021 (NMA)	0.92	-1.55	-0.23	car	pbo	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	quetiapine+lithium/divalproate	Adverse events, Somnolence	"eSMD=-0.76 [-1.33, -0.2] <br> <img src=""https://www.linkpicture.com/q/Diapositive2.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.44	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Network meta-analysis	Adults	Maintenance	placebo+lithium/divalproate	combo	-0.76	0.29	III (Low)	Kishi T., 2021 (NMA)	0.76	-1.33	-0.2	que+lit/div	pbo+lit/div	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine+lithium/divalproate	Adverse events, Somnolence	"eSMD=-0.47 [-1.33, 0.36] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.84	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Network meta-analysis	Adults	Maintenance	placebo+lithium/divalproate	combo	-0.47	0.43	IV (Very Low)	Kishi T., 2021 (NMA)	0.47	-1.33	0.36	ola+lit/div	pbo+lit/div	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Adverse events, Somnolence	"eSMD=-0.37 [-0.89, 0.14] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.85	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Maintenance	risperidone LAI	mono	-0.37	0.26	IV (Very Low)	Kishi T., 2021 (NMA)	0.37	-0.89	0.14	ola	rispLAI	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Adverse events, Somnolence	"eSMD=-0.28 [-1.01, 0.46] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.37	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	oxcarbazepine	mono	-0.28	0.38	II (Moderate)	Kishi T., 2021 (NMA)	0.28	-1.01	0.46	div	oxc	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Adverse events, Somnolence	"eSMD=-0.16 [-0.43, 0.11] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=11.1	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	-0.16	0.14	II (Moderate)	Kishi T., 2021 (NMA)	0.16	-0.43	0.11	ari	lit	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Adverse events, Somnolence	"eSMD=-0.15 [-0.44, 0.14] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=11.84	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Maintenance	lithium	mono	-0.15	0.15	IV (Very Low)	Kishi T., 2021 (NMA)	0.15	-0.44	0.14	div	lit	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Adverse events, Somnolence	"eSMD=-0.14 [-0.53, 0.25] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=12.68	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	ziprasidone	mono	-0.14	0.2	II (Moderate)	Kishi T., 2021 (NMA)	0.14	-0.53	0.25	hal	zip	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	asenapine	Adverse events, Somnolence	"eSMD=-0.1 [-0.31, 0.11] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=17.74	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.1	0.11	II (Moderate)	Kishi T., 2021 (NMA)	0.1	-0.31	0.11	ase	ola	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Adverse events, Somnolence	"eSMD=-0.09 [-0.35, 0.17] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=19.71	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	-0.09	0.13	II (Moderate)	Kishi T., 2021 (NMA)	0.09	-0.35	0.17	div	lit	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Adverse events, Somnolence	"eSMD=-0.05 [-0.21, 0.11] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=35.46	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	risperidone	mono	-0.05	0.08	II (Moderate)	Kishi T., 2021 (NMA)	0.05	-0.21	0.11	ola	risp	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Adverse events, Somnolence	"eSMD=-0.02 [-0.32, 0.29] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=88.63	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	risperidone	mono	-0.02	0.16	II (Moderate)	Kishi T., 2021 (NMA)	0.02	-0.32	0.29	hal	risp	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Adverse events, Somnolence	"eSMD=0.03 [-0.25, 0.33] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=59.09	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	0.03	0.15	II (Moderate)	Kishi T., 2021 (NMA)	-0.03	-0.25	0.33	hal	ola	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Adverse events, Somnolence	"eSMD=0.11 [-0.81, 1.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=16.13	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	0.11	0.47	II (Moderate)	Kishi T., 2021 (NMA)	-0.11	-0.81	1.05	lam	lit	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Adverse events, Somnolence	"eSMD=0.11 [-0.19, 0.43] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=16.13	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	0.11	0.16	II (Moderate)	Kishi T., 2021 (NMA)	-0.11	-0.19	0.43	hal	que	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Adverse events, Somnolence	"eSMD=0.33 [0.2, 0.46] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.42	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	0.33	0.07	I (High)	Kishi T., 2021 (NMA)	-0.33	0.2	0.46	div	ola	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Adverse events, Somnolence	"eSMD=0.33 [0.07, 0.58] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.42	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	0.33	0.13	I (High)	Kishi T., 2021 (NMA)	-0.33	0.07	0.58	pal	que	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Somnolence	"eSMD=0.36 [-0.03, 0.74] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.98	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Maintenance	quetiapine	mono	0.36	0.2	IV (Very Low)	Kishi T., 2021 (NMA)	-0.36	-0.03	0.74	lit	que	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Somnolence	"eSMD=0.42 [0.17, 0.68] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.28	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	0.42	0.13	I (High)	Kishi T., 2021 (NMA)	-0.42	0.17	0.68	lit	ola	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Somnolence	"eSMD=0.51 [0.23, 0.76] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.55	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	37	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	0.51	0.14	I (High)	Kishi T., 2021 (NMA)	-0.51	0.23	0.76	lit	que	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Somnolence	"eSMD=0.7 [0.17, 1.27] <br> <img src=""https://www.linkpicture.com/q/Diapositive18.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.64	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Maintenance	olanzapine	mono	0.7	0.28	II (Moderate)	Kishi T., 2021 (NMA)	-0.7	0.17	1.27	lit	ola	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	lithium	Adverse events, Somnolence	"eSMD=-0.45 [-0.7, -0.21] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.01	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	7	Pairwise meta-analysis	Mixed (Children-Adults)	Mania/Mixed	placebo	mono	-0.45	0.12	I (High)	McKnight R.F., 2019 (MA)	0.45	-0.7	-0.21	lit	pbo	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	lithium	Adverse events, Somnolence	"eSMD=-0.79 [-1.47, -0.06] <br> <img src=""https://www.linkpicture.com/q/Diapositive2.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.36	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Mixed (Children-Adults)	Mania/Mixed	risperidone	mono	-0.79	0.36	I (High)	McKnight R.F., 2019 (MA)	0.79	-1.47	-0.06	lit	risp	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	divalproate	Adverse events, Somnolence	"eSMD=-0.42 [-0.68, -0.15] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.28	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	4	Pairwise meta-analysis	Mixed (Children-Adults)	Mania/Mixed	lithium	mono	-0.42	0.14	II (Moderate)	McKnight R.F., 2019 (MA)	0.42	-0.68	-0.15	div	lit	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Rendell J.M., 2010 (MA)</a>"	risperidone	Adverse events, Somnolence	"eSMD=-0.53 [-1.01, -0.07] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.42	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	aug	-0.53	0.24	I (High)	Rendell J.M., 2010 (MA)	0.53	-1.01	-0.07	risp	pbo	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Scherk H., 2007 (MA)</a>"	quetiapine	Adverse events, Somnolence	"eSMD=-0.72 [-0.95, -0.52] <br> <img src=""https://www.linkpicture.com/q/Diapositive2.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.57	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	aug	-0.72	0.11	II (Moderate)	Scherk H., 2007 (MA)	0.72	-0.95	-0.52	que	pbo	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Silva M.T., 2013 (MA)</a>"	olanzapine	Adverse events, Somnolence	"eSMD=-0.14 [-0.37, 0.09] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=12.68	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Bipolar Depression	olanzapine+fluoxetine	combo	-0.14	0.12	III (Low)	Silva M.T., 2013 (MA)	0.14	-0.37	0.09	ola	ola+fluo	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Suttajit S., 2014 (MA)</a>"	quetiapine	Adverse events, Somnolence	"eSMD=-0.72 [-0.89, -0.58] <br> <img src=""https://www.linkpicture.com/q/Diapositive2.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.57	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Pairwise meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	-0.72	0.08	II (Moderate)	Suttajit S., 2014 (MA)	0.72	-0.89	-0.58	que	pbo	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Zhang J., 2021 (MA)</a>"	ECT	Adverse events, Somnolence	"eSMD=-0.61 [-2.16, 0.86] <br> <img src=""https://www.linkpicture.com/q/Diapositive4.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania	TAU	mono	-0.61	0.77	IV (Very Low)	Zhang J., 2021 (MA)	0.61	-2.16	0.86	ECT	tau	AE, Somnolence
"<a href='https://doi.org/' target=""_blank"">Jochim J., 2019 (MA)</a>"	divalproate	Adverse events, Speech disorder	"eSMD=1.33 [0.38, 2.16] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.53	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	olanzapine	mono	1.33	0.45	I (High)	Jochim J., 2019 (MA)	-1.33	0.38	2.16	div	ola	AE, Speech disorder
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	lithium	Adverse events, Switch to mania	"eSMD=0.48 [-0.24, 1.17] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.76	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.48	0.36	IV (Very Low)	Bahji A., 2020 (NMA)	-0.48	-0.24	1.17	lit	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	carbamazepine	Adverse events, Switch to mania	"eSMD=0.38 [-1.17, 1.93] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.72	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.38	0.79	IV (Very Low)	Bahji A., 2020 (NMA)	-0.38	-1.17	1.93	cbz	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	quetiapine	Adverse events, Switch to mania	"eSMD=0.33 [0.1, 0.56] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.42	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.33	0.12	III (Low)	Bahji A., 2020 (NMA)	-0.33	0.1	0.56	que	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	escitalopram	Adverse events, Switch to mania	"eSMD=0.28 [-1.47, 1.93] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.37	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.28	0.87	IV (Very Low)	Bahji A., 2020 (NMA)	-0.28	-1.47	1.93	escit	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	imipramine	Adverse events, Switch to mania	"eSMD=0.2 [-0.4, 0.81] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.89	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.2	0.31	IV (Very Low)	Bahji A., 2020 (NMA)	-0.2	-0.4	0.81	imp	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	olanzapine+fluoxetine	Adverse events, Switch to mania	"eSMD=0.17 [-0.19, 0.53] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=10.45	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.17	0.18	IV (Very Low)	Bahji A., 2020 (NMA)	-0.17	-0.19	0.53	ola+fluo	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	olanzapine	Adverse events, Switch to mania	"eSMD=0.17 [-0.14, 0.48] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=10.45	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.17	0.16	IV (Very Low)	Bahji A., 2020 (NMA)	-0.17	-0.14	0.48	ola	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	phenelzine	Adverse events, Switch to mania	"eSMD=0.16 [-1.22, 1.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=11.1	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.16	0.71	IV (Very Low)	Bahji A., 2020 (NMA)	-0.16	-1.22	1.55	phen	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	ziprasidone	Adverse events, Switch to mania	"eSMD=0.14 [-0.65, 0.92] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=12.68	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.14	0.4	IV (Very Low)	Bahji A., 2020 (NMA)	-0.14	-0.65	0.92	zip	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	fluoxetine	Adverse events, Switch to mania	"eSMD=0.1 [-0.48, 0.68] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=17.74	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.1	0.3	IV (Very Low)	Bahji A., 2020 (NMA)	-0.1	-0.48	0.68	fluo	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	cariprazine	Adverse events, Switch to mania	"eSMD=0.1 [-0.44, 0.63] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=17.74	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.1	0.27	IV (Very Low)	Bahji A., 2020 (NMA)	-0.1	-0.44	0.63	car	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	aripiprazole	Adverse events, Switch to mania	"eSMD=0.08 [-0.53, 0.7] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=22.17	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.08	0.31	IV (Very Low)	Bahji A., 2020 (NMA)	-0.08	-0.53	0.7	ari	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	lurasidone	Adverse events, Switch to mania	"eSMD=-0.06 [-0.61, 0.49] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=29.55	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	-0.06	0.28	IV (Very Low)	Bahji A., 2020 (NMA)	0.06	-0.61	0.49	lur	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	gabapentin	Adverse events, Switch to mania	"eSMD=-0.07 [-1.47, 1.27] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=25.33	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	-0.07	0.7	IV (Very Low)	Bahji A., 2020 (NMA)	0.07	-1.47	1.27	gaba	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	divalproate	Adverse events, Switch to mania	"eSMD=-0.09 [-0.63, 0.45] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=19.71	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	-0.09	0.28	IV (Very Low)	Bahji A., 2020 (NMA)	0.09	-0.63	0.45	div	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	lamotrigine	Adverse events, Switch to mania	"eSMD=-0.15 [-0.47, 0.17] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=11.84	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	-0.15	0.16	IV (Very Low)	Bahji A., 2020 (NMA)	0.15	-0.47	0.17	lam	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	paroxetine	Adverse events, Switch to mania	"eSMD=-0.28 [-0.68, 0.13] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.37	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	-0.28	0.21	IV (Very Low)	Bahji A., 2020 (NMA)	0.28	-0.68	0.13	par	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	paroxetine	Adverse events, Switch to mania	"eSMD=-0.72 [-1.12, -0.29] <br> <img src=""https://www.linkpicture.com/q/Diapositive2.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.57	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	quetiapine	mono	-0.72	0.21	II (Moderate)	Bahji A., 2020 (NMA)	0.72	-1.12	-0.29	par	que	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	imipramine	Adverse events, Switch to mania	"eSMD=-0.32 [-1.05, 0.42] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.59	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	tranylcypromine	mono	-0.32	0.38	IV (Very Low)	Bahji A., 2020 (NMA)	0.32	-1.05	0.42	imp	tran	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	lamotrigine	Adverse events, Switch to mania	"eSMD=-0.16 [-0.68, 0.36] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=11.1	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	olanzapine+fluoxetine	combo	-0.16	0.27	IV (Very Low)	Bahji A., 2020 (NMA)	0.16	-0.68	0.36	lam	ola+fluo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	fluoxetine	Adverse events, Switch to mania	"eSMD=-0.11 [-0.79, 0.57] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=16.13	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	imipramine	mono	-0.11	0.35	IV (Very Low)	Bahji A., 2020 (NMA)	0.11	-0.79	0.57	fluo	imp	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	fluoxetine	Adverse events, Switch to mania	"eSMD=-0.07 [-1.65, 1.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=25.33	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	olanzapine	mono	-0.07	0.82	IV (Very Low)	Bahji A., 2020 (NMA)	0.07	-1.65	1.55	fluo	ola	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	imipramine	Adverse events, Switch to mania	"eSMD=-0.05 [-1.65, 1.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=35.46	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	phenelzine	mono	-0.05	0.82	IV (Very Low)	Bahji A., 2020 (NMA)	0.05	-1.65	1.55	imp	phen	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	lithium	Adverse events, Switch to mania	"eSMD=-0.01 [-1.55, 1.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=177.25	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	venlafaxine	mono	-0.01	0.79	IV (Very Low)	Bahji A., 2020 (NMA)	0.01	-1.55	1.55	lit	ven	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	fluoxetine	Adverse events, Switch to mania	"eSMD=0 [-1.65, 1.65] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	olanzapine+fluoxetine	combo	0	0.84	IV (Very Low)	Bahji A., 2020 (NMA)	0	-1.65	1.65	fluo	ola+fluo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	gabapentin	Adverse events, Switch to mania	"eSMD=0 [-1.55, 1.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	lamotrigine	mono	0	0.79	IV (Very Low)	Bahji A., 2020 (NMA)	0	-1.55	1.55	gaba	lam	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	olanzapine	Adverse events, Switch to mania	"eSMD=0.07 [-0.45, 0.59] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=25.33	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	olanzapine+fluoxetine	combo	0.07	0.27	IV (Very Low)	Bahji A., 2020 (NMA)	-0.07	-0.45	0.59	ola	ola+fluo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	lithium	Adverse events, Switch to mania	"eSMD=0.14 [-0.47, 0.76] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=12.68	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	sertraline	mono	0.14	0.31	IV (Very Low)	Bahji A., 2020 (NMA)	-0.14	-0.47	0.76	lit	sert	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	lithium	Adverse events, Switch to mania	"eSMD=0.23 [-0.47, 0.92] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.74	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	quetiapine	mono	0.23	0.35	IV (Very Low)	Bahji A., 2020 (NMA)	-0.23	-0.47	0.92	lit	que	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	imipramine	Adverse events, Switch to mania	"eSMD=0.61 [-0.7, 1.93] <br> <img src=""https://www.linkpicture.com/q/Diapositive17.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	moclobemide	mono	0.61	0.67	IV (Very Low)	Bahji A., 2020 (NMA)	-0.61	-0.7	1.93	imp	moc	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	citalopram	Adverse events, Switch to mania	"eSMD=0.48 [-0.24, 1.22] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.76	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.48	0.37	II (Moderate)	Bahji A., 2021 (NMA)	-0.48	-0.24	1.22	cit	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	ziprasidone	Adverse events, Switch to mania	"eSMD=0.37 [-0.95, 1.65] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.85	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.37	0.66	II (Moderate)	Bahji A., 2021 (NMA)	-0.37	-0.95	1.65	zip	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	dextromethorphan	Adverse events, Switch to mania	"eSMD=0.36 [-1.17, 1.93] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.98	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.36	0.79	II (Moderate)	Bahji A., 2021 (NMA)	-0.36	-1.17	1.93	dexm	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	t3 hormone	Adverse events, Switch to mania	"eSMD=0.33 [-1.08, 1.77] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.42	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.33	0.73	II (Moderate)	Bahji A., 2021 (NMA)	-0.33	-1.08	1.77	t3	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	lurasidone	Adverse events, Switch to mania	"eSMD=0.31 [-0.51, 1.12] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.76	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.31	0.42	II (Moderate)	Bahji A., 2021 (NMA)	-0.31	-0.51	1.12	lur	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	pramipexole	Adverse events, Switch to mania	"eSMD=0.24 [-0.7, 1.17] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.42	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.24	0.48	II (Moderate)	Bahji A., 2021 (NMA)	-0.24	-0.7	1.17	pram	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	fluoxetine	Adverse events, Switch to mania	"eSMD=0.14 [-0.17, 0.47] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=12.68	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.14	0.16	II (Moderate)	Bahji A., 2021 (NMA)	-0.14	-0.17	0.47	fluo	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	memantine	Adverse events, Switch to mania	"eSMD=0.14 [-0.65, 0.92] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=12.68	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.14	0.4	II (Moderate)	Bahji A., 2021 (NMA)	-0.14	-0.65	0.92	mem	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	imipramine	Adverse events, Switch to mania	"eSMD=0.1 [-0.38, 0.58] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=17.74	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.1	0.24	II (Moderate)	Bahji A., 2021 (NMA)	-0.1	-0.38	0.58	imp	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	sAME	Adverse events, Switch to mania	"eSMD=0.06 [-1.39, 1.47] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=29.55	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.06	0.73	II (Moderate)	Bahji A., 2021 (NMA)	-0.06	-1.39	1.47	sAME	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	t4 hormone	Adverse events, Switch to mania	"eSMD=0.06 [-0.98, 1.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=29.55	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.06	0.53	II (Moderate)	Bahji A., 2021 (NMA)	-0.06	-0.98	1.08	t4	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	coenzyme Q10	Adverse events, Switch to mania	"eSMD=0.05 [-1.47, 1.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=35.46	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.05	0.77	II (Moderate)	Bahji A., 2021 (NMA)	-0.05	-1.47	1.55	coQ10	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	pregnenolone	Adverse events, Switch to mania	"eSMD=0.05 [-1.47, 1.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=35.46	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.05	0.77	II (Moderate)	Bahji A., 2021 (NMA)	-0.05	-1.47	1.55	preg	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	paroxetine+bupropion	Adverse events, Switch to mania	"eSMD=0.03 [-0.3, 0.37] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=59.09	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.03	0.17	II (Moderate)	Bahji A., 2021 (NMA)	-0.03	-0.3	0.37	par+bup	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	minocycline+acetylsalicylic acid	Adverse events, Switch to mania	"eSMD=0.02 [-1.47, 1.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=88.63	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.02	0.77	II (Moderate)	Bahji A., 2021 (NMA)	-0.02	-1.47	1.55	mino+asa	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	celecoxib	Adverse events, Switch to mania	"eSMD=0 [-1.05, 1.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0	0.54	II (Moderate)	Bahji A., 2021 (NMA)	0	-1.05	1.05	cel	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	ketamine	Adverse events, Switch to mania	"eSMD=0 [-1.05, 1.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0	0.54	II (Moderate)	Bahji A., 2021 (NMA)	0	-1.05	1.05	ket	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	pindolol	Adverse events, Switch to mania	"eSMD=0 [-1.05, 1.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0	0.54	II (Moderate)	Bahji A., 2021 (NMA)	0	-1.05	1.05	pin	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	quetiapine	Adverse events, Switch to mania	"eSMD=0 [-1.55, 1.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0	0.79	II (Moderate)	Bahji A., 2021 (NMA)	0	-1.55	1.55	que	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	pioglitazone	Adverse events, Switch to mania	"eSMD=-0.03 [-1.08, 1.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=59.09	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.03	0.53	II (Moderate)	Bahji A., 2021 (NMA)	0.03	-1.08	1.01	pio	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	vitD3	Adverse events, Switch to mania	"eSMD=-0.03 [-1.55, 1.47] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=59.09	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.03	0.77	II (Moderate)	Bahji A., 2021 (NMA)	0.03	-1.55	1.47	vitD3	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	infliximab	Adverse events, Switch to mania	"eSMD=-0.04 [-1.55, 1.47] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=44.32	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.04	0.77	II (Moderate)	Bahji A., 2021 (NMA)	0.04	-1.55	1.47	infx	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	aripiprazole	Adverse events, Switch to mania	"eSMD=-0.05 [-1.55, 1.39] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=35.46	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.05	0.75	II (Moderate)	Bahji A., 2021 (NMA)	0.05	-1.55	1.39	ari	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	n-acetyl cysteine	Adverse events, Switch to mania	"eSMD=-0.12 [-0.58, 0.35] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=14.79	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.12	0.24	II (Moderate)	Bahji A., 2021 (NMA)	0.12	-0.58	0.35	nac	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	lamotrigine	Adverse events, Switch to mania	"eSMD=-0.13 [-0.51, 0.26] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=13.65	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.13	0.2	II (Moderate)	Bahji A., 2021 (NMA)	0.13	-0.51	0.26	lam	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	lisdexamfetamine	Adverse events, Switch to mania	"eSMD=-0.13 [-1.55, 1.33] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=13.65	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.13	0.73	II (Moderate)	Bahji A., 2021 (NMA)	0.13	-1.55	1.33	lisdex	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	paroxetine	Adverse events, Switch to mania	"eSMD=-0.14 [-1.65, 1.39] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=12.68	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.14	0.78	II (Moderate)	Bahji A., 2021 (NMA)	0.14	-1.65	1.39	par	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	omega3	Adverse events, Switch to mania	"eSMD=-0.17 [-0.52, 0.17] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=10.45	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.17	0.18	II (Moderate)	Bahji A., 2021 (NMA)	0.17	-0.52	0.17	omega3	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	armodafinil	Adverse events, Switch to mania	"eSMD=-0.18 [-0.61, 0.25] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=9.87	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.18	0.22	II (Moderate)	Bahji A., 2021 (NMA)	0.18	-0.61	0.25	armo	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	bupropion	Adverse events, Switch to mania	"eSMD=-0.19 [-1.55, 1.22] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=9.36	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.19	0.71	II (Moderate)	Bahji A., 2021 (NMA)	0.19	-1.55	1.22	bup	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	inositol	Adverse events, Switch to mania	"eSMD=-0.19 [-1.12, 0.74] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=9.36	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.19	0.47	II (Moderate)	Bahji A., 2021 (NMA)	0.19	-1.12	0.74	ino	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	n-acetyl cysteine+acetylsalicylic acid	Adverse events, Switch to mania	"eSMD=-0.25 [-1.65, 1.22] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.13	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.25	0.73	II (Moderate)	Bahji A., 2021 (NMA)	0.25	-1.65	1.22	nac+asa	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	minocycline	Adverse events, Switch to mania	"eSMD=-0.25 [-1.77, 1.27] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.13	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.25	0.78	II (Moderate)	Bahji A., 2021 (NMA)	0.25	-1.77	1.27	mino	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	agomelatin	Adverse events, Switch to mania	"eSMD=-0.31 [-0.98, 0.36] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.76	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.31	0.34	II (Moderate)	Bahji A., 2021 (NMA)	0.31	-0.98	0.36	ago	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	levetiracetam	Adverse events, Switch to mania	"eSMD=-0.31 [-1.55, 0.95] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.76	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.31	0.64	II (Moderate)	Bahji A., 2021 (NMA)	0.31	-1.55	0.95	levt	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	creatine	Adverse events, Switch to mania	"eSMD=-0.38 [-1.65, 0.84] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.72	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.38	0.64	II (Moderate)	Bahji A., 2021 (NMA)	0.38	-1.65	0.84	creatine	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	acetylsalicylic acid	Adverse events, Switch to mania	"eSMD=-0.42 [-1.47, 0.61] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.28	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.42	0.53	II (Moderate)	Bahji A., 2021 (NMA)	0.42	-1.47	0.61	asa	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	imipramine	Adverse events, Switch to mania	"eSMD=-0.65 [-1.55, 0.21] <br> <img src=""https://www.linkpicture.com/q/Diapositive3.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.82	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	moclobemide	aug	-0.65	0.45	II (Moderate)	Bahji A., 2021 (NMA)	0.65	-1.55	0.21	imp	moc	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	acetylsalicylic acid	Adverse events, Switch to mania	"eSMD=-0.32 [-1.77, 1.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.59	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	n-acetyl cysteine+acetylsalicylic acid	aug	-0.32	0.73	II (Moderate)	Bahji A., 2021 (NMA)	0.32	-1.77	1.08	asa	nac+asa	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	imipramine	Adverse events, Switch to mania	"eSMD=-0.29 [-1.55, 1.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.15	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	paroxetine	aug	-0.29	0.65	II (Moderate)	Bahji A., 2021 (NMA)	0.29	-1.55	1.01	imp	par	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	acetylsalicylic acid	Adverse events, Switch to mania	"eSMD=-0.27 [-1.77, 1.23] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.6	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	minocycline+acetylsalicylic acid	aug	-0.27	0.77	II (Moderate)	Bahji A., 2021 (NMA)	0.27	-1.77	1.23	asa	mino+asa	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	minocycline	Adverse events, Switch to mania	"eSMD=-0.27 [-1.77, 1.23] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.6	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	minocycline+acetylsalicylic acid	aug	-0.27	0.77	II (Moderate)	Bahji A., 2021 (NMA)	0.27	-1.77	1.23	mino	mino+asa	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	acetylsalicylic acid	Adverse events, Switch to mania	"eSMD=-0.26 [-1.65, 1.14] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.86	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	n-acetyl cysteine	aug	-0.26	0.71	II (Moderate)	Bahji A., 2021 (NMA)	0.26	-1.65	1.14	asa	nac	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	lamotrigine	Adverse events, Switch to mania	"eSMD=-0.2 [-1.47, 1.02] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=8.89	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	tranylcypromine	aug	-0.2	0.64	II (Moderate)	Bahji A., 2021 (NMA)	0.2	-1.47	1.02	lam	tran	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	lamotrigine	Adverse events, Switch to mania	"eSMD=-0.16 [-0.92, 0.59] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=11.1	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	risperidone	aug	-0.16	0.39	II (Moderate)	Bahji A., 2021 (NMA)	0.16	-0.92	0.59	lam	risp	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	fluoxetine	Adverse events, Switch to mania	"eSMD=-0.09 [-0.61, 0.45] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=19.71	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	imipramine	aug	-0.09	0.27	II (Moderate)	Bahji A., 2021 (NMA)	0.09	-0.61	0.45	fluo	imp	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	n-acetyl cysteine	Adverse events, Switch to mania	"eSMD=-0.06 [-1.47, 1.39] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=29.55	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	n-acetyl cysteine+acetylsalicylic acid	aug	-0.06	0.73	II (Moderate)	Bahji A., 2021 (NMA)	0.06	-1.47	1.39	nac	nac+asa	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	amitriptyline	Adverse events, Switch to mania	"eSMD=0 [-1.47, 1.47] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	l-sulpride	aug	0	0.75	II (Moderate)	Bahji A., 2021 (NMA)	0	-1.47	1.47	amit	l-sulpr	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	citalopram	Adverse events, Switch to mania	"eSMD=0 [-1.47, 1.47] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	lamotrigine	aug	0	0.75	II (Moderate)	Bahji A., 2021 (NMA)	0	-1.47	1.47	cit	lam	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	acetylsalicylic acid	Adverse events, Switch to mania	"eSMD=0 [-1.47, 1.49] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	minocycline	aug	0	0.76	II (Moderate)	Bahji A., 2021 (NMA)	0	-1.47	1.49	asa	mino	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	paroxetine	Adverse events, Switch to mania	"eSMD=0 [-1.47, 1.47] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	risperidone	aug	0	0.75	II (Moderate)	Bahji A., 2021 (NMA)	0	-1.47	1.47	par	risp	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	paroxetine	Adverse events, Switch to mania	"eSMD=0 [-1.47, 1.47] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	risperidone+paroxetine	aug	0	0.75	II (Moderate)	Bahji A., 2021 (NMA)	0	-1.47	1.47	par	risp+par	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	risperidone	Adverse events, Switch to mania	"eSMD=0 [-1.47, 1.47] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	risperidone+paroxetine	aug	0	0.75	II (Moderate)	Bahji A., 2021 (NMA)	0	-1.47	1.47	risp	risp+par	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	bupropion	Adverse events, Switch to mania	"eSMD=0 [-1.47, 1.49] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	topiramate	aug	0	0.76	II (Moderate)	Bahji A., 2021 (NMA)	0	-1.47	1.49	bup	top	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	inositol	Adverse events, Switch to mania	"eSMD=0.05 [-0.76, 0.86] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=35.46	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	risperidone	aug	0.05	0.41	II (Moderate)	Bahji A., 2021 (NMA)	-0.05	-0.76	0.86	ino	risp	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	amitriptyline	Adverse events, Switch to mania	"eSMD=0.11 [-1.39, 1.65] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=16.13	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	paroxetine	aug	0.11	0.78	II (Moderate)	Bahji A., 2021 (NMA)	-0.11	-1.39	1.65	amit	par	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	fluoxetine	Adverse events, Switch to mania	"eSMD=0.12 [-0.38, 0.63] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=14.79	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	lamotrigine	aug	0.12	0.26	II (Moderate)	Bahji A., 2021 (NMA)	-0.12	-0.38	0.63	fluo	lam	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	lithium	Adverse events, Switch to mania	"eSMD=0.2 [-1.27, 1.65] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.89	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	paroxetine	aug	0.2	0.74	II (Moderate)	Bahji A., 2021 (NMA)	-0.2	-1.27	1.65	lit	par	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	inositol	Adverse events, Switch to mania	"eSMD=0.21 [-0.55, 0.98] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.47	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	lamotrigine	aug	0.21	0.39	II (Moderate)	Bahji A., 2021 (NMA)	-0.21	-0.55	0.98	ino	lam	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	bupropion	Adverse events, Switch to mania	"eSMD=0.31 [-0.59, 1.22] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.76	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	sertraline	aug	0.31	0.46	II (Moderate)	Bahji A., 2021 (NMA)	-0.31	-0.59	1.22	bup	sert	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	sertraline	Adverse events, Switch to mania	"eSMD=0.44 [-0.17, 1.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.09	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	venlafaxine	aug	0.44	0.31	II (Moderate)	Bahji A., 2021 (NMA)	-0.44	-0.17	1.05	sert	ven	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	bupropion	Adverse events, Switch to mania	"eSMD=0.68 [-0.44, 1.77] <br> <img src=""https://www.linkpicture.com/q/Diapositive18.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.71	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	desipramine	aug	0.68	0.56	II (Moderate)	Bahji A., 2021 (NMA)	-0.68	-0.44	1.77	bup	desimp	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	bupropion	Adverse events, Switch to mania	"eSMD=0.76 [-0.06, 1.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive19.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.44	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	venlafaxine	aug	0.76	0.41	II (Moderate)	Bahji A., 2021 (NMA)	-0.76	-0.06	1.55	bup	ven	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	paroxetine	Adverse events, Switch to mania	"eSMD=0.76 [-0.42, 1.93] <br> <img src=""https://www.linkpicture.com/q/Diapositive19.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.44	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	venlafaxine	aug	0.76	0.6	II (Moderate)	Bahji A., 2021 (NMA)	-0.76	-0.42	1.93	par	ven	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	cariprazine	Adverse events, Switch to mania	"eSMD=0.05 [-0.3, 0.49] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=35.46	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	16	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.05	0.2	III (Low)	Kadakia A., 2021 (NMA)	-0.05	-0.3	0.49	car	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Takeshima M., 2020 (MA)</a>"	bright light therapy	Adverse events, Switch to mania	"eSMD=0 [-0.7, 0.7] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	6	Pairwise meta-analysis	Adults	Bipolar Depression	TAU/sham	mono	0	0.36	III (Low)	Takeshima M., 2020 (MA)	0	-0.7	0.7	BLT	tau/sham	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Taylor D.M., 2014 (NMA)</a>"	ziprasidone	Adverse events, Switch to mania	"eSMD=0.81 [-0.18, 1.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.31	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.81	0.44	IV (Very Low)	Taylor D.M., 2014 (NMA)	-0.81	-0.18	1.55	zip	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Taylor D.M., 2014 (NMA)</a>"	quetiapine	Adverse events, Switch to mania	"eSMD=0.39 [0.03, 0.68] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.6	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.39	0.17	III (Low)	Taylor D.M., 2014 (NMA)	-0.39	0.03	0.68	que	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Taylor D.M., 2014 (NMA)</a>"	olanzapine+fluoxetine	Adverse events, Switch to mania	"eSMD=0.02 [-0.56, 0.49] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=88.63	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.02	0.27	IV (Very Low)	Taylor D.M., 2014 (NMA)	-0.02	-0.56	0.49	ola+fluo	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Taylor D.M., 2014 (NMA)</a>"	divalproate	Adverse events, Switch to mania	"eSMD=0.02 [-0.76, 0.58] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=88.63	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.02	0.34	IV (Very Low)	Taylor D.M., 2014 (NMA)	-0.02	-0.76	0.58	div	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Taylor D.M., 2014 (NMA)</a>"	lithium	Adverse events, Switch to mania	"eSMD=-0.15 [-0.7, 0.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=11.84	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.15	0.32	IV (Very Low)	Taylor D.M., 2014 (NMA)	0.15	-0.7	0.55	lit	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Taylor D.M., 2014 (NMA)</a>"	olanzapine	Adverse events, Switch to mania	"eSMD=-0.18 [-0.61, 0.31] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=9.87	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.18	0.23	IV (Very Low)	Taylor D.M., 2014 (NMA)	0.18	-0.61	0.31	ola	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Taylor D.M., 2014 (NMA)</a>"	lamotrigine	Adverse events, Switch to mania	"eSMD=-0.45 [-0.92, 0.17] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.01	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.45	0.28	IV (Very Low)	Taylor D.M., 2014 (NMA)	0.45	-0.92	0.17	lam	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Taylor D.M., 2014 (NMA)</a>"	lurasidone	Adverse events, Switch to mania	"eSMD=-0.45 [-1.01, 0.27] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.01	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.45	0.33	IV (Very Low)	Taylor D.M., 2014 (NMA)	0.45	-1.01	0.27	lur	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Taylor D.M., 2014 (NMA)</a>"	aripiprazole	Adverse events, Switch to mania	"eSMD=-0.52 [-1.01, 0.12] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.49	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.52	0.29	IV (Very Low)	Taylor D.M., 2014 (NMA)	0.52	-1.01	0.12	ari	pbo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Taylor D.M., 2014 (NMA)</a>"	lithium	Adverse events, Switch to mania	"eSMD=-0.52 [-1.05, 0.2] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.49	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Bipolar Depression	quetiapine	mono	-0.52	0.32	IV (Very Low)	Taylor D.M., 2014 (NMA)	0.52	-1.05	0.2	lit	que	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Taylor D.M., 2014 (NMA)</a>"	lamotrigine	Adverse events, Switch to mania	"eSMD=-0.42 [-0.92, 0.26] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.28	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Bipolar Depression	olanzapine+fluoxetine	combo	-0.42	0.3	IV (Very Low)	Taylor D.M., 2014 (NMA)	0.42	-0.92	0.26	lam	ola+fluo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Taylor D.M., 2014 (NMA)</a>"	olanzapine	Adverse events, Switch to mania	"eSMD=-0.18 [-0.74, 0.52] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=9.87	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Bipolar Depression	olanzapine+fluoxetine	combo	-0.18	0.32	IV (Very Low)	Taylor D.M., 2014 (NMA)	0.18	-0.74	0.52	ola	ola+fluo	AE, Switch to mania
"<a href='https://doi.org/' target=""_blank"">Vita A., 2013 (MA)</a>"	asenapine	Adverse events, Tardive dyskinesia	"eSMD=-0.92 [-2.16, 0.31] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.06	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.92	0.63	IV (Very Low)	Vita A., 2013 (MA)	0.92	-2.16	0.31	ase	ola	AE, Tardive dyskinesia
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2013 (MA)</a>"	divalproate	Adverse events, Thirst, increase	"eSMD=0.63 [0.24, 1.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive18.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.91	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Low	2	Pairwise meta-analysis	Mixed (Children-Adults)	Maintenance	lithium	mono	0.63	0.21	I (High)	Cipriani A., 2013 (MA)	-0.63	0.24	1.05	div	lit	AE, Thirst, increase
"<a href='https://doi.org/' target=""_blank"">Pinto J.V., 2020 (MA)</a>"	cariprazine	Adverse events, Treatment emergent	"eSMD=-0.12 [-0.25, 0.4] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=14.79	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	4	Pairwise meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.12	0.17	III (Low)	Pinto J.V., 2020 (MA)	0.12	-0.25	0.4	car	pbo	AE, Treatment emergent
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2006 (MA)</a>"	haloperidol	Adverse events, Tremor	"eSMD=-0.66 [-0.98, -0.34] <br> <img src=""https://www.linkpicture.com/q/Diapositive3.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.78	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.66	0.16	I (High)	Cipriani A., 2006 (MA)	0.66	-0.98	-0.34	hal	pbo	AE, Tremor
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2013 (MA)</a>"	divalproate	Adverse events, Tremor	"eSMD=-0.49 [-0.72, -0.25] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.69	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Low	2	Pairwise meta-analysis	Adults	Maintenance	placebo	mono	-0.49	0.12	II (Moderate)	Cipriani A., 2013 (MA)	0.49	-0.72	-0.25	div	pbo	AE, Tremor
"<a href='https://doi.org/' target=""_blank"">Jochim J., 2019 (MA)</a>"	divalproate	Adverse events, Tremor	"eSMD=0.7 [0.11, 1.33] <br> <img src=""https://www.linkpicture.com/q/Diapositive18.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.64	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	olanzapine	mono	0.7	0.31	I (High)	Jochim J., 2019 (MA)	-0.7	0.11	1.33	div	ola	AE, Tremor
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	lithium	Adverse events, Tremor	"eSMD=-0.65 [-0.89, -0.4] <br> <img src=""https://www.linkpicture.com/q/Diapositive3.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.82	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	6	Pairwise meta-analysis	Mixed (Children-Adults)	Mania/Mixed	placebo	mono	-0.65	0.12	I (High)	McKnight R.F., 2019 (MA)	0.65	-0.89	-0.4	lit	pbo	AE, Tremor
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	lamotrigine	Adverse events, Tremor	"eSMD=0.14 [-0.4, 0.68] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=12.68	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	lithium	mono	0.14	0.28	III (Low)	McKnight R.F., 2019 (MA)	-0.14	-0.4	0.68	lam	lit	AE, Tremor
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	divalproate	Adverse events, Tremor	"eSMD=1.27 [0.37, 2.16] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.59	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Mixed (Children-Adults)	Mania/Mixed	lithium	mono	1.27	0.46	I (High)	McKnight R.F., 2019 (MA)	-1.27	0.37	2.16	div	lit	AE, Tremor
"<a href='https://doi.org/' target=""_blank"">Rendell J.M., 2010 (MA)</a>"	risperidone	Adverse events, Tremor	"eSMD=-0.33 [-1.12, 0.47] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.42	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	aug	-0.33	0.41	III (Low)	Rendell J.M., 2010 (MA)	0.33	-1.12	0.47	risp	pbo	AE, Tremor
"<a href='https://doi.org/' target=""_blank"">Rendell J.M., 2010 (MA)</a>"	risperidone	Adverse events, Tremor	"eSMD=-0.7 [-2.16, 0.79] <br> <img src=""https://www.linkpicture.com/q/Diapositive3.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.64	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.7	0.75	III (Low)	Rendell J.M., 2010 (MA)	0.7	-2.16	0.79	risp	pbo	AE, Tremor
"<a href='https://doi.org/' target=""_blank"">Jochim J., 2019 (MA)</a>"	divalproate	Adverse events, Upper respiratory tract infection	"eSMD=-0.65 [-1.17, -0.14] <br> <img src=""https://www.linkpicture.com/q/Diapositive3.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.82	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.65	0.26	I (High)	Jochim J., 2019 (MA)	0.65	-1.17	-0.14	div	pbo	AE, Upper respiratory tract infection
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2019 (MA)</a>"	ramelteon	Adverse events, Upper respiratory tract infection	"eSMD=0.19 [-0.18, 0.56] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=9.36	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Maintenance	placebo	mono	0.19	0.19	III (Low)	Kishi T., 2019 (MA)	-0.19	-0.18	0.56	ram	pbo	AE, Upper respiratory tract infection
"<a href='https://doi.org/' target=""_blank"">Jochim J., 2019 (MA)</a>"	divalproate	Adverse events, Vomiting	"eSMD=-0.65 [-0.95, -0.32] <br> <img src=""https://www.linkpicture.com/q/Diapositive3.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.82	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	4	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.65	0.16	I (High)	Jochim J., 2019 (MA)	0.65	-0.95	-0.32	div	pbo	AE, Vomiting
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	lithium	Adverse events, Vomiting	"eSMD=-0.98 [-1.33, -0.65] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1.95	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	6	Pairwise meta-analysis	Mixed (Children-Adults)	Mania/Mixed	placebo	mono	-0.98	0.17	I (High)	McKnight R.F., 2019 (MA)	0.98	-1.33	-0.65	lit	pbo	AE, Vomiting
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	lithium	Adverse events, Vomiting	"eSMD=-0.56 [-1.01, -0.11] <br> <img src=""https://www.linkpicture.com/q/Diapositive4.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.25	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Mixed (Children-Adults)	Mania/Mixed	risperidone	mono	-0.56	0.23	I (High)	McKnight R.F., 2019 (MA)	0.56	-1.01	-0.11	lit	risp	AE, Vomiting
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	lamotrigine	Adverse events, Vomiting	"eSMD=0.31 [-0.16, 0.79] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.76	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	lithium	mono	0.31	0.24	III (Low)	McKnight R.F., 2019 (MA)	-0.31	-0.16	0.79	lam	lit	AE, Vomiting
"<a href='https://doi.org/' target=""_blank"">Vita A., 2013 (MA)</a>"	asenapine	Adverse events, Waist circumference, change from baseline	"eSMD=-0.16 [-0.33, 0.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=11.1	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.16	0.09	IV (Very Low)	Vita A., 2013 (MA)	0.16	-0.33	0.01	ase	pbo	AE, Waist circumference, change
"<a href='https://doi.org/' target=""_blank"">Vita A., 2013 (MA)</a>"	asenapine	Adverse events, Waist circumference, change from baseline	"eSMD=-0.34 [-0.5, -0.18] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.26	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.34	0.08	IV (Very Low)	Vita A., 2013 (MA)	0.34	-0.5	-0.18	ase	ola	AE, Waist circumference, change
"<a href='https://doi.org/' target=""_blank"">Gomes-da-Costa S., 2021 (MA)</a>"	lithium	Adverse events, Weight increase (continuous)	"eSMD=0.35 [-0.3, 1.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.12	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Mixed (Children-Adults)	Maintenance	placebo	mono	0.35	0.33	II (Moderate)	Gomes-da-Costa S., 2021 (MA)	-0.35	-0.3	1.01	lit	pbo	AE, Weight increase, continuous
"<a href='https://doi.org/' target=""_blank"">Nunez N.A., 2020 (MA)</a>"	armodafinil	Adverse events, Weight increase (continuous)	"eSMD=0.59 [0.15, 1.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive17.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.09	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Bipolar Depression	placebo	aug	0.59	0.23	II (Moderate)	Nunez N.A., 2020 (MA)	-0.59	0.15	1.05	armo	pbo	AE, Weight increase, continuous
"<a href='https://doi.org/' target=""_blank"">Correll C.U., 2010 (MA)</a>"	lithium	Adverse events, Weight increase (continuous), change from baseline	"eSMD=0.03 [-0.11, 0.17] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=59.09	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	0.03	0.07	IV (Very Low)	Correll C.U., 2010 (MA)	-0.03	-0.11	0.17	lit	pbo	AE, Weight increase, continuous, change
"<a href='https://doi.org/' target=""_blank"">Correll C.U., 2010 (MA)</a>"	aripiprazole	Adverse events, Weight increase (continuous), change from baseline	"eSMD=-0.05 [-0.16, 0.07] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=35.46	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	4	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.05	0.06	IV (Very Low)	Correll C.U., 2010 (MA)	0.05	-0.16	0.07	ari	pbo	AE, Weight increase, continuous, change
"<a href='https://doi.org/' target=""_blank"">Correll C.U., 2010 (MA)</a>"	haloperidol	Adverse events, Weight increase (continuous), change from baseline	"eSMD=-0.06 [-0.22, 0.1] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=29.55	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	4	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.06	0.08	IV (Very Low)	Correll C.U., 2010 (MA)	0.06	-0.22	0.1	hal	pbo	AE, Weight increase, continuous, change
"<a href='https://doi.org/' target=""_blank"">Correll C.U., 2010 (MA)</a>"	risperidone	Adverse events, Weight increase (continuous), change from baseline	"eSMD=-0.24 [-0.38, -0.11] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.42	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.24	0.07	IV (Very Low)	Correll C.U., 2010 (MA)	0.24	-0.38	-0.11	risp	pbo	AE, Weight increase, continuous, change
"<a href='https://doi.org/' target=""_blank"">Correll C.U., 2010 (MA)</a>"	carbamazepine	Adverse events, Weight increase (continuous), change from baseline	"eSMD=-0.33 [-0.52, -0.14] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.42	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.33	0.1	IV (Very Low)	Correll C.U., 2010 (MA)	0.33	-0.52	-0.14	cbz	pbo	AE, Weight increase, continuous, change
"<a href='https://doi.org/' target=""_blank"">Correll C.U., 2010 (MA)</a>"	divalproate	Adverse events, Weight increase (continuous), change from baseline	"eSMD=-0.39 [-0.6, -0.19] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.6	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.39	0.1	IV (Very Low)	Correll C.U., 2010 (MA)	0.39	-0.6	-0.19	div	pbo	AE, Weight increase, continuous, change
"<a href='https://doi.org/' target=""_blank"">Correll C.U., 2010 (MA)</a>"	olanzapine	Adverse events, Weight increase (continuous), change from baseline	"eSMD=-0.73 [-0.99, -0.47] <br> <img src=""https://www.linkpicture.com/q/Diapositive2.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.54	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.73	0.13	IV (Very Low)	Correll C.U., 2010 (MA)	0.73	-0.99	-0.47	ola	pbo	AE, Weight increase, continuous, change
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	aripiprazole	Adverse events, Weight increase (continuous), change from baseline	"eSMD=-0.2 [-1, 0.59] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=8.89	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	14	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.2	0.41	III (Low)	Kadakia A., 2021 (NMA)	0.2	-1	0.59	ari	pbo	AE, Weight increase, continuous, change
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	lurasidone	Adverse events, Weight increase (continuous), change from baseline	"eSMD=-0.34 [-0.89, 0.22] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.26	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	14	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.34	0.28	III (Low)	Kadakia A., 2021 (NMA)	0.34	-0.89	0.22	lur	pbo	AE, Weight increase, continuous, change
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	cariprazine	Adverse events, Weight increase (continuous), change from baseline	"eSMD=-0.65 [-0.96, -0.34] <br> <img src=""https://www.linkpicture.com/q/Diapositive3.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.82	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	14	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.65	0.16	II (Moderate)	Kadakia A., 2021 (NMA)	0.65	-0.96	-0.34	car	pbo	AE, Weight increase, continuous, change
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	quetiapine	Adverse events, Weight increase (continuous), change from baseline	"eSMD=-1.17 [-1.49, -0.84] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1.69	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	14	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-1.17	0.17	II (Moderate)	Kadakia A., 2021 (NMA)	1.17	-1.49	-0.84	que	pbo	AE, Weight increase, continuous, change
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	olanzapine	Adverse events, Weight increase (continuous), change from baseline	"eSMD=-2.88 [-3.36, -2.4] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1.04	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	14	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-2.88	0.24	I (High)	Kadakia A., 2021 (NMA)	2.88	-3.36	-2.4	ola	pbo	AE, Weight increase, continuous, change
"<a href='https://doi.org/' target=""_blank"">Lao K.S.J., 2016 (MA)</a>"	cariprazine	Adverse events, Weight increase (continuous), change from baseline	"eSMD=-0.34 [-0.67, -0.02] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.26	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.34	0.17	I (High)	Lao K.S.J., 2016 (MA)	0.34	-0.67	-0.02	car	pbo	AE, Weight increase, continuous, change
"<a href='https://doi.org/' target=""_blank"">Macritchie K., 2003 (MA)</a>"	divalproate	Adverse events, Weight increase (continuous), change from baseline	"eSMD=2.14 [1.62, 2.65] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.15	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	olanzapine	mono	2.14	0.26	I (High)	Macritchie K., 2003 (MA)	-2.14	1.62	2.65	div	ola	AE, Weight increase, continuous, change
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	lithium	Adverse events, Weight increase (continuous), change from baseline	"eSMD=-0.16 [-0.82, 0.5] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=11.1	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Mixed (Children-Adults)	Mania/Mixed	placebo	mono	-0.16	0.34	III (Low)	McKnight R.F., 2019 (MA)	0.16	-0.82	0.5	lit	pbo	AE, Weight increase, continuous, change
"<a href='https://doi.org/' target=""_blank"">Rendell J.M., 2010 (MA)</a>"	risperidone	Adverse events, Weight increase (continuous), change from baseline	"eSMD=-1.47 [-2.13, -0.82] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1.43	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	aug	-1.47	0.33	III (Low)	Rendell J.M., 2010 (MA)	1.47	-2.13	-0.82	risp	pbo	AE, Weight increase, continuous, change
"<a href='https://doi.org/' target=""_blank"">Silva M.T., 2013 (MA)</a>"	olanzapine	Adverse events, Weight increase (continuous), change from baseline	"eSMD=-0.09 [-0.45, 0.26] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=19.71	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Bipolar Depression	olanzapine+fluoxetine	combo	-0.09	0.18	III (Low)	Silva M.T., 2013 (MA)	0.09	-0.45	0.26	ola	ola+fluo	AE, Weight increase, continuous, change
"<a href='https://doi.org/' target=""_blank"">Suttajit S., 2014 (MA)</a>"	quetiapine	Adverse events, Weight increase (continuous), change from baseline	"eSMD=-0.47 [-0.76, -0.16] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.84	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	4	Pairwise meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	-0.47	0.15	II (Moderate)	Suttajit S., 2014 (MA)	0.47	-0.76	-0.16	que	pbo	AE, Weight increase, continuous, change
"<a href='https://doi.org/' target=""_blank"">Vita A., 2013 (MA)</a>"	asenapine	Adverse events, Weight increase (continuous), change from baseline	"eSMD=-0.4 [-0.57, -0.24] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.49	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.4	0.08	IV (Very Low)	Vita A., 2013 (MA)	0.4	-0.57	-0.24	ase	ola	AE, Weight increase, continuous, change
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	tamoxifen	Adverse events, Weight, increase	"eSMD=0.61 [-1.08, 2.16] <br> <img src=""https://www.linkpicture.com/q/Diapositive17.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.61	0.83	II (Moderate)	Kishi T., 2021 (NMA)	-0.61	-1.08	2.16	tamox	pbo	AE, Weight, increase
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Adverse events, Weight, increase	"eSMD=0.21 [-0.05, 0.48] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.47	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.21	0.14	II (Moderate)	Kishi T., 2021 (NMA)	-0.21	-0.05	0.48	ari	pbo	AE, Weight, increase
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	carbamazepine	Adverse events, Weight, increase	"eSMD=-0.01 [-2.16, 2.16] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=177.25	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.01	1.1	II (Moderate)	Kishi T., 2021 (NMA)	0.01	-2.16	2.16	cbz	pbo	AE, Weight, increase
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	asenapine	Adverse events, Weight, increase	"eSMD=-0.06 [-1.55, 1.47] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=29.55	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	13	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.06	0.77	IV (Very Low)	Kishi T., 2021 (NMA)	0.06	-1.55	1.47	ase	pbo	AE, Weight, increase
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Adverse events, Weight, increase	"eSMD=-0.09 [-1.65, 1.47] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=19.71	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	13	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.09	0.8	IV (Very Low)	Kishi T., 2021 (NMA)	0.09	-1.65	1.47	pal	pbo	AE, Weight, increase
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Adverse events, Weight, increase	"eSMD=-0.12 [-1.08, 0.86] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=14.79	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	13	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.12	0.49	IV (Very Low)	Kishi T., 2021 (NMA)	0.12	-1.08	0.86	ola	pbo	AE, Weight, increase
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Weight, increase	"eSMD=-0.14 [-1.27, 1.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=12.68	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	13	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.14	0.58	IV (Very Low)	Kishi T., 2021 (NMA)	0.14	-1.27	1.01	lit	pbo	AE, Weight, increase
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole LAI	Adverse events, Weight, increase	"eSMD=-0.17 [-1.65, 1.33] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=10.45	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	13	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.17	0.76	IV (Very Low)	Kishi T., 2021 (NMA)	0.17	-1.65	1.33	ariLAI	pbo	AE, Weight, increase
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	cariprazine	Adverse events, Weight, increase	"eSMD=-0.23 [-1.01, 0.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.74	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.23	0.4	II (Moderate)	Kishi T., 2021 (NMA)	0.23	-1.01	0.55	car	pbo	AE, Weight, increase
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Adverse events, Weight, increase	"eSMD=-0.33 [-0.74, 0.1] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.42	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.33	0.21	II (Moderate)	Kishi T., 2021 (NMA)	0.33	-0.74	0.1	hal	pbo	AE, Weight, increase
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Weight, increase	"eSMD=-0.35 [-0.83, 0.14] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.12	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.35	0.25	II (Moderate)	Kishi T., 2021 (NMA)	0.35	-0.83	0.14	lit	pbo	AE, Weight, increase
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	quetiapine	Adverse events, Weight, increase	"eSMD=-0.36 [-1.93, 1.12] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.98	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	13	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.36	0.78	IV (Very Low)	Kishi T., 2021 (NMA)	0.36	-1.93	1.12	que	pbo	AE, Weight, increase
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	risperidone	Adverse events, Weight, increase	"eSMD=-0.4 [-0.95, 0.14] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.49	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.4	0.28	II (Moderate)	Kishi T., 2021 (NMA)	0.4	-0.95	0.14	risp	pbo	AE, Weight, increase
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Adverse events, Weight, increase	"eSMD=-0.42 [-1.77, 0.92] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.28	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	13	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.42	0.69	IV (Very Low)	Kishi T., 2021 (NMA)	0.42	-1.77	0.92	div	pbo	AE, Weight, increase
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	risperidone LAI	Adverse events, Weight, increase	"eSMD=-0.47 [-1.47, 0.58] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.84	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	13	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.47	0.52	IV (Very Low)	Kishi T., 2021 (NMA)	0.47	-1.47	0.58	rispLAI	pbo	AE, Weight, increase
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	ziprasidone	Adverse events, Weight, increase	"eSMD=-0.59 [-1.05, -0.13] <br> <img src=""https://www.linkpicture.com/q/Diapositive4.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.09	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.59	0.23	I (High)	Kishi T., 2021 (NMA)	0.59	-1.05	-0.13	zip	pbo	AE, Weight, increase
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Adverse events, Weight, increase	"eSMD=-0.61 [-1.17, -0.06] <br> <img src=""https://www.linkpicture.com/q/Diapositive4.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.61	0.28	I (High)	Kishi T., 2021 (NMA)	0.61	-1.17	-0.06	pal	pbo	AE, Weight, increase
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	asenapine	Adverse events, Weight, increase	"eSMD=-0.7 [-1.12, -0.31] <br> <img src=""https://www.linkpicture.com/q/Diapositive3.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.64	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.7	0.21	I (High)	Kishi T., 2021 (NMA)	0.7	-1.12	-0.31	ase	pbo	AE, Weight, increase
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Adverse events, Weight, increase	"eSMD=-0.76 [-2.54, 0.84] <br> <img src=""https://www.linkpicture.com/q/Diapositive2.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.44	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	13	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.76	0.86	IV (Very Low)	Kishi T., 2021 (NMA)	0.76	-2.54	0.84	ari	pbo	AE, Weight, increase
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	quetiapine	Adverse events, Weight, increase	"eSMD=-0.79 [-1.17, -0.42] <br> <img src=""https://www.linkpicture.com/q/Diapositive2.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.36	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.79	0.19	I (High)	Kishi T., 2021 (NMA)	0.79	-1.17	-0.42	que	pbo	AE, Weight, increase
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Adverse events, Weight, increase	"eSMD=-0.92 [-1.27, -0.56] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.06	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.92	0.18	I (High)	Kishi T., 2021 (NMA)	0.92	-1.27	-0.56	div	pbo	AE, Weight, increase
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Adverse events, Weight, increase	"eSMD=-1.17 [-1.47, -0.81] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1.69	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-1.17	0.17	I (High)	Kishi T., 2021 (NMA)	1.17	-1.47	-0.81	ola	pbo	AE, Weight, increase
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Adverse events, Weight, increase	"eSMD=-1.22 [-2.54, 0.38] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1.63	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	oxcarbazepine	mono	-1.22	0.74	II (Moderate)	Kishi T., 2021 (NMA)	1.22	-2.54	0.38	div	oxc	AE, Weight, increase
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine+lithium/divalproate	Adverse events, Weight, increase	"eSMD=-0.81 [-1.47, -0.17] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.31	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	6	Network meta-analysis	Adults	Maintenance	placebo+lithium/divalproate	combo	-0.81	0.33	III (Low)	Kishi T., 2021 (NMA)	0.81	-1.47	-0.17	ola+lit/div	pbo+lit/div	AE, Weight, increase
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Adverse events, Weight, increase	"eSMD=-0.74 [-1.22, -0.3] <br> <img src=""https://www.linkpicture.com/q/Diapositive2.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.5	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	risperidone	mono	-0.74	0.23	I (High)	Kishi T., 2021 (NMA)	0.74	-1.22	-0.3	ola	risp	AE, Weight, increase
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	quetiapine+lithium/divalproate	Adverse events, Weight, increase	"eSMD=-0.66 [-0.95, -0.38] <br> <img src=""https://www.linkpicture.com/q/Diapositive3.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.78	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	6	Network meta-analysis	Adults	Maintenance	placebo+lithium/divalproate	combo	-0.66	0.15	III (Low)	Kishi T., 2021 (NMA)	0.66	-0.95	-0.38	que+lit/div	pbo+lit/div	AE, Weight, increase
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lurasidone+lithium/divalproate	Adverse events, Weight, increase	"eSMD=-0.39 [-0.79, 0.02] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.6	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	6	Network meta-analysis	Adults	Maintenance	placebo+lithium/divalproate	combo	-0.39	0.21	IV (Very Low)	Kishi T., 2021 (NMA)	0.39	-0.79	0.02	lur+lit/div	pbo+lit/div	AE, Weight, increase
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Adverse events, Weight, increase	"eSMD=-0.27 [-1.47, 0.9] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.6	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	13	Network meta-analysis	Adults	Maintenance	lithium	mono	-0.27	0.6	IV (Very Low)	Kishi T., 2021 (NMA)	0.27	-1.47	0.9	div	lit	AE, Weight, increase
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole+divalproate	Adverse events, Weight, increase	"eSMD=-0.1 [-1.65, 1.47] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=17.74	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	13	Network meta-analysis	Adults	Maintenance	divalproate	mono	-0.1	0.8	IV (Very Low)	Kishi T., 2021 (NMA)	0.1	-1.65	1.47	ari+div	div	AE, Weight, increase
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole+lithium/divalproate	Adverse events, Weight, increase	"eSMD=-0.08 [-0.38, 0.23] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=22.17	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	6	Network meta-analysis	Adults	Maintenance	placebo+lithium/divalproate	combo	-0.08	0.16	IV (Very Low)	Kishi T., 2021 (NMA)	0.08	-0.38	0.23	ari+lit/div	pbo+lit/div	AE, Weight, increase
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Weight, increase	"eSMD=-0.03 [-1.22, 1.12] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=59.09	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	13	Network meta-analysis	Adults	Maintenance	olanzapine	mono	-0.03	0.6	IV (Very Low)	Kishi T., 2021 (NMA)	0.03	-1.22	1.12	lit	ola	AE, Weight, increase
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	ziprasidone+lithium/divalproate	Adverse events, Weight, increase	"eSMD=-0.02 [-0.59, 0.56] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=88.63	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	6	Network meta-analysis	Adults	Maintenance	placebo+lithium/divalproate	combo	-0.02	0.29	IV (Very Low)	Kishi T., 2021 (NMA)	0.02	-0.59	0.56	zip+lit/div	pbo+lit/div	AE, Weight, increase
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Adverse events, Weight, increase	"eSMD=0.17 [-0.33, 0.68] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=10.45	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	0.17	0.26	II (Moderate)	Kishi T., 2021 (NMA)	-0.17	-0.33	0.68	pal	que	AE, Weight, increase
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Adverse events, Weight, increase	"eSMD=0.26 [0.11, 0.41] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.86	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	0.26	0.08	I (High)	Kishi T., 2021 (NMA)	-0.26	0.11	0.41	div	ola	AE, Weight, increase
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Adverse events, Weight, increase	"eSMD=0.26 [-0.13, 0.66] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.86	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	ziprasidone	mono	0.26	0.2	II (Moderate)	Kishi T., 2021 (NMA)	-0.26	-0.13	0.66	hal	zip	AE, Weight, increase
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Adverse events, Weight, increase	"eSMD=0.35 [-0.86, 1.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.12	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	13	Network meta-analysis	Adults	Maintenance	risperidone LAI	mono	0.35	0.61	IV (Very Low)	Kishi T., 2021 (NMA)	-0.35	-0.86	1.55	ola	rispLAI	AE, Weight, increase
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Weight, increase	"eSMD=0.44 [0.07, 0.79] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.09	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	0.44	0.18	I (High)	Kishi T., 2021 (NMA)	-0.44	0.07	0.79	lit	que	AE, Weight, increase
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	asenapine	Adverse events, Weight, increase	"eSMD=0.45 [0.21, 0.68] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.01	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	0.45	0.12	I (High)	Kishi T., 2021 (NMA)	-0.45	0.21	0.68	ase	ola	AE, Weight, increase
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Adverse events, Weight, increase	"eSMD=0.45 [0.01, 0.89] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.01	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	0.45	0.22	I (High)	Kishi T., 2021 (NMA)	-0.45	0.01	0.89	hal	que	AE, Weight, increase
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Weight, increase	"eSMD=0.56 [-1.12, 2.16] <br> <img src=""https://www.linkpicture.com/q/Diapositive17.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.25	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	13	Network meta-analysis	Adults	Maintenance	lithium+oxcarbazepine	combo	0.56	0.84	IV (Very Low)	Kishi T., 2021 (NMA)	-0.56	-1.12	2.16	lit	lit+oxc	AE, Weight, increase
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Adverse events, Weight, increase	"eSMD=0.81 [0.26, 1.39] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.31	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	0.81	0.29	I (High)	Kishi T., 2021 (NMA)	-0.81	0.26	1.39	lit	ola	AE, Weight, increase
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Adverse events, Weight, increase	"eSMD=0.84 [0.33, 1.33] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.23	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	0.84	0.26	I (High)	Kishi T., 2021 (NMA)	-0.84	0.33	1.33	hal	ola	AE, Weight, increase
"<a href='https://doi.org/' target=""_blank"">Meduri M., 2016 (MA)</a>"	aripiprazole	Adverse events, Weight, increase	"eSMD=0.02 [-0.37, 0.4] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=88.63	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	aug	0.02	0.2	II (Moderate)	Meduri M., 2016 (MA)	-0.02	-0.37	0.4	ari	pbo	AE, Weight, increase
"<a href='https://doi.org/' target=""_blank"">Scherk H., 2007 (MA)</a>"	risperidone	Adverse events, Weight, increase	"eSMD=0.37 [0.13, 0.81] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.85	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	aug	0.37	0.17	III (Low)	Scherk H., 2007 (MA)	-0.37	0.13	0.81	risp	pbo	AE, Weight, increase
"<a href='https://doi.org/' target=""_blank"">Scherk H., 2007 (MA)</a>"	quetiapine	Adverse events, Weight, increase	"eSMD=0.35 [0.2, 0.56] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.12	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	aug	0.35	0.09	III (Low)	Scherk H., 2007 (MA)	-0.35	0.2	0.56	que	pbo	AE, Weight, increase
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	aripiprazole	Adverse events, Weight, increase >7%	"eSMD=-0.28 [-0.74, 0.32] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.37	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	15	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.28	0.27	IV (Very Low)	Kadakia A., 2021 (NMA)	0.28	-0.74	0.32	ari	pbo	AE, Weight, increase >7%
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	quetiapine	Adverse events, Weight, increase >7%	"eSMD=-0.68 [-0.98, -0.36] <br> <img src=""https://www.linkpicture.com/q/Diapositive3.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.71	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	15	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.68	0.16	II (Moderate)	Kadakia A., 2021 (NMA)	0.68	-0.98	-0.36	que	pbo	AE, Weight, increase >7%
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	cariprazine	Adverse events, Weight, increase >7%	"eSMD=-0.68 [-1.17, -0.13] <br> <img src=""https://www.linkpicture.com/q/Diapositive3.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.71	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	15	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.68	0.27	II (Moderate)	Kadakia A., 2021 (NMA)	0.68	-1.17	-0.13	car	pbo	AE, Weight, increase >7%
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	lurasidone	Adverse events, Weight, increase >7%	"eSMD=-1.65 [-2.54, 0.23] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1.32	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	15	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-1.65	0.71	IV (Very Low)	Kadakia A., 2021 (NMA)	1.65	-2.54	0.23	lur	pbo	AE, Weight, increase >7%
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	olanzapine	Adverse events, Weight, increase >7%	"eSMD=-2.54 [-Inf, -1.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1.08	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	15	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-2.54	Inf	II (Moderate)	Kadakia A., 2021 (NMA)	2.54	-Inf	-1.55	ola	pbo	AE, Weight, increase >7%
"<a href='https://doi.org/' target=""_blank"">Silva M.T., 2013 (MA)</a>"	olanzapine	Adverse events, Weight, increase >7%	"eSMD=-0.02 [-0.28, 0.23] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=88.63	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Bipolar Depression	olanzapine+fluoxetine	combo	-0.02	0.13	III (Low)	Silva M.T., 2013 (MA)	0.02	-0.28	0.23	ola	ola+fluo	AE, Weight, increase >7%
"<a href='https://doi.org/' target=""_blank"">Rendell J.M., 2010 (MA)</a>"	risperidone	Adverse events, Worsening of mania	"eSMD=0.61 [-0.39, 1.65] <br> <img src=""https://www.linkpicture.com/q/Diapositive17.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	aug	0.61	0.52	III (Low)	Rendell J.M., 2010 (MA)	-0.61	-0.39	1.65	risp	pbo	AE, Worsening of mania
"<a href='https://doi.org/' target=""_blank"">Lao K.S.J., 2016 (MA)</a>"	cariprazine	Akathisia scale, BAS	"eSMD=-0.5 [-0.67, -0.33] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.62	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.5	0.09	II (Moderate)	Lao K.S.J., 2016 (MA)	0.5	-0.67	-0.33	car	pbo	Akathisia scale, BAS
"<a href='https://doi.org/' target=""_blank"">Rendell J.M., 2010 (MA)</a>"	olanzapine	Akathisia scale, BAS	"eSMD=0.13 [-0.06, 0.32] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=13.65	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	0.13	0.1	II (Moderate)	Rendell J.M., 2010 (MA)	-0.13	-0.06	0.32	ola	pbo	Akathisia scale, BAS
"<a href='https://doi.org/' target=""_blank"">Scherk H., 2007 (MA)</a>"	ziprasidone	Akathisia scale, BAS	"eSMD=-0.22 [-0.43, -0.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=8.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.22	0.11	III (Low)	Scherk H., 2007 (MA)	0.22	-0.43	-0.01	zip	pbo	Akathisia scale, BAS
"<a href='https://doi.org/' target=""_blank"">Scherk H., 2007 (MA)</a>"	aripiprazole	Akathisia scale, BAS	"eSMD=-0.34 [-0.56, -0.12] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.26	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.34	0.11	III (Low)	Scherk H., 2007 (MA)	0.34	-0.56	-0.12	ari	pbo	Akathisia scale, BAS
"<a href='https://doi.org/' target=""_blank"">Vita A., 2013 (MA)</a>"	asenapine	Akathisia scale, BAS	"eSMD=-0.17 [-0.55, 0.2] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=10.45	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.17	0.19	IV (Very Low)	Vita A., 2013 (MA)	0.17	-0.55	0.2	ase	pbo	Akathisia scale, BAS
"<a href='https://doi.org/' target=""_blank"">Vita A., 2013 (MA)</a>"	asenapine	Akathisia scale, BAS	"eSMD=-0.11 [-0.27, 0.04] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=16.13	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.11	0.08	IV (Very Low)	Vita A., 2013 (MA)	0.11	-0.27	0.04	ase	ola	Akathisia scale, BAS
"<a href='https://doi.org/' target=""_blank"">Chiesa A., 2012 (MA)</a>"	quetiapine	Anxiety symptoms scale, HAM-A, change from baseline	"eSMD=2.27 [2.57, 2.97] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.12	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Pairwise meta-analysis	Adults	Bipolar Depression	placebo	mono	2.27	0.1	I (High)	Chiesa A., 2012 (MA)	-2.27	2.57	2.97	que	pbo	Anxiety sxs, HAM-A, change
"<a href='https://doi.org/' target=""_blank"">Nunez N.A., 2020 (MA)</a>"	armodafinil	Anxiety symptoms scale, HAM-A, change from baseline	"eSMD=0.27 [0.1, 0.46] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.6	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Pairwise meta-analysis	Adults	Bipolar Depression	placebo	aug	0.27	0.09	III (Low)	Nunez N.A., 2020 (MA)	-0.27	0.1	0.46	armo	pbo	Anxiety sxs, HAM-A, change
"<a href='https://doi.org/' target=""_blank"">Smith L.A., 2010 (MA)</a>"	divalproate	Anxiety symptoms scale, HAM-A, change from baseline	"eSMD=0.32 [-0.08, 0.72] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.59	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Bipolar Depression	placebo	mono	0.32	0.2	III (Low)	Smith L.A., 2010 (MA)	-0.32	-0.08	0.72	div	pbo	Anxiety sxs, HAM-A, change
"<a href='https://doi.org/' target=""_blank"">Suttajit S., 2014 (MA)</a>"	quetiapine	Anxiety symptoms scale, HAM-A, change from baseline	"eSMD=2.44 [1.55, 3.34] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.09	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Pairwise meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	2.44	0.46	I (High)	Suttajit S., 2014 (MA)	-2.44	1.55	3.34	que	pbo	Anxiety sxs, HAM-A, change
"<a href='https://doi.org/' target=""_blank"">Silva M.T., 2013 (MA)</a>"	olanzapine	Biochemical, ALT, change from baseline	"eSMD=-0.27 [-1.27, 0.7] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.6	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Bipolar Depression	olanzapine+fluoxetine	combo	-0.27	0.5	III (Low)	Silva M.T., 2013 (MA)	0.27	-1.27	0.7	ola	ola+fluo	Biochemical, ALT, change
"<a href='https://doi.org/' target=""_blank"">Silva M.T., 2013 (MA)</a>"	olanzapine	Biochemical, AST, change from baseline	"eSMD=-0.74 [-1.93, 0.49] <br> <img src=""https://www.linkpicture.com/q/Diapositive2.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.5	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Bipolar Depression	olanzapine+fluoxetine	combo	-0.74	0.62	III (Low)	Silva M.T., 2013 (MA)	0.74	-1.93	0.49	ola	ola+fluo	Biochemical, AST, change
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2020 (NMA)</a>"	lurasidone	Biochemical, Cholesterol HDL, change from baseline	"eSMD=0.16 [-0.06, 0.37] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=11.1	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.16	0.11	IV (Very Low)	Kishi T., 2020 (NMA)	-0.16	-0.06	0.37	lur	pbo	Biochemical, Cholesterol HDL, change
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2020 (NMA)</a>"	quetiapine	Biochemical, Cholesterol HDL, change from baseline	"eSMD=-0.06 [-0.27, 0.15] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=29.55	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.06	0.11	IV (Very Low)	Kishi T., 2020 (NMA)	0.06	-0.27	0.15	que	pbo	Biochemical, Cholesterol HDL, change
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2020 (NMA)</a>"	olanzapine	Biochemical, Cholesterol HDL, change from baseline	"eSMD=-0.12 [-0.31, 0.07] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=14.79	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.12	0.1	IV (Very Low)	Kishi T., 2020 (NMA)	0.12	-0.31	0.07	ola	pbo	Biochemical, Cholesterol HDL, change
"<a href='https://doi.org/' target=""_blank"">Vita A., 2013 (MA)</a>"	asenapine	Biochemical, Cholesterol HDL, change from baseline	"eSMD=-0.88 [-2.61, 0.85] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.14	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.88	0.88	IV (Very Low)	Vita A., 2013 (MA)	0.88	-2.61	0.85	ase	pbo	Biochemical, Cholesterol HDL, change
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	cariprazine	Biochemical, Cholesterol LDL, change from baseline	"eSMD=0.67 [-0.42, 3.23] <br> <img src=""https://www.linkpicture.com/q/Diapositive18.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.74	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	12	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.67	0.93	III (Low)	Kadakia A., 2021 (NMA)	-0.67	-0.42	3.23	car	pbo	Biochemical, Cholesterol LDL, change
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	quetiapine	Biochemical, Cholesterol LDL, change from baseline	"eSMD=0.59 [-3, 4.23] <br> <img src=""https://www.linkpicture.com/q/Diapositive17.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	12	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.59	1.84	III (Low)	Kadakia A., 2021 (NMA)	-0.59	-3	4.23	que	pbo	Biochemical, Cholesterol LDL, change
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	aripiprazole	Biochemical, Cholesterol LDL, change from baseline	"eSMD=0.5 [-3.14, 4.09] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.62	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	12	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.5	1.84	III (Low)	Kadakia A., 2021 (NMA)	-0.5	-3.14	4.09	ari	pbo	Biochemical, Cholesterol LDL, change
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	olanzapine	Biochemical, Cholesterol LDL, change from baseline	"eSMD=-0.42 [-2.16, 1.23] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.28	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	12	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.42	0.86	III (Low)	Kadakia A., 2021 (NMA)	0.42	-2.16	1.23	ola	pbo	Biochemical, Cholesterol LDL, change
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	lurasidone	Biochemical, Cholesterol LDL, change from baseline	"eSMD=-1.18 [-6.23, 3.86] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1.68	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	12	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-1.18	2.57	III (Low)	Kadakia A., 2021 (NMA)	1.18	-6.23	3.86	lur	pbo	Biochemical, Cholesterol LDL, change
"<a href='https://doi.org/' target=""_blank"">Vita A., 2013 (MA)</a>"	asenapine	Biochemical, Cholesterol LDL, change from baseline	"eSMD=-0.06 [-0.23, 0.11] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=29.55	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.06	0.09	IV (Very Low)	Vita A., 2013 (MA)	0.06	-0.23	0.11	ase	pbo	Biochemical, Cholesterol LDL, change
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	cariprazine	Biochemical, Cholesterol total, change from baseline	"eSMD=2.05 [-1.67, 5.9] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.17	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	13	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	2.05	1.93	III (Low)	Kadakia A., 2021 (NMA)	-2.05	-1.67	5.9	car	pbo	Biochemical, Cholesterol tot, change
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	aripiprazole	Biochemical, Cholesterol total, change from baseline	"eSMD=-0.5 [-6.6, 5.64] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.62	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	13	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.5	3.12	III (Low)	Kadakia A., 2021 (NMA)	0.5	-6.6	5.64	ari	pbo	Biochemical, Cholesterol tot, change
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	quetiapine	Biochemical, Cholesterol total, change from baseline	"eSMD=-0.5 [-5.88, 4.86] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.62	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	13	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.5	2.74	III (Low)	Kadakia A., 2021 (NMA)	0.5	-5.88	4.86	que	pbo	Biochemical, Cholesterol tot, change
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	lurasidone	Biochemical, Cholesterol total, change from baseline	"eSMD=-1.72 [-9.94, 6.56] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1.29	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	13	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-1.72	4.21	III (Low)	Kadakia A., 2021 (NMA)	1.72	-9.94	6.56	lur	pbo	Biochemical, Cholesterol tot, change
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	olanzapine	Biochemical, Cholesterol total, change from baseline	"eSMD=-7.06 [-12, -2.47] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	13	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-7.06	2.43	I (High)	Kadakia A., 2021 (NMA)	7.06	-12	-2.47	ola	pbo	Biochemical, Cholesterol tot, change
"<a href='https://doi.org/' target=""_blank"">Silva M.T., 2013 (MA)</a>"	olanzapine	Biochemical, Cholesterol total, change from baseline	"eSMD=0.12 [-0.79, 1.03] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=14.79	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Bipolar Depression	olanzapine+fluoxetine	combo	0.12	0.46	III (Low)	Silva M.T., 2013 (MA)	-0.12	-0.79	1.03	ola	ola+fluo	Biochemical, Cholesterol tot, change
"<a href='https://doi.org/' target=""_blank"">Vita A., 2013 (MA)</a>"	asenapine	Biochemical, Cholesterol total, change from baseline	"eSMD=-0.08 [-0.25, 0.09] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=22.17	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.08	0.09	IV (Very Low)	Vita A., 2013 (MA)	0.08	-0.25	0.09	ase	pbo	Biochemical, Cholesterol tot, change
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	lurasidone	Biochemical, Glucose, change from baseline	"eSMD=1.45 [-2.64, 5.5] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.44	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	15	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	1.45	2.08	III (Low)	Kadakia A., 2021 (NMA)	-1.45	-2.64	5.5	lur	pbo	Biochemical, Glucose, change
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	olanzapine	Biochemical, Glucose, change from baseline	"eSMD=0.34 [-2.17, 3.18] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.26	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	15	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.34	1.36	III (Low)	Kadakia A., 2021 (NMA)	-0.34	-2.17	3.18	ola	pbo	Biochemical, Glucose, change
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	cariprazine	Biochemical, Glucose, change from baseline	"eSMD=-0.07 [-1.7, 1.31] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=25.33	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	15	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.07	0.77	III (Low)	Kadakia A., 2021 (NMA)	0.07	-1.7	1.31	car	pbo	Biochemical, Glucose, change
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	aripiprazole	Biochemical, Glucose, change from baseline	"eSMD=-0.9 [-4.12, 2.17] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.1	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	15	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.9	1.6	III (Low)	Kadakia A., 2021 (NMA)	0.9	-4.12	2.17	ari	pbo	Biochemical, Glucose, change
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	quetiapine	Biochemical, Glucose, change from baseline	"eSMD=-1.15 [-3.12, 0.82] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1.71	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	15	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-1.15	1.01	III (Low)	Kadakia A., 2021 (NMA)	1.15	-3.12	0.82	que	pbo	Biochemical, Glucose, change
"<a href='https://doi.org/' target=""_blank"">Silva M.T., 2013 (MA)</a>"	olanzapine	Biochemical, Glucose, change from baseline	"eSMD=0.03 [-0.59, 0.64] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=59.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Bipolar Depression	olanzapine+fluoxetine	combo	0.03	0.31	III (Low)	Silva M.T., 2013 (MA)	-0.03	-0.59	0.64	ola	ola+fluo	Biochemical, Glucose, change
"<a href='https://doi.org/' target=""_blank"">Vita A., 2013 (MA)</a>"	asenapine	Biochemical, Glucose, change from baseline	"eSMD=-0.2 [-0.37, -0.03] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=8.89	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.2	0.09	IV (Very Low)	Vita A., 2013 (MA)	0.2	-0.37	-0.03	ase	pbo	Biochemical, Glucose, change
"<a href='https://doi.org/' target=""_blank"">Wang H., 2020 (MA)</a>"	lurasidone	Biochemical, Glucose, change from baseline	"eSMD=-0.35 [-1.79, 1.09] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.12	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.35	0.73	II (Moderate)	Wang H., 2020 (MA)	0.35	-1.79	1.09	lur	pbo	Biochemical, Glucose, change
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2020 (NMA)</a>"	quetiapine	Biochemical, HbA1c, change from baseline	"eSMD=0 [-0.21, 0.21] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0	0.11	IV (Very Low)	Kishi T., 2020 (NMA)	0	-0.21	0.21	que	pbo	Biochemical, HbA1c, change
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2020 (NMA)</a>"	olanzapine	Biochemical, HbA1c, change from baseline	"eSMD=-0.05 [-0.24, 0.15] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=35.46	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.05	0.1	IV (Very Low)	Kishi T., 2020 (NMA)	0.05	-0.24	0.15	ola	pbo	Biochemical, HbA1c, change
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2020 (NMA)</a>"	lurasidone	Biochemical, HbA1c, change from baseline	"eSMD=-0.14 [-0.35, 0.07] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=12.68	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.14	0.11	IV (Very Low)	Kishi T., 2020 (NMA)	0.14	-0.35	0.07	lur	pbo	Biochemical, HbA1c, change
"<a href='https://doi.org/' target=""_blank"">Chang H., 2017 (MA)</a>"	paliperidone	Biochemical, Prolactin, change from baseline	"eSMD=-1.35 [-1.57, -1.13] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1.51	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	-1.35	0.11	IV (Very Low)	Chang H., 2017 (MA)	1.35	-1.57	-1.13	pal	pbo	Biochemical, Prolactin, change
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	aripiprazole	Biochemical, Prolactin, change from baseline	"eSMD=-0.37 [-2.42, 1.72] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.85	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	8	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.37	1.06	III (Low)	Kadakia A., 2021 (NMA)	0.37	-2.42	1.72	ari	pbo	Biochemical, Prolactin, change
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	quetiapine	Biochemical, Prolactin, change from baseline	"eSMD=-1.04 [-3.55, 1.42] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1.86	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	8	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-1.04	1.27	III (Low)	Kadakia A., 2021 (NMA)	1.04	-3.55	1.42	que	pbo	Biochemical, Prolactin, change
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	cariprazine	Biochemical, Prolactin, change from baseline	"eSMD=-2.22 [-3.57, -0.89] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1.13	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	8	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-2.22	0.68	I (High)	Kadakia A., 2021 (NMA)	2.22	-3.57	-0.89	car	pbo	Biochemical, Prolactin, change
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	lurasidone	Biochemical, Prolactin, change from baseline	"eSMD=-7.2 [-12.33, -2.06] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	8	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-7.2	2.62	I (High)	Kadakia A., 2021 (NMA)	7.2	-12.33	-2.06	lur	pbo	Biochemical, Prolactin, change
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2020 (NMA)</a>"	olanzapine	Biochemical, Prolactin, change from baseline	"eSMD=-0.12 [-0.31, 0.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=14.79	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.12	0.1	IV (Very Low)	Kishi T., 2020 (NMA)	0.12	-0.31	0.08	ola	pbo	Biochemical, Prolactin, change
"<a href='https://doi.org/' target=""_blank"">Vita A., 2013 (MA)</a>"	asenapine	Biochemical, Prolactin, change from baseline	"eSMD=-0.88 [-2.61, 0.85] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.14	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.88	0.88	IV (Very Low)	Vita A., 2013 (MA)	0.88	-2.61	0.85	ase	pbo	Biochemical, Prolactin, change
"<a href='https://doi.org/' target=""_blank"">Vita A., 2013 (MA)</a>"	asenapine	Biochemical, Prolactin, change from baseline	"eSMD=-0.17 [-0.33, -0.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=10.45	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.17	0.08	IV (Very Low)	Vita A., 2013 (MA)	0.17	-0.33	-0.01	ase	ola	Biochemical, Prolactin, change
"<a href='https://doi.org/' target=""_blank"">Meduri M., 2016 (MA)</a>"	aripiprazole	Biochemical, Prolactin, increase	"eSMD=0.34 [0.05, 0.63] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.26	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	0.34	0.15	I (High)	Meduri M., 2016 (MA)	-0.34	0.05	0.63	ari	pbo	Biochemical, Prolactin, increase
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	lurasidone	Biochemical, Triglycerids, change from baseline	"eSMD=3.05 [-9.55, 15.37] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.03	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	12	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	3.05	6.36	III (Low)	Kadakia A., 2021 (NMA)	-3.05	-9.55	15.37	lur	pbo	Biochemical, Triglycerids, change
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	aripiprazole	Biochemical, Triglycerids, change from baseline	"eSMD=-0.98 [-12.47, 10.48] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1.95	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	12	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.98	5.85	III (Low)	Kadakia A., 2021 (NMA)	0.98	-12.47	10.48	ari	pbo	Biochemical, Triglycerids, change
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	cariprazine	Biochemical, Triglycerids, change from baseline	"eSMD=-1.35 [-6.5, 1.27] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1.51	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	12	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-1.35	1.98	III (Low)	Kadakia A., 2021 (NMA)	1.35	-6.5	1.27	car	pbo	Biochemical, Triglycerids, change
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	olanzapine	Biochemical, Triglycerids, change from baseline	"eSMD=-1.85 [-8.64, 1.88] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1.24	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	12	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-1.85	2.68	III (Low)	Kadakia A., 2021 (NMA)	1.85	-8.64	1.88	ola	pbo	Biochemical, Triglycerids, change
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	quetiapine	Biochemical, Triglycerids, change from baseline	"eSMD=-11.1 [-24.86, 2.75] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	12	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-11.1	7.04	III (Low)	Kadakia A., 2021 (NMA)	11.1	-24.86	2.75	que	pbo	Biochemical, Triglycerids, change
"<a href='https://doi.org/' target=""_blank"">Vita A., 2013 (MA)</a>"	asenapine	Biochemical, Triglycerids, change from baseline	"eSMD=-0.14 [-0.31, 0.03] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=12.68	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.14	0.09	IV (Very Low)	Vita A., 2013 (MA)	0.14	-0.31	0.03	ase	pbo	Biochemical, Triglycerids, change
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	lithium	Biochemical, TSH, increase	"eSMD=-1.55 [-2.54, -0.39] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1.38	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Mixed (Children-Adults)	Mania/Mixed	placebo	mono	-1.55	0.55	I (High)	McKnight R.F., 2019 (MA)	1.55	-2.54	-0.39	lit	pbo	Biochemical, TSH, increase
"<a href='https://doi.org/' target=""_blank"">Rendell J.M., 2010 (MA)</a>"	olanzapine	Biochemical, Increased ALT/AST/GPT	"eSMD=-1.27 [-1.93, -0.58] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1.59	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	-1.27	0.34	I (High)	Rendell J.M., 2010 (MA)	1.27	-1.93	-0.58	ola	pbo	Biochemical, Increased ALT/AST/GPT
"<a href='https://doi.org/' target=""_blank"">Fountoulakis K.N., 2011 (MA)</a>"	aripiprazole	Mania severity scale, CGI-BP, change from baseline	"eSMD=0.47 [0.37, 0.57] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.84	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	4	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	0.47	0.05	IV (Very Low)	Fountoulakis K.N., 2011 (MA)	-0.47	0.37	0.57	ari	pbo	CGI-BP mania, change
"<a href='https://doi.org/' target=""_blank"">Rendell J.M., 2010 (MA)</a>"	olanzapine	Mania severity scale, CGI-BP, change from baseline	"eSMD=0.75 [0.38, 1.12] <br> <img src=""https://www.linkpicture.com/q/Diapositive19.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.47	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	0.75	0.19	I (High)	Rendell J.M., 2010 (MA)	-0.75	0.38	1.12	ola	pbo	CGI-BP mania, change
"<a href='https://doi.org/' target=""_blank"">Fountoulakis K.N., 2011 (MA)</a>"	aripiprazole	Depression severity scale, CGI-BP-S, change from baseline	"eSMD=0 [-0.1, 0.1] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	4	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	0	0.05	IV (Very Low)	Fountoulakis K.N., 2011 (MA)	0	-0.1	0.1	ari	pbo	CGI-BP-S depression, change
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	lurasidone	Depression severity scale, CGI-BP-S, change from baseline	"eSMD=0.63 [0.14, 1.12] <br> <img src=""https://www.linkpicture.com/q/Diapositive18.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.91	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.63	0.25	II (Moderate)	Kadakia A., 2021 (NMA)	-0.63	0.14	1.12	lur	pbo	CGI-BP-S depression, change
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	olanzapine	Depression severity scale, CGI-BP-S, change from baseline	"eSMD=0.32 [-0.08, 0.72] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.59	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.32	0.2	III (Low)	Kadakia A., 2021 (NMA)	-0.32	-0.08	0.72	ola	pbo	CGI-BP-S depression, change
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	aripiprazole	Depression severity scale, CGI-BP-S, change from baseline	"eSMD=0.21 [-0.2, 0.63] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.47	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.21	0.21	III (Low)	Kadakia A., 2021 (NMA)	-0.21	-0.2	0.63	ari	pbo	CGI-BP-S depression, change
"<a href='https://doi.org/' target=""_blank"">Rendell J.M., 2010 (MA)</a>"	olanzapine	Depression severity scale, CGI-BP-S, change from baseline	"eSMD=-0.1 [-0.41, 0.2] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=17.74	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.1	0.16	III (Low)	Rendell J.M., 2010 (MA)	0.1	-0.41	0.2	ola	pbo	CGI-BP-S depression, change
"<a href='https://doi.org/' target=""_blank"">Chang H., 2017 (MA)</a>"	paliperidone	Clinical global impressions scale, severity, CGI-BP-S, change from baseline	"eSMD=0.21 [0.09, 0.32] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.47	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	0.21	0.06	II (Moderate)	Chang H., 2017 (MA)	-0.21	0.09	0.32	pal	pbo	CGI-BP-S, change
"<a href='https://doi.org/' target=""_blank"">Correll C.U., 2010 (MA)</a>"	ziprasidone	Clinical global impressions scale, severity, CGI-BP-S, change from baseline	"eSMD=0.37 [0.21, 0.54] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.85	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	0.37	0.08	IV (Very Low)	Correll C.U., 2010 (MA)	-0.37	0.21	0.54	zip	pbo	CGI-BP-S, change
"<a href='https://doi.org/' target=""_blank"">Correll C.U., 2010 (MA)</a>"	quetiapine	Clinical global impressions scale, severity, CGI-BP-S, change from baseline	"eSMD=0.5 [0.3, 0.7] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.62	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	0.5	0.1	IV (Very Low)	Correll C.U., 2010 (MA)	-0.5	0.3	0.7	que	pbo	CGI-BP-S, change
"<a href='https://doi.org/' target=""_blank"">Correll C.U., 2010 (MA)</a>"	haloperidol	Clinical global impressions scale, severity, CGI-BP-S, change from baseline	"eSMD=0.5 [0.37, 0.63] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.62	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	4	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	0.5	0.07	IV (Very Low)	Correll C.U., 2010 (MA)	-0.5	0.37	0.63	hal	pbo	CGI-BP-S, change
"<a href='https://doi.org/' target=""_blank"">Correll C.U., 2010 (MA)</a>"	risperidone	Clinical global impressions scale, severity, CGI-BP-S, change from baseline	"eSMD=0.67 [0.53, 0.81] <br> <img src=""https://www.linkpicture.com/q/Diapositive18.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.74	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	0.67	0.07	IV (Very Low)	Correll C.U., 2010 (MA)	-0.67	0.53	0.81	risp	pbo	CGI-BP-S, change
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	lurasidone	Clinical global impressions scale, severity, CGI-BP-S, change from baseline	"eSMD=0.63 [0.39, 0.87] <br> <img src=""https://www.linkpicture.com/q/Diapositive18.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.91	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	13	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.63	0.12	II (Moderate)	Kadakia A., 2021 (NMA)	-0.63	0.39	0.87	lur	pbo	CGI-BP-S, change
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	olanzapine	Clinical global impressions scale, severity, CGI-BP-S, change from baseline	"eSMD=0.59 [-0.76, 2.06] <br> <img src=""https://www.linkpicture.com/q/Diapositive17.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	13	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.59	0.72	III (Low)	Kadakia A., 2021 (NMA)	-0.59	-0.76	2.06	ola	pbo	CGI-BP-S, change
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	quetiapine	Clinical global impressions scale, severity, CGI-BP-S, change from baseline	"eSMD=0.55 [0.41, 0.68] <br> <img src=""https://www.linkpicture.com/q/Diapositive17.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.3	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	13	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.55	0.07	II (Moderate)	Kadakia A., 2021 (NMA)	-0.55	0.41	0.68	que	pbo	CGI-BP-S, change
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	cariprazine	Clinical global impressions scale, severity, CGI-BP-S, change from baseline	"eSMD=0.25 [0.11, 0.38] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.13	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	13	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.25	0.07	II (Moderate)	Kadakia A., 2021 (NMA)	-0.25	0.11	0.38	car	pbo	CGI-BP-S, change
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	ziprasidone	Clinical global impressions scale, severity, CGI-BP-S, change from baseline	"eSMD=0.05 [-0.17, 0.26] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=35.46	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	13	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.05	0.11	III (Low)	Kadakia A., 2021 (NMA)	-0.05	-0.17	0.26	zip	pbo	CGI-BP-S, change
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	divalproate	Clinical global impressions scale, severity, CGI-BP-S, change from baseline	"eSMD=0.02 [-0.25, 0.29] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=88.63	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	lithium	mono	0.02	0.14	II (Moderate)	McKnight R.F., 2019 (MA)	-0.02	-0.25	0.29	div	lit	CGI-BP-S, change
"<a href='https://doi.org/' target=""_blank"">Ostacher M., 2018 (NMA)</a>"	aripiprazole	Clinical global impressions scale, severity, CGI-BP-S, change from baseline	"eSMD=0.21 [-0.03, 0.45] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.47	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	13	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.21	0.12	IV (Very Low)	Ostacher M., 2018 (NMA)	-0.21	-0.03	0.45	ari	pbo	CGI-BP-S, change
"<a href='https://doi.org/' target=""_blank"">Rendell J.M., 2010 (MA)</a>"	olanzapine	Clinical global impressions scale, severity, CGI-BP-S, change from baseline	"eSMD=0.58 [0.24, 0.93] <br> <img src=""https://www.linkpicture.com/q/Diapositive17.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.14	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	0.58	0.18	I (High)	Rendell J.M., 2010 (MA)	-0.58	0.24	0.93	ola	pbo	CGI-BP-S, change
"<a href='https://doi.org/' target=""_blank"">Suttajit S., 2014 (MA)</a>"	quetiapine	Clinical global impressions scale, severity, CGI-BP-S, change from baseline	"eSMD=0.45 [0.34, 0.56] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.01	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	7	Pairwise meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.45	0.06	II (Moderate)	Suttajit S., 2014 (MA)	-0.45	0.34	0.56	que	pbo	CGI-BP-S, change
"<a href='https://doi.org/' target=""_blank"">Suttajit S., 2014 (MA)</a>"	quetiapine	Clinical global impressions scale, severity, CGI-BP-S, change from baseline	"eSMD=0.26 [0.02, 0.51] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.86	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Children & Adolescents	Bipolar Depression	placebo	mono	0.26	0.12	II (Moderate)	Suttajit S., 2014 (MA)	-0.26	0.02	0.51	que	pbo	CGI-BP-S, change
"<a href='https://doi.org/' target=""_blank"">Vita A., 2013 (MA)</a>"	asenapine	Clinical global impressions scale, severity, CGI-BP-S, change from baseline	"eSMD=0.51 [-0.5, 1.5] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.55	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	olanzapine	mono	0.51	0.51	IV (Very Low)	Vita A., 2013 (MA)	-0.51	-0.5	1.5	ase	ola	CGI-BP-S, change
"<a href='https://doi.org/' target=""_blank"">Vita A., 2013 (MA)</a>"	asenapine	Clinical global impressions scale, severity, CGI-BP-S, change from baseline	"eSMD=0.34 [0.61, 0.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.26	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	0.34	0.14	III (Low)	Vita A., 2013 (MA)	-0.34	0.61	0.05	ase	pbo	CGI-BP-S, change
"<a href='https://doi.org/' target=""_blank"">Fountoulakis K.N., 2011 (MA)</a>"	aripiprazole	Clinical global impressions scale, improvement, CGI-I, change from baseline	"eSMD=0.36 [0.26, 0.46] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.98	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	4	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	0.36	0.05	IV (Very Low)	Fountoulakis K.N., 2011 (MA)	-0.36	0.26	0.46	ari	pbo	CGI-I, change
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	lithium	Clinical global impressions scale, improvement, CGI-I, change from baseline	"eSMD=0.25 [0.16, 0.35] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.13	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	4	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	0.25	0.05	III (Low)	McKnight R.F., 2019 (MA)	-0.25	0.16	0.35	lit	pbo	CGI-I, change
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	lithium	Clinical global impressions scale, improvement, CGI-I, change from baseline	"eSMD=-0.9 [-1.41, -0.39] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.1	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	risperidone	mono	-0.9	0.26	II (Moderate)	McKnight R.F., 2019 (MA)	0.9	-1.41	-0.39	lit	risp	CGI-I, change
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	clonazepam	Clinical global impressions scale, improvement, CGI-I, change from baseline	"eSMD=-0.41 [-1.46, 0.65] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.38	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	lithium	mono	-0.41	0.54	III (Low)	McKnight R.F., 2019 (MA)	0.41	-1.46	0.65	clon	lit	CGI-I, change
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	lamotrigine	Clinical global impressions scale, improvement, CGI-I, change from baseline	"eSMD=-0.35 [-1.24, 0.53] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.12	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Mania/Mixed	lithium	mono	-0.35	0.45	IV (Very Low)	McKnight R.F., 2019 (MA)	0.35	-1.24	0.53	lam	lit	CGI-I, change
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	carbamazepine	Clinical global impressions scale, improvement, CGI-I, change from baseline	"eSMD=0.68 [-0.4, 1.76] <br> <img src=""https://www.linkpicture.com/q/Diapositive18.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.71	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	lithium	mono	0.68	0.55	III (Low)	McKnight R.F., 2019 (MA)	-0.68	-0.4	1.76	cbz	lit	CGI-I, change
"<a href='https://doi.org/' target=""_blank"">Pinto J.V., 2020 (MA)</a>"	cariprazine	Clinical global impressions scale, improvement, CGI-I, change from baseline	"eSMD=0.47 [0.08, 0.86] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.84	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	0.47	0.2	II (Moderate)	Pinto J.V., 2020 (MA)	-0.47	0.08	0.86	car	pbo	CGI-I, change
"<a href='https://doi.org/' target=""_blank"">Suttajit S., 2014 (MA)</a>"	quetiapine	Clinical global impressions scale, improvement, CGI-I, change from baseline	"eSMD=0.62 [0.49, 0.76] <br> <img src=""https://www.linkpicture.com/q/Diapositive17.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.95	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	7	Pairwise meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.62	0.07	II (Moderate)	Suttajit S., 2014 (MA)	-0.62	0.49	0.76	que	pbo	CGI-I, change
"<a href='https://doi.org/' target=""_blank"">Pittas S., 2021 (MA)</a>"	n-acetyl cysteine	Clinical global impressions scale, severity, CGI-S, change from baseline	"eSMD=0.13 [-0.08, 0.33] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=13.65	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Bipolar Depression	placebo	aug	0.13	0.1	III (Low)	Pittas S., 2021 (MA)	-0.13	-0.08	0.33	nac	pbo	CGI-S, change
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2016 (MA)</a>"	risperidone LAI	Clinical global impressions scale, severity, CGI-S, endpoint score	"eSMD=0.76 [0.5, 1.03] <br> <img src=""https://www.linkpicture.com/q/Diapositive19.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.44	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Maintenance	placebo	mono	0.76	0.14	I (High)	Kishi T., 2016 (MA)	-0.76	0.5	1.03	rispLAI	pbo	CGI-S, endpoint score
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	lithium	Clinical global impressions scale, severity, CGI-S, endpoint score	"eSMD=-0.35 [-0.74, 0.04] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.12	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.35	0.2	III (Low)	McKnight R.F., 2019 (MA)	0.35	-0.74	0.04	lit	ola	CGI-S, endpoint score
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	erythropoietin	Cognition, attention and vigilance	"eSMD=0.61 [0, 1.23] <br> <img src=""https://www.linkpicture.com/q/Diapositive17.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Network meta-analysis	Adults	Maintenance	TAU	combo	0.61	0.31	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	-0.61	0	1.23	epo	tau	Cognition, attention and vigilance
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	rTMS	Cognition, attention and vigilance	"eSMD=0.21 [-0.33, 0.76] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.47	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Network meta-analysis	Adults	Maintenance	TAU	combo	0.21	0.28	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	-0.21	-0.33	0.76	rTMS	tau	Cognition, attention and vigilance
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	lurasidone	Cognition, attention and vigilance	"eSMD=0.06 [-0.66, 0.78] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=29.55	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Network meta-analysis	Adults	Maintenance	TAU	combo	0.06	0.37	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	-0.06	-0.66	0.78	lur	tau	Cognition, attention and vigilance
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	memantine	Cognition, attention and vigilance	"eSMD=-0.01 [-0.32, 0.31] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=177.25	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Network meta-analysis	Adults	Maintenance	TAU	combo	-0.01	0.16	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	0.01	-0.32	0.31	mem	tau	Cognition, attention and vigilance
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	quetiapine	Cognition, attention and vigilance	"eSMD=-0.63 [-1.75, 0.5] <br> <img src=""https://www.linkpicture.com/q/Diapositive3.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.91	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Network meta-analysis	Adults	Maintenance	TAU	mono	-0.63	0.57	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	0.63	-1.75	0.5	que	tau	Cognition, attention and vigilance
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	erythropoietin	Cognition, executive function	"eSMD=0.61 [-0.1, 1.12] <br> <img src=""https://www.linkpicture.com/q/Diapositive17.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	7	Network meta-analysis	Adults	Maintenance	TAU	combo	0.61	0.31	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	-0.61	-0.1	1.12	epo	tau	Cognition, executive function
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	insulin	Cognition, executive function	"eSMD=0.38 [-0.15, 0.85] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.72	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	7	Network meta-analysis	Adults	Maintenance	TAU	combo	0.38	0.26	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	-0.38	-0.15	0.85	insulin	tau	Cognition, executive function
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	tDCS	Cognition, executive function	"eSMD=0.38 [-0.31, 0.91] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.72	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	7	Network meta-analysis	Adults	Maintenance	TAU	combo	0.38	0.31	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	-0.38	-0.31	0.91	tDCS	tau	Cognition, executive function
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	rTMS low	Cognition, executive function	"eSMD=0.27 [-0.49, 1.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.6	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	4	Network meta-analysis	Adults	Bipolar Depression	TAU	combo	0.27	0.4	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	-0.27	-0.49	1.08	rTMS low	tau	Cognition, executive function
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	n-acetyl cysteine	Cognition, executive function	"eSMD=0.18 [-0.85, 1.14] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=9.87	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	7	Network meta-analysis	Adults	Maintenance	TAU	combo	0.18	0.51	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	-0.18	-0.85	1.14	nac	tau	Cognition, executive function
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	creatine	Cognition, executive function	"eSMD=0.08 [-0.85, 1.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=22.17	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	4	Network meta-analysis	Adults	Bipolar Depression	TAU	combo	0.08	0.47	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	-0.08	-0.85	1.01	creatine	tau	Cognition, executive function
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	mifepristone	Cognition, executive function	"eSMD=0.06 [-0.57, 0.7] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=29.55	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	4	Network meta-analysis	Adults	Bipolar Depression	TAU	combo	0.06	0.32	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	-0.06	-0.57	0.7	mifeprist	tau	Cognition, executive function
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	lurasidone	Cognition, executive function	"eSMD=-0.11 [-0.83, 0.92] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=16.13	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	7	Network meta-analysis	Adults	Maintenance	TAU	combo	-0.11	0.45	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	0.11	-0.83	0.92	lur	tau	Cognition, executive function
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	quetiapine	Cognition, executive function	"eSMD=-0.2 [-1.3, 0.95] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=8.89	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	7	Network meta-analysis	Adults	Maintenance	TAU	mono	-0.2	0.57	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	0.2	-1.3	0.95	que	tau	Cognition, executive function
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	rTMS high	Cognition, executive function	"eSMD=-0.27 [-0.6, 0.3] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.6	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	4	Network meta-analysis	Adults	Bipolar Depression	TAU	combo	-0.27	0.23	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	0.27	-0.6	0.3	rTMS high	tau	Cognition, executive function
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	galantamine	Cognition, executive function	"eSMD=-0.42 [-1.45, 0.8] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.28	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	7	Network meta-analysis	Adults	Maintenance	TAU	N/A	-0.42	0.57	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	0.42	-1.45	0.8	galant	tau	Cognition, executive function
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	galantamine	Cognition, processing speed	"eSMD=0.91 [-1.8, 0.17] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.08	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	9	Network meta-analysis	Adults	Maintenance	TAU	N/A	0.91	0.5	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	-0.91	-1.8	0.17	galant	tau	Cognition, processing speed
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	rTMS high	Cognition, processing speed	"eSMD=0.38 [-0.12, 0.8] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.72	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	4	Network meta-analysis	Adults	Bipolar Depression	TAU	combo	0.38	0.23	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	-0.38	-0.12	0.8	rTMS high	tau	Cognition, processing speed
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	n-acetyl cysteine	Cognition, processing speed	"eSMD=0.37 [-0.68, 1.43] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.85	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	9	Network meta-analysis	Adults	Maintenance	TAU	combo	0.37	0.54	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	-0.37	-0.68	1.43	nac	tau	Cognition, processing speed
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	rTMS low	Cognition, processing speed	"eSMD=0.36 [-0.7, 0.9] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.98	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	4	Network meta-analysis	Adults	Bipolar Depression	TAU	combo	0.36	0.41	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	-0.36	-0.7	0.9	rTMS low	tau	Cognition, processing speed
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	withania somnifer	Cognition, processing speed	"eSMD=0.36 [-0.2, 0.9] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.98	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	9	Network meta-analysis	Adults	Maintenance	TAU	combo	0.36	0.28	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	-0.36	-0.2	0.9	withania	tau	Cognition, processing speed
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	infliximab	Cognition, processing speed	"eSMD=0.28 [-0.4, 0.9] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.37	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	4	Network meta-analysis	Adults	Bipolar Depression	TAU	combo	0.28	0.33	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	-0.28	-0.4	0.9	infx	tau	Cognition, processing speed
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	tDCS	Cognition, processing speed	"eSMD=0.18 [-0.42, 0.79] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=9.87	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	9	Network meta-analysis	Adults	Maintenance	TAU	combo	0.18	0.31	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	-0.18	-0.42	0.79	tDCS	tau	Cognition, processing speed
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	erythropoietin	Cognition, processing speed	"eSMD=0.14 [-0.46, 0.74] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=12.68	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	9	Network meta-analysis	Adults	Maintenance	TAU	combo	0.14	0.31	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	-0.14	-0.46	0.74	epo	tau	Cognition, processing speed
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	insulin	Cognition, processing speed	"eSMD=0.1 [-0.4, 0.6] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=17.74	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	9	Network meta-analysis	Adults	Maintenance	TAU	combo	0.1	0.26	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	-0.1	-0.4	0.6	insulin	tau	Cognition, processing speed
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	rTMS	Cognition, processing speed	"eSMD=0.04 [-0.54, 0.58] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=44.32	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	9	Network meta-analysis	Adults	Maintenance	TAU	combo	0.04	0.29	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	-0.04	-0.54	0.58	rTMS	tau	Cognition, processing speed
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	lurasidone	Cognition, processing speed	"eSMD=-0.06 [-0.72, 0.8] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=29.55	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	9	Network meta-analysis	Adults	Maintenance	TAU	combo	-0.06	0.39	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	0.06	-0.72	0.8	lur	tau	Cognition, processing speed
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	mifepristone	Cognition, processing speed	"eSMD=-0.15 [-0.71, 0.46] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=11.84	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	4	Network meta-analysis	Adults	Bipolar Depression	TAU	combo	-0.15	0.3	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	0.15	-0.71	0.46	mifeprist	tau	Cognition, processing speed
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	quetiapine	Cognition, processing speed	"eSMD=-0.6 [-1.72, 0.52] <br> <img src=""https://www.linkpicture.com/q/Diapositive4.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.04	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	9	Network meta-analysis	Adults	Maintenance	TAU	mono	-0.6	0.57	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	0.6	-1.72	0.52	que	tau	Cognition, processing speed
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	withania somnifer	Cognition, social cognition	"eSMD=0.21 [-0.58, 0.75] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.47	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Network meta-analysis	Adults	Maintenance	TAU	combo	0.21	0.34	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	-0.21	-0.58	0.75	withania	tau	Cognition, social cognition
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	rTMS	Cognition, social cognition	"eSMD=0.18 [-0.28, 0.73] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=9.87	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Network meta-analysis	Adults	Maintenance	TAU	combo	0.18	0.26	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	-0.18	-0.28	0.73	rTMS	tau	Cognition, social cognition
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	galantamine	Cognition, verbal learning	"eSMD=1.22 [0.1, 2.35] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.63	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	9	Network meta-analysis	Adults	Maintenance	TAU	N/A	1.22	0.57	II (Moderate)	Chen Wen-Yin, 2021 (NMA)	-1.22	0.1	2.35	galant	tau	Cognition, verbal learning
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	mifepristone	Cognition, verbal learning	"eSMD=0.29 [-0.44, 0.88] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.15	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Network meta-analysis	Adults	Bipolar Depression	TAU	combo	0.29	0.34	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	-0.29	-0.44	0.88	mifeprist	tau	Cognition, verbal learning
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	erythropoietin	Cognition, verbal learning	"eSMD=0.27 [-0.33, 0.87] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.6	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	9	Network meta-analysis	Adults	Maintenance	TAU	combo	0.27	0.31	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	-0.27	-0.33	0.87	epo	tau	Cognition, verbal learning
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	n-acetyl cysteine	Cognition, verbal learning	"eSMD=0.12 [-0.93, 1.16] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=14.79	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	9	Network meta-analysis	Adults	Maintenance	TAU	combo	0.12	0.53	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	-0.12	-0.93	1.16	nac	tau	Cognition, verbal learning
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	insulin	Cognition, verbal learning	"eSMD=0.08 [-0.52, 0.68] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=22.17	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	9	Network meta-analysis	Adults	Maintenance	TAU	combo	0.08	0.31	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	-0.08	-0.52	0.68	insulin	tau	Cognition, verbal learning
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	rTMS high	Cognition, verbal learning	"eSMD=0 [-0.58, 0.6] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Network meta-analysis	Adults	Bipolar Depression	TAU	combo	0	0.3	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	0	-0.58	0.6	rTMS high	tau	Cognition, verbal learning
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	lurasidone	Cognition, verbal learning	"eSMD=-0.02 [-0.74, 0.7] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=88.63	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	9	Network meta-analysis	Adults	Maintenance	TAU	combo	-0.02	0.37	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	0.02	-0.74	0.7	lur	tau	Cognition, verbal learning
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	withania somnifer	Cognition, verbal learning	"eSMD=-0.07 [-0.61, 0.47] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=25.33	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	9	Network meta-analysis	Adults	Maintenance	TAU	combo	-0.07	0.28	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	0.07	-0.61	0.47	withania	tau	Cognition, verbal learning
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	rTMS	Cognition, verbal learning	"eSMD=-0.08 [-0.62, 0.47] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=22.17	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	9	Network meta-analysis	Adults	Maintenance	TAU	combo	-0.08	0.28	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	0.08	-0.62	0.47	rTMS	tau	Cognition, verbal learning
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	tianeptine	Cognition, verbal learning	"eSMD=-0.1 [-0.53, 0.4] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=17.74	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Network meta-analysis	Adults	Bipolar Depression	TAU	combo	-0.1	0.24	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	0.1	-0.53	0.4	tianep	tau	Cognition, verbal learning
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	memantine	Cognition, verbal learning	"eSMD=-0.2 [-0.53, 0.13] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=8.89	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	9	Network meta-analysis	Adults	Maintenance	TAU	combo	-0.2	0.17	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	0.2	-0.53	0.13	mem	tau	Cognition, verbal learning
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	quetiapine	Cognition, verbal learning	"eSMD=-0.3 [-1.41, 0.8] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.95	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	9	Network meta-analysis	Adults	Maintenance	TAU	mono	-0.3	0.56	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	0.3	-1.41	0.8	que	tau	Cognition, verbal learning
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	creatine	Cognition, visual learning	"eSMD=0.41 [-0.58, 1.34] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.38	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Network meta-analysis	Adults	Bipolar Depression	TAU	combo	0.41	0.49	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	-0.41	-0.58	1.34	creatine	tau	Cognition, visual learning
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	rTMS high	Cognition, visual learning	"eSMD=0.02 [-0.62, 0.58] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=88.63	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Network meta-analysis	Adults	Bipolar Depression	TAU	combo	0.02	0.31	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	-0.02	-0.62	0.58	rTMS high	tau	Cognition, visual learning
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	withania somnifer	Cognition, working memory	"eSMD=0.58 [0.03, 1.13] <br> <img src=""https://www.linkpicture.com/q/Diapositive17.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.14	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	6	Network meta-analysis	Adults	Maintenance	TAU	combo	0.58	0.28	III (Low)	Chen Wen-Yin, 2021 (NMA)	-0.58	0.03	1.13	withania	tau	Cognition, working memory
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	rTMS	Cognition, working memory	"eSMD=0.5 [-0.05, 1.06] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.62	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	6	Network meta-analysis	Adults	Maintenance	TAU	combo	0.5	0.28	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	-0.5	-0.05	1.06	rTMS	tau	Cognition, working memory
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	lurasidone	Cognition, working memory	"eSMD=0.45 [-0.27, 1.18] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.01	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	6	Network meta-analysis	Adults	Maintenance	TAU	combo	0.45	0.37	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	-0.45	-0.27	1.18	lur	tau	Cognition, working memory
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	rTMS high	Cognition, working memory	"eSMD=0.38 [-0.22, 0.9] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.72	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	4	Network meta-analysis	Adults	Bipolar Depression	TAU	combo	0.38	0.29	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	-0.38	-0.22	0.9	rTMS high	tau	Cognition, working memory
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	mifepristone	Cognition, working memory	"eSMD=0.29 [-0.41, 0.7] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.15	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	4	Network meta-analysis	Adults	Bipolar Depression	TAU	combo	0.29	0.28	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	-0.29	-0.41	0.7	mifeprist	tau	Cognition, working memory
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	erythropoietin	Cognition, working memory	"eSMD=0.19 [-0.41, 0.79] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=9.36	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	6	Network meta-analysis	Adults	Maintenance	TAU	combo	0.19	0.31	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	-0.19	-0.41	0.79	epo	tau	Cognition, working memory
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	tianeptine	Cognition, working memory	"eSMD=0.13 [-0.35, 0.5] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=13.65	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	4	Network meta-analysis	Adults	Bipolar Depression	TAU	combo	0.13	0.22	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	-0.13	-0.35	0.5	tianep	tau	Cognition, working memory
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	n-acetyl cysteine	Cognition, working memory	"eSMD=0 [-1.04, 1.04] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	6	Network meta-analysis	Adults	Maintenance	TAU	combo	0	0.53	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	0	-1.04	1.04	nac	tau	Cognition, working memory
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	creatine	Cognition, working memory	"eSMD=-0.17 [-1, 0.76] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=10.45	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	4	Network meta-analysis	Adults	Bipolar Depression	TAU	combo	-0.17	0.45	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	0.17	-1	0.76	creatine	tau	Cognition, working memory
"<a href='https://doi.org/' target=""_blank"">Chen Wen-Yin, 2021 (NMA)</a>"	quetiapine	Cognition, working memory	"eSMD=-0.84 [-1.99, 0.31] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.23	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	6	Network meta-analysis	Adults	Maintenance	TAU	mono	-0.84	0.59	IV (Very Low)	Chen Wen-Yin, 2021 (NMA)	0.84	-1.99	0.31	que	tau	Cognition, working memory
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	aripiprazole	Completion of treatment	"eSMD=-0.28 [-0.55, -0.02] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.37	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	-0.28	0.14	II (Moderate)	Bahji A., 2020 (NMA)	0.28	-0.55	-0.02	ari	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	phenelzine	Completion of treatment	"eSMD=-0.24 [-1.39, 0.94] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.42	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	-0.24	0.59	III (Low)	Bahji A., 2020 (NMA)	0.24	-1.39	0.94	phen	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	ziprasidone	Completion of treatment	"eSMD=-0.17 [-0.53, 0.19] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=10.45	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	-0.17	0.18	III (Low)	Bahji A., 2020 (NMA)	0.17	-0.53	0.19	zip	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	cariprazine	Completion of treatment	"eSMD=-0.08 [-0.36, 0.2] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=22.17	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	-0.08	0.14	III (Low)	Bahji A., 2020 (NMA)	0.08	-0.36	0.2	car	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	paroxetine	Completion of treatment	"eSMD=-0.02 [-0.37, 0.33] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=88.63	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	-0.02	0.18	III (Low)	Bahji A., 2020 (NMA)	0.02	-0.37	0.33	par	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	lithium	Completion of treatment	"eSMD=-0.02 [-0.38, 0.35] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=88.63	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	-0.02	0.19	III (Low)	Bahji A., 2020 (NMA)	0.02	-0.38	0.35	lit	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	lurasidone	Completion of treatment	"eSMD=0.01 [-0.3, 0.32] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=177.25	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.01	0.16	III (Low)	Bahji A., 2020 (NMA)	-0.01	-0.3	0.32	lur	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	gabapentin	Completion of treatment	"eSMD=0.02 [-1.39, 1.39] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=88.63	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.02	0.71	III (Low)	Bahji A., 2020 (NMA)	-0.02	-1.39	1.39	gaba	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	lamotrigine	Completion of treatment	"eSMD=0.03 [-0.15, 0.2] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=59.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.03	0.09	III (Low)	Bahji A., 2020 (NMA)	-0.03	-0.15	0.2	lam	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	divalproate	Completion of treatment	"eSMD=0.06 [-0.35, 0.47] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=29.55	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.06	0.21	III (Low)	Bahji A., 2020 (NMA)	-0.06	-0.35	0.47	div	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	quetiapine	Completion of treatment	"eSMD=0.06 [-0.08, 0.2] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=29.55	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.06	0.07	III (Low)	Bahji A., 2020 (NMA)	-0.06	-0.08	0.2	que	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	olanzapine	Completion of treatment	"eSMD=0.11 [-0.12, 0.34] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=16.13	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.11	0.12	III (Low)	Bahji A., 2020 (NMA)	-0.11	-0.12	0.34	ola	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	olanzapine+fluoxetine	Completion of treatment	"eSMD=0.17 [-0.06, 0.4] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=10.45	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.17	0.12	III (Low)	Bahji A., 2020 (NMA)	-0.17	-0.06	0.4	ola+fluo	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	imipramine	Completion of treatment	"eSMD=0.2 [-0.38, 0.79] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.89	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.2	0.3	III (Low)	Bahji A., 2020 (NMA)	-0.2	-0.38	0.79	imp	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	escitalopram	Completion of treatment	"eSMD=0.28 [-1.47, 2.03] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.37	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.28	0.89	III (Low)	Bahji A., 2020 (NMA)	-0.28	-1.47	2.03	escit	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	carbamazepine	Completion of treatment	"eSMD=0.34 [-0.3, 0.97] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.26	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.34	0.32	III (Low)	Bahji A., 2020 (NMA)	-0.34	-0.3	0.97	cbz	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	fluoxetine	Completion of treatment	"eSMD=0.4 [-0.17, 0.98] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.49	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.4	0.29	III (Low)	Bahji A., 2020 (NMA)	-0.4	-0.17	0.98	fluo	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	imipramine	Completion of treatment	"eSMD=0.36 [-1.05, 1.77] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.98	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	phenelzine	mono	0.36	0.72	III (Low)	Bahji A., 2020 (NMA)	-0.36	-1.05	1.77	imp	phen	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	fluoxetine	Completion of treatment	"eSMD=0.22 [-0.42, 0.86] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	imipramine	mono	0.22	0.33	III (Low)	Bahji A., 2020 (NMA)	-0.22	-0.42	0.86	fluo	imp	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	lamotrigine	Completion of treatment	"eSMD=0.06 [-0.32, 0.44] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=29.55	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	olanzapine+fluoxetine	combo	0.06	0.19	III (Low)	Bahji A., 2020 (NMA)	-0.06	-0.32	0.44	lam	ola+fluo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	fluoxetine	Completion of treatment	"eSMD=0 [-1.65, 1.65] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	olanzapine+fluoxetine	combo	0	0.84	III (Low)	Bahji A., 2020 (NMA)	0	-1.65	1.65	fluo	ola+fluo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	gabapentin	Completion of treatment	"eSMD=0 [-1.55, 1.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	lamotrigine	mono	0	0.79	III (Low)	Bahji A., 2020 (NMA)	0	-1.55	1.55	gaba	lam	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	imipramine	Completion of treatment	"eSMD=-0.07 [-1.65, 1.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=25.33	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	moclobemide	mono	-0.07	0.82	III (Low)	Bahji A., 2020 (NMA)	0.07	-1.65	1.55	imp	moc	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	fluoxetine	Completion of treatment	"eSMD=-0.07 [-1.77, 1.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=25.33	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	olanzapine	mono	-0.07	0.85	III (Low)	Bahji A., 2020 (NMA)	0.07	-1.77	1.55	fluo	ola	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	lithium	Completion of treatment	"eSMD=-0.1 [-0.48, 0.28] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=17.74	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	quetiapine	mono	-0.1	0.19	III (Low)	Bahji A., 2020 (NMA)	0.1	-0.48	0.28	lit	que	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	paroxetine	Completion of treatment	"eSMD=-0.16 [-0.53, 0.22] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=11.1	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	quetiapine	mono	-0.16	0.19	III (Low)	Bahji A., 2020 (NMA)	0.16	-0.53	0.22	par	que	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	lithium	Completion of treatment	"eSMD=-0.28 [-0.83, 0.25] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.37	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	sertraline	mono	-0.28	0.28	III (Low)	Bahji A., 2020 (NMA)	0.28	-0.83	0.25	lit	sert	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	olanzapine	Completion of treatment	"eSMD=-0.33 [-0.72, 0.06] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.42	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	olanzapine+fluoxetine	combo	-0.33	0.2	III (Low)	Bahji A., 2020 (NMA)	0.33	-0.72	0.06	ola	ola+fluo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	imipramine	Completion of treatment	"eSMD=-0.92 [-1.77, -0.12] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.06	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	tranylcypromine	mono	-0.92	0.42	I (High)	Bahji A., 2020 (NMA)	0.92	-1.77	-0.12	imp	tran	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	lithium	Completion of treatment	"eSMD=-1.55 [-2.16, -1.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1.38	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	venlafaxine	mono	-1.55	0.29	I (High)	Bahji A., 2020 (NMA)	1.55	-2.16	-1.01	lit	ven	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	levetiracetam	Completion of treatment	"eSMD=-0.12 [-0.39, 0.15] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=14.79	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.12	0.14	II (Moderate)	Bahji A., 2021 (NMA)	0.12	-0.39	0.15	levt	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	infliximab	Completion of treatment	"eSMD=-0.08 [-0.24, 0.07] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=22.17	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.08	0.08	II (Moderate)	Bahji A., 2021 (NMA)	0.08	-0.24	0.07	infx	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	pregnenolone	Completion of treatment	"eSMD=-0.08 [-0.22, 0.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=22.17	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.08	0.07	II (Moderate)	Bahji A., 2021 (NMA)	0.08	-0.22	0.05	preg	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	ziprasidone	Completion of treatment	"eSMD=-0.08 [-0.17, 0.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=22.17	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.08	0.05	II (Moderate)	Bahji A., 2021 (NMA)	0.08	-0.17	0.01	zip	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	dextromethorphan	Completion of treatment	"eSMD=-0.06 [-0.15, 0.03] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=29.55	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.06	0.05	II (Moderate)	Bahji A., 2021 (NMA)	0.06	-0.15	0.03	dexm	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	minocycline+acetylsalicylic acid	Completion of treatment	"eSMD=-0.06 [-0.22, 0.09] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=29.55	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.06	0.08	II (Moderate)	Bahji A., 2021 (NMA)	0.06	-0.22	0.09	mino+asa	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	t3 hormone	Completion of treatment	"eSMD=-0.05 [-0.15, 0.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=35.46	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.05	0.05	II (Moderate)	Bahji A., 2021 (NMA)	0.05	-0.15	0.05	t3	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	ketamine	Completion of treatment	"eSMD=-0.05 [-0.2, 0.11] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=35.46	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.05	0.08	II (Moderate)	Bahji A., 2021 (NMA)	0.05	-0.2	0.11	ket	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	agomelatin	Completion of treatment	"eSMD=-0.02 [-0.08, 0.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=88.63	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.02	0.03	II (Moderate)	Bahji A., 2021 (NMA)	0.02	-0.08	0.05	ago	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	lurasidone	Completion of treatment	"eSMD=-0.01 [-0.05, 0.02] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=177.25	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.01	0.02	II (Moderate)	Bahji A., 2021 (NMA)	0.01	-0.05	0.02	lur	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	vitD3	Completion of treatment	"eSMD=-0.01 [-0.22, 0.2] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=177.25	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.01	0.11	II (Moderate)	Bahji A., 2021 (NMA)	0.01	-0.22	0.2	vitD3	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	armodafinil	Completion of treatment	"eSMD=-0.01 [-0.03, 0.02] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=177.25	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.01	0.01	II (Moderate)	Bahji A., 2021 (NMA)	0.01	-0.03	0.02	armo	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	minocycline	Completion of treatment	"eSMD=-0.01 [-0.17, 0.15] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=177.25	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.01	0.08	II (Moderate)	Bahji A., 2021 (NMA)	0.01	-0.17	0.15	mino	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	paroxetine+bupropion	Completion of treatment	"eSMD=-0.01 [-0.08, 0.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=177.25	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.01	0.04	II (Moderate)	Bahji A., 2021 (NMA)	0.01	-0.08	0.08	par+bup	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	pioglitazone	Completion of treatment	"eSMD=-0.01 [-0.08, 0.06] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=177.25	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.01	0.04	II (Moderate)	Bahji A., 2021 (NMA)	0.01	-0.08	0.06	pio	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	acetylsalicylic acid	Completion of treatment	"eSMD=0 [-0.16, 0.16] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0	0.08	II (Moderate)	Bahji A., 2021 (NMA)	0	-0.16	0.16	asa	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	bupropion	Completion of treatment	"eSMD=0 [-0.18, 0.18] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0	0.09	II (Moderate)	Bahji A., 2021 (NMA)	0	-0.18	0.18	bup	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	coenzyme Q10	Completion of treatment	"eSMD=0 [-0.04, 0.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0	0.02	II (Moderate)	Bahji A., 2021 (NMA)	0	-0.04	0.05	coQ10	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	creatine	Completion of treatment	"eSMD=0 [-0.18, 0.18] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0	0.09	II (Moderate)	Bahji A., 2021 (NMA)	0	-0.18	0.18	creatine	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	pindolol	Completion of treatment	"eSMD=0 [-0.05, 0.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0	0.03	II (Moderate)	Bahji A., 2021 (NMA)	0	-0.05	0.05	pin	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	omega3	Completion of treatment	"eSMD=0.01 [-0.06, 0.07] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=177.25	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.01	0.03	II (Moderate)	Bahji A., 2021 (NMA)	-0.01	-0.06	0.07	omega3	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	n-acetyl cysteine	Completion of treatment	"eSMD=0.01 [-0.08, 0.1] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=177.25	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.01	0.05	II (Moderate)	Bahji A., 2021 (NMA)	-0.01	-0.08	0.1	nac	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	lamotrigine	Completion of treatment	"eSMD=0.02 [-0.06, 0.09] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=88.63	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.02	0.04	II (Moderate)	Bahji A., 2021 (NMA)	-0.02	-0.06	0.09	lam	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	sAME	Completion of treatment	"eSMD=0.02 [-0.27, 0.31] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=88.63	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.02	0.15	II (Moderate)	Bahji A., 2021 (NMA)	-0.02	-0.27	0.31	sAME	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	pramipexole	Completion of treatment	"eSMD=0.03 [-0.1, 0.17] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=59.09	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.03	0.07	II (Moderate)	Bahji A., 2021 (NMA)	-0.03	-0.1	0.17	pram	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	imipramine	Completion of treatment	"eSMD=0.03 [-0.14, 0.2] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=59.09	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.03	0.09	II (Moderate)	Bahji A., 2021 (NMA)	-0.03	-0.14	0.2	imp	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	inositol	Completion of treatment	"eSMD=0.03 [-0.09, 0.16] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=59.09	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.03	0.06	II (Moderate)	Bahji A., 2021 (NMA)	-0.03	-0.09	0.16	ino	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	t4 hormone	Completion of treatment	"eSMD=0.03 [-0.08, 0.14] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=59.09	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.03	0.06	II (Moderate)	Bahji A., 2021 (NMA)	-0.03	-0.08	0.14	t4	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	citalopram	Completion of treatment	"eSMD=0.04 [-0.02, 0.1] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=44.32	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.04	0.03	II (Moderate)	Bahji A., 2021 (NMA)	-0.04	-0.02	0.1	cit	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	aripiprazole	Completion of treatment	"eSMD=0.05 [-0.19, 0.28] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=35.46	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.05	0.12	II (Moderate)	Bahji A., 2021 (NMA)	-0.05	-0.19	0.28	ari	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	fluoxetine	Completion of treatment	"eSMD=0.06 [-0.01, 0.12] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=29.55	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.06	0.03	II (Moderate)	Bahji A., 2021 (NMA)	-0.06	-0.01	0.12	fluo	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	memantine	Completion of treatment	"eSMD=0.07 [-0.08, 0.22] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=25.33	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.07	0.08	II (Moderate)	Bahji A., 2021 (NMA)	-0.07	-0.08	0.22	mem	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	celecoxib	Completion of treatment	"eSMD=0.08 [-0.04, 0.2] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=22.17	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.08	0.06	II (Moderate)	Bahji A., 2021 (NMA)	-0.08	-0.04	0.2	cel	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	lisdexamfetamine	Completion of treatment	"eSMD=0.08 [-0.1, 0.26] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=22.17	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.08	0.09	II (Moderate)	Bahji A., 2021 (NMA)	-0.08	-0.1	0.26	lisdex	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	paroxetine	Completion of treatment	"eSMD=0.12 [-0.05, 0.29] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=14.79	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.12	0.09	II (Moderate)	Bahji A., 2021 (NMA)	-0.12	-0.05	0.29	par	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	quetiapine	Completion of treatment	"eSMD=0.2 [-0.05, 0.45] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.89	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.2	0.13	II (Moderate)	Bahji A., 2021 (NMA)	-0.2	-0.05	0.45	que	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	n-acetyl cysteine+acetylsalicylic acid	Completion of treatment	"eSMD=0.25 [-0.04, 0.52] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.13	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.25	0.14	II (Moderate)	Bahji A., 2021 (NMA)	-0.25	-0.04	0.52	nac+asa	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	lamotrigine	Completion of treatment	"eSMD=0.38 [0.05, 0.7] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.72	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	risperidone	aug	0.38	0.17	I (High)	Bahji A., 2021 (NMA)	-0.38	0.05	0.7	lam	risp	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	inositol	Completion of treatment	"eSMD=0.36 [0.03, 0.7] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.98	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	risperidone	aug	0.36	0.17	I (High)	Bahji A., 2021 (NMA)	-0.36	0.03	0.7	ino	risp	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	acetylsalicylic acid	Completion of treatment	"eSMD=0.26 [-0.2, 0.7] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.86	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	n-acetyl cysteine	aug	0.26	0.23	II (Moderate)	Bahji A., 2021 (NMA)	-0.26	-0.2	0.7	asa	nac	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	paroxetine	Completion of treatment	"eSMD=0.26 [-0.12, 0.65] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.86	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	risperidone	aug	0.26	0.2	II (Moderate)	Bahji A., 2021 (NMA)	-0.26	-0.12	0.65	par	risp	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	paroxetine	Completion of treatment	"eSMD=0.16 [-0.17, 0.49] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=11.1	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	risperidone+paroxetine	aug	0.16	0.17	II (Moderate)	Bahji A., 2021 (NMA)	-0.16	-0.17	0.49	par	risp+par	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	bupropion	Completion of treatment	"eSMD=0.14 [-0.13, 0.42] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=12.68	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	topiramate	aug	0.14	0.14	II (Moderate)	Bahji A., 2021 (NMA)	-0.14	-0.13	0.42	bup	top	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	bupropion	Completion of treatment	"eSMD=0.11 [-0.04, 0.27] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=16.13	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	venlafaxine	aug	0.11	0.08	II (Moderate)	Bahji A., 2021 (NMA)	-0.11	-0.04	0.27	bup	ven	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	fluoxetine	Completion of treatment	"eSMD=0.11 [-0.17, 0.38] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=16.13	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	imipramine	aug	0.11	0.14	II (Moderate)	Bahji A., 2021 (NMA)	-0.11	-0.17	0.38	fluo	imp	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	bupropion	Completion of treatment	"eSMD=0.09 [-0.07, 0.25] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=19.71	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	sertraline	aug	0.09	0.08	II (Moderate)	Bahji A., 2021 (NMA)	-0.09	-0.07	0.25	bup	sert	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	fluoxetine	Completion of treatment	"eSMD=0.06 [-0.02, 0.14] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=29.55	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	lamotrigine	aug	0.06	0.04	II (Moderate)	Bahji A., 2021 (NMA)	-0.06	-0.02	0.14	fluo	lam	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	minocycline	Completion of treatment	"eSMD=0.06 [-0.12, 0.24] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=29.55	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	minocycline+acetylsalicylic acid	aug	0.06	0.09	II (Moderate)	Bahji A., 2021 (NMA)	-0.06	-0.12	0.24	mino	mino+asa	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	amitriptyline	Completion of treatment	"eSMD=0.05 [-0.09, 0.18] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=35.46	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	paroxetine	aug	0.05	0.07	II (Moderate)	Bahji A., 2021 (NMA)	-0.05	-0.09	0.18	amit	par	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	paroxetine	Completion of treatment	"eSMD=0.05 [-0.1, 0.2] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=35.46	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	venlafaxine	aug	0.05	0.08	II (Moderate)	Bahji A., 2021 (NMA)	-0.05	-0.1	0.2	par	ven	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	imipramine	Completion of treatment	"eSMD=0.03 [-0.09, 0.15] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=59.09	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	moclobemide	aug	0.03	0.06	II (Moderate)	Bahji A., 2021 (NMA)	-0.03	-0.09	0.15	imp	moc	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	sertraline	Completion of treatment	"eSMD=0.03 [-0.14, 0.2] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=59.09	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	venlafaxine	aug	0.03	0.09	II (Moderate)	Bahji A., 2021 (NMA)	-0.03	-0.14	0.2	sert	ven	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	acetylsalicylic acid	Completion of treatment	"eSMD=0.02 [-0.17, 0.21] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=88.63	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	minocycline+acetylsalicylic acid	aug	0.02	0.1	II (Moderate)	Bahji A., 2021 (NMA)	-0.02	-0.17	0.21	asa	mino+asa	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	bupropion	Completion of treatment	"eSMD=0.01 [-0.21, 0.23] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=177.25	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	desipramine	aug	0.01	0.11	II (Moderate)	Bahji A., 2021 (NMA)	-0.01	-0.21	0.23	bup	desimp	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	inositol	Completion of treatment	"eSMD=-0.02 [-0.2, 0.17] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=88.63	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	lamotrigine	aug	-0.02	0.09	II (Moderate)	Bahji A., 2021 (NMA)	0.02	-0.2	0.17	ino	lam	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	acetylsalicylic acid	Completion of treatment	"eSMD=-0.04 [-0.24, 0.16] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=44.32	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	minocycline	aug	-0.04	0.1	II (Moderate)	Bahji A., 2021 (NMA)	0.04	-0.24	0.16	asa	mino	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	acetylsalicylic acid	Completion of treatment	"eSMD=-0.06 [-0.33, 0.21] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=29.55	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	n-acetyl cysteine+acetylsalicylic acid	aug	-0.06	0.14	II (Moderate)	Bahji A., 2021 (NMA)	0.06	-0.33	0.21	asa	nac+asa	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	amitriptyline	Completion of treatment	"eSMD=-0.08 [-0.18, 0.03] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=22.17	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	l-sulpride	aug	-0.08	0.05	II (Moderate)	Bahji A., 2021 (NMA)	0.08	-0.18	0.03	amit	l-sulpr	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	risperidone	Completion of treatment	"eSMD=-0.1 [-0.55, 0.34] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=17.74	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	risperidone+paroxetine	aug	-0.1	0.23	II (Moderate)	Bahji A., 2021 (NMA)	0.1	-0.55	0.34	risp	risp+par	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	imipramine	Completion of treatment	"eSMD=-0.14 [-0.32, 0.04] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=12.68	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	paroxetine	aug	-0.14	0.09	II (Moderate)	Bahji A., 2021 (NMA)	0.14	-0.32	0.04	imp	par	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	citalopram	Completion of treatment	"eSMD=-0.19 [-0.59, 0.22] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=9.36	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	lamotrigine	aug	-0.19	0.21	II (Moderate)	Bahji A., 2021 (NMA)	0.19	-0.59	0.22	cit	lam	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	lithium	Completion of treatment	"eSMD=-0.25 [-0.45, -0.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.13	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	paroxetine	aug	-0.25	0.1	I (High)	Bahji A., 2021 (NMA)	0.25	-0.45	-0.05	lit	par	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	lamotrigine	Completion of treatment	"eSMD=-0.27 [-0.7, 0.14] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.6	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	tranylcypromine	aug	-0.27	0.21	II (Moderate)	Bahji A., 2021 (NMA)	0.27	-0.7	0.14	lam	tran	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	n-acetyl cysteine	Completion of treatment	"eSMD=-0.32 [-0.72, 0.09] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.59	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	n-acetyl cysteine+acetylsalicylic acid	aug	-0.32	0.21	II (Moderate)	Bahji A., 2021 (NMA)	0.32	-0.72	0.09	nac	nac+asa	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Bond D.J., 2010 (MA)</a>"	divalproate	Completion of treatment	"eSMD=0.07 [-0.09, 0.23] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=25.33	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	4	Pairwise meta-analysis	Adults	Bipolar Depression	placebo	mono	0.07	0.08	IV (Very Low)	Bond D.J., 2010 (MA)	-0.07	-0.09	0.23	div	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Severus E., 2014 (MA)</a>"	lithium	Completion of treatment	"eSMD=0.29 [0.06, 0.52] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.15	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	7	Pairwise meta-analysis	Adults	Maintenance	placebo	mono	0.29	0.12	II (Moderate)	Severus E., 2014 (MA)	-0.29	0.06	0.52	lit	pbo	Completion of treatment
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2013 (MA)</a>"	lithium	Deliberate Self-Harm	"eSMD=0.28 [-0.15, 0.72] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.37	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Maintenance	placebo	mono	0.28	0.22	III (Low)	Cipriani A., 2013 (MA)	-0.28	-0.15	0.72	lit	pbo	Deliberate Self-Harm
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2013 (MA)</a>"	carbamazepine	Deliberate Self-Harm	"eSMD=-1.08 [-2.16, -0.1] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1.8	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Maintenance	lithium	mono	-1.08	0.53	I (High)	Cipriani A., 2013 (MA)	1.08	-2.16	-0.1	cbz	lit	Deliberate Self-Harm
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2013 (MA)</a>"	lamotrigine	Deliberate Self-Harm	"eSMD=-1.05 [-2.54, 0.49] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1.84	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Maintenance	lithium	mono	-1.05	0.77	II (Moderate)	Cipriani A., 2013 (MA)	1.05	-2.54	0.49	lam	lit	Deliberate Self-Harm
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2019 (MA)</a>"	ramelteon	Depression symptoms scale, endpoint score	"eSMD=-0.07 [-0.46, 0.32] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=25.33	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Maintenance	placebo	mono	-0.07	0.2	III (Low)	Kishi T., 2019 (MA)	0.07	-0.46	0.32	ram	pbo	Depression sxs, endpoint score
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	psychoeducation	Depression symptoms scale, endpoint score	"eSMD=-0.17 [-0.6, 0.27] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=10.45	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	21	Network meta-analysis	Mixed (Children-Adults)	Maintenance	supportive therapy	aug	-0.17	0.22	III (Low)	Miklowitz D.J., 2020 (NMA)	0.17	-0.6	0.27	PE	supp	Depression sxs, endpoint score
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	CBT	Depression symptoms scale, endpoint score	"eSMD=-0.13 [-0.64, 0.39] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=13.65	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	21	Network meta-analysis	Mixed (Children-Adults)	Maintenance	family/conjoint therapy	aug	-0.13	0.26	III (Low)	Miklowitz D.J., 2020 (NMA)	0.13	-0.64	0.39	CBT	family/conjoint	Depression sxs, endpoint score
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	CBT	Depression symptoms scale, endpoint score	"eSMD=-0.11 [-0.67, 0.45] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=16.13	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	21	Network meta-analysis	Mixed (Children-Adults)	Maintenance	IPSRT	aug	-0.11	0.29	III (Low)	Miklowitz D.J., 2020 (NMA)	0.11	-0.67	0.45	CBT	IPSRT	Depression sxs, endpoint score
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	family/conjoint therapy	Depression symptoms scale, endpoint score	"eSMD=0.02 [-0.58, 0.61] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=88.63	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	21	Network meta-analysis	Mixed (Children-Adults)	Maintenance	IPSRT	aug	0.02	0.3	III (Low)	Miklowitz D.J., 2020 (NMA)	-0.02	-0.58	0.61	family/conjoint	IPSRT	Depression sxs, endpoint score
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	IPSRT	Depression symptoms scale, endpoint score	"eSMD=0.05 [-0.56, 0.65] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=35.46	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	21	Network meta-analysis	Mixed (Children-Adults)	Maintenance	psychoeducation brief	aug	0.05	0.31	III (Low)	Miklowitz D.J., 2020 (NMA)	-0.05	-0.56	0.65	IPSRT	PE brief	Depression sxs, endpoint score
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	CBT	Depression symptoms scale, endpoint score	"eSMD=0.06 [-0.39, 0.51] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=29.55	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	21	Network meta-analysis	Mixed (Children-Adults)	Maintenance	supportive therapy	aug	0.06	0.23	III (Low)	Miklowitz D.J., 2020 (NMA)	-0.06	-0.39	0.51	CBT	supp	Depression sxs, endpoint score
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	family/conjoint therapy	Depression symptoms scale, endpoint score	"eSMD=0.06 [-0.32, 0.45] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=29.55	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	21	Network meta-analysis	Mixed (Children-Adults)	Maintenance	psychoeducation brief	aug	0.06	0.2	III (Low)	Miklowitz D.J., 2020 (NMA)	-0.06	-0.32	0.45	family/conjoint	PE brief	Depression sxs, endpoint score
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	psychoeducation	Depression symptoms scale, endpoint score	"eSMD=0.1 [-0.22, 0.42] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=17.74	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	21	Network meta-analysis	Mixed (Children-Adults)	Maintenance	TAU	N/A	0.1	0.16	III (Low)	Miklowitz D.J., 2020 (NMA)	-0.1	-0.22	0.42	PE	tau	Depression sxs, endpoint score
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	IPSRT	Depression symptoms scale, endpoint score	"eSMD=0.17 [-0.39, 0.72] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=10.45	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	21	Network meta-analysis	Mixed (Children-Adults)	Maintenance	supportive therapy	aug	0.17	0.28	III (Low)	Miklowitz D.J., 2020 (NMA)	-0.17	-0.39	0.72	IPSRT	supp	Depression sxs, endpoint score
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	family/conjoint therapy	Depression symptoms scale, endpoint score	"eSMD=0.18 [-0.41, 0.77] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=9.87	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	21	Network meta-analysis	Mixed (Children-Adults)	Maintenance	supportive therapy	aug	0.18	0.3	III (Low)	Miklowitz D.J., 2020 (NMA)	-0.18	-0.41	0.77	family/conjoint	supp	Depression sxs, endpoint score
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	CBT	Depression symptoms scale, endpoint score	"eSMD=0.22 [-0.11, 0.56] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	21	Network meta-analysis	Mixed (Children-Adults)	Maintenance	psychoeducation	aug	0.22	0.17	III (Low)	Miklowitz D.J., 2020 (NMA)	-0.22	-0.11	0.56	CBT	PE	Depression sxs, endpoint score
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	CBT	Depression symptoms scale, endpoint score	"eSMD=0.33 [0.06, 0.6] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.42	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	21	Network meta-analysis	Mixed (Children-Adults)	Maintenance	TAU	N/A	0.33	0.14	II (Moderate)	Miklowitz D.J., 2020 (NMA)	-0.33	0.06	0.6	CBT	tau	Depression sxs, endpoint score
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	family/conjoint therapy	Depression symptoms scale, endpoint score	"eSMD=0.45 [-0.08, 0.98] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.01	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	21	Network meta-analysis	Mixed (Children-Adults)	Maintenance	TAU	N/A	0.45	0.27	III (Low)	Miklowitz D.J., 2020 (NMA)	-0.45	-0.08	0.98	family/conjoint	tau	Depression sxs, endpoint score
"<a href='https://doi.org/' target=""_blank"">Yilmaz S., 2022 (MA)</a>"	psychoeducation	Depression symptoms scale, endpoint score	"eSMD=0.1 [-0.25, 0.45] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=17.74	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Bipolar Depression	placebo	aug	0.1	0.18	III (Low)	Yilmaz S., 2022 (MA)	-0.1	-0.25	0.45	PE	pbo	Depression sxs, endpoint score
"<a href='https://doi.org/' target=""_blank"">Yilmaz S., 2022 (MA)</a>"	CBT	Depression symptoms scale, endpoint score	"eSMD=0.08 [-0.18, 0.34] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=22.17	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Bipolar Depression	placebo	aug	0.08	0.13	III (Low)	Yilmaz S., 2022 (MA)	-0.08	-0.18	0.34	CBT	pbo	Depression sxs, endpoint score
"<a href='https://doi.org/' target=""_blank"">Yilmaz S., 2022 (MA)</a>"	psychoeducation	Depression symptoms scale, endpoint score	"eSMD=0.15 [-0.05, 0.34] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=11.84	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	8	Pairwise meta-analysis	Adults	Bipolar Depression	TAU	N/A	0.15	0.1	III (Low)	Yilmaz S., 2022 (MA)	-0.15	-0.05	0.34	PE	tau	Depression sxs, endpoint score
"<a href='https://doi.org/' target=""_blank"">Yilmaz S., 2022 (MA)</a>"	CBT	Depression symptoms scale, endpoint score	"eSMD=0.51 [0.27, 0.75] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.55	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	6	Pairwise meta-analysis	Adults	Bipolar Depression	TAU	N/A	0.51	0.12	II (Moderate)	Yilmaz S., 2022 (MA)	-0.51	0.27	0.75	CBT	tau	Depression sxs, endpoint score
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	gabapentin	Depression symptoms scale, change from baseline	"eSMD=1.84 [-3.01, 0.67] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.24	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	45	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	1.84	0.94	III (Low)	Bahji A., 2020 (NMA)	-1.84	-3.01	0.67	gaba	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	fluoxetine	Depression symptoms scale, change from baseline	"eSMD=1.41 [0.27, 2.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.47	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	45	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	1.41	0.58	I (High)	Bahji A., 2020 (NMA)	-1.41	0.27	2.55	fluo	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	divalproate	Depression symptoms scale, change from baseline	"eSMD=1.25 [0.47, 2.03] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.6	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	45	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	1.25	0.4	I (High)	Bahji A., 2020 (NMA)	-1.25	0.47	2.03	div	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	lurasidone	Depression symptoms scale, change from baseline	"eSMD=1.15 [0.37, 1.92] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.71	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	45	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	1.15	0.4	II (Moderate)	Bahji A., 2020 (NMA)	-1.15	0.37	1.92	lur	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	imipramine	Depression symptoms scale, change from baseline	"eSMD=0.86 [-0.01, 1.72] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.19	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	45	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.86	0.44	III (Low)	Bahji A., 2020 (NMA)	-0.86	-0.01	1.72	imp	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	cariprazine	Depression symptoms scale, change from baseline	"eSMD=0.85 [0.08, 1.62] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.21	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	45	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.85	0.39	II (Moderate)	Bahji A., 2020 (NMA)	-0.85	0.08	1.62	car	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	phenelzine	Depression symptoms scale, change from baseline	"eSMD=0.77 [-0.38, 1.91] <br> <img src=""https://www.linkpicture.com/q/Diapositive19.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.42	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	45	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.77	0.58	III (Low)	Bahji A., 2020 (NMA)	-0.77	-0.38	1.91	phen	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	olanzapine	Depression symptoms scale, change from baseline	"eSMD=0.72 [0.09, 1.35] <br> <img src=""https://www.linkpicture.com/q/Diapositive19.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.57	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	45	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.72	0.32	II (Moderate)	Bahji A., 2020 (NMA)	-0.72	0.09	1.35	ola	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	quetiapine	Depression symptoms scale, change from baseline	"eSMD=0.48 [0.14, 0.82] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.76	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	45	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.48	0.17	II (Moderate)	Bahji A., 2020 (NMA)	-0.48	0.14	0.82	que	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	carbamazepine	Depression symptoms scale, change from baseline	"eSMD=0.4 [-1.58, 0.78] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.49	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	45	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.4	0.6	III (Low)	Bahji A., 2020 (NMA)	-0.4	-1.58	0.78	cbz	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	olanzapine+fluoxetine	Depression symptoms scale, change from baseline	"eSMD=0.39 [-0.24, 1.02] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.6	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	45	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.39	0.32	III (Low)	Bahji A., 2020 (NMA)	-0.39	-0.24	1.02	ola+fluo	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	escitalopram	Depression symptoms scale, change from baseline	"eSMD=0.33 [-1.34, 2] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.42	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	45	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.33	0.85	III (Low)	Bahji A., 2020 (NMA)	-0.33	-1.34	2	escit	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	lithium	Depression symptoms scale, change from baseline	"eSMD=0.24 [-0.72, 1.21] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.42	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	45	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.24	0.49	III (Low)	Bahji A., 2020 (NMA)	-0.24	-0.72	1.21	lit	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	paroxetine	Depression symptoms scale, change from baseline	"eSMD=0.18 [-0.79, 1.15] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=9.87	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	45	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.18	0.49	III (Low)	Bahji A., 2020 (NMA)	-0.18	-0.79	1.15	par	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	lamotrigine	Depression symptoms scale, change from baseline	"eSMD=0.07 [-0.37, 0.51] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=25.33	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	45	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.07	0.22	III (Low)	Bahji A., 2020 (NMA)	-0.07	-0.37	0.51	lam	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	ziprasidone	Depression symptoms scale, change from baseline	"eSMD=0.05 [-0.64, 0.54] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=35.46	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	45	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.05	0.3	III (Low)	Bahji A., 2020 (NMA)	-0.05	-0.64	0.54	zip	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	aripiprazole	Depression symptoms scale, change from baseline	"eSMD=0.04 [-0.73, 0.82] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=44.32	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	45	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.04	0.4	III (Low)	Bahji A., 2020 (NMA)	-0.04	-0.73	0.82	ari	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	gabapentin	Depression symptoms scale, change from baseline	"eSMD=-0.92 [-2.14, 0.31] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.06	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	45	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	lamotrigine	mono	-0.92	0.63	III (Low)	Bahji A., 2020 (NMA)	0.92	-2.14	0.31	gaba	lam	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	lamotrigine	Depression symptoms scale, change from baseline	"eSMD=-0.26 [-1.35, 0.84] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.86	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	45	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	olanzapine+fluoxetine	combo	-0.26	0.56	III (Low)	Bahji A., 2020 (NMA)	0.26	-1.35	0.84	lam	ola+fluo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	imipramine	Depression symptoms scale, change from baseline	"eSMD=-0.24 [-1.52, 1.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.42	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	45	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	moclobemide	mono	-0.24	0.66	III (Low)	Bahji A., 2020 (NMA)	0.24	-1.52	1.05	imp	moc	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	paroxetine	Depression symptoms scale, change from baseline	"eSMD=-0.23 [-1.32, 0.86] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.74	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	45	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	quetiapine	mono	-0.23	0.56	III (Low)	Bahji A., 2020 (NMA)	0.23	-1.32	0.86	par	que	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	lithium	Depression symptoms scale, change from baseline	"eSMD=-0.01 [-1.1, 1.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=177.25	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	45	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	quetiapine	mono	-0.01	0.56	III (Low)	Bahji A., 2020 (NMA)	0.01	-1.1	1.08	lit	que	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	lithium	Depression symptoms scale, change from baseline	"eSMD=0 [-1.15, 1.15] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	45	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	sertraline	mono	0	0.59	III (Low)	Bahji A., 2020 (NMA)	0	-1.15	1.15	lit	sert	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	olanzapine	Depression symptoms scale, change from baseline	"eSMD=0.04 [-1.14, 1.06] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=44.32	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	45	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	olanzapine+fluoxetine	combo	0.04	0.56	III (Low)	Bahji A., 2020 (NMA)	-0.04	-1.14	1.06	ola	ola+fluo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	lithium	Depression symptoms scale, change from baseline	"eSMD=0.1 [-1.03, 1.23] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=17.74	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	45	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	venlafaxine	mono	0.1	0.58	III (Low)	Bahji A., 2020 (NMA)	-0.1	-1.03	1.23	lit	ven	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	imipramine	Depression symptoms scale, change from baseline	"eSMD=0.12 [-1.1, 1.33] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=14.79	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	45	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	phenelzine	mono	0.12	0.62	III (Low)	Bahji A., 2020 (NMA)	-0.12	-1.1	1.33	imp	phen	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	imipramine	Depression symptoms scale, change from baseline	"eSMD=0.3 [-0.69, 1.3] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.95	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	45	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	tranylcypromine	mono	0.3	0.51	III (Low)	Bahji A., 2020 (NMA)	-0.3	-0.69	1.3	imp	tran	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	fluoxetine	Depression symptoms scale, change from baseline	"eSMD=0.58 [-0.61, 1.77] <br> <img src=""https://www.linkpicture.com/q/Diapositive17.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.14	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	45	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	imipramine	mono	0.58	0.61	III (Low)	Bahji A., 2020 (NMA)	-0.58	-0.61	1.77	fluo	imp	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	t3 hormone	Depression symptoms scale, change from baseline	"eSMD=4.18 [-1.35, 7.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	4.18	2.13	III (Low)	Bahji A., 2021 (NMA)	-4.18	-1.35	7.01	t3	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	bupropion	Depression symptoms scale, change from baseline	"eSMD=3.01 [-0.19, 5.83] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.03	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	3.01	1.54	III (Low)	Bahji A., 2021 (NMA)	-3.01	-0.19	5.83	bup	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	fluoxetine	Depression symptoms scale, change from baseline	"eSMD=2.48 [-1.37, 3.58] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	2.48	1.26	III (Low)	Bahji A., 2021 (NMA)	-2.48	-1.37	3.58	fluo	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	ketamine	Depression symptoms scale, change from baseline	"eSMD=2.23 [-0.59, 3.88] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.13	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	2.23	1.14	III (Low)	Bahji A., 2021 (NMA)	-2.23	-0.59	3.88	ket	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	pindolol	Depression symptoms scale, change from baseline	"eSMD=1.5 [-0.07, 3.06] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.41	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	1.5	0.8	III (Low)	Bahji A., 2021 (NMA)	-1.5	-0.07	3.06	pin	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	pramipexole	Depression symptoms scale, change from baseline	"eSMD=1.25 [-0.38, 2.89] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.6	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	1.25	0.83	III (Low)	Bahji A., 2021 (NMA)	-1.25	-0.38	2.89	pram	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	lurasidone	Depression symptoms scale, change from baseline	"eSMD=1.02 [-0.48, 2.53] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.89	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	1.02	0.77	III (Low)	Bahji A., 2021 (NMA)	-1.02	-0.48	2.53	lur	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	t4 hormone	Depression symptoms scale, change from baseline	"eSMD=0.88 [-0.71, 2.47] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.14	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.88	0.81	III (Low)	Bahji A., 2021 (NMA)	-0.88	-0.71	2.47	t4	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	coenzyme Q10	Depression symptoms scale, change from baseline	"eSMD=0.87 [-1.3, 3.04] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.17	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.87	1.11	III (Low)	Bahji A., 2021 (NMA)	-0.87	-1.3	3.04	coQ10	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	creatine	Depression symptoms scale, change from baseline	"eSMD=0.84 [-1.49, 3.16] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.23	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.84	1.19	III (Low)	Bahji A., 2021 (NMA)	-0.84	-1.49	3.16	creatine	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	n-acetyl cysteine+acetylsalicylic acid	Depression symptoms scale, change from baseline	"eSMD=0.77 [-1.51, 3.06] <br> <img src=""https://www.linkpicture.com/q/Diapositive19.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.42	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.77	1.17	III (Low)	Bahji A., 2021 (NMA)	-0.77	-1.51	3.06	nac+asa	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	n-acetyl cysteine	Depression symptoms scale, change from baseline	"eSMD=0.74 [-0.39, 1.87] <br> <img src=""https://www.linkpicture.com/q/Diapositive19.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.5	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.74	0.58	III (Low)	Bahji A., 2021 (NMA)	-0.74	-0.39	1.87	nac	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	omega3	Depression symptoms scale, change from baseline	"eSMD=0.65 [-0.67, 1.97] <br> <img src=""https://www.linkpicture.com/q/Diapositive18.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.82	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.65	0.67	III (Low)	Bahji A., 2021 (NMA)	-0.65	-0.67	1.97	omega3	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	imipramine	Depression symptoms scale, change from baseline	"eSMD=0.57 [-0.96, 2.1] <br> <img src=""https://www.linkpicture.com/q/Diapositive17.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.19	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.57	0.78	III (Low)	Bahji A., 2021 (NMA)	-0.57	-0.96	2.1	imp	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	acetylsalicylic acid	Depression symptoms scale, change from baseline	"eSMD=0.48 [-1.12, 2.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.76	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.48	0.82	III (Low)	Bahji A., 2021 (NMA)	-0.48	-1.12	2.08	asa	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	lamotrigine	Depression symptoms scale, change from baseline	"eSMD=0.45 [-1.06, 1.96] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.01	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.45	0.77	III (Low)	Bahji A., 2021 (NMA)	-0.45	-1.06	1.96	lam	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	paroxetine	Depression symptoms scale, change from baseline	"eSMD=0.45 [-1.71, 2.62] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.01	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.45	1.1	III (Low)	Bahji A., 2021 (NMA)	-0.45	-1.71	2.62	par	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	celecoxib	Depression symptoms scale, change from baseline	"eSMD=0.42 [-1.15, 1.98] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.28	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.42	0.8	III (Low)	Bahji A., 2021 (NMA)	-0.42	-1.15	1.98	cel	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	inositol	Depression symptoms scale, change from baseline	"eSMD=0.31 [-1.31, 1.93] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.76	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.31	0.83	III (Low)	Bahji A., 2021 (NMA)	-0.31	-1.31	1.93	ino	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	armodafinil	Depression symptoms scale, change from baseline	"eSMD=0.27 [-0.68, 1.23] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.6	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.27	0.49	III (Low)	Bahji A., 2021 (NMA)	-0.27	-0.68	1.23	armo	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	citalopram	Depression symptoms scale, change from baseline	"eSMD=0.23 [-1.92, 2.37] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.74	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.23	1.09	III (Low)	Bahji A., 2021 (NMA)	-0.23	-1.92	2.37	cit	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	memantine	Depression symptoms scale, change from baseline	"eSMD=0.19 [-1.35, 1.74] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=9.36	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.19	0.79	III (Low)	Bahji A., 2021 (NMA)	-0.19	-1.35	1.74	mem	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	minocycline+acetylsalicylic acid	Depression symptoms scale, change from baseline	"eSMD=0.17 [-2, 2.34] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=10.45	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.17	1.11	III (Low)	Bahji A., 2021 (NMA)	-0.17	-2	2.34	mino+asa	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	quetiapine	Depression symptoms scale, change from baseline	"eSMD=0.16 [-1.99, 2.31] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=11.1	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.16	1.1	III (Low)	Bahji A., 2021 (NMA)	-0.16	-1.99	2.31	que	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	dextromethorphan	Depression symptoms scale, change from baseline	"eSMD=0.14 [-1.99, 2.27] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=12.68	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.14	1.09	III (Low)	Bahji A., 2021 (NMA)	-0.14	-1.99	2.27	dexm	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	agomelatin	Depression symptoms scale, change from baseline	"eSMD=0.12 [-2.01, 2.24] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=14.79	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.12	1.08	III (Low)	Bahji A., 2021 (NMA)	-0.12	-2.01	2.24	ago	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	aripiprazole	Depression symptoms scale, change from baseline	"eSMD=0.12 [-2.15, 2.39] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=14.79	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.12	1.16	III (Low)	Bahji A., 2021 (NMA)	-0.12	-2.15	2.39	ari	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	minocycline	Depression symptoms scale, change from baseline	"eSMD=0.06 [-2.13, 2.25] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=29.55	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.06	1.12	III (Low)	Bahji A., 2021 (NMA)	-0.06	-2.13	2.25	mino	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	lisdexamfetamine	Depression symptoms scale, change from baseline	"eSMD=0.02 [-2.23, 2.28] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=88.63	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.02	1.15	III (Low)	Bahji A., 2021 (NMA)	-0.02	-2.23	2.28	lisdex	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	pregnenolone	Depression symptoms scale, change from baseline	"eSMD=-0.08 [-2.25, 2.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=22.17	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.08	1.1	III (Low)	Bahji A., 2021 (NMA)	0.08	-2.25	2.08	preg	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	ziprasidone	Depression symptoms scale, change from baseline	"eSMD=-0.08 [-2.21, 2.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=22.17	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.08	1.09	III (Low)	Bahji A., 2021 (NMA)	0.08	-2.21	2.05	zip	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	sAME	Depression symptoms scale, change from baseline	"eSMD=-0.14 [-2.46, 2.18] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=12.68	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.14	1.18	III (Low)	Bahji A., 2021 (NMA)	0.14	-2.46	2.18	sAME	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	infliximab	Depression symptoms scale, change from baseline	"eSMD=-0.19 [-2.36, 1.99] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=9.36	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.19	1.11	III (Low)	Bahji A., 2021 (NMA)	0.19	-2.36	1.99	infx	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	levetiracetam	Depression symptoms scale, change from baseline	"eSMD=-0.27 [-2.5, 1.95] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.6	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.27	1.14	III (Low)	Bahji A., 2021 (NMA)	0.27	-2.5	1.95	levt	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	pioglitazone	Depression symptoms scale, change from baseline	"eSMD=-0.95 [-2.53, 0.64] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.01	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.95	0.81	III (Low)	Bahji A., 2021 (NMA)	0.95	-2.53	0.64	pio	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	vitD3	Depression symptoms scale, change from baseline	"eSMD=-1.16 [-3.4, 1.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1.7	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-1.16	1.14	III (Low)	Bahji A., 2021 (NMA)	1.16	-3.4	1.08	vitD3	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	paroxetine	Depression symptoms scale, change from baseline	"eSMD=-1 [-3.31, 1.32] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1.92	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	risperidone	aug	-1	1.18	III (Low)	Bahji A., 2021 (NMA)	1	-3.31	1.32	par	risp	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	inositol	Depression symptoms scale, change from baseline	"eSMD=-0.92 [-3.12, 1.29] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.06	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	lamotrigine	aug	-0.92	1.12	III (Low)	Bahji A., 2021 (NMA)	0.92	-3.12	1.29	ino	lam	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	lamotrigine	Depression symptoms scale, change from baseline	"eSMD=-0.74 [-3.05, 1.58] <br> <img src=""https://www.linkpicture.com/q/Diapositive2.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.5	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	tranylcypromine	aug	-0.74	1.18	III (Low)	Bahji A., 2021 (NMA)	0.74	-3.05	1.58	lam	tran	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	n-acetyl cysteine	Depression symptoms scale, change from baseline	"eSMD=-0.56 [-2.89, 1.76] <br> <img src=""https://www.linkpicture.com/q/Diapositive4.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.25	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	n-acetyl cysteine+acetylsalicylic acid	aug	-0.56	1.19	III (Low)	Bahji A., 2021 (NMA)	0.56	-2.89	1.76	nac	nac+asa	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	amitriptyline	Depression symptoms scale, change from baseline	"eSMD=-0.55 [-1.65, 2.76] <br> <img src=""https://www.linkpicture.com/q/Diapositive4.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.3	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	paroxetine	aug	-0.55	1.12	III (Low)	Bahji A., 2021 (NMA)	0.55	-1.65	2.76	amit	par	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	amitriptyline	Depression symptoms scale, change from baseline	"eSMD=-0.29 [-2.52, 1.94] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.15	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	l-sulpride	aug	-0.29	1.14	III (Low)	Bahji A., 2021 (NMA)	0.29	-2.52	1.94	amit	l-sulpr	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	inositol	Depression symptoms scale, change from baseline	"eSMD=-0.25 [-2.44, 1.95] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.13	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	risperidone	aug	-0.25	1.12	III (Low)	Bahji A., 2021 (NMA)	0.25	-2.44	1.95	ino	risp	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	paroxetine	Depression symptoms scale, change from baseline	"eSMD=-0.25 [-2.42, 1.93] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.13	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	venlafaxine	aug	-0.25	1.11	III (Low)	Bahji A., 2021 (NMA)	0.25	-2.42	1.93	par	ven	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	sertraline	Depression symptoms scale, change from baseline	"eSMD=-0.23 [-2.37, 1.91] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.74	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	venlafaxine	aug	-0.23	1.09	III (Low)	Bahji A., 2021 (NMA)	0.23	-2.37	1.91	sert	ven	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	acetylsalicylic acid	Depression symptoms scale, change from baseline	"eSMD=-0.2 [-2.58, 2.18] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=8.89	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	n-acetyl cysteine+acetylsalicylic acid	aug	-0.2	1.21	III (Low)	Bahji A., 2021 (NMA)	0.2	-2.58	2.18	asa	nac+asa	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	minocycline	Depression symptoms scale, change from baseline	"eSMD=-0.11 [-2.3, 2.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=16.13	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	minocycline+acetylsalicylic acid	aug	-0.11	1.12	III (Low)	Bahji A., 2021 (NMA)	0.11	-2.3	2.08	mino	mino+asa	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	imipramine	Depression symptoms scale, change from baseline	"eSMD=-0.06 [-2.22, 2.1] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=29.55	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	paroxetine	aug	-0.06	1.1	III (Low)	Bahji A., 2021 (NMA)	0.06	-2.22	2.1	imp	par	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	bupropion	Depression symptoms scale, change from baseline	"eSMD=0.03 [-2.12, 2.17] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=59.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	venlafaxine	aug	0.03	1.09	III (Low)	Bahji A., 2021 (NMA)	-0.03	-2.12	2.17	bup	ven	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	paroxetine	Depression symptoms scale, change from baseline	"eSMD=0.19 [-2.1, 2.47] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=9.36	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	risperidone+paroxetine	aug	0.19	1.17	III (Low)	Bahji A., 2021 (NMA)	-0.19	-2.1	2.47	par	risp+par	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	acetylsalicylic acid	Depression symptoms scale, change from baseline	"eSMD=0.24 [-1.94, 2.43] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.42	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	minocycline+acetylsalicylic acid	aug	0.24	1.11	III (Low)	Bahji A., 2021 (NMA)	-0.24	-1.94	2.43	asa	mino+asa	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	fluoxetine	Depression symptoms scale, change from baseline	"eSMD=0.25 [-1.87, 2.37] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.13	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	lamotrigine	aug	0.25	1.08	III (Low)	Bahji A., 2021 (NMA)	-0.25	-1.87	2.37	fluo	lam	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	bupropion	Depression symptoms scale, change from baseline	"eSMD=0.26 [-1.89, 2.4] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.86	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	sertraline	aug	0.26	1.09	III (Low)	Bahji A., 2021 (NMA)	-0.26	-1.89	2.4	bup	sert	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	fluoxetine	Depression symptoms scale, change from baseline	"eSMD=0.27 [-1.9, 2.44] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.6	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	imipramine	aug	0.27	1.11	III (Low)	Bahji A., 2021 (NMA)	-0.27	-1.9	2.44	fluo	imp	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	acetylsalicylic acid	Depression symptoms scale, change from baseline	"eSMD=0.35 [-1.85, 2.56] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.12	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	minocycline	aug	0.35	1.12	III (Low)	Bahji A., 2021 (NMA)	-0.35	-1.85	2.56	asa	mino	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	acetylsalicylic acid	Depression symptoms scale, change from baseline	"eSMD=0.35 [-2.04, 2.75] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.12	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	n-acetyl cysteine	aug	0.35	1.22	III (Low)	Bahji A., 2021 (NMA)	-0.35	-2.04	2.75	asa	nac	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	citalopram	Depression symptoms scale, change from baseline	"eSMD=0.37 [-1.92, 2.66] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.85	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	lamotrigine	aug	0.37	1.17	III (Low)	Bahji A., 2021 (NMA)	-0.37	-1.92	2.66	cit	lam	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	imipramine	Depression symptoms scale, change from baseline	"eSMD=0.4 [-1.74, 2.53] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.49	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	moclobemide	aug	0.4	1.09	III (Low)	Bahji A., 2021 (NMA)	-0.4	-1.74	2.53	imp	moc	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	lamotrigine	Depression symptoms scale, change from baseline	"eSMD=0.67 [-1.53, 2.87] <br> <img src=""https://www.linkpicture.com/q/Diapositive18.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.74	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	risperidone	aug	0.67	1.12	III (Low)	Bahji A., 2021 (NMA)	-0.67	-1.53	2.87	lam	risp	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	risperidone	Depression symptoms scale, change from baseline	"eSMD=1.18 [-1.14, 3.51] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.68	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	risperidone+paroxetine	aug	1.18	1.19	III (Low)	Bahji A., 2021 (NMA)	-1.18	-1.14	3.51	risp	risp+par	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	lithium	Depression symptoms scale, change from baseline	"eSMD=1.39 [-0.9, 3.67] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.48	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	67	Network meta-analysis	Adults	Bipolar Depression	paroxetine	aug	1.39	1.17	III (Low)	Bahji A., 2021 (NMA)	-1.39	-0.9	3.67	lit	par	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Bisdounis L., 2022 (MA)</a>"	bright light therapy	Depression symptoms scale, change from baseline	"eSMD=0.74 [0.42, 1.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive19.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.5	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Pairwise meta-analysis	Adults	Bipolar Depression	TAU/sham	mono	0.74	0.16	II (Moderate)	Bisdounis L., 2022 (MA)	-0.74	0.42	1.05	BLT	tau/sham	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Chatterton M.L., 2017 (NMA)</a>"	CBT	Depression symptoms scale, change from baseline	"eSMD=-0.14 [-0.9, 0.62] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=12.68	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	25	Network meta-analysis	Adults	Maintenance	TAU	N/A	-0.14	0.39	IV (Very Low)	Chatterton M.L., 2017 (NMA)	0.14	-0.9	0.62	CBT	tau	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Chatterton M.L., 2017 (NMA)</a>"	psychoeducation	Depression symptoms scale, change from baseline	"eSMD=0.14 [-1.01, 1.3] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=12.68	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	25	Network meta-analysis	Adults	Maintenance	TAU	N/A	0.14	0.59	IV (Very Low)	Chatterton M.L., 2017 (NMA)	-0.14	-1.01	1.3	PE	tau	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Chatterton M.L., 2017 (NMA)</a>"	family focused therapy	Depression symptoms scale, change from baseline	"eSMD=0.26 [-0.2, 0.72] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.86	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	25	Network meta-analysis	Adults	Maintenance	TAU	N/A	0.26	0.23	IV (Very Low)	Chatterton M.L., 2017 (NMA)	-0.26	-0.2	0.72	FFT	tau	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Chatterton M.L., 2017 (NMA)</a>"	CBT+psychoeducation	Depression symptoms scale, change from baseline	"eSMD=0.58 [-1.25, 2.41] <br> <img src=""https://www.linkpicture.com/q/Diapositive17.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.14	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	25	Network meta-analysis	Adults	Maintenance	TAU	N/A	0.58	0.93	IV (Very Low)	Chatterton M.L., 2017 (NMA)	-0.58	-1.25	2.41	CBT+PE	tau	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Fountoulakis K.N., 2011 (MA)</a>"	aripiprazole	Depression symptoms scale, change from baseline	"eSMD=-0.14 [-0.24, -0.04] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=12.68	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	4	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.14	0.05	IV (Very Low)	Fountoulakis K.N., 2011 (MA)	0.14	-0.24	-0.04	ari	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	cariprazine	Depression symptoms scale, change from baseline	"eSMD=2.29 [1.09, 3.47] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.12	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	18	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	2.29	0.61	I (High)	Kadakia A., 2021 (NMA)	-2.29	1.09	3.47	car	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2016 (MA)</a>"	risperidone LAI	Depression symptoms scale, change from baseline	"eSMD=1.76 [0.28, 3.23] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.27	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Maintenance	placebo	mono	1.76	0.75	I (High)	Kishi T., 2016 (MA)	-1.76	0.28	3.23	rispLAI	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (MA)</a>"	omega3	Depression symptoms scale, change from baseline	"eSMD=0.48 [0.01, 0.97] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.76	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Pairwise meta-analysis	Adults	Maintenance	placebo	aug	0.48	0.24	II (Moderate)	Kishi T., 2021 (MA)	-0.48	0.01	0.97	omega3	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Maiti R., 2021 (NMA)</a>"	acetyl-L-carnitine+alpha-lipoic acid	Depression symptoms scale, change from baseline	"eSMD=0.55 [-1.52, 2.63] <br> <img src=""https://www.linkpicture.com/q/Diapositive17.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.3	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	15	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.55	1.06	III (Low)	Maiti R., 2021 (NMA)	-0.55	-1.52	2.63	alcar+ala	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Maiti R., 2021 (NMA)</a>"	folic acid	Depression symptoms scale, change from baseline	"eSMD=0.26 [-1.96, 2.47] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.86	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	15	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.26	1.13	III (Low)	Maiti R., 2021 (NMA)	-0.26	-1.96	2.47	folac	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Maiti R., 2021 (NMA)</a>"	choline	Depression symptoms scale, change from baseline	"eSMD=0 [-2.41, 2.41] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	15	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0	1.23	III (Low)	Maiti R., 2021 (NMA)	0	-2.41	2.41	choline	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Maiti R., 2021 (NMA)</a>"	melatonin	Depression symptoms scale, change from baseline	"eSMD=-0.22 [-2.39, 1.94] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=8.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	15	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.22	1.1	III (Low)	Maiti R., 2021 (NMA)	0.22	-2.39	1.94	mel	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	lithium	Depression symptoms scale, change from baseline	"eSMD=1.12 [-5.44, 7.69] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.75	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	1.12	3.35	IV (Very Low)	McKnight R.F., 2019 (MA)	-1.12	-5.44	7.69	lit	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	lamotrigine	Depression symptoms scale, change from baseline	"eSMD=-1.74 [-3.72, 0.24] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1.28	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	lithium	mono	-1.74	1.01	III (Low)	McKnight R.F., 2019 (MA)	1.74	-3.72	0.24	lam	lit	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	lithium	Depression symptoms scale, change from baseline	"eSMD=-0.9 [-2.12, 0.32] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.1	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	quetiapine	mono	-0.9	0.62	II (Moderate)	McKnight R.F., 2019 (MA)	0.9	-2.12	0.32	lit	que	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Pinto J.V., 2020 (MA)</a>"	cariprazine	Depression symptoms scale, change from baseline	"eSMD=0.15 [-0.22, 0.52] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=11.84	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	0.15	0.19	III (Low)	Pinto J.V., 2020 (MA)	-0.15	-0.22	0.52	car	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Ramirez-Mahaluf J.P., 2020 (MA)</a>"	total sleep deprivation	Depression symptoms scale, change from baseline	"eSMD=0.45 [-0.09, 0.99] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.01	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Bipolar Depression	TAU	mono	0.45	0.28	III (Low)	Ramirez-Mahaluf J.P., 2020 (MA)	-0.45	-0.09	0.99	TSD	tau	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Rendell J.M., 2010 (MA)</a>"	olanzapine	Depression symptoms scale, change from baseline	"eSMD=1.22 [-0.48, 2.92] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.63	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	1.22	0.87	II (Moderate)	Rendell J.M., 2010 (MA)	-1.22	-0.48	2.92	ola	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Sarris J., 2010 (MA)</a>"	omega3	Depression symptoms scale, change from baseline	"eSMD=-0.34 [-0.64, -0.03] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.26	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	6	Pairwise meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	aug	-0.34	0.16	II (Moderate)	Sarris J., 2010 (MA)	0.34	-0.64	-0.03	omega3	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Suttajit S., 2014 (MA)</a>"	quetiapine	Depression symptoms scale, change from baseline	"eSMD=1.82 [-2.34, 5.98] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.25	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Children & Adolescents	Bipolar Depression	placebo	mono	1.82	2.12	II (Moderate)	Suttajit S., 2014 (MA)	-1.82	-2.34	5.98	que	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Taylor D.M., 2014 (NMA)</a>"	olanzapine+fluoxetine	Depression symptoms scale, change from baseline	"eSMD=0.56 [0.15, 0.98] <br> <img src=""https://www.linkpicture.com/q/Diapositive17.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.25	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.56	0.21	IV (Very Low)	Taylor D.M., 2014 (NMA)	-0.56	0.15	0.98	ola+fluo	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Taylor D.M., 2014 (NMA)</a>"	olanzapine	Depression symptoms scale, change from baseline	"eSMD=0.51 [0.17, -0.87] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.55	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.51	0.27	IV (Very Low)	Taylor D.M., 2014 (NMA)	-0.51	0.17	-0.87	ola	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Taylor D.M., 2014 (NMA)</a>"	divalproate	Depression symptoms scale, change from baseline	"eSMD=0.44 [-0.07, 0.96] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.09	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.44	0.26	IV (Very Low)	Taylor D.M., 2014 (NMA)	-0.44	-0.07	0.96	div	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Taylor D.M., 2014 (NMA)</a>"	lurasidone	Depression symptoms scale, change from baseline	"eSMD=0.36 [-0.06, 0.78] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.98	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.36	0.21	IV (Very Low)	Taylor D.M., 2014 (NMA)	-0.36	-0.06	0.78	lur	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Taylor D.M., 2014 (NMA)</a>"	quetiapine	Depression symptoms scale, change from baseline	"eSMD=0.33 [0.07, 0.59] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.42	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.33	0.13	IV (Very Low)	Taylor D.M., 2014 (NMA)	-0.33	0.07	0.59	que	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Taylor D.M., 2014 (NMA)</a>"	lamotrigine	Depression symptoms scale, change from baseline	"eSMD=0.21 [0.01, 0.45] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.47	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.21	0.11	IV (Very Low)	Taylor D.M., 2014 (NMA)	-0.21	0.01	0.45	lam	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Taylor D.M., 2014 (NMA)</a>"	lithium	Depression symptoms scale, change from baseline	"eSMD=0.16 [-0.38, 0.69] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=11.1	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.16	0.27	IV (Very Low)	Taylor D.M., 2014 (NMA)	-0.16	-0.38	0.69	lit	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Taylor D.M., 2014 (NMA)</a>"	aripiprazole	Depression symptoms scale, change from baseline	"eSMD=0.1 [-0.32, 0.52] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=17.74	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.1	0.21	IV (Very Low)	Taylor D.M., 2014 (NMA)	-0.1	-0.32	0.52	ari	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Taylor D.M., 2014 (NMA)</a>"	ziprasidone	Depression symptoms scale, change from baseline	"eSMD=0.02 [-0.58, 0.62] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=88.63	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.02	0.31	IV (Very Low)	Taylor D.M., 2014 (NMA)	-0.02	-0.58	0.62	zip	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Taylor D.M., 2014 (NMA)</a>"	lamotrigine	Depression symptoms scale, change from baseline	"eSMD=-0.35 [-0.78, 0.07] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.12	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Bipolar Depression	olanzapine+fluoxetine	combo	-0.35	0.22	IV (Very Low)	Taylor D.M., 2014 (NMA)	0.35	-0.78	0.07	lam	ola+fluo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Taylor D.M., 2014 (NMA)</a>"	lithium	Depression symptoms scale, change from baseline	"eSMD=-0.18 [-0.7, 0.35] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=9.87	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Bipolar Depression	quetiapine	mono	-0.18	0.27	IV (Very Low)	Taylor D.M., 2014 (NMA)	0.18	-0.7	0.35	lit	que	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Taylor D.M., 2014 (NMA)</a>"	olanzapine	Depression symptoms scale, change from baseline	"eSMD=-0.05 [-0.51, 0.43] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=35.46	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Bipolar Depression	olanzapine+fluoxetine	combo	-0.05	0.24	IV (Very Low)	Taylor D.M., 2014 (NMA)	0.05	-0.51	0.43	ola	ola+fluo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Tee M.M.K., 2020 (MA)</a>"	rTMS	Depression symptoms scale, change from baseline	"eSMD=-0.3 [-0.55, -0.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.95	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	9	Pairwise meta-analysis	Adults	Bipolar Depression	sham	aug	-0.3	0.13	II (Moderate)	Tee M.M.K., 2020 (MA)	0.3	-0.55	-0.05	rTMS	sham	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Vita A., 2013 (MA)</a>"	asenapine	Depression symptoms scale, change from baseline	"eSMD=0.2 [-0.05, 0.45] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.89	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	0.2	0.13	IV (Very Low)	Vita A., 2013 (MA)	-0.2	-0.05	0.45	ase	pbo	Depressive sxs, change
"<a href='https://doi.org/' target=""_blank"">Jochim J., 2019 (MA)</a>"	divalproate	Discontinuation, due to lack of efficacy	"eSMD=-0.24 [-0.83, 0.37] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.42	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Children & Adolescents	Mania/Mixed	placebo	mono	-0.24	0.31	III (Low)	Jochim J., 2019 (MA)	0.24	-0.83	0.37	div	pbo	Discontinuation (lack of efficacy)
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	quetiapine	Discontinuation, due to lack of efficacy	"eSMD=0.81 [0.51, 1.17] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.31	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	17	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.81	0.17	II (Moderate)	Kadakia A., 2021 (NMA)	-0.81	0.51	1.17	que	pbo	Discontinuation (lack of efficacy)
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	olanzapine	Discontinuation, due to lack of efficacy	"eSMD=0.48 [0.04, 1.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.76	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	17	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.48	0.27	II (Moderate)	Kadakia A., 2021 (NMA)	-0.48	0.04	1.08	ola	pbo	Discontinuation (lack of efficacy)
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	cariprazine	Discontinuation, due to lack of efficacy	"eSMD=0.38 [-0.02, 0.89] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.72	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	17	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.38	0.23	III (Low)	Kadakia A., 2021 (NMA)	-0.38	-0.02	0.89	car	pbo	Discontinuation (lack of efficacy)
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	aripiprazole	Discontinuation, due to lack of efficacy	"eSMD=0.24 [-0.25, 0.92] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.42	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	17	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.24	0.3	III (Low)	Kadakia A., 2021 (NMA)	-0.24	-0.25	0.92	ari	pbo	Discontinuation (lack of efficacy)
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	lurasidone	Discontinuation, due to lack of efficacy	"eSMD=0.14 [-0.43, 0.95] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=12.68	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	17	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.14	0.35	III (Low)	Kadakia A., 2021 (NMA)	-0.14	-0.43	0.95	lur	pbo	Discontinuation (lack of efficacy)
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	ziprasidone	Discontinuation, due to lack of efficacy	"eSMD=-0.34 [-0.89, 0.34] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.26	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	17	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.34	0.31	III (Low)	Kadakia A., 2021 (NMA)	0.34	-0.89	0.34	zip	pbo	Discontinuation (lack of efficacy)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Discontinuation, due to lack of efficacy	"eSMD=0.58 [0.32, 0.84] <br> <img src=""https://www.linkpicture.com/q/Diapositive17.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.14	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	50	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.58	0.13	I (High)	Kishi T., 2021 (NMA)	-0.58	0.32	0.84	pal	pbo	Discontinuation (lack of efficacy)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Discontinuation, due to lack of efficacy	"eSMD=0.52 [0.37, 0.66] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.49	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	50	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.52	0.07	I (High)	Kishi T., 2021 (NMA)	-0.52	0.37	0.66	hal	pbo	Discontinuation (lack of efficacy)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	cariprazine	Discontinuation, due to lack of efficacy	"eSMD=0.49 [0.21, 0.76] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.69	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	50	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.49	0.14	I (High)	Kishi T., 2021 (NMA)	-0.49	0.21	0.76	car	pbo	Discontinuation (lack of efficacy)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	risperidone	Discontinuation, due to lack of efficacy	"eSMD=0.47 [0.26, 0.68] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.84	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	50	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.47	0.11	I (High)	Kishi T., 2021 (NMA)	-0.47	0.26	0.68	risp	pbo	Discontinuation (lack of efficacy)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	carbamazepine	Discontinuation, due to lack of efficacy	"eSMD=0.43 [0.14, 0.72] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.19	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	50	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.43	0.15	I (High)	Kishi T., 2021 (NMA)	-0.43	0.14	0.72	cbz	pbo	Discontinuation (lack of efficacy)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Discontinuation, due to lack of efficacy	"eSMD=0.38 [0.26, 0.51] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.72	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	50	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.38	0.06	I (High)	Kishi T., 2021 (NMA)	-0.38	0.26	0.51	ola	pbo	Discontinuation (lack of efficacy)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	asenapine	Discontinuation, due to lack of efficacy	"eSMD=0.36 [0.14, 0.59] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.98	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	50	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.36	0.11	I (High)	Kishi T., 2021 (NMA)	-0.36	0.14	0.59	ase	pbo	Discontinuation (lack of efficacy)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	quetiapine	Discontinuation, due to lack of efficacy	"eSMD=0.36 [0.17, 0.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.98	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	50	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.36	0.1	I (High)	Kishi T., 2021 (NMA)	-0.36	0.17	0.55	que	pbo	Discontinuation (lack of efficacy)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	ziprasidone	Discontinuation, due to lack of efficacy	"eSMD=0.29 [0.13, 0.45] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.15	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	50	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.29	0.08	I (High)	Kishi T., 2021 (NMA)	-0.29	0.13	0.45	zip	pbo	Discontinuation (lack of efficacy)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Discontinuation, due to lack of efficacy	"eSMD=0.26 [0.12, 0.4] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.86	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	50	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.26	0.07	I (High)	Kishi T., 2021 (NMA)	-0.26	0.12	0.4	div	pbo	Discontinuation (lack of efficacy)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Discontinuation, due to lack of efficacy	"eSMD=0.26 [0.13, 0.38] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.86	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	50	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.26	0.06	I (High)	Kishi T., 2021 (NMA)	-0.26	0.13	0.38	ari	pbo	Discontinuation (lack of efficacy)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	tamoxifen	Discontinuation, due to lack of efficacy	"eSMD=0.22 [-0.61, 1.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.09	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	50	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.22	0.43	II (Moderate)	Kishi T., 2021 (NMA)	-0.22	-0.61	1.08	tamox	pbo	Discontinuation (lack of efficacy)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Discontinuation, due to lack of efficacy	"eSMD=0.2 [-0.24, 0.65] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.89	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	50	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.2	0.23	II (Moderate)	Kishi T., 2021 (NMA)	-0.2	-0.24	0.65	lam	pbo	Discontinuation (lack of efficacy)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Discontinuation, due to lack of efficacy	"eSMD=0.18 [0.02, 0.35] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=9.87	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	50	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.18	0.08	I (High)	Kishi T., 2021 (NMA)	-0.18	0.02	0.35	lit	pbo	Discontinuation (lack of efficacy)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	verapamil	Discontinuation, due to lack of efficacy	"eSMD=-0.05 [-0.43, 0.32] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=35.46	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	50	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.05	0.19	II (Moderate)	Kishi T., 2021 (NMA)	0.05	-0.43	0.32	verapamil	pbo	Discontinuation (lack of efficacy)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	topiramate	Discontinuation, due to lack of efficacy	"eSMD=-0.1 [-0.3, 0.09] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=17.74	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	50	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.1	0.1	II (Moderate)	Kishi T., 2021 (NMA)	0.1	-0.3	0.09	top	pbo	Discontinuation (lack of efficacy)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	brexpiprazole	Discontinuation, due to lack of efficacy	"eSMD=-0.11 [-0.74, 0.51] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=16.13	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	50	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.11	0.32	II (Moderate)	Kishi T., 2021 (NMA)	0.11	-0.74	0.51	brex	pbo	Discontinuation (lack of efficacy)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	valnoctamide	Discontinuation, due to lack of efficacy	"eSMD=-0.3 [-0.79, 0.19] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.95	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	50	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.3	0.25	II (Moderate)	Kishi T., 2021 (NMA)	0.3	-0.79	0.19	valnoctamide	pbo	Discontinuation (lack of efficacy)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Discontinuation, due to lack of efficacy	"eSMD=-0.26 [-0.44, -0.09] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.86	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	50	Network meta-analysis	Adults	Mania/Mixed	haloperidol	mono	-0.26	0.09	I (High)	Kishi T., 2021 (NMA)	0.26	-0.44	-0.09	ari	hal	Discontinuation (lack of efficacy)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Discontinuation, due to lack of efficacy	"eSMD=-0.12 [-0.29, 0.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=14.79	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	50	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.12	0.09	II (Moderate)	Kishi T., 2021 (NMA)	0.12	-0.29	0.05	div	ola	Discontinuation (lack of efficacy)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Discontinuation, due to lack of efficacy	"eSMD=-0.09 [-0.33, 0.15] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=19.71	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	50	Network meta-analysis	Adults	Mania/Mixed	risperidone	mono	-0.09	0.12	II (Moderate)	Kishi T., 2021 (NMA)	0.09	-0.33	0.15	ola	risp	Discontinuation (lack of efficacy)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	asenapine	Discontinuation, due to lack of efficacy	"eSMD=-0.02 [-0.25, 0.23] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=88.63	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	50	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.02	0.12	II (Moderate)	Kishi T., 2021 (NMA)	0.02	-0.25	0.23	ase	ola	Discontinuation (lack of efficacy)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Discontinuation, due to lack of efficacy	"eSMD=0.02 [-0.44, 0.47] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=88.63	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	50	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	0.02	0.23	II (Moderate)	Kishi T., 2021 (NMA)	-0.02	-0.44	0.47	lam	lit	Discontinuation (lack of efficacy)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Discontinuation, due to lack of efficacy	"eSMD=0.05 [-0.2, 0.3] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=35.46	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	50	Network meta-analysis	Adults	Mania/Mixed	risperidone	mono	0.05	0.13	II (Moderate)	Kishi T., 2021 (NMA)	-0.05	-0.2	0.3	hal	risp	Discontinuation (lack of efficacy)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Discontinuation, due to lack of efficacy	"eSMD=0.07 [-0.13, 0.27] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=25.33	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	50	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	0.07	0.1	II (Moderate)	Kishi T., 2021 (NMA)	-0.07	-0.13	0.27	ari	lit	Discontinuation (lack of efficacy)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Discontinuation, due to lack of efficacy	"eSMD=0.08 [-0.12, 0.28] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=22.17	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	50	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	0.08	0.1	II (Moderate)	Kishi T., 2021 (NMA)	-0.08	-0.12	0.28	div	lit	Discontinuation (lack of efficacy)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Discontinuation, due to lack of efficacy	"eSMD=0.14 [-0.03, 0.31] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=12.68	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	50	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	0.14	0.09	II (Moderate)	Kishi T., 2021 (NMA)	-0.14	-0.03	0.31	hal	ola	Discontinuation (lack of efficacy)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Discontinuation, due to lack of efficacy	"eSMD=0.16 [-0.06, 0.38] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=11.1	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	50	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	0.16	0.11	II (Moderate)	Kishi T., 2021 (NMA)	-0.16	-0.06	0.38	hal	que	Discontinuation (lack of efficacy)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Discontinuation, due to lack of efficacy	"eSMD=0.22 [-0.09, 0.53] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.09	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	50	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	0.22	0.16	II (Moderate)	Kishi T., 2021 (NMA)	-0.22	-0.09	0.53	pal	que	Discontinuation (lack of efficacy)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Discontinuation, due to lack of efficacy	"eSMD=0.23 [0.03, 0.43] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.74	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	50	Network meta-analysis	Adults	Mania/Mixed	ziprasidone	mono	0.23	0.1	I (High)	Kishi T., 2021 (NMA)	-0.23	0.03	0.43	hal	zip	Discontinuation (lack of efficacy)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Discontinuation, due to lack of efficacy	"eSMD=0.29 [0.06, 0.52] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.15	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	50	Network meta-analysis	Adults	Mania/Mixed	topiramate	mono	0.29	0.12	I (High)	Kishi T., 2021 (NMA)	-0.29	0.06	0.52	lit	top	Discontinuation (lack of efficacy)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	risperidone	Discontinuation, due to lack of efficacy	"eSMD=0.76 [0.26, 1.27] <br> <img src=""https://www.linkpicture.com/q/Diapositive19.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.44	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	50	Network meta-analysis	Adults	Mania/Mixed	valnoctamide	mono	0.76	0.26	I (High)	Kishi T., 2021 (NMA)	-0.76	0.26	1.27	risp	valnoctamide	Discontinuation (lack of efficacy)
"<a href='https://doi.org/' target=""_blank"">Dean R.L., 2021 (MA)</a>"	memantine	Discontinuation, due to lack of efficacy	"eSMD=0.27 [-0.38, 0.95] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.6	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Low	2	Pairwise meta-analysis	Adults	Bipolar Depression	placebo	aug	0.27	0.34	III (Low)	Dean R.L., 2021 (MA)	-0.27	-0.38	0.95	mem	pbo	Discontinuation (lack of efficacy)
"<a href='https://doi.org/' target=""_blank"">Dean R.L., 2021 (MA)</a>"	ketamine	Discontinuation, due to lack of efficacy	"eSMD=-0.95 [-2.16, 0.15] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.01	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Low	2	Pairwise meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.95	0.59	II (Moderate)	Dean R.L., 2021 (MA)	0.95	-2.16	0.15	ket	pbo	Discontinuation (lack of efficacy)
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	lithium	Discontinuation, due to lack of efficacy	"eSMD=0.32 [-0.04, 0.68] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.59	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	6	Pairwise meta-analysis	Mixed (Children-Adults)	Mania/Mixed	placebo	mono	0.32	0.18	III (Low)	McKnight R.F., 2019 (MA)	-0.32	-0.04	0.68	lit	pbo	Discontinuation (lack of efficacy)
"<a href='https://doi.org/' target=""_blank"">Scherk H., 2007 (MA)</a>"	quetiapine	Discontinuation, due to lack of efficacy	"eSMD=0.26 [-0.04, 0.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.86	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	aug	0.26	0.15	IV (Very Low)	Scherk H., 2007 (MA)	-0.26	-0.04	0.55	que	pbo	Discontinuation (lack of efficacy)
"<a href='https://doi.org/' target=""_blank"">Scherk H., 2007 (MA)</a>"	risperidone	Discontinuation, due to lack of efficacy	"eSMD=0.12 [-0.53, 0.79] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=14.79	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	aug	0.12	0.34	IV (Very Low)	Scherk H., 2007 (MA)	-0.12	-0.53	0.79	risp	pbo	Discontinuation (lack of efficacy)
"<a href='https://doi.org/' target=""_blank"">Smith L.A., 2010 (MA)</a>"	divalproate	Discontinuation, due to lack of efficacy	"eSMD=0.08 [-0.31, 0.47] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=22.17	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	4	Pairwise meta-analysis	Adults	Bipolar Depression	placebo	mono	0.08	0.2	III (Low)	Smith L.A., 2010 (MA)	-0.08	-0.31	0.47	div	pbo	Discontinuation (lack of efficacy)
"<a href='https://doi.org/' target=""_blank"">Jochim J., 2019 (MA)</a>"	divalproate	Discontinuation, due to other causes	"eSMD=-0.09 [-0.28, 0.1] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=19.71	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	6	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.09	0.1	III (Low)	Jochim J., 2019 (MA)	0.09	-0.28	0.1	div	pbo	Discontinuation (other causes)
"<a href='https://doi.org/' target=""_blank"">Jochim J., 2019 (MA)</a>"	divalproate	Discontinuation, due to other causes	"eSMD=-0.2 [-0.76, 0.37] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=8.89	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Children & Adolescents	Mania/Mixed	placebo	mono	-0.2	0.29	III (Low)	Jochim J., 2019 (MA)	0.2	-0.76	0.37	div	pbo	Discontinuation (other causes)
"<a href='https://doi.org/' target=""_blank"">Jochim J., 2019 (MA)</a>"	divalproate	Discontinuation, due to other causes	"eSMD=-0.35 [-0.74, 0.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.12	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Children & Adolescents	Mania/Mixed	risperidone	mono	-0.35	0.2	III (Low)	Jochim J., 2019 (MA)	0.35	-0.74	0.05	div	risp	Discontinuation (other causes)
"<a href='https://doi.org/' target=""_blank"">Jochim J., 2019 (MA)</a>"	divalproate	Discontinuation, due to other causes	"eSMD=-0.07 [-0.3, 0.15] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=25.33	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.07	0.11	II (Moderate)	Jochim J., 2019 (MA)	0.07	-0.3	0.15	div	ola	Discontinuation (other causes)
"<a href='https://doi.org/' target=""_blank"">Jochim J., 2019 (MA)</a>"	divalproate	Discontinuation, due to other causes	"eSMD=0.28 [-0.18, 0.74] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.37	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	lithium	mono	0.28	0.23	III (Low)	Jochim J., 2019 (MA)	-0.28	-0.18	0.74	div	lit	Discontinuation (other causes)
"<a href='https://doi.org/' target=""_blank"">Vita A., 2013 (MA)</a>"	asenapine	Discontinuation, due to serious adverse events	"eSMD=0.15 [-0.21, 0.06] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=11.84	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	0.15	0.07	IV (Very Low)	Vita A., 2013 (MA)	-0.15	-0.21	0.06	ase	pbo	Discontinuation (serious AEs)
"<a href='https://doi.org/' target=""_blank"">Vita A., 2013 (MA)</a>"	asenapine	Discontinuation, due to serious adverse events	"eSMD=-0.1 [-0.36, 0.15] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=17.74	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.1	0.13	IV (Very Low)	Vita A., 2013 (MA)	0.1	-0.36	0.15	ase	ola	Discontinuation (serious AEs)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2016 (MA)</a>"	risperidone LAI	Discontinuation, due to withdrawal consent	"eSMD=-0.04 [-0.31, 0.24] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=44.32	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Maintenance	placebo	mono	-0.04	0.14	II (Moderate)	Kishi T., 2016 (MA)	0.04	-0.31	0.24	rispLAI	pbo	Discontinuation (withdrawal consent)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Discontinuation, due to withdrawal consent	"eSMD=0.25 [0.06, 0.42] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.13	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	42	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.25	0.09	I (High)	Kishi T., 2021 (NMA)	-0.25	0.06	0.42	ola	pbo	Discontinuation (withdrawal consent)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Discontinuation, due to withdrawal consent	"eSMD=0.05 [-0.21, 0.3] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=35.46	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	42	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.05	0.13	II (Moderate)	Kishi T., 2021 (NMA)	-0.05	-0.21	0.3	div	pbo	Discontinuation (withdrawal consent)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	carbamazepine	Discontinuation, due to withdrawal consent	"eSMD=0.04 [-0.23, 0.31] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=44.32	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	42	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.04	0.14	II (Moderate)	Kishi T., 2021 (NMA)	-0.04	-0.23	0.31	cbz	pbo	Discontinuation (withdrawal consent)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	quetiapine	Discontinuation, due to withdrawal consent	"eSMD=0 [-0.24, 0.24] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	42	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0	0.12	II (Moderate)	Kishi T., 2021 (NMA)	0	-0.24	0.24	que	pbo	Discontinuation (withdrawal consent)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Discontinuation, due to withdrawal consent	"eSMD=-0.06 [-0.27, 0.16] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=29.55	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	42	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.06	0.11	II (Moderate)	Kishi T., 2021 (NMA)	0.06	-0.27	0.16	lit	pbo	Discontinuation (withdrawal consent)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	ziprasidone	Discontinuation, due to withdrawal consent	"eSMD=-0.06 [-0.25, 0.12] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=29.55	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	42	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.06	0.09	II (Moderate)	Kishi T., 2021 (NMA)	0.06	-0.25	0.12	zip	pbo	Discontinuation (withdrawal consent)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Discontinuation, due to withdrawal consent	"eSMD=-0.1 [-0.25, 0.06] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=17.74	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	42	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.1	0.08	II (Moderate)	Kishi T., 2021 (NMA)	0.1	-0.25	0.06	hal	pbo	Discontinuation (withdrawal consent)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Discontinuation, due to withdrawal consent	"eSMD=-0.1 [-0.23, 0.03] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=17.74	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	42	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.1	0.07	II (Moderate)	Kishi T., 2021 (NMA)	0.1	-0.23	0.03	ari	pbo	Discontinuation (withdrawal consent)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	asenapine	Discontinuation, due to withdrawal consent	"eSMD=-0.1 [-0.32, 0.11] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=17.74	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	42	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.1	0.11	II (Moderate)	Kishi T., 2021 (NMA)	0.1	-0.32	0.11	ase	pbo	Discontinuation (withdrawal consent)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	cariprazine	Discontinuation, due to withdrawal consent	"eSMD=-0.12 [-0.37, 0.14] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=14.79	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	42	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.12	0.13	II (Moderate)	Kishi T., 2021 (NMA)	0.12	-0.37	0.14	car	pbo	Discontinuation (withdrawal consent)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	risperidone	Discontinuation, due to withdrawal consent	"eSMD=-0.12 [-0.38, 0.14] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=14.79	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	42	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.12	0.13	II (Moderate)	Kishi T., 2021 (NMA)	0.12	-0.38	0.14	risp	pbo	Discontinuation (withdrawal consent)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	topiramate	Discontinuation, due to withdrawal consent	"eSMD=-0.12 [-0.37, 0.12] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=14.79	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	42	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.12	0.12	II (Moderate)	Kishi T., 2021 (NMA)	0.12	-0.37	0.12	top	pbo	Discontinuation (withdrawal consent)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Discontinuation, due to withdrawal consent	"eSMD=-0.15 [-0.4, 0.1] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=11.84	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	42	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.15	0.13	II (Moderate)	Kishi T., 2021 (NMA)	0.15	-0.4	0.1	pal	pbo	Discontinuation (withdrawal consent)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	brexpiprazole	Discontinuation, due to withdrawal consent	"eSMD=-0.15 [-0.4, 0.09] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=11.84	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	42	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.15	0.12	II (Moderate)	Kishi T., 2021 (NMA)	0.15	-0.4	0.09	brex	pbo	Discontinuation (withdrawal consent)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	valnoctamide	Discontinuation, due to withdrawal consent	"eSMD=-0.27 [-0.98, 0.43] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.6	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	42	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.27	0.36	II (Moderate)	Kishi T., 2021 (NMA)	0.27	-0.98	0.43	valnoctamide	pbo	Discontinuation (withdrawal consent)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	verapamil	Discontinuation, due to withdrawal consent	"eSMD=-1.12 [-2.54, 0.43] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1.75	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	42	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-1.12	0.76	II (Moderate)	Kishi T., 2021 (NMA)	1.12	-2.54	0.43	verapamil	pbo	Discontinuation (withdrawal consent)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	asenapine	Discontinuation, due to withdrawal consent	"eSMD=-0.34 [-0.56, -0.13] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.26	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	42	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.34	0.11	I (High)	Kishi T., 2021 (NMA)	0.34	-0.56	-0.13	ase	ola	Discontinuation (withdrawal consent)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Discontinuation, due to withdrawal consent	"eSMD=-0.34 [-0.55, -0.13] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.26	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	42	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.34	0.11	I (High)	Kishi T., 2021 (NMA)	0.34	-0.55	-0.13	hal	ola	Discontinuation (withdrawal consent)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Discontinuation, due to withdrawal consent	"eSMD=-0.31 [-0.58, -0.03] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.76	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	42	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.31	0.14	I (High)	Kishi T., 2021 (NMA)	0.31	-0.58	-0.03	lit	ola	Discontinuation (withdrawal consent)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Discontinuation, due to withdrawal consent	"eSMD=-0.2 [-0.45, 0.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=8.89	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	42	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.2	0.13	II (Moderate)	Kishi T., 2021 (NMA)	0.2	-0.45	0.05	div	ola	Discontinuation (withdrawal consent)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Discontinuation, due to withdrawal consent	"eSMD=-0.11 [-1.17, 0.95] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=16.13	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	42	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.11	0.54	II (Moderate)	Kishi T., 2021 (NMA)	0.11	-1.17	0.95	lam	ola	Discontinuation (withdrawal consent)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Discontinuation, due to withdrawal consent	"eSMD=-0.1 [-0.37, 0.17] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=17.74	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	42	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	-0.1	0.14	II (Moderate)	Kishi T., 2021 (NMA)	0.1	-0.37	0.17	hal	que	Discontinuation (withdrawal consent)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Discontinuation, due to withdrawal consent	"eSMD=-0.04 [-0.26, 0.18] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=44.32	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	42	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	-0.04	0.11	II (Moderate)	Kishi T., 2021 (NMA)	0.04	-0.26	0.18	ari	lit	Discontinuation (withdrawal consent)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Discontinuation, due to withdrawal consent	"eSMD=-0.03 [-0.25, 0.18] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=59.09	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	42	Network meta-analysis	Adults	Mania/Mixed	ziprasidone	mono	-0.03	0.11	II (Moderate)	Kishi T., 2021 (NMA)	0.03	-0.25	0.18	hal	zip	Discontinuation (withdrawal consent)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Discontinuation, due to withdrawal consent	"eSMD=-0.01 [-0.18, 0.17] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=177.25	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	42	Network meta-analysis	Adults	Mania/Mixed	haloperidol	mono	-0.01	0.09	II (Moderate)	Kishi T., 2021 (NMA)	0.01	-0.18	0.17	ari	hal	Discontinuation (withdrawal consent)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Discontinuation, due to withdrawal consent	"eSMD=0.06 [-0.24, 0.36] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=29.55	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	42	Network meta-analysis	Adults	Mania/Mixed	topiramate	mono	0.06	0.15	II (Moderate)	Kishi T., 2021 (NMA)	-0.06	-0.24	0.36	lit	top	Discontinuation (withdrawal consent)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Discontinuation, due to withdrawal consent	"eSMD=0.11 [-0.23, 0.43] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=16.13	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	42	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	0.11	0.17	II (Moderate)	Kishi T., 2021 (NMA)	-0.11	-0.23	0.43	div	lit	Discontinuation (withdrawal consent)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	risperidone	Discontinuation, due to withdrawal consent	"eSMD=0.16 [-0.52, 0.84] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=11.1	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	42	Network meta-analysis	Adults	Mania/Mixed	valnoctamide	mono	0.16	0.35	II (Moderate)	Kishi T., 2021 (NMA)	-0.16	-0.52	0.84	risp	valnoctamide	Discontinuation (withdrawal consent)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Discontinuation, due to withdrawal consent	"eSMD=0.2 [-0.83, 1.22] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.89	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	42	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	0.2	0.52	II (Moderate)	Kishi T., 2021 (NMA)	-0.2	-0.83	1.22	lam	lit	Discontinuation (withdrawal consent)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Discontinuation, due to withdrawal consent	"eSMD=0.35 [-0.95, 1.63] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.12	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	42	Network meta-analysis	Adults	Mania/Mixed	endoxifen	mono	0.35	0.66	II (Moderate)	Kishi T., 2021 (NMA)	-0.35	-0.95	1.63	div	end	Discontinuation (withdrawal consent)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Discontinuation, due to withdrawal consent	"eSMD=0.36 [0.08, 0.65] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.98	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	42	Network meta-analysis	Adults	Mania/Mixed	risperidone	mono	0.36	0.15	I (High)	Kishi T., 2021 (NMA)	-0.36	0.08	0.65	ola	risp	Discontinuation (withdrawal consent)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Discontinuation, due to withdrawal consent	"eSMD=0.63 [-0.45, 0.14] <br> <img src=""https://www.linkpicture.com/q/Diapositive18.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.91	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	42	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	0.63	0.15	II (Moderate)	Kishi T., 2021 (NMA)	-0.63	-0.45	0.14	pal	que	Discontinuation (withdrawal consent)
"<a href='https://doi.org/' target=""_blank"">Rendell J.M., 2010 (MA)</a>"	olanzapine	Extrapyramidal symptoms scale, SAS/ESRS	"eSMD=0.33 [-0.09, 0.74] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.42	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	0.33	0.21	II (Moderate)	Rendell J.M., 2010 (MA)	-0.33	-0.09	0.74	ola	pbo	Extrapyramidal sxs, SAS
"<a href='https://doi.org/' target=""_blank"">Lao K.S.J., 2016 (MA)</a>"	cariprazine	Extrapyramidal symptoms scale, SAS, change from baseline	"eSMD=-0.45 [-0.64, -0.27] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.01	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.45	0.09	II (Moderate)	Lao K.S.J., 2016 (MA)	0.45	-0.64	-0.27	car	pbo	Extrapyramidal sxs, SAS, change
"<a href='https://doi.org/' target=""_blank"">Scherk H., 2007 (MA)</a>"	ziprasidone	Extrapyramidal symptoms scale, SAS/ESRS	"eSMD=-0.13 [-0.34, 0.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=13.65	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.13	0.11	III (Low)	Scherk H., 2007 (MA)	0.13	-0.34	0.08	zip	pbo	Extrapyramidal sxs, SAS/ESRS
"<a href='https://doi.org/' target=""_blank"">Scherk H., 2007 (MA)</a>"	aripiprazole	Extrapyramidal symptoms scale, SAS/ESRS	"eSMD=-0.17 [-0.35, 0] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=10.45	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.17	0.09	III (Low)	Scherk H., 2007 (MA)	0.17	-0.35	0	ari	pbo	Extrapyramidal sxs, SAS/ESRS
"<a href='https://doi.org/' target=""_blank"">Vita A., 2013 (MA)</a>"	asenapine	Extrapyramidal symptoms scale, SAS/ESRS	"eSMD=-0.72 [-1.39, -0.06] <br> <img src=""https://www.linkpicture.com/q/Diapositive2.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.57	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.72	0.34	III (Low)	Vita A., 2013 (MA)	0.72	-1.39	-0.06	ase	pbo	Extrapyramidal sxs, SAS/ESRS
"<a href='https://doi.org/' target=""_blank"">Vita A., 2013 (MA)</a>"	asenapine	Extrapyramidal symptoms scale, SAS/ESRS	"eSMD=-0.12 [-0.28, 0.03] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=14.79	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.12	0.08	IV (Very Low)	Vita A., 2013 (MA)	0.12	-0.28	0.03	ase	ola	Extrapyramidal sxs, SAS/ESRS
"<a href='https://doi.org/' target=""_blank"">Chang H., 2017 (MA)</a>"	paliperidone	Functioning scale, GAF, change from baseline	"eSMD=0.16 [0.01, 0.31] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=11.1	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	0.16	0.08	II (Moderate)	Chang H., 2017 (MA)	-0.16	0.01	0.31	pal	pbo	Functioning, GAF, change
"<a href='https://doi.org/' target=""_blank"">Chatterton M.L., 2017 (NMA)</a>"	CBT+psychoeducation	Functioning scale, GAF, change from baseline	"eSMD=2.55 [1.69, 3.4] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.08	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	14	Network meta-analysis	Adults	Maintenance	TAU	N/A	2.55	0.44	II (Moderate)	Chatterton M.L., 2017 (NMA)	-2.55	1.69	3.4	CBT+PE	tau	Functioning, GAF, change
"<a href='https://doi.org/' target=""_blank"">Chatterton M.L., 2017 (NMA)</a>"	carer focused intervention	Functioning scale, GAF, change from baseline	"eSMD=0.62 [-0.63, 1.87] <br> <img src=""https://www.linkpicture.com/q/Diapositive17.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.95	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	14	Network meta-analysis	Adults	Maintenance	TAU	N/A	0.62	0.64	IV (Very Low)	Chatterton M.L., 2017 (NMA)	-0.62	-0.63	1.87	carer focused int	tau	Functioning, GAF, change
"<a href='https://doi.org/' target=""_blank"">Chatterton M.L., 2017 (NMA)</a>"	CBT	Functioning scale, GAF, change from baseline	"eSMD=0.22 [-0.15, 0.59] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.09	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	14	Network meta-analysis	Adults	Maintenance	TAU	N/A	0.22	0.19	IV (Very Low)	Chatterton M.L., 2017 (NMA)	-0.22	-0.15	0.59	CBT	tau	Functioning, GAF, change
"<a href='https://doi.org/' target=""_blank"">Chatterton M.L., 2017 (NMA)</a>"	psychoeducation	Functioning scale, GAF, change from baseline	"eSMD=0.2 [-0.17, 0.58] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.89	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	14	Network meta-analysis	Adults	Maintenance	TAU	N/A	0.2	0.19	IV (Very Low)	Chatterton M.L., 2017 (NMA)	-0.2	-0.17	0.58	PE	tau	Functioning, GAF, change
"<a href='https://doi.org/' target=""_blank"">Pittas S., 2021 (MA)</a>"	n-acetyl cysteine	Functioning scale, GAF, change from baseline	"eSMD=3.21 [-12.55, 18.97] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.02	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Bipolar Depression	placebo	aug	3.21	8.04	III (Low)	Pittas S., 2021 (MA)	-3.21	-12.55	18.97	nac	pbo	Functioning, GAF, change
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	lamotrigine	Functioning scale, GAS, change from baseline	"eSMD=-4.36 [-9.37, 0.65] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	lithium	mono	-4.36	2.56	III (Low)	McKnight R.F., 2019 (MA)	4.36	-9.37	0.65	lam	lit	Functioning, GAS, change
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	lithium	Functioning scale, GAS, endpoint score	"eSMD=3.17 [-7.02, 13.37] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.03	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	3.17	5.2	IV (Very Low)	McKnight R.F., 2019 (MA)	-3.17	-7.02	13.37	lit	pbo	Functioning, GAS, endpoint score
"<a href='https://doi.org/' target=""_blank"">Pittas S., 2021 (MA)</a>"	n-acetyl cysteine	Functioning scale, LIFE-RIFT, change from baseline	"eSMD=2.01 [-7.04, 11.06] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.18	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Bipolar Depression	placebo	aug	2.01	4.62	IV (Very Low)	Pittas S., 2021 (MA)	-2.01	-7.04	11.06	nac	pbo	Functioning, LIFE-RIFT, change
"<a href='https://doi.org/' target=""_blank"">Suttajit S., 2014 (MA)</a>"	quetiapine	Functioning scale, SDS, change frome baseline	"eSMD=1.42 [0.53, 2.32] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.46	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	1.42	0.46	I (High)	Suttajit S., 2014 (MA)	-1.42	0.53	2.32	que	pbo	Functioning, SDS, change
"<a href='https://doi.org/' target=""_blank"">Pittas S., 2021 (MA)</a>"	n-acetyl cysteine	Functioning scale, SOFAS, change from baseline	"eSMD=0.47 [-4.6, 5.53] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.84	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Bipolar Depression	placebo	aug	0.47	2.58	III (Low)	Pittas S., 2021 (MA)	-0.47	-4.6	5.53	nac	pbo	Functioning, SOFAS, change
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	haloperidol	General psychopathology scale, BPRS, change from baseline	"eSMD=2.4 [-1.5, 6.31] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.1	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Mania/Mixed	lithium	mono	2.4	1.99	IV (Very Low)	McKnight R.F., 2019 (MA)	-2.4	-1.5	6.31	hal	lit	General sxs, BPRS, change
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	lamotrigine	General psychopathology scale, BPRS, change from baseline	"eSMD=1.82 [-0.14, 3.78] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.25	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Mania/Mixed	lithium	mono	1.82	1	III (Low)	McKnight R.F., 2019 (MA)	-1.82	-0.14	3.78	lam	lit	General sxs, BPRS, change
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	chlorpromazine	General psychopathology scale, BPRS, change from baseline	"eSMD=0.59 [-0.57, 1.75] <br> <img src=""https://www.linkpicture.com/q/Diapositive17.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	lithium	mono	0.59	0.59	III (Low)	McKnight R.F., 2019 (MA)	-0.59	-0.57	1.75	chlorp	lit	General sxs, BPRS, change
"<a href='https://doi.org/' target=""_blank"">Macritchie K., 2003 (MA)</a>"	divalproate	Global assessment scale, GAS, endpoint score	"eSMD=7.77 [2.54, 13] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	7.77	2.67	I (High)	Macritchie K., 2003 (MA)	-7.77	2.54	13	div	pbo	Global assessment, GAS, endpoint score
"<a href='https://doi.org/' target=""_blank"">Ceron-Litvoc D., 2009 (MA)</a>"	carbamazepine	Hospitalization	"eSMD=-0.1 [-0.31, 0.1] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=17.74	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Maintenance	lithium	mono	-0.1	0.1	III (Low)	Ceron-Litvoc D., 2009 (MA)	0.1	-0.31	0.1	cbz	lit	Hospitalization
"<a href='https://doi.org/' target=""_blank"">Rogers J., 2017 (NMA)</a>"	olanzapine	Hospitalization	"eSMD=0.72 [0.47, 1.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive19.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.57	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Maintenance	placebo	mono	0.72	0.14	III (Low)	Rogers J., 2017 (NMA)	-0.72	0.47	1.01	ola	pbo	Hospitalization
"<a href='https://doi.org/' target=""_blank"">Rogers J., 2017 (NMA)</a>"	lithium	Hospitalization	"eSMD=0.45 [0.29, 0.63] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.01	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Maintenance	placebo	mono	0.45	0.09	III (Low)	Rogers J., 2017 (NMA)	-0.45	0.29	0.63	lit	pbo	Hospitalization
"<a href='https://doi.org/' target=""_blank"">Rogers J., 2017 (NMA)</a>"	imipramine	Hospitalization	"eSMD=-0.07 [-0.51, 0.37] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=25.33	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.07	0.22	IV (Very Low)	Rogers J., 2017 (NMA)	0.07	-0.51	0.37	imp	pbo	Hospitalization
"<a href='https://doi.org/' target=""_blank"">Rogers J., 2017 (NMA)</a>"	flupentixol+lithium	Hospitalization	"eSMD=-0.22 [-1.77, 1.39] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=8.09	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Maintenance	placebo+lithium	combo	-0.22	0.81	IV (Very Low)	Rogers J., 2017 (NMA)	0.22	-1.77	1.39	flupentix+lit	pbo+lit	Hospitalization
"<a href='https://doi.org/' target=""_blank"">Rendell J.M., 2010 (MA)</a>"	olanzapine	Hostility	"eSMD=0.37 [-0.11, 0.86] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.85	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	0.37	0.25	II (Moderate)	Rendell J.M., 2010 (MA)	-0.37	-0.11	0.86	ola	pbo	Hostility
"<a href='https://doi.org/' target=""_blank"">Chatterton M.L., 2017 (NMA)</a>"	CBT	Mania symptoms scale, change from baseline	"eSMD=0.17 [-0.43, 0.78] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=10.45	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	18	Network meta-analysis	Adults	Maintenance	TAU	N/A	0.17	0.31	IV (Very Low)	Chatterton M.L., 2017 (NMA)	-0.17	-0.43	0.78	CBT	tau	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Chatterton M.L., 2017 (NMA)</a>"	psychoeducation	Mania symptoms scale, change from baseline	"eSMD=0.22 [-0.2, 0.64] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.09	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	18	Network meta-analysis	Adults	Maintenance	TAU	N/A	0.22	0.21	IV (Very Low)	Chatterton M.L., 2017 (NMA)	-0.22	-0.2	0.64	PE	tau	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Chatterton M.L., 2017 (NMA)</a>"	CBT+psychoeducation	Mania symptoms scale, change from baseline	"eSMD=0.95 [0.43, 1.47] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.01	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	18	Network meta-analysis	Adults	Maintenance	TAU	N/A	0.95	0.27	II (Moderate)	Chatterton M.L., 2017 (NMA)	-0.95	0.43	1.47	CBT+PE	tau	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2011 (NMA)</a>"	haloperidol	Mania symptoms scale, change from baseline	"eSMD=0.56 [0.43, 0.69] <br> <img src=""https://www.linkpicture.com/q/Diapositive17.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.25	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	63	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.56	0.07	II (Moderate)	Cipriani A., 2011 (NMA)	-0.56	0.43	0.69	hal	pbo	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2011 (NMA)</a>"	risperidone	Mania symptoms scale, change from baseline	"eSMD=0.5 [0.38, 0.63] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.62	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	63	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.5	0.06	II (Moderate)	Cipriani A., 2011 (NMA)	-0.5	0.38	0.63	risp	pbo	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2011 (NMA)</a>"	olanzapine	Mania symptoms scale, change from baseline	"eSMD=0.43 [0.32, 0.54] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.19	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	63	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.43	0.06	II (Moderate)	Cipriani A., 2011 (NMA)	-0.43	0.32	0.54	ola	pbo	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2011 (NMA)</a>"	quetiapine	Mania symptoms scale, change from baseline	"eSMD=0.37 [0.23, 0.51] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.85	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	65	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.37	0.07	II (Moderate)	Cipriani A., 2011 (NMA)	-0.37	0.23	0.51	que	pbo	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2011 (NMA)</a>"	lithium	Mania symptoms scale, change from baseline	"eSMD=0.37 [0.11, 0.63] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.85	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	63	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.37	0.13	II (Moderate)	Cipriani A., 2011 (NMA)	-0.37	0.11	0.63	lit	pbo	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2011 (NMA)</a>"	aripiprazole	Mania symptoms scale, change from baseline	"eSMD=0.37 [0.23, 0.51] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.85	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	63	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.37	0.07	II (Moderate)	Cipriani A., 2011 (NMA)	-0.37	0.23	0.51	ari	pbo	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2011 (NMA)</a>"	carbamazepine	Mania symptoms scale, change from baseline	"eSMD=0.36 [0.11, 0.6] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.98	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	63	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.36	0.12	II (Moderate)	Cipriani A., 2011 (NMA)	-0.36	0.11	0.6	cbz	pbo	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2011 (NMA)</a>"	asenapine	Mania symptoms scale, change from baseline	"eSMD=0.3 [0.07, 0.53] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.95	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	63	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.3	0.12	II (Moderate)	Cipriani A., 2011 (NMA)	-0.3	0.07	0.53	ase	pbo	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2011 (NMA)</a>"	divalproate	Mania symptoms scale, change from baseline	"eSMD=0.2 [0.04, 0.37] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.89	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	63	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.2	0.08	II (Moderate)	Cipriani A., 2011 (NMA)	-0.2	0.04	0.37	div	pbo	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2011 (NMA)</a>"	ziprasidone	Mania symptoms scale, change from baseline	"eSMD=0.2 [0.03, 0.37] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.89	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	63	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.2	0.09	II (Moderate)	Cipriani A., 2011 (NMA)	-0.2	0.03	0.37	zip	pbo	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2011 (NMA)</a>"	lamotrigine	Mania symptoms scale, change from baseline	"eSMD=0.08 [-0.18, 0.34] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=22.17	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	63	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.08	0.13	III (Low)	Cipriani A., 2011 (NMA)	-0.08	-0.18	0.34	lam	pbo	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2011 (NMA)</a>"	lamotrigine	Mania symptoms scale, change from baseline	"eSMD=-0.32 [-0.67, 0.06] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.59	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	63	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	-0.32	0.19	III (Low)	Cipriani A., 2011 (NMA)	0.32	-0.67	0.06	lam	lit	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2011 (NMA)</a>"	gabapentin	Mania symptoms scale, change from baseline	"eSMD=-0.32 [-0.82, 0.18] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.59	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	63	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.32	0.26	III (Low)	Cipriani A., 2011 (NMA)	0.32	-0.82	0.18	gaba	pbo	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2011 (NMA)</a>"	divalproate	Mania symptoms scale, change from baseline	"eSMD=-0.23 [-0.4, -0.06] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.74	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	63	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.23	0.09	II (Moderate)	Cipriani A., 2011 (NMA)	0.23	-0.4	-0.06	div	ola	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2011 (NMA)</a>"	carbamazapine	Mania symptoms scale, change from baseline	"eSMD=-0.2 [-0.36, -0.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=8.89	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	63	Network meta-analysis	Adults	Mania/Mixed	haloperidol	mono	-0.2	0.09	II (Moderate)	Cipriani A., 2011 (NMA)	0.2	-0.36	-0.01	cbz	hal	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2011 (NMA)</a>"	aripiprazole	Mania symptoms scale, change from baseline	"eSMD=-0.19 [-0.36, -0.02] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=9.36	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	63	Network meta-analysis	Adults	Mania/Mixed	haloperidol	mono	-0.19	0.09	II (Moderate)	Cipriani A., 2011 (NMA)	0.19	-0.36	-0.02	ari	hal	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2011 (NMA)</a>"	asenapine	Mania symptoms scale, change from baseline	"eSMD=-0.14 [-0.36, 0.1] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=12.68	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	63	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.14	0.12	III (Low)	Cipriani A., 2011 (NMA)	0.14	-0.36	0.1	ase	ola	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2011 (NMA)</a>"	lithium	Mania symptoms scale, change from baseline	"eSMD=-0.13 [-0.3, 0.04] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=13.65	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	63	Network meta-analysis	Adults	Mania/Mixed	risperidone	mono	-0.13	0.09	III (Low)	Cipriani A., 2011 (NMA)	0.13	-0.3	0.04	lit	risp	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2011 (NMA)</a>"	quetiapine	Mania symptoms scale, change from baseline	"eSMD=-0.13 [-0.31, 0.04] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=13.65	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	63	Network meta-analysis	Adults	Mania/Mixed	risperidone	mono	-0.13	0.09	III (Low)	Cipriani A., 2011 (NMA)	0.13	-0.31	0.04	que	risp	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2011 (NMA)</a>"	divalproate	Mania symptoms scale, change from baseline	"eSMD=-0.1 [-0.41, 0.23] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=17.74	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	63	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	-0.1	0.16	III (Low)	Cipriani A., 2011 (NMA)	0.1	-0.41	0.23	div	lit	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2011 (NMA)</a>"	topiramate	Mania symptoms scale, change from baseline	"eSMD=-0.07 [-0.24, 0.09] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=25.33	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	63	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.07	0.08	III (Low)	Cipriani A., 2011 (NMA)	0.07	-0.24	0.09	top	pbo	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2011 (NMA)</a>"	olanzapine	Mania symptoms scale, change from baseline	"eSMD=-0.07 [-0.22, 0.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=25.33	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	63	Network meta-analysis	Adults	Mania/Mixed	risperidone	mono	-0.07	0.08	III (Low)	Cipriani A., 2011 (NMA)	0.07	-0.22	0.08	ola	risp	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2011 (NMA)</a>"	lithium	Mania symptoms scale, change from baseline	"eSMD=-0.06 [-0.22, 0.1] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=29.55	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	63	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.06	0.08	III (Low)	Cipriani A., 2011 (NMA)	0.06	-0.22	0.1	lit	ola	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2011 (NMA)</a>"	carbamazepine	Mania symptoms scale, change from baseline	"eSMD=-0.02 [-0.28, 0.24] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=88.63	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	63	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	-0.02	0.13	III (Low)	Cipriani A., 2011 (NMA)	0.02	-0.28	0.24	cbz	lit	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2011 (NMA)</a>"	aripiprazole	Mania symptoms scale, change from baseline	"eSMD=-0.01 [-0.18, 0.17] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=177.25	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	63	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	-0.01	0.09	III (Low)	Cipriani A., 2011 (NMA)	0.01	-0.18	0.17	ari	lit	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2011 (NMA)</a>"	lithium	Mania symptoms scale, change from baseline	"eSMD=0.01 [-0.17, 0.18] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=177.25	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	63	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	0.01	0.09	III (Low)	Cipriani A., 2011 (NMA)	-0.01	-0.17	0.18	lit	que	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2011 (NMA)</a>"	haloperidol	Mania symptoms scale, change from baseline	"eSMD=0.06 [-0.11, 0.22] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=29.55	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	63	Network meta-analysis	Adults	Mania/Mixed	risperidone	mono	0.06	0.08	III (Low)	Cipriani A., 2011 (NMA)	-0.06	-0.11	0.22	hal	risp	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2011 (NMA)</a>"	haloperidol	Mania symptoms scale, change from baseline	"eSMD=0.12 [0.02, 0.28] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=14.79	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	63	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	0.12	0.07	II (Moderate)	Cipriani A., 2011 (NMA)	-0.12	0.02	0.28	hal	ola	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2011 (NMA)</a>"	carbamazepine	Mania symptoms scale, change from baseline	"eSMD=0.15 [-0.13, 0.44] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=11.84	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	63	Network meta-analysis	Adults	Mania/Mixed	divalproate	mono	0.15	0.15	III (Low)	Cipriani A., 2011 (NMA)	-0.15	-0.13	0.44	cbz	div	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2011 (NMA)</a>"	haloperidol	Mania symptoms scale, change from baseline	"eSMD=0.19 [0.01, 0.36] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=9.36	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	63	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	0.19	0.09	II (Moderate)	Cipriani A., 2011 (NMA)	-0.19	0.01	0.36	hal	lit	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2011 (NMA)</a>"	haloperidol	Mania symptoms scale, change from baseline	"eSMD=0.19 [0.01, 0.37] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=9.36	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	63	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	0.19	0.09	II (Moderate)	Cipriani A., 2011 (NMA)	-0.19	0.01	0.37	hal	que	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2011 (NMA)</a>"	haloperidol	Mania symptoms scale, change from baseline	"eSMD=0.36 [0.15, 0.56] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.98	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	63	Network meta-analysis	Adults	Mania/Mixed	ziprasidone	mono	0.36	0.1	II (Moderate)	Cipriani A., 2011 (NMA)	-0.36	0.15	0.56	hal	zip	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2011 (NMA)</a>"	lithium	Mania symptoms scale, change from baseline	"eSMD=0.45 [0.14, 0.75] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.01	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	63	Network meta-analysis	Adults	Mania/Mixed	topiramate	mono	0.45	0.16	II (Moderate)	Cipriani A., 2011 (NMA)	-0.45	0.14	0.75	lit	top	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Bartoli F., 2017 (MA)</a>"	allopurinol	Mania symptoms scale, change from baseline	"eSMD=0.34 [0.09, 0.6] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.26	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	aug	0.34	0.13	III (Low)	Bartoli F., 2017 (MA)	-0.34	0.09	0.6	allopur	pbo	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Jochim J., 2019 (MA)</a>"	divalproate	Mania symptoms scale, change from baseline	"eSMD=0.14 [-0.17, 0.45] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=12.68	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Children & Adolescents	Mania/Mixed	placebo	mono	0.14	0.16	III (Low)	Jochim J., 2019 (MA)	-0.14	-0.17	0.45	div	pbo	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Jochim J., 2019 (MA)</a>"	divalproate	Mania symptoms scale, change from baseline	"eSMD=-1.01 [-1.29, -0.74] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1.91	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Children & Adolescents	Mania/Mixed	risperidone	mono	-1.01	0.14	II (Moderate)	Jochim J., 2019 (MA)	1.01	-1.29	-0.74	div	risp	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Jochim J., 2019 (MA)</a>"	divalproate	Mania symptoms scale, change from baseline	"eSMD=0.41 [-0.35, 1.16] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.38	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Children & Adolescents	Mania/Mixed	topiramate	mono	0.41	0.39	III (Low)	Jochim J., 2019 (MA)	-0.41	-0.35	1.16	div	top	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2016 (MA)</a>"	risperidone LAI	Mania symptoms scale, change from baseline	"eSMD=5.8 [4.04, 7.57] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Maintenance	placebo	mono	5.8	0.9	I (High)	Kishi T., 2016 (MA)	-5.8	4.04	7.57	rispLAI	pbo	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	tamoxifen	Mania symptoms scale, change from baseline	"eSMD=1.81 [1.16, 2.45] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.25	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	61	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	1.81	0.33	I (High)	Kishi T., 2021 (NMA)	-1.81	1.16	2.45	tamox	pbo	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	cariprazine	Mania symptoms scale, change from baseline	"eSMD=0.5 [0.28, 0.71] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.62	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	61	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.5	0.11	I (High)	Kishi T., 2021 (NMA)	-0.5	0.28	0.71	car	pbo	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Mania symptoms scale, change from baseline	"eSMD=0.38 [0.13, 0.62] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.72	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	61	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.38	0.12	I (High)	Kishi T., 2021 (NMA)	-0.38	0.13	0.62	pal	pbo	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	eslicarbazepine	Mania symptoms scale, change from baseline	"eSMD=0.17 [-0.23, 0.57] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=10.45	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	61	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.17	0.2	II (Moderate)	Kishi T., 2021 (NMA)	-0.17	-0.23	0.57	eslicbz	pbo	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	licarbazepine	Mania symptoms scale, change from baseline	"eSMD=0.09 [-0.26, 0.44] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=19.71	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	61	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.09	0.18	II (Moderate)	Kishi T., 2021 (NMA)	-0.09	-0.26	0.44	licbz	pbo	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	brexpiprazole	Mania symptoms scale, change from baseline	"eSMD=0.08 [-0.18, 0.35] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=22.17	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	61	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.08	0.14	II (Moderate)	Kishi T., 2021 (NMA)	-0.08	-0.18	0.35	brex	pbo	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	verapamil	Mania symptoms scale, change from baseline	"eSMD=-0.02 [-0.77, 0.74] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=88.63	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	61	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.02	0.39	II (Moderate)	Kishi T., 2021 (NMA)	0.02	-0.77	0.74	verapamil	pbo	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Mania symptoms scale, change from baseline	"eSMD=-0.39 [-0.66, -0.12] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.6	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	61	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.39	0.14	I (High)	Kishi T., 2021 (NMA)	0.39	-0.66	-0.12	lam	ola	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Mania symptoms scale, change from baseline	"eSMD=-0.13 [-0.71, 0.46] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=13.65	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	61	Network meta-analysis	Adults	Mania/Mixed	oxcarbazepine	mono	-0.13	0.3	II (Moderate)	Kishi T., 2021 (NMA)	0.13	-0.71	0.46	div	oxc	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Mania symptoms scale, change from baseline	"eSMD=0 [-0.26, 0.26] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	61	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	0	0.13	II (Moderate)	Kishi T., 2021 (NMA)	0	-0.26	0.26	pal	que	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	lithium	Mania symptoms scale, change from baseline	"eSMD=2.85 [2.55, 3.14] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.05	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	4	Pairwise meta-analysis	Mixed (Children-Adults)	Mania/Mixed	placebo	mono	2.85	0.15	I (High)	McKnight R.F., 2019 (MA)	-2.85	2.55	3.14	lit	pbo	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	lithium	Mania symptoms scale, change from baseline	"eSMD=-7.28 [-9.34, -5.22] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Mixed (Children-Adults)	Mania/Mixed	risperidone	mono	-7.28	1.05	I (High)	McKnight R.F., 2019 (MA)	7.28	-9.34	-5.22	lit	risp	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	carbamazepine	Mania symptoms scale, change from baseline	"eSMD=0.21 [-0.18, 0.6] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.47	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Mixed (Children-Adults)	Mania/Mixed	lithium	mono	0.21	0.2	III (Low)	McKnight R.F., 2019 (MA)	-0.21	-0.18	0.6	cbz	lit	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	divalproate	Mania symptoms scale, change from baseline	"eSMD=0.43 [-0.36, 1.23] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.19	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Pairwise meta-analysis	Mixed (Children-Adults)	Mania/Mixed	lithium	mono	0.43	0.41	III (Low)	McKnight R.F., 2019 (MA)	-0.43	-0.36	1.23	div	lit	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Meduri M., 2016 (MA)</a>"	aripiprazole	Mania symptoms scale, change from baseline	"eSMD=1.08 [0.85, 1.32] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.8	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Children & Adolescents	Mania/Mixed	placebo	mono	1.08	0.12	II (Moderate)	Meduri M., 2016 (MA)	-1.08	0.85	1.32	ari	pbo	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Ogawa Y., 2014 (MA)</a>"	risperidone	Mania symptoms scale, change from baseline	"eSMD=0.42 [0.15, 0.7] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.28	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	aug	0.42	0.14	I (High)	Ogawa Y., 2014 (MA)	-0.42	0.15	0.7	risp	pbo	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Ogawa Y., 2014 (MA)</a>"	olanzapine	Mania symptoms scale, change from baseline	"eSMD=0.31 [0.02, 0.6] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.76	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	aug	0.31	0.15	I (High)	Ogawa Y., 2014 (MA)	-0.31	0.02	0.6	ola	pbo	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Ogawa Y., 2014 (MA)</a>"	quetiapine	Mania symptoms scale, change from baseline	"eSMD=0.28 [0.02, 0.54] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.37	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	aug	0.28	0.13	I (High)	Ogawa Y., 2014 (MA)	-0.28	0.02	0.54	que	pbo	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Pittas S., 2021 (MA)</a>"	n-acetyl cysteine	Mania symptoms scale, change from baseline	"eSMD=0.7 [-0.75, 2.15] <br> <img src=""https://www.linkpicture.com/q/Diapositive18.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.64	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Pairwise meta-analysis	Adults	Bipolar Depression	placebo	aug	0.7	0.74	III (Low)	Pittas S., 2021 (MA)	-0.7	-0.75	2.15	nac	pbo	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Yildiz A., 2015 (NMA)</a>"	divalproate	Mania symptoms scale, change from baseline	"eSMD=0.22 [-0.02, 0.43] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.09	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	56	Network meta-analysis	Adults	Mania/Mixed	haloperidol	mono	0.22	0.11	IV (Very Low)	Yildiz A., 2015 (NMA)	-0.22	-0.02	0.43	div	hal	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Zhang J., 2021 (MA)</a>"	ECT	Mania symptoms scale, change from baseline	"eSMD=3.5 [2.44, 4.57] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.01	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	12	Pairwise meta-analysis	Adults	Mania	TAU	mono	3.5	0.54	II (Moderate)	Zhang J., 2021 (MA)	-3.5	2.44	4.57	ECT	tau	Manic sxs, change
"<a href='https://doi.org/' target=""_blank"">Bavaresco D., 2019 (MA)</a>"	celecoxib	Mania symptoms scale, endpoint change	"eSMD=5.54 [3.26, 7.83] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Low	3	Pairwise meta-analysis	Mixed (Children-Adults)	Mania	placebo	aug	5.54	1.17	I (High)	Bavaresco D., 2019 (MA)	-5.54	3.26	7.83	cel	pbo	Manic sxs, endpoint change
"<a href='https://doi.org/' target=""_blank"">Sarris J., 2010 (MA)</a>"	omega3	Mania symptoms scale, endpoint change	"eSMD=0.2 [-0.04, 0.43] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.89	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	6	Pairwise meta-analysis	Mixed (Children-Adults)	Mania/Mixed	placebo	aug	0.2	0.12	III (Low)	Sarris J., 2010 (MA)	-0.2	-0.04	0.43	omega3	pbo	Manic sxs, endpoint change
"<a href='https://doi.org/' target=""_blank"">Tee M.M.K., 2020 (MA)</a>"	rTMS	Mania symptoms scale, endpoint change	"eSMD=-0.3 [-1.37, 0.77] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.95	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Mixed (Children-Adults)	Mania	sham	aug	-0.3	0.55	IV (Very Low)	Tee M.M.K., 2020 (MA)	0.3	-1.37	0.77	rTMS	sham	Manic sxs, endpoint change
"<a href='https://doi.org/' target=""_blank"">Gregory V.L., 2010 (MA)</a>"	CBT	Mania symptoms scale, endpoint score	"eSMD=0.26 [-0.02, 0.54] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.86	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	4	Pairwise meta-analysis	Adults	Mania/Mixed	TAU/waiting list	aug	0.26	0.14	IV (Very Low)	Gregory V.L., 2010 (MA)	-0.26	-0.02	0.54	CBT	tau/wl	Manic sxs, endpoint score
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	IPSRT	Mania symptoms scale, endpoint score	"eSMD=-0.3 [-0.93, 0.34] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.95	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	19	Network meta-analysis	Mixed (Children-Adults)	Maintenance	psychoeducation brief	aug	-0.3	0.32	III (Low)	Miklowitz D.J., 2020 (NMA)	0.3	-0.93	0.34	IPSRT	PE brief	Manic sxs, endpoint score
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	IPSRT	Mania symptoms scale, endpoint score	"eSMD=-0.26 [-0.85, 0.33] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.86	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	19	Network meta-analysis	Mixed (Children-Adults)	Maintenance	supportive therapy	aug	-0.26	0.3	III (Low)	Miklowitz D.J., 2020 (NMA)	0.26	-0.85	0.33	IPSRT	supp	Manic sxs, endpoint score
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	psychoeducation	Mania symptoms scale, endpoint score	"eSMD=-0.14 [-0.6, 0.32] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=12.68	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	19	Network meta-analysis	Mixed (Children-Adults)	Maintenance	supportive therapy	aug	-0.14	0.23	III (Low)	Miklowitz D.J., 2020 (NMA)	0.14	-0.6	0.32	PE	supp	Manic sxs, endpoint score
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	CBT	Mania symptoms scale, endpoint score	"eSMD=-0.06 [-0.63, 0.52] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=29.55	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	19	Network meta-analysis	Mixed (Children-Adults)	Maintenance	psychoeducation brief	aug	-0.06	0.29	III (Low)	Miklowitz D.J., 2020 (NMA)	0.06	-0.63	0.52	CBT	PE brief	Manic sxs, endpoint score
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	CBT	Mania symptoms scale, endpoint score	"eSMD=-0.03 [-0.57, 0.51] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=59.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	19	Network meta-analysis	Mixed (Children-Adults)	Maintenance	family/conjoint therapy	aug	-0.03	0.28	III (Low)	Miklowitz D.J., 2020 (NMA)	0.03	-0.57	0.51	CBT	family/conjoint	Manic sxs, endpoint score
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	family/conjoint therapy	Mania symptoms scale, endpoint score	"eSMD=-0.03 [-0.43, 0.38] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=59.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	19	Network meta-analysis	Mixed (Children-Adults)	Maintenance	psychoeducation brief	aug	-0.03	0.21	III (Low)	Miklowitz D.J., 2020 (NMA)	0.03	-0.43	0.38	family/conjoint	PE brief	Manic sxs, endpoint score
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	CBT	Mania symptoms scale, endpoint score	"eSMD=-0.02 [-0.49, 0.46] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=88.63	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	19	Network meta-analysis	Mixed (Children-Adults)	Maintenance	supportive therapy	aug	-0.02	0.24	III (Low)	Miklowitz D.J., 2020 (NMA)	0.02	-0.49	0.46	CBT	supp	Manic sxs, endpoint score
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	family/conjoint therapy	Mania symptoms scale, endpoint score	"eSMD=0.01 [-0.61, 0.63] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=177.25	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	19	Network meta-analysis	Mixed (Children-Adults)	Maintenance	supportive therapy	aug	0.01	0.32	III (Low)	Miklowitz D.J., 2020 (NMA)	-0.01	-0.61	0.63	family/conjoint	supp	Manic sxs, endpoint score
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	CBT	Mania symptoms scale, endpoint score	"eSMD=0.12 [-0.24, 0.48] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=14.79	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	19	Network meta-analysis	Mixed (Children-Adults)	Maintenance	psychoeducation	aug	0.12	0.18	III (Low)	Miklowitz D.J., 2020 (NMA)	-0.12	-0.24	0.48	CBT	PE	Manic sxs, endpoint score
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	psychoeducation	Mania symptoms scale, endpoint score	"eSMD=0.16 [-0.19, 0.5] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=11.1	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	19	Network meta-analysis	Mixed (Children-Adults)	Maintenance	TAU	N/A	0.16	0.18	III (Low)	Miklowitz D.J., 2020 (NMA)	-0.16	-0.19	0.5	PE	tau	Manic sxs, endpoint score
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	CBT	Mania symptoms scale, endpoint score	"eSMD=0.24 [-0.35, 0.84] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.42	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	19	Network meta-analysis	Mixed (Children-Adults)	Maintenance	IPSRT	aug	0.24	0.3	III (Low)	Miklowitz D.J., 2020 (NMA)	-0.24	-0.35	0.84	CBT	IPSRT	Manic sxs, endpoint score
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	family/conjoint therapy	Mania symptoms scale, endpoint score	"eSMD=0.27 [-0.36, 0.9] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.6	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	19	Network meta-analysis	Mixed (Children-Adults)	Maintenance	IPSRT	aug	0.27	0.32	III (Low)	Miklowitz D.J., 2020 (NMA)	-0.27	-0.36	0.9	family/conjoint	IPSRT	Manic sxs, endpoint score
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	CBT	Mania symptoms scale, endpoint score	"eSMD=0.28 [-0.03, 0.58] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.37	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	19	Network meta-analysis	Mixed (Children-Adults)	Maintenance	TAU	N/A	0.28	0.16	III (Low)	Miklowitz D.J., 2020 (NMA)	-0.28	-0.03	0.58	CBT	tau	Manic sxs, endpoint score
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	family/conjoint therapy	Mania symptoms scale, endpoint score	"eSMD=0.3 [-0.25, 0.86] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.95	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	19	Network meta-analysis	Mixed (Children-Adults)	Maintenance	TAU	N/A	0.3	0.28	III (Low)	Miklowitz D.J., 2020 (NMA)	-0.3	-0.25	0.86	family/conjoint	tau	Manic sxs, endpoint score
"<a href='https://doi.org/' target=""_blank"">Chatterton M.L., 2017 (NMA)</a>"	carer focused intervention	Medication non-adherence	"eSMD=0.08 [-0.17, 0.34] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=22.17	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Maintenance	TAU	N/A	0.08	0.13	IV (Very Low)	Chatterton M.L., 2017 (NMA)	-0.08	-0.17	0.34	carer focused int	tau	Medication non-adherence
"<a href='https://doi.org/' target=""_blank"">Chatterton M.L., 2017 (NMA)</a>"	CBT	Medication non-adherence	"eSMD=0.2 [-0.05, 0.47] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.89	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Maintenance	TAU	N/A	0.2	0.13	IV (Very Low)	Chatterton M.L., 2017 (NMA)	-0.2	-0.05	0.47	CBT	tau	Medication non-adherence
"<a href='https://doi.org/' target=""_blank"">Chatterton M.L., 2017 (NMA)</a>"	psychoeducation	Medication non-adherence	"eSMD=0.72 [0.35, 1.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive19.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.57	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Maintenance	TAU	N/A	0.72	0.19	II (Moderate)	Chatterton M.L., 2017 (NMA)	-0.72	0.35	1.08	PE	tau	Medication non-adherence
"<a href='https://doi.org/' target=""_blank"">Chatterton M.L., 2017 (NMA)</a>"	family focused therapy	Medication non-adherence	"eSMD=0.98 [-0.02, 1.93] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.95	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Maintenance	TAU	N/A	0.98	0.5	IV (Very Low)	Chatterton M.L., 2017 (NMA)	-0.98	-0.02	1.93	FFT	tau	Medication non-adherence
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	quetiapine	Medication use, Anticholinergic agents use	"eSMD=-0.02 [-0.27, 0.23] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=88.63	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	20	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.02	0.13	III (Low)	Kishi T., 2021 (NMA)	0.02	-0.27	0.23	que	pbo	Medication use, Anticholinergic
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Medication use, Anticholinergic agents use	"eSMD=-0.1 [-0.39, 0.2] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=17.74	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	20	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.1	0.15	III (Low)	Kishi T., 2021 (NMA)	0.1	-0.39	0.2	lit	pbo	Medication use, Anticholinergic
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Medication use, Anticholinergic agents use	"eSMD=-0.48 [-0.76, -0.18] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.76	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	20	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.48	0.15	I (High)	Kishi T., 2021 (NMA)	0.48	-0.76	-0.18	pal	pbo	Medication use, Anticholinergic
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Medication use, Anticholinergic agents use	"eSMD=-0.52 [-0.79, -0.24] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.49	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	20	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.52	0.14	I (High)	Kishi T., 2021 (NMA)	0.52	-0.79	-0.24	ari	pbo	Medication use, Anticholinergic
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	cariprazine	Medication use, Anticholinergic agents use	"eSMD=-0.52 [-0.74, -0.3] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.49	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	20	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.52	0.11	I (High)	Kishi T., 2021 (NMA)	0.52	-0.74	-0.3	car	pbo	Medication use, Anticholinergic
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	asenapine	Medication use, Anticholinergic agents use	"eSMD=-0.59 [-1.33, 0.11] <br> <img src=""https://www.linkpicture.com/q/Diapositive4.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	20	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.59	0.37	III (Low)	Kishi T., 2021 (NMA)	0.59	-1.33	0.11	ase	pbo	Medication use, Anticholinergic
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	risperidone	Medication use, Anticholinergic agents use	"eSMD=-0.61 [-0.89, -0.34] <br> <img src=""https://www.linkpicture.com/q/Diapositive4.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	20	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.61	0.14	I (High)	Kishi T., 2021 (NMA)	0.61	-0.89	-0.34	risp	pbo	Medication use, Anticholinergic
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	ziprasidone	Medication use, Anticholinergic agents use	"eSMD=-0.76 [-1.08, -0.44] <br> <img src=""https://www.linkpicture.com/q/Diapositive2.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.44	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	20	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.76	0.16	I (High)	Kishi T., 2021 (NMA)	0.76	-1.08	-0.44	zip	pbo	Medication use, Anticholinergic
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Medication use, Anticholinergic agents use	"eSMD=-1.01 [-1.27, -0.79] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1.91	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	20	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-1.01	0.12	I (High)	Kishi T., 2021 (NMA)	1.01	-1.27	-0.79	hal	pbo	Medication use, Anticholinergic
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Medication use, Anticholinergic agents use	"eSMD=-0.98 [-1.27, -0.7] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1.95	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	20	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	-0.98	0.15	I (High)	Kishi T., 2021 (NMA)	0.98	-1.27	-0.7	hal	que	Medication use, Anticholinergic
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Medication use, Anticholinergic agents use	"eSMD=-0.45 [-0.76, -0.13] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.01	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	20	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	-0.45	0.16	I (High)	Kishi T., 2021 (NMA)	0.45	-0.76	-0.13	pal	que	Medication use, Anticholinergic
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Medication use, Anticholinergic agents use	"eSMD=-0.42 [-0.74, -0.09] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.28	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	20	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	-0.42	0.17	I (High)	Kishi T., 2021 (NMA)	0.42	-0.74	-0.09	ari	lit	Medication use, Anticholinergic
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Medication use, Anticholinergic agents use	"eSMD=-0.4 [-0.74, -0.06] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.49	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	20	Network meta-analysis	Adults	Mania/Mixed	risperidone	mono	-0.4	0.17	I (High)	Kishi T., 2021 (NMA)	0.4	-0.74	-0.06	hal	risp	Medication use, Anticholinergic
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Medication use, Anticholinergic agents use	"eSMD=-0.25 [-0.52, 0.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.13	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	20	Network meta-analysis	Adults	Mania/Mixed	ziprasidone	mono	-0.25	0.14	III (Low)	Kishi T., 2021 (NMA)	0.25	-0.52	0.01	hal	zip	Medication use, Anticholinergic
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Medication use, Anticholinergic agents use	"eSMD=-0.08 [-0.37, 0.22] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=22.17	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	20	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	-0.08	0.15	III (Low)	Kishi T., 2021 (NMA)	0.08	-0.37	0.22	lit	que	Medication use, Anticholinergic
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Medication use, Anticholinergic agents use	"eSMD=0.16 [-0.3, 0.63] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=11.1	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	20	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	0.16	0.24	III (Low)	Kishi T., 2021 (NMA)	-0.16	-0.3	0.63	div	ola	Medication use, Anticholinergic
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Medication use, Anticholinergic agents use	"eSMD=0.25 [-0.22, 0.72] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.13	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	20	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	0.25	0.24	III (Low)	Kishi T., 2021 (NMA)	-0.25	-0.22	0.72	lit	ola	Medication use, Anticholinergic
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Medication use, Anticholinergic agents use	"eSMD=0.26 [-0.08, 0.61] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.86	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	20	Network meta-analysis	Adults	Mania/Mixed	risperidone	mono	0.26	0.18	III (Low)	Kishi T., 2021 (NMA)	-0.26	-0.08	0.61	ola	risp	Medication use, Anticholinergic
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Medication use, Anticholinergic agents use	"eSMD=0.49 [0.22, 0.76] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.69	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	20	Network meta-analysis	Adults	Mania/Mixed	haloperidol	mono	0.49	0.14	I (High)	Kishi T., 2021 (NMA)	-0.49	0.22	0.76	ari	hal	Medication use, Anticholinergic
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	tamoxifen	Medication use, Anxiolytics use	"eSMD=0.22 [-0.22, 0.66] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.09	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	28	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.22	0.22	II (Moderate)	Kishi T., 2021 (NMA)	-0.22	-0.22	0.66	tamox	pbo	Medication use, Anxiolytics
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	quetiapine	Medication use, Anxiolytics use	"eSMD=0.14 [0.07, 0.23] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=12.68	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	28	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.14	0.04	I (High)	Kishi T., 2021 (NMA)	-0.14	0.07	0.23	que	pbo	Medication use, Anxiolytics
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Medication use, Anxiolytics use	"eSMD=0.08 [-0.03, 0.18] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=22.17	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	28	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.08	0.05	II (Moderate)	Kishi T., 2021 (NMA)	-0.08	-0.03	0.18	pal	pbo	Medication use, Anxiolytics
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Medication use, Anxiolytics use	"eSMD=0.07 [0.02, 0.12] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=25.33	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	28	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.07	0.03	I (High)	Kishi T., 2021 (NMA)	-0.07	0.02	0.12	ola	pbo	Medication use, Anxiolytics
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Medication use, Anxiolytics use	"eSMD=0.05 [-0.01, 0.11] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=35.46	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	28	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.05	0.03	II (Moderate)	Kishi T., 2021 (NMA)	-0.05	-0.01	0.11	div	pbo	Medication use, Anxiolytics
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	asenapine	Medication use, Anxiolytics use	"eSMD=0.04 [-0.03, 0.1] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=44.32	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	28	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.04	0.03	II (Moderate)	Kishi T., 2021 (NMA)	-0.04	-0.03	0.1	ase	pbo	Medication use, Anxiolytics
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Medication use, Anxiolytics use	"eSMD=0.02 [-0.03, 0.06] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=88.63	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	28	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.02	0.02	II (Moderate)	Kishi T., 2021 (NMA)	-0.02	-0.03	0.06	lit	pbo	Medication use, Anxiolytics
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	cariprazine	Medication use, Anxiolytics use	"eSMD=0.01 [-0.06, 0.06] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=177.25	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	28	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.01	0.03	II (Moderate)	Kishi T., 2021 (NMA)	-0.01	-0.06	0.06	car	pbo	Medication use, Anxiolytics
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	carbamazepine	Medication use, Anxiolytics use	"eSMD=0.01 [-0.07, 0.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=177.25	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	28	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.01	0.04	II (Moderate)	Kishi T., 2021 (NMA)	-0.01	-0.07	0.08	cbz	pbo	Medication use, Anxiolytics
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	risperidone	Medication use, Anxiolytics use	"eSMD=0.01 [-0.06, 0.07] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=177.25	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	28	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.01	0.03	II (Moderate)	Kishi T., 2021 (NMA)	-0.01	-0.06	0.07	risp	pbo	Medication use, Anxiolytics
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Medication use, Anxiolytics use	"eSMD=0 [-0.08, 0.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	28	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0	0.04	II (Moderate)	Kishi T., 2021 (NMA)	0	-0.08	0.08	hal	pbo	Medication use, Anxiolytics
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Medication use, Anxiolytics use	"eSMD=-0.02 [-0.06, 0.02] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=88.63	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	28	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.02	0.02	II (Moderate)	Kishi T., 2021 (NMA)	0.02	-0.06	0.02	ari	pbo	Medication use, Anxiolytics
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	ziprasidone	Medication use, Anxiolytics use	"eSMD=-0.02 [-0.1, 0.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=88.63	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	28	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.02	0.04	II (Moderate)	Kishi T., 2021 (NMA)	0.02	-0.1	0.05	zip	pbo	Medication use, Anxiolytics
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Medication use, Anxiolytics use	"eSMD=-0.14 [-0.25, -0.03] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=12.68	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	28	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	-0.14	0.06	I (High)	Kishi T., 2021 (NMA)	0.14	-0.25	-0.03	hal	que	Medication use, Anxiolytics
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Medication use, Anxiolytics use	"eSMD=-0.13 [-0.21, -0.04] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=13.65	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	28	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	-0.13	0.04	I (High)	Kishi T., 2021 (NMA)	0.13	-0.21	-0.04	lit	que	Medication use, Anxiolytics
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Medication use, Anxiolytics use	"eSMD=-0.07 [-0.18, 0.03] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=25.33	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	28	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	-0.07	0.05	II (Moderate)	Kishi T., 2021 (NMA)	0.07	-0.18	0.03	pal	que	Medication use, Anxiolytics
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Medication use, Anxiolytics use	"eSMD=-0.06 [-0.13, 0.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=29.55	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	28	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	-0.06	0.04	II (Moderate)	Kishi T., 2021 (NMA)	0.06	-0.13	0.01	lam	lit	Medication use, Anxiolytics
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Medication use, Anxiolytics use	"eSMD=-0.05 [-0.11, 0.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=35.46	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	28	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.05	0.03	II (Moderate)	Kishi T., 2021 (NMA)	0.05	-0.11	0.01	lit	ola	Medication use, Anxiolytics
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Medication use, Anxiolytics use	"eSMD=-0.04 [-0.09, 0.02] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=44.32	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	28	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	-0.04	0.03	II (Moderate)	Kishi T., 2021 (NMA)	0.04	-0.09	0.02	ari	lit	Medication use, Anxiolytics
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	asenapine	Medication use, Anxiolytics use	"eSMD=-0.03 [-0.1, 0.03] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=59.09	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	28	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.03	0.03	II (Moderate)	Kishi T., 2021 (NMA)	0.03	-0.1	0.03	ase	ola	Medication use, Anxiolytics
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Medication use, Anxiolytics use	"eSMD=-0.02 [-0.09, 0.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=88.63	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	28	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.02	0.04	II (Moderate)	Kishi T., 2021 (NMA)	0.02	-0.09	0.05	div	ola	Medication use, Anxiolytics
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Medication use, Anxiolytics use	"eSMD=-0.02 [-0.1, 0.06] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=88.63	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	28	Network meta-analysis	Adults	Mania/Mixed	haloperidol	mono	-0.02	0.04	II (Moderate)	Kishi T., 2021 (NMA)	0.02	-0.1	0.06	ari	hal	Medication use, Anxiolytics
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Medication use, Anxiolytics use	"eSMD=-0.01 [-0.1, 0.09] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=177.25	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	28	Network meta-analysis	Adults	Mania/Mixed	risperidone	mono	-0.01	0.05	II (Moderate)	Kishi T., 2021 (NMA)	0.01	-0.1	0.09	hal	risp	Medication use, Anxiolytics
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Medication use, Anxiolytics use	"eSMD=0.03 [-0.04, 0.1] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=59.09	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	28	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	0.03	0.04	II (Moderate)	Kishi T., 2021 (NMA)	-0.03	-0.04	0.1	div	lit	Medication use, Anxiolytics
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	lithium	Medication use, any	"eSMD=0.06 [-0.25, 0.36] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=29.55	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	0.06	0.16	III (Low)	McKnight R.F., 2019 (MA)	-0.06	-0.25	0.36	lit	pbo	Medication use, any
"<a href='https://doi.org/' target=""_blank"">Rendell J.M., 2010 (MA)</a>"	risperidone	Medication use, any	"eSMD=-0.08 [-0.17, 0.02] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=22.17	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	aug	-0.08	0.05	III (Low)	Rendell J.M., 2010 (MA)	0.08	-0.17	0.02	risp	pbo	Medication use, any
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	lithium	Medication use, Sleep medication use	"eSMD=-0.1 [-0.35, 0.14] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=17.74	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	quetiapine	mono	-0.1	0.12	II (Moderate)	McKnight R.F., 2019 (MA)	0.1	-0.35	0.14	lit	que	Medication use, Sleep
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2013 (MA)</a>"	carbamazepine	Mortality Rate	"eSMD=-0.61 [-1.65, 0.48] <br> <img src=""https://www.linkpicture.com/q/Diapositive4.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Maintenance	lithium	mono	-0.61	0.54	II (Moderate)	Cipriani A., 2013 (MA)	0.61	-1.65	0.48	cbz	lit	Mortality Rate
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Mortality Rate	"eSMD=0.32 [-0.72, 1.39] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.59	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Maintenance	placebo	mono	0.32	0.54	III (Low)	Kishi T., 2021 (NMA)	-0.32	-0.72	1.39	lit	pbo	Mortality Rate
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	quetiapine	Mortality Rate	"eSMD=0.07 [-1.12, 1.27] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=25.33	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Maintenance	placebo	mono	0.07	0.61	III (Low)	Kishi T., 2021 (NMA)	-0.07	-1.12	1.27	que	pbo	Mortality Rate
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	asenapine	Mortality Rate	"eSMD=-0.01 [-2.16, 2.16] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=177.25	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.01	1.1	III (Low)	Kishi T., 2021 (NMA)	0.01	-2.16	2.16	ase	pbo	Mortality Rate
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	risperidone LAI	Mortality Rate	"eSMD=-0.19 [-2.16, 1.77] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=9.36	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.19	1	III (Low)	Kishi T., 2021 (NMA)	0.19	-2.16	1.77	rispLAI	pbo	Mortality Rate
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Mortality Rate	"eSMD=-0.26 [-1.77, 1.22] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.86	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.26	0.76	III (Low)	Kishi T., 2021 (NMA)	0.26	-1.77	1.22	lam	pbo	Mortality Rate
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Mortality Rate	"eSMD=-0.36 [-1.77, 1.12] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.98	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.36	0.74	III (Low)	Kishi T., 2021 (NMA)	0.36	-1.77	1.12	ola	pbo	Mortality Rate
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole LAI	Mortality Rate	"eSMD=-0.61 [-2.54, 1.17] <br> <img src=""https://www.linkpicture.com/q/Diapositive4.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.61	0.95	III (Low)	Kishi T., 2021 (NMA)	0.61	-2.54	1.17	ariLAI	pbo	Mortality Rate
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Mortality Rate	"eSMD=-0.89 [-2.54, 0.81] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.12	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.89	0.85	III (Low)	Kishi T., 2021 (NMA)	0.89	-2.54	0.81	pal	pbo	Mortality Rate
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Mortality Rate	"eSMD=-0.58 [-2.16, 0.92] <br> <img src=""https://www.linkpicture.com/q/Diapositive4.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.14	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Maintenance	lithium	mono	-0.58	0.79	III (Low)	Kishi T., 2021 (NMA)	0.58	-2.16	0.92	lam	lit	Mortality Rate
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Mortality Rate	"eSMD=-0.23 [-1.22, 0.77] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.74	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Maintenance	lithium	mono	-0.23	0.51	III (Low)	Kishi T., 2021 (NMA)	0.23	-1.22	0.77	div	lit	Mortality Rate
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Mortality Rate	"eSMD=-0.18 [-2.16, 1.77] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=9.87	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Maintenance	risperidone LAI	mono	-0.18	1	III (Low)	Kishi T., 2021 (NMA)	0.18	-2.16	1.77	ola	rispLAI	Mortality Rate
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole+lamotrigine	Mortality Rate	"eSMD=0.02 [-2.16, 2.16] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=88.63	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Maintenance	lamotrigine	mono	0.02	1.1	III (Low)	Kishi T., 2021 (NMA)	-0.02	-2.16	2.16	ari+lam	lam	Mortality Rate
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Mortality Rate	"eSMD=0.17 [-0.68, 1] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=10.45	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Maintenance	lithium+divalproate	combo	0.17	0.43	III (Low)	Kishi T., 2021 (NMA)	-0.17	-0.68	1	div	lit+div	Mortality Rate
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Mortality Rate	"eSMD=0.25 [-1.22, 1.65] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.13	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Maintenance	quetiapine	mono	0.25	0.73	III (Low)	Kishi T., 2021 (NMA)	-0.25	-1.22	1.65	lit	que	Mortality Rate
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Mortality Rate	"eSMD=0.39 [-0.56, 1.33] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.6	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Maintenance	lithium+divalproate	combo	0.39	0.48	III (Low)	Kishi T., 2021 (NMA)	-0.39	-0.56	1.33	lit	lit+div	Mortality Rate
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Mortality Rate	"eSMD=0.68 [-0.7, 2.16] <br> <img src=""https://www.linkpicture.com/q/Diapositive18.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.71	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	11	Network meta-analysis	Adults	Maintenance	olanzapine	mono	0.68	0.73	III (Low)	Kishi T., 2021 (NMA)	-0.68	-0.7	2.16	lit	ola	Mortality Rate
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	tamoxifen	Psychotic symptoms scale, PANSS/BPRS, change from baseline	"eSMD=1.64 [0.94, 2.33] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.33	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	30	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	1.64	0.35	I (High)	Kishi T., 2021 (NMA)	-1.64	0.94	2.33	tamox	pbo	Psychotic sxs, PANSS/BPRS, change
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Psychotic symptoms scale, PANSS/BPRS, change from baseline	"eSMD=0.47 [0.24, 0.71] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.84	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	30	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.47	0.12	II (Moderate)	Kishi T., 2021 (NMA)	-0.47	0.24	0.71	hal	pbo	Psychotic sxs, PANSS/BPRS, change
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	risperidone	Psychotic symptoms scale, PANSS/BPRS, change from baseline	"eSMD=0.43 [0.2, 0.66] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.19	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	30	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.43	0.12	II (Moderate)	Kishi T., 2021 (NMA)	-0.43	0.2	0.66	risp	pbo	Psychotic sxs, PANSS/BPRS, change
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	cariprazine	Psychotic symptoms scale, PANSS/BPRS, change from baseline	"eSMD=0.42 [0.15, 0.69] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.28	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	30	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.42	0.14	II (Moderate)	Kishi T., 2021 (NMA)	-0.42	0.15	0.69	car	pbo	Psychotic sxs, PANSS/BPRS, change
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Psychotic symptoms scale, PANSS/BPRS, change from baseline	"eSMD=0.39 [0.09, 0.69] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.6	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	30	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.39	0.15	II (Moderate)	Kishi T., 2021 (NMA)	-0.39	0.09	0.69	ola	pbo	Psychotic sxs, PANSS/BPRS, change
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	ziprasidone	Psychotic symptoms scale, PANSS/BPRS, change from baseline	"eSMD=0.38 [0.11, 0.66] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.72	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	30	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.38	0.14	II (Moderate)	Kishi T., 2021 (NMA)	-0.38	0.11	0.66	zip	pbo	Psychotic sxs, PANSS/BPRS, change
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	asenapine	Psychotic symptoms scale, PANSS/BPRS, change from baseline	"eSMD=0.36 [-0.12, 0.84] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.98	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	30	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.36	0.24	III (Low)	Kishi T., 2021 (NMA)	-0.36	-0.12	0.84	ase	pbo	Psychotic sxs, PANSS/BPRS, change
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	quetiapine	Psychotic symptoms scale, PANSS/BPRS, change from baseline	"eSMD=0.35 [0.11, 0.6] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.12	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	30	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.35	0.12	II (Moderate)	Kishi T., 2021 (NMA)	-0.35	0.11	0.6	que	pbo	Psychotic sxs, PANSS/BPRS, change
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Psychotic symptoms scale, PANSS/BPRS, change from baseline	"eSMD=0.27 [0.04, 0.49] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.6	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	30	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.27	0.11	II (Moderate)	Kishi T., 2021 (NMA)	-0.27	0.04	0.49	ari	pbo	Psychotic sxs, PANSS/BPRS, change
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Psychotic symptoms scale, PANSS/BPRS, change from baseline	"eSMD=0.23 [-0.08, 0.54] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.74	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	30	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.23	0.16	III (Low)	Kishi T., 2021 (NMA)	-0.23	-0.08	0.54	pal	pbo	Psychotic sxs, PANSS/BPRS, change
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Psychotic symptoms scale, PANSS/BPRS, change from baseline	"eSMD=0.1 [-0.14, 0.35] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=17.74	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	30	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.1	0.12	III (Low)	Kishi T., 2021 (NMA)	-0.1	-0.14	0.35	lit	pbo	Psychotic sxs, PANSS/BPRS, change
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	valnoctamide	Psychotic symptoms scale, PANSS/BPRS, change from baseline	"eSMD=0.05 [-0.43, 0.54] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=35.46	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	30	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.05	0.25	III (Low)	Kishi T., 2021 (NMA)	-0.05	-0.43	0.54	valnoctamide	pbo	Psychotic sxs, PANSS/BPRS, change
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Psychotic symptoms scale, PANSS/BPRS, change from baseline	"eSMD=-0.05 [-0.46, 0.36] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=35.46	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	30	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.05	0.21	III (Low)	Kishi T., 2021 (NMA)	0.05	-0.46	0.36	lam	pbo	Psychotic sxs, PANSS/BPRS, change
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Psychotic symptoms scale, PANSS/BPRS, change from baseline	"eSMD=-0.52 [-0.99, -0.04] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.49	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	30	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.52	0.24	II (Moderate)	Kishi T., 2021 (NMA)	0.52	-0.99	-0.04	div	ola	Psychotic sxs, PANSS/BPRS, change
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Psychotic symptoms scale, PANSS/BPRS, change from baseline	"eSMD=-0.44 [-0.89, 0.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	30	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.44	0.23	III (Low)	Kishi T., 2021 (NMA)	0.44	-0.89	0.01	lam	ola	Psychotic sxs, PANSS/BPRS, change
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Psychotic symptoms scale, PANSS/BPRS, change from baseline	"eSMD=-0.32 [-0.65, 0.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.59	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	30	Network meta-analysis	Adults	Mania/Mixed	risperidone	mono	-0.32	0.17	III (Low)	Kishi T., 2021 (NMA)	0.32	-0.65	0.01	lit	risp	Psychotic sxs, PANSS/BPRS, change
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Psychotic symptoms scale, PANSS/BPRS, change from baseline	"eSMD=-0.28 [-0.59, 0.02] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.37	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	30	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.28	0.16	III (Low)	Kishi T., 2021 (NMA)	0.28	-0.59	0.02	lit	ola	Psychotic sxs, PANSS/BPRS, change
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Psychotic symptoms scale, PANSS/BPRS, change from baseline	"eSMD=-0.25 [-0.56, 0.06] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.13	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	30	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	-0.25	0.16	III (Low)	Kishi T., 2021 (NMA)	0.25	-0.56	0.06	lit	que	Psychotic sxs, PANSS/BPRS, change
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Psychotic symptoms scale, PANSS/BPRS, change from baseline	"eSMD=-0.23 [-0.75, 0.29] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.74	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	30	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	-0.23	0.27	III (Low)	Kishi T., 2021 (NMA)	0.23	-0.75	0.29	div	lit	Psychotic sxs, PANSS/BPRS, change
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Psychotic symptoms scale, PANSS/BPRS, change from baseline	"eSMD=-0.21 [-0.51, 0.09] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=8.47	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	30	Network meta-analysis	Adults	Mania/Mixed	haloperidol	mono	-0.21	0.15	III (Low)	Kishi T., 2021 (NMA)	0.21	-0.51	0.09	ari	hal	Psychotic sxs, PANSS/BPRS, change
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Psychotic symptoms scale, PANSS/BPRS, change from baseline	"eSMD=-0.15 [-0.55, 0.24] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=11.84	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	30	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	-0.15	0.2	III (Low)	Kishi T., 2021 (NMA)	0.15	-0.55	0.24	lam	lit	Psychotic sxs, PANSS/BPRS, change
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Psychotic symptoms scale, PANSS/BPRS, change from baseline	"eSMD=-0.12 [-0.47, 0.22] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=14.79	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	30	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	-0.12	0.18	III (Low)	Kishi T., 2021 (NMA)	0.12	-0.47	0.22	pal	que	Psychotic sxs, PANSS/BPRS, change
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Psychotic symptoms scale, PANSS/BPRS, change from baseline	"eSMD=0.05 [-0.24, 0.34] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=35.46	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	30	Network meta-analysis	Adults	Mania/Mixed	risperidone	mono	0.05	0.15	III (Low)	Kishi T., 2021 (NMA)	-0.05	-0.24	0.34	hal	risp	Psychotic sxs, PANSS/BPRS, change
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	carbamazepine	Psychotic symptoms scale, PANSS/BPRS, change from baseline	"eSMD=0.06 [-0.78, 0.91] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=29.55	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	30	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	0.06	0.43	III (Low)	Kishi T., 2021 (NMA)	-0.06	-0.78	0.91	cbz	lit	Psychotic sxs, PANSS/BPRS, change
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Psychotic symptoms scale, PANSS/BPRS, change from baseline	"eSMD=0.09 [-0.23, 0.41] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=19.71	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	30	Network meta-analysis	Adults	Mania/Mixed	ziprasidone	mono	0.09	0.16	III (Low)	Kishi T., 2021 (NMA)	-0.09	-0.23	0.41	hal	zip	Psychotic sxs, PANSS/BPRS, change
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Psychotic symptoms scale, PANSS/BPRS, change from baseline	"eSMD=0.16 [-0.14, 0.46] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=11.1	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	30	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	0.16	0.15	III (Low)	Kishi T., 2021 (NMA)	-0.16	-0.14	0.46	ari	lit	Psychotic sxs, PANSS/BPRS, change
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Psychotic symptoms scale, PANSS/BPRS, change from baseline	"eSMD=0.37 [0.04, 0.7] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.85	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	30	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	0.37	0.17	II (Moderate)	Kishi T., 2021 (NMA)	-0.37	0.04	0.7	hal	lit	Psychotic sxs, PANSS/BPRS, change
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	risperidone	Psychotic symptoms scale, PANSS/BPRS, change from baseline	"eSMD=0.37 [-0.11, 0.85] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.85	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	30	Network meta-analysis	Adults	Mania/Mixed	valnoctamide	mono	0.37	0.24	III (Low)	Kishi T., 2021 (NMA)	-0.37	-0.11	0.85	risp	valnoctamide	Psychotic sxs, PANSS/BPRS, change
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2019 (MA)</a>"	ramelteon	Quality of life scale	"eSMD=-0.04 [-0.22, 0.13] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=44.32	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Maintenance	placebo	mono	-0.04	0.09	III (Low)	Kishi T., 2019 (MA)	0.04	-0.22	0.13	ram	pbo	Quality of life
"<a href='https://doi.org/' target=""_blank"">Chiesa A., 2012 (MA)</a>"	quetiapine	Quality of life scale, QLESQ, change from baseline	"eSMD=2.39 [1.69, 4.16] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.1	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	4	Pairwise meta-analysis	Adults	Bipolar Depression	placebo	mono	2.39	0.63	I (High)	Chiesa A., 2012 (MA)	-2.39	1.69	4.16	que	pbo	Quality of life, QLESQ, change
"<a href='https://doi.org/' target=""_blank"">Pittas S., 2021 (MA)</a>"	n-acetyl cysteine	Quality of life scale, QLESQ, change from baseline	"eSMD=2.27 [-9.13, 13.67] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.12	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Bipolar Depression	placebo	aug	2.27	5.82	III (Low)	Pittas S., 2021 (MA)	-2.27	-9.13	13.67	nac	pbo	Quality of life, QLESQ, change
"<a href='https://doi.org/' target=""_blank"">Suttajit S., 2014 (MA)</a>"	quetiapine	Quality of life scale, QLESQ, change from baseline	"eSMD=2.95 [1.7, 4.2] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.04	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	2.95	0.64	I (High)	Suttajit S., 2014 (MA)	-2.95	1.7	4.2	que	pbo	Quality of life, QLESQ, change
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2019 (MA)</a>"	ramelteon	Relapse, manic/hypomanic episode	"eSMD=-0.03 [-0.52, 0.47] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=59.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Maintenance	placebo	mono	-0.03	0.25	III (Low)	Kishi T., 2019 (MA)	0.03	-0.52	0.47	ram	pbo	Relapse, (hypo)manic
"<a href='https://doi.org/' target=""_blank"">Bond K., 2015 (MA)</a>"	psychoeducation individual	Relapse, manic/hypomanic/mixed episode	"eSMD=0.1 [-0.44, 0.63] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=17.74	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Maintenance	TAU	N/A	0.1	0.27	III (Low)	Bond K., 2015 (MA)	-0.1	-0.44	0.63	PEind	tau	Relapse, (hypo)manic/mixed
"<a href='https://doi.org/' target=""_blank"">Bond K., 2015 (MA)</a>"	psychoeducation group	Relapse, manic/hypomanic/mixed episode	"eSMD=0.4 [0.06, 0.74] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.49	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Pairwise meta-analysis	Adults	Maintenance	TAU	N/A	0.4	0.17	I (High)	Bond K., 2015 (MA)	-0.4	0.06	0.74	PEgroup	tau	Relapse, (hypo)manic/mixed
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	asenapine	Relapse, manic/hypomanic/mixed episode	"eSMD=0.86 [0.35, 1.39] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.19	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	25	Network meta-analysis	Adults	Maintenance	placebo	mono	0.86	0.27	II (Moderate)	Kishi T., 2021 (NMA)	-0.86	0.35	1.39	ase	pbo	Relapse, (hypo)manic/mixed
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole LAI	Relapse, manic/hypomanic/mixed episode	"eSMD=0.66 [0.33, 0.98] <br> <img src=""https://www.linkpicture.com/q/Diapositive18.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.78	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	25	Network meta-analysis	Adults	Maintenance	placebo	mono	0.66	0.17	II (Moderate)	Kishi T., 2021 (NMA)	-0.66	0.33	0.98	ariLAI	pbo	Relapse, (hypo)manic/mixed
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Relapse, manic/hypomanic/mixed episode	"eSMD=0.58 [0.44, 0.74] <br> <img src=""https://www.linkpicture.com/q/Diapositive17.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.14	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	25	Network meta-analysis	Adults	Maintenance	placebo	mono	0.58	0.08	II (Moderate)	Kishi T., 2021 (NMA)	-0.58	0.44	0.74	ola	pbo	Relapse, (hypo)manic/mixed
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	risperidone LAI	Relapse, manic/hypomanic/mixed episode	"eSMD=0.55 [0.37, 0.72] <br> <img src=""https://www.linkpicture.com/q/Diapositive17.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.3	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	25	Network meta-analysis	Adults	Maintenance	placebo	mono	0.55	0.09	II (Moderate)	Kishi T., 2021 (NMA)	-0.55	0.37	0.72	rispLAI	pbo	Relapse, (hypo)manic/mixed
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Relapse, manic/hypomanic/mixed episode	"eSMD=0.48 [0.1, 0.86] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.76	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	25	Network meta-analysis	Adults	Maintenance	placebo	mono	0.48	0.19	II (Moderate)	Kishi T., 2021 (NMA)	-0.48	0.1	0.86	ari	pbo	Relapse, (hypo)manic/mixed
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Relapse, manic/hypomanic/mixed episode	"eSMD=0.34 [0.24, 0.45] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.26	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	25	Network meta-analysis	Adults	Maintenance	placebo	mono	0.34	0.05	II (Moderate)	Kishi T., 2021 (NMA)	-0.34	0.24	0.45	lit	pbo	Relapse, (hypo)manic/mixed
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	quetiapine	Relapse, manic/hypomanic/mixed episode	"eSMD=0.33 [0.19, 0.47] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.42	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	25	Network meta-analysis	Adults	Maintenance	placebo	mono	0.33	0.07	II (Moderate)	Kishi T., 2021 (NMA)	-0.33	0.19	0.47	que	pbo	Relapse, (hypo)manic/mixed
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Relapse, manic/hypomanic/mixed episode	"eSMD=0.29 [0.08, 0.51] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.15	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	25	Network meta-analysis	Adults	Maintenance	placebo	mono	0.29	0.11	II (Moderate)	Kishi T., 2021 (NMA)	-0.29	0.08	0.51	pal	pbo	Relapse, (hypo)manic/mixed
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Relapse, manic/hypomanic/mixed episode	"eSMD=0.25 [0.08, 0.4] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.13	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	25	Network meta-analysis	Adults	Maintenance	placebo	mono	0.25	0.08	II (Moderate)	Kishi T., 2021 (NMA)	-0.25	0.08	0.4	div	pbo	Relapse, (hypo)manic/mixed
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Relapse, manic/hypomanic/mixed episode	"eSMD=0.06 [-0.11, 0.24] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=29.55	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	25	Network meta-analysis	Adults	Maintenance	placebo	mono	0.06	0.09	III (Low)	Kishi T., 2021 (NMA)	-0.06	-0.11	0.24	lam	pbo	Relapse, (hypo)manic/mixed
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	cariprazine	Relapse, manic/hypomanic/mixed episode	"eSMD=-0.74 [-1.93, 0.4] <br> <img src=""https://www.linkpicture.com/q/Diapositive2.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.5	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	25	Network meta-analysis	Adults	Maintenance	lithium	mono	-0.74	0.59	III (Low)	Kishi T., 2021 (NMA)	0.74	-1.93	0.4	car	lit	Relapse, (hypo)manic/mixed
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Relapse, manic/hypomanic/mixed episode	"eSMD=-0.32 [-0.92, 0.27] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.59	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	25	Network meta-analysis	Adults	Maintenance	lithium+oxcarbazepine	combo	-0.32	0.3	III (Low)	Kishi T., 2021 (NMA)	0.32	-0.92	0.27	lit	lit+oxc	Relapse, (hypo)manic/mixed
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Relapse, manic/hypomanic/mixed episode	"eSMD=-0.27 [-0.47, -0.09] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.6	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	25	Network meta-analysis	Adults	Maintenance	lithium	mono	-0.27	0.1	II (Moderate)	Kishi T., 2021 (NMA)	0.27	-0.47	-0.09	lam	lit	Relapse, (hypo)manic/mixed
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Relapse, manic/hypomanic/mixed episode	"eSMD=-0.27 [-0.83, 0.28] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.6	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	25	Network meta-analysis	Adults	Maintenance	lamotrigine+divalproate	combo	-0.27	0.28	III (Low)	Kishi T., 2021 (NMA)	0.27	-0.83	0.28	lam	lam+div	Relapse, (hypo)manic/mixed
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Relapse, manic/hypomanic/mixed episode	"eSMD=-0.26 [-0.47, -0.06] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.86	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	25	Network meta-analysis	Adults	Maintenance	lithium+divalproate	combo	-0.26	0.1	II (Moderate)	Kishi T., 2021 (NMA)	0.26	-0.47	-0.06	div	lit+div	Relapse, (hypo)manic/mixed
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Relapse, manic/hypomanic/mixed episode	"eSMD=-0.25 [-0.39, -0.09] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.13	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	25	Network meta-analysis	Adults	Maintenance	olanzapine	mono	-0.25	0.08	II (Moderate)	Kishi T., 2021 (NMA)	0.25	-0.39	-0.09	lit	ola	Relapse, (hypo)manic/mixed
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Relapse, manic/hypomanic/mixed episode	"eSMD=-0.17 [-0.37, 0.04] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=10.45	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	25	Network meta-analysis	Adults	Maintenance	lithium+divalproate	combo	-0.17	0.1	III (Low)	Kishi T., 2021 (NMA)	0.17	-0.37	0.04	lit	lit+div	Relapse, (hypo)manic/mixed
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Relapse, manic/hypomanic/mixed episode	"eSMD=-0.1 [-0.23, 0.04] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=17.74	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	25	Network meta-analysis	Adults	Maintenance	lithium	mono	-0.1	0.07	III (Low)	Kishi T., 2021 (NMA)	0.1	-0.23	0.04	div	lit	Relapse, (hypo)manic/mixed
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Relapse, manic/hypomanic/mixed episode	"eSMD=0.02 [-0.14, 0.17] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=88.63	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	25	Network meta-analysis	Adults	Maintenance	quetiapine	mono	0.02	0.08	III (Low)	Kishi T., 2021 (NMA)	-0.02	-0.14	0.17	lit	que	Relapse, (hypo)manic/mixed
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Relapse, manic/hypomanic/mixed episode	"eSMD=0.03 [-0.19, 0.26] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=59.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	25	Network meta-analysis	Adults	Maintenance	risperidone LAI	mono	0.03	0.11	III (Low)	Kishi T., 2021 (NMA)	-0.03	-0.19	0.26	ola	rispLAI	Relapse, (hypo)manic/mixed
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole+divalproate	Relapse, manic/hypomanic/mixed episode	"eSMD=0.11 [-0.66, 0.92] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=16.13	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	25	Network meta-analysis	Adults	Maintenance	divalproate	mono	0.11	0.4	III (Low)	Kishi T., 2021 (NMA)	-0.11	-0.66	0.92	ari+div	div	Relapse, (hypo)manic/mixed
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole+lamotrigine	Relapse, manic/hypomanic/mixed episode	"eSMD=0.3 [-0.02, 0.63] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.95	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	25	Network meta-analysis	Adults	Maintenance	lamotrigine	mono	0.3	0.17	III (Low)	Kishi T., 2021 (NMA)	-0.3	-0.02	0.63	ari+lam	lam	Relapse, (hypo)manic/mixed
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lurasidone+lithium/divalproate	Relapse, manic/hypomanic/mixed episode	"eSMD=0.33 [-0.01, 0.68] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.42	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Network meta-analysis	Adults	Maintenance	placebo+lithium/divalproate	combo	0.33	0.18	IV (Very Low)	Kishi T., 2021 (NMA)	-0.33	-0.01	0.68	lur+lit/div	pbo+lit/div	Relapse, (hypo)manic/mixed
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	ziprasidone+lithium/divalproate	Relapse, manic/hypomanic/mixed episode	"eSMD=0.45 [-0.03, 0.92] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.01	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Network meta-analysis	Adults	Maintenance	placebo+lithium/divalproate	combo	0.45	0.24	IV (Very Low)	Kishi T., 2021 (NMA)	-0.45	-0.03	0.92	zip+lit/div	pbo+lit/div	Relapse, (hypo)manic/mixed
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	quetiapine+lithium/divalproate	Relapse, manic/hypomanic/mixed episode	"eSMD=0.52 [0.36, 0.66] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.49	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Network meta-analysis	Adults	Maintenance	placebo+lithium/divalproate	combo	0.52	0.08	II (Moderate)	Kishi T., 2021 (NMA)	-0.52	0.36	0.66	que+lit/div	pbo+lit/div	Relapse, (hypo)manic/mixed
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole+lithium/divalproate	Relapse, manic/hypomanic/mixed episode	"eSMD=0.63 [0.2, 1.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive18.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.91	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Network meta-analysis	Adults	Maintenance	placebo+lithium/divalproate	combo	0.63	0.22	II (Moderate)	Kishi T., 2021 (NMA)	-0.63	0.2	1.05	ari+lit/div	pbo+lit/div	Relapse, (hypo)manic/mixed
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	lithium+imipramine	Relapse, manic/hypomanic/mixed episode	"eSMD=0.14 [-0.25, 0.52] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=12.68	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	24	Network meta-analysis	Adults	Maintenance	placebo	mono	0.14	0.2	IV (Very Low)	Miura T., 2014 (NMA)	-0.14	-0.25	0.52	lit+imp	pbo	Relapse, (hypo)manic/mixed
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	imipramine	Relapse, manic/hypomanic/mixed episode	"eSMD=-0.15 [-0.53, 0.23] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=11.84	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	24	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.15	0.19	IV (Very Low)	Miura T., 2014 (NMA)	0.15	-0.53	0.23	imp	pbo	Relapse, (hypo)manic/mixed
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	carbamazepine	Relapse, manic/hypomanic/mixed episode	"eSMD=-0.58 [-1.55, 0.39] <br> <img src=""https://www.linkpicture.com/q/Diapositive4.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.14	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	24	Network meta-analysis	Adults	Maintenance	lithium	mono	-0.58	0.49	IV (Very Low)	Miura T., 2014 (NMA)	0.58	-1.55	0.39	cbz	lit	Relapse, (hypo)manic/mixed
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	imipramine	Relapse, manic/hypomanic/mixed episode	"eSMD=-0.45 [-0.81, -0.1] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.01	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	24	Network meta-analysis	Adults	Maintenance	lithium	mono	-0.45	0.18	II (Moderate)	Miura T., 2014 (NMA)	0.45	-0.81	-0.1	imp	lit	Relapse, (hypo)manic/mixed
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	imipramine	Relapse, manic/hypomanic/mixed episode	"eSMD=-0.29 [-0.65, 0.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.15	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	24	Network meta-analysis	Adults	Maintenance	lithium+imipramine	combo	-0.29	0.19	IV (Very Low)	Miura T., 2014 (NMA)	0.29	-0.65	0.08	imp	lit+imp	Relapse, (hypo)manic/mixed
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	lithium	Relapse, manic/hypomanic/mixed episode	"eSMD=0.16 [-0.19, 0.51] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=11.1	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	24	Network meta-analysis	Adults	Maintenance	lithium+imipramine	combo	0.16	0.18	IV (Very Low)	Miura T., 2014 (NMA)	-0.16	-0.19	0.51	lit	lit+imp	Relapse, (hypo)manic/mixed
"<a href='https://doi.org/' target=""_blank"">Bond K., 2015 (MA)</a>"	psychoeducation individual	Relapse, any mood episode	"eSMD=-0.06 [-0.44, 0.31] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=29.55	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Maintenance	TAU	N/A	-0.06	0.19	III (Low)	Bond K., 2015 (MA)	0.06	-0.44	0.31	PEind	tau	Relapse, any
"<a href='https://doi.org/' target=""_blank"">Bond K., 2015 (MA)</a>"	psychoeducation group	Relapse, any mood episode	"eSMD=0.56 [0.27, 0.86] <br> <img src=""https://www.linkpicture.com/q/Diapositive17.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.25	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Pairwise meta-analysis	Adults	Maintenance	TAU	N/A	0.56	0.15	I (High)	Bond K., 2015 (MA)	-0.56	0.27	0.86	PEgroup	tau	Relapse, any
"<a href='https://doi.org/' target=""_blank"">Chatterton M.L., 2017 (NMA)</a>"	psychoeducation	Relapse, any mood episode	"eSMD=-0.06 [-0.43, 0.3] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=29.55	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	24	Network meta-analysis	Adults	Maintenance	TAU	N/A	-0.06	0.19	IV (Very Low)	Chatterton M.L., 2017 (NMA)	0.06	-0.43	0.3	PE	tau	Relapse, any
"<a href='https://doi.org/' target=""_blank"">Chatterton M.L., 2017 (NMA)</a>"	CBT	Relapse, any mood episode	"eSMD=0.06 [-0.09, 0.21] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=29.55	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	24	Network meta-analysis	Adults	Maintenance	TAU	N/A	0.06	0.08	IV (Very Low)	Chatterton M.L., 2017 (NMA)	-0.06	-0.09	0.21	CBT	tau	Relapse, any
"<a href='https://doi.org/' target=""_blank"">Chatterton M.L., 2017 (NMA)</a>"	family focused therapy	Relapse, any mood episode	"eSMD=0.13 [-0.07, 0.34] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=13.65	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	24	Network meta-analysis	Adults	Maintenance	TAU	N/A	0.13	0.1	IV (Very Low)	Chatterton M.L., 2017 (NMA)	-0.13	-0.07	0.34	FFT	tau	Relapse, any
"<a href='https://doi.org/' target=""_blank"">Chatterton M.L., 2017 (NMA)</a>"	carer focused intervention	Relapse, any mood episode	"eSMD=0.27 [0.08, 0.45] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.6	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	24	Network meta-analysis	Adults	Maintenance	TAU	N/A	0.27	0.09	III (Low)	Chatterton M.L., 2017 (NMA)	-0.27	0.08	0.45	carer focused int	tau	Relapse, any
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2013 (MA)</a>"	divalproate	Relapse, any mood episode	"eSMD=-0.01 [-0.1, 0.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=177.25	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Low	4	Pairwise meta-analysis	Mixed (Children-Adults)	Maintenance	lithium	mono	-0.01	0.05	II (Moderate)	Cipriani A., 2013 (MA)	0.01	-0.1	0.08	div	lit	Relapse, any
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	asenapine	Relapse, any mood episode	"eSMD=0.74 [0.36, 1.12] <br> <img src=""https://www.linkpicture.com/q/Diapositive19.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.5	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Maintenance	placebo	mono	0.74	0.19	II (Moderate)	Kishi T., 2021 (NMA)	-0.74	0.36	1.12	ase	pbo	Relapse, any
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Relapse, any mood episode	"eSMD=0.38 [0.26, 0.51] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.72	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Maintenance	placebo	mono	0.38	0.06	II (Moderate)	Kishi T., 2021 (NMA)	-0.38	0.26	0.51	ola	pbo	Relapse, any
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole LAI	Relapse, any mood episode	"eSMD=0.36 [0.12, 0.61] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.98	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Maintenance	placebo	mono	0.36	0.12	II (Moderate)	Kishi T., 2021 (NMA)	-0.36	0.12	0.61	ariLAI	pbo	Relapse, any
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	quetiapine	Relapse, any mood episode	"eSMD=0.35 [0.22, 0.49] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.12	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Maintenance	placebo	mono	0.35	0.07	II (Moderate)	Kishi T., 2021 (NMA)	-0.35	0.22	0.49	que	pbo	Relapse, any
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Relapse, any mood episode	"eSMD=0.26 [0.01, 0.53] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.86	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Maintenance	placebo	mono	0.26	0.13	II (Moderate)	Kishi T., 2021 (NMA)	-0.26	0.01	0.53	ari	pbo	Relapse, any
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Relapse, any mood episode	"eSMD=0.26 [0.18, 0.34] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.86	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Maintenance	placebo	mono	0.26	0.04	II (Moderate)	Kishi T., 2021 (NMA)	-0.26	0.18	0.34	lit	pbo	Relapse, any
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Relapse, any mood episode	"eSMD=0.26 [0.1, 0.4] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.86	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Maintenance	placebo	mono	0.26	0.08	II (Moderate)	Kishi T., 2021 (NMA)	-0.26	0.1	0.4	div	pbo	Relapse, any
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	risperidone LAI	Relapse, any mood episode	"eSMD=0.25 [0.1, 0.4] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.13	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Maintenance	placebo	mono	0.25	0.08	II (Moderate)	Kishi T., 2021 (NMA)	-0.25	0.1	0.4	rispLAI	pbo	Relapse, any
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Relapse, any mood episode	"eSMD=0.15 [0.04, 0.26] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=11.84	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Maintenance	placebo	mono	0.15	0.06	II (Moderate)	Kishi T., 2021 (NMA)	-0.15	0.04	0.26	lam	pbo	Relapse, any
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Relapse, any mood episode	"eSMD=0.1 [-0.1, 0.31] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=17.74	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Maintenance	placebo	mono	0.1	0.1	III (Low)	Kishi T., 2021 (NMA)	-0.1	-0.1	0.31	pal	pbo	Relapse, any
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Relapse, any mood episode	"eSMD=-0.23 [-0.59, 0.12] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.74	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Maintenance	lithium+oxcarbazepine	combo	-0.23	0.18	III (Low)	Kishi T., 2021 (NMA)	0.23	-0.59	0.12	lit	lit+oxc	Relapse, any
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Relapse, any mood episode	"eSMD=-0.12 [-0.25, 0.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=14.79	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Maintenance	olanzapine	mono	-0.12	0.07	III (Low)	Kishi T., 2021 (NMA)	0.12	-0.25	0.01	lit	ola	Relapse, any
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Relapse, any mood episode	"eSMD=-0.11 [-0.24, 0.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=16.13	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Maintenance	lithium	mono	-0.11	0.06	III (Low)	Kishi T., 2021 (NMA)	0.11	-0.24	0.01	lam	lit	Relapse, any
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Relapse, any mood episode	"eSMD=-0.1 [-0.29, 0.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=17.74	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Maintenance	lithium+divalproate	combo	-0.1	0.09	III (Low)	Kishi T., 2021 (NMA)	0.1	-0.29	0.08	div	lit+div	Relapse, any
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Relapse, any mood episode	"eSMD=-0.1 [-0.28, 0.1] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=17.74	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Maintenance	lithium+divalproate	combo	-0.1	0.1	III (Low)	Kishi T., 2021 (NMA)	0.1	-0.28	0.1	lit	lit+div	Relapse, any
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Relapse, any mood episode	"eSMD=-0.1 [-0.24, 0.06] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=17.74	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Maintenance	quetiapine	mono	-0.1	0.08	III (Low)	Kishi T., 2021 (NMA)	0.1	-0.24	0.06	lit	que	Relapse, any
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	cariprazine	Relapse, any mood episode	"eSMD=-0.05 [-0.27, 0.17] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=35.46	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Maintenance	lithium	mono	-0.05	0.11	III (Low)	Kishi T., 2021 (NMA)	0.05	-0.27	0.17	car	lit	Relapse, any
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Relapse, any mood episode	"eSMD=-0.01 [-0.14, 0.12] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=177.25	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Maintenance	lithium	mono	-0.01	0.07	III (Low)	Kishi T., 2021 (NMA)	0.01	-0.14	0.12	div	lit	Relapse, any
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine+lithium/divalproate	Relapse, any mood episode	"eSMD=0.03 [-0.3, 0.36] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=59.09	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Network meta-analysis	Adults	Maintenance	placebo+lithium/divalproate	combo	0.03	0.17	IV (Very Low)	Kishi T., 2021 (NMA)	-0.03	-0.3	0.36	ola+lit/div	pbo+lit/div	Relapse, any
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Relapse, any mood episode	"eSMD=0.14 [-0.05, 0.31] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=12.68	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Maintenance	risperidone LAI	mono	0.14	0.09	III (Low)	Kishi T., 2021 (NMA)	-0.14	-0.05	0.31	ola	rispLAI	Relapse, any
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole+lamotrigine	Relapse, any mood episode	"eSMD=0.2 [-0.05, 0.45] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.89	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Maintenance	lamotrigine	mono	0.2	0.13	III (Low)	Kishi T., 2021 (NMA)	-0.2	-0.05	0.45	ari+lam	lam	Relapse, any
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	ziprasidone+lithium/divalproate	Relapse, any mood episode	"eSMD=0.27 [0.03, 0.52] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.6	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Network meta-analysis	Adults	Maintenance	placebo+lithium/divalproate	combo	0.27	0.12	III (Low)	Kishi T., 2021 (NMA)	-0.27	0.03	0.52	zip+lit/div	pbo+lit/div	Relapse, any
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole+lithium/divalproate	Relapse, any mood episode	"eSMD=0.29 [0.06, 0.51] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.15	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Network meta-analysis	Adults	Maintenance	placebo+lithium/divalproate	combo	0.29	0.11	III (Low)	Kishi T., 2021 (NMA)	-0.29	0.06	0.51	ari+lit/div	pbo+lit/div	Relapse, any
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole+divalproate	Relapse, any mood episode	"eSMD=0.43 [-0.07, 0.92] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.19	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Maintenance	divalproate	mono	0.43	0.25	III (Low)	Kishi T., 2021 (NMA)	-0.43	-0.07	0.92	ari+div	div	Relapse, any
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lurasidone+lithium/divalproate	Relapse, any mood episode	"eSMD=0.51 [0.35, 0.65] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.55	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Network meta-analysis	Adults	Maintenance	placebo+lithium/divalproate	combo	0.51	0.08	III (Low)	Kishi T., 2021 (NMA)	-0.51	0.35	0.65	lur+lit/div	pbo+lit/div	Relapse, any
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	quetiapine+lithium/divalproate	Relapse, any mood episode	"eSMD=0.53 [0.43, 0.63] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.42	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Network meta-analysis	Adults	Maintenance	placebo+lithium/divalproate	combo	0.53	0.05	III (Low)	Kishi T., 2021 (NMA)	-0.53	0.43	0.63	que+lit/div	pbo+lit/div	Relapse, any
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	IPSRT	Relapse, any mood episode	"eSMD=-0.31 [-1.01, 0.39] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.76	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	24	Network meta-analysis	Mixed (Children-Adults)	Maintenance	supportive therapy	aug	-0.31	0.36	III (Low)	Miklowitz D.J., 2020 (NMA)	0.31	-1.01	0.39	IPSRT	supp	Relapse, any
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	CBT	Relapse, any mood episode	"eSMD=-0.01 [-0.28, 0.27] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=177.25	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	24	Network meta-analysis	Mixed (Children-Adults)	Maintenance	psychoeducation	aug	-0.01	0.14	III (Low)	Miklowitz D.J., 2020 (NMA)	0.01	-0.28	0.27	CBT	PE	Relapse, any
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	family/conjoint therapy	Relapse, any mood episode	"eSMD=0.08 [-0.25, 0.41] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=22.17	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	24	Network meta-analysis	Mixed (Children-Adults)	Maintenance	psychoeducation brief	aug	0.08	0.17	III (Low)	Miklowitz D.J., 2020 (NMA)	-0.08	-0.25	0.41	family/conjoint	PE brief	Relapse, any
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	CBT	Relapse, any mood episode	"eSMD=0.28 [-0.1, 0.66] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.37	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	24	Network meta-analysis	Mixed (Children-Adults)	Maintenance	supportive therapy	aug	0.28	0.19	III (Low)	Miklowitz D.J., 2020 (NMA)	-0.28	-0.1	0.66	CBT	supp	Relapse, any
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	psychoeducation	Relapse, any mood episode	"eSMD=0.29 [-0.03, 0.61] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.15	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	24	Network meta-analysis	Mixed (Children-Adults)	Maintenance	supportive therapy	aug	0.29	0.16	III (Low)	Miklowitz D.J., 2020 (NMA)	-0.29	-0.03	0.61	PE	supp	Relapse, any
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	family/conjoint therapy	Relapse, any mood episode	"eSMD=0.3 [-0.08, 0.68] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.95	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	24	Network meta-analysis	Mixed (Children-Adults)	Maintenance	psychoeducation	aug	0.3	0.19	III (Low)	Miklowitz D.J., 2020 (NMA)	-0.3	-0.08	0.68	family/conjoint	PE	Relapse, any
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	CBT	Relapse, any mood episode	"eSMD=0.36 [0.13, 0.59] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.98	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	24	Network meta-analysis	Mixed (Children-Adults)	Maintenance	TAU	N/A	0.36	0.12	II (Moderate)	Miklowitz D.J., 2020 (NMA)	-0.36	0.13	0.59	CBT	tau	Relapse, any
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	psychoeducation	Relapse, any mood episode	"eSMD=0.36 [0.1, 0.63] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.98	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	24	Network meta-analysis	Mixed (Children-Adults)	Maintenance	TAU	N/A	0.36	0.14	II (Moderate)	Miklowitz D.J., 2020 (NMA)	-0.36	0.1	0.63	PE	tau	Relapse, any
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	psychoeducation brief	Relapse, any mood episode	"eSMD=0.59 [0.17, 1.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive17.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.09	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	24	Network meta-analysis	Mixed (Children-Adults)	Maintenance	TAU	N/A	0.59	0.21	II (Moderate)	Miklowitz D.J., 2020 (NMA)	-0.59	0.17	1.01	PE brief	tau	Relapse, any
"<a href='https://doi.org/' target=""_blank"">Miklowitz D.J., 2020 (NMA)</a>"	family/conjoint therapy	Relapse, any mood episode	"eSMD=0.66 [0.35, 0.98] <br> <img src=""https://www.linkpicture.com/q/Diapositive18.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.78	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	24	Network meta-analysis	Mixed (Children-Adults)	Maintenance	TAU	N/A	0.66	0.16	II (Moderate)	Miklowitz D.J., 2020 (NMA)	-0.66	0.35	0.98	family/conjoint	tau	Relapse, any
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	lithium+imipramine	Relapse, any mood episode	"eSMD=0.26 [0.02, 0.51] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.86	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Maintenance	placebo	mono	0.26	0.12	III (Low)	Miura T., 2014 (NMA)	-0.26	0.02	0.51	lit+imp	pbo	Relapse, any
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	imipramine	Relapse, any mood episode	"eSMD=0.03 [-0.17, 0.23] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=59.09	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Maintenance	placebo	mono	0.03	0.1	IV (Very Low)	Miura T., 2014 (NMA)	-0.03	-0.17	0.23	imp	pbo	Relapse, any
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	imipramine	Relapse, any mood episode	"eSMD=-0.24 [-0.43, -0.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.42	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Maintenance	lithium	mono	-0.24	0.1	III (Low)	Miura T., 2014 (NMA)	0.24	-0.43	-0.05	imp	lit	Relapse, any
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	imipramine	Relapse, any mood episode	"eSMD=-0.23 [-0.47, 0] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.74	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Maintenance	lithium+imipramine	combo	-0.23	0.12	IV (Very Low)	Miura T., 2014 (NMA)	0.23	-0.47	0	imp	lit+imp	Relapse, any
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	carbamazepine	Relapse, any mood episode	"eSMD=-0.05 [-0.28, 0.18] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=35.46	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Maintenance	lithium	mono	-0.05	0.12	IV (Very Low)	Miura T., 2014 (NMA)	0.05	-0.28	0.18	cbz	lit	Relapse, any
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	lithium	Relapse, any mood episode	"eSMD=0 [-0.23, 0.23] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Maintenance	lithium+imipramine	combo	0	0.12	IV (Very Low)	Miura T., 2014 (NMA)	0	-0.23	0.23	lit	lit+imp	Relapse, any
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2016 (MA)</a>"	risperidone LAI	Relapse, any mood symptoms	"eSMD=0.26 [0.14, 0.37] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.86	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Maintenance	placebo	mono	0.26	0.06	I (High)	Kishi T., 2016 (MA)	-0.26	0.14	0.37	rispLAI	pbo	Relapse, any (symptoms)
"<a href='https://doi.org/' target=""_blank"">Bond K., 2015 (MA)</a>"	psychoeducation individual	Relapse, depressive episode	"eSMD=-0.15 [-0.45, 0.15] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=11.84	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Maintenance	TAU	N/A	-0.15	0.15	III (Low)	Bond K., 2015 (MA)	0.15	-0.45	0.15	PEind	tau	Relapse, depressive
"<a href='https://doi.org/' target=""_blank"">Bond K., 2015 (MA)</a>"	psychoeducation group	Relapse, depressive episode	"eSMD=0.4 [0.03, 0.79] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.49	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Pairwise meta-analysis	Adults	Maintenance	TAU	N/A	0.4	0.19	I (High)	Bond K., 2015 (MA)	-0.4	0.03	0.79	PEgroup	tau	Relapse, depressive
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2013 (MA)</a>"	divalproate	Relapse, depressive episode	"eSMD=-0.06 [-0.22, 0.1] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=29.55	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Low	4	Pairwise meta-analysis	Mixed (Children-Adults)	Maintenance	lithium	mono	-0.06	0.08	II (Moderate)	Cipriani A., 2013 (MA)	0.06	-0.22	0.1	div	lit	Relapse, depressive
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2019 (MA)</a>"	ramelteon	Relapse, depressive episode	"eSMD=0.22 [0.03, 0.4] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.09	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Maintenance	placebo	mono	0.22	0.09	II (Moderate)	Kishi T., 2019 (MA)	-0.22	0.03	0.4	ram	pbo	Relapse, depressive
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	asenapine	Relapse, depressive episode	"eSMD=0.53 [-0.04, 1.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.42	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	25	Network meta-analysis	Adults	Maintenance	placebo	mono	0.53	0.29	III (Low)	Kishi T., 2021 (NMA)	-0.53	-0.04	1.08	ase	pbo	Relapse, depressive
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole LAI	Relapse, depressive episode	"eSMD=-0.03 [-0.37, 0.31] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=59.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	25	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.03	0.17	III (Low)	Kishi T., 2021 (NMA)	0.03	-0.37	0.31	ariLAI	pbo	Relapse, depressive
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	cariprazine	Relapse, depressive episode	"eSMD=-0.68 [-1.47, 0.11] <br> <img src=""https://www.linkpicture.com/q/Diapositive3.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.71	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	25	Network meta-analysis	Adults	Maintenance	lithium	mono	-0.68	0.4	III (Low)	Kishi T., 2021 (NMA)	0.68	-1.47	0.11	car	lit	Relapse, depressive
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	ziprasidone+lithium/divalproate	Relapse, depressive episode	"eSMD=0.06 [-0.29, 0.42] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=29.55	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Network meta-analysis	Adults	Maintenance	placebo+lithium/divalproate	combo	0.06	0.18	IV (Very Low)	Kishi T., 2021 (NMA)	-0.06	-0.29	0.42	zip+lit/div	pbo+lit/div	Relapse, depressive
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole+lithium/divalproate	Relapse, depressive episode	"eSMD=0.14 [-0.19, 0.47] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=12.68	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Network meta-analysis	Adults	Maintenance	placebo+lithium/divalproate	combo	0.14	0.17	IV (Very Low)	Kishi T., 2021 (NMA)	-0.14	-0.19	0.47	ari+lit/div	pbo+lit/div	Relapse, depressive
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	quetiapine+lithium/divalproate	Relapse, depressive episode	"eSMD=0.53 [0.39, 0.68] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.42	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Network meta-analysis	Adults	Maintenance	placebo+lithium/divalproate	combo	0.53	0.07	III (Low)	Kishi T., 2021 (NMA)	-0.53	0.39	0.68	que+lit/div	pbo+lit/div	Relapse, depressive
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lurasidone+lithium/divalproate	Relapse, depressive episode	"eSMD=0.66 [0.47, 0.86] <br> <img src=""https://www.linkpicture.com/q/Diapositive18.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.78	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Network meta-analysis	Adults	Maintenance	placebo+lithium/divalproate	combo	0.66	0.1	III (Low)	Kishi T., 2021 (NMA)	-0.66	0.47	0.86	lur+lit/div	pbo+lit/div	Relapse, depressive
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	quetiapine	Relapse, depressive episode	"eSMD=0.4 [0.22, 0.59] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.49	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	26	Network meta-analysis	Adults	Maintenance	placebo	mono	0.4	0.09	II (Moderate)	Miura T., 2014 (NMA)	-0.4	0.22	0.59	que	pbo	Relapse, depressive
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	lithium+imipramine	Relapse, depressive episode	"eSMD=0.34 [-0.04, 0.72] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.26	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	26	Network meta-analysis	Adults	Maintenance	placebo	mono	0.34	0.19	IV (Very Low)	Miura T., 2014 (NMA)	-0.34	-0.04	0.72	lit+imp	pbo	Relapse, depressive
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	lamotrigine	Relapse, depressive episode	"eSMD=0.2 [0.03, 0.38] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.89	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	26	Network meta-analysis	Adults	Maintenance	placebo	mono	0.2	0.09	III (Low)	Miura T., 2014 (NMA)	-0.2	0.03	0.38	lam	pbo	Relapse, depressive
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	imipramine	Relapse, depressive episode	"eSMD=0.17 [-0.22, 0.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=10.45	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	26	Network meta-analysis	Adults	Maintenance	placebo	mono	0.17	0.2	IV (Very Low)	Miura T., 2014 (NMA)	-0.17	-0.22	0.55	imp	pbo	Relapse, depressive
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	lithium	Relapse, depressive episode	"eSMD=0.15 [0.04, 0.27] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=11.84	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	26	Network meta-analysis	Adults	Maintenance	placebo	mono	0.15	0.06	III (Low)	Miura T., 2014 (NMA)	-0.15	0.04	0.27	lit	pbo	Relapse, depressive
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	divalproate	Relapse, depressive episode	"eSMD=0.14 [-0.08, 0.38] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=12.68	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	26	Network meta-analysis	Adults	Maintenance	placebo	mono	0.14	0.12	IV (Very Low)	Miura T., 2014 (NMA)	-0.14	-0.08	0.38	div	pbo	Relapse, depressive
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	olanzapine	Relapse, depressive episode	"eSMD=0.12 [-0.06, 0.31] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=14.79	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	26	Network meta-analysis	Adults	Maintenance	placebo	mono	0.12	0.09	IV (Very Low)	Miura T., 2014 (NMA)	-0.12	-0.06	0.31	ola	pbo	Relapse, depressive
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	aripiprazole	Relapse, depressive episode	"eSMD=0.05 [-0.4, 0.51] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=35.46	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	26	Network meta-analysis	Adults	Maintenance	placebo	mono	0.05	0.23	IV (Very Low)	Miura T., 2014 (NMA)	-0.05	-0.4	0.51	ari	pbo	Relapse, depressive
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	paliperidone	Relapse, depressive episode	"eSMD=-0.15 [-0.48, 0.17] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=11.84	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	26	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.15	0.17	IV (Very Low)	Miura T., 2014 (NMA)	0.15	-0.48	0.17	pal	pbo	Relapse, depressive
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	risperidone LAI	Relapse, depressive episode	"eSMD=-0.15 [-0.4, 0.1] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=11.84	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	26	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.15	0.13	IV (Very Low)	Miura T., 2014 (NMA)	0.15	-0.4	0.1	rispLAI	pbo	Relapse, depressive
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	carbamazepine	Relapse, depressive episode	"eSMD=-0.68 [-1.47, 0.11] <br> <img src=""https://www.linkpicture.com/q/Diapositive3.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.71	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	26	Network meta-analysis	Adults	Maintenance	lithium	mono	-0.68	0.4	IV (Very Low)	Miura T., 2014 (NMA)	0.68	-1.47	0.11	cbz	lit	Relapse, depressive
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	lithium	Relapse, depressive episode	"eSMD=-0.55 [-1.22, 0.14] <br> <img src=""https://www.linkpicture.com/q/Diapositive4.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.3	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	26	Network meta-analysis	Adults	Maintenance	lithium+oxcarbazepine	combo	-0.55	0.35	IV (Very Low)	Miura T., 2014 (NMA)	0.55	-1.22	0.14	lit	lit+oxc	Relapse, depressive
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	lithium	Relapse, depressive episode	"eSMD=-0.25 [-1.12, -0.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.13	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	26	Network meta-analysis	Adults	Maintenance	quetiapine	mono	-0.25	0.27	III (Low)	Miura T., 2014 (NMA)	0.25	-1.12	-0.05	lit	que	Relapse, depressive
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	lamotrigine	Relapse, depressive episode	"eSMD=-0.23 [-0.53, 0.07] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.74	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	26	Network meta-analysis	Adults	Maintenance	lamotrigine+divalproate	combo	-0.23	0.15	IV (Very Low)	Miura T., 2014 (NMA)	0.23	-0.53	0.07	lam	lam+div	Relapse, depressive
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	lithium	Relapse, depressive episode	"eSMD=-0.19 [-0.56, 0.19] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=9.36	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	26	Network meta-analysis	Adults	Maintenance	lithium+imipramine	combo	-0.19	0.19	IV (Very Low)	Miura T., 2014 (NMA)	0.19	-0.56	0.19	lit	lit+imp	Relapse, depressive
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	imipramine	Relapse, depressive episode	"eSMD=-0.17 [-0.61, 0.26] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=10.45	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	26	Network meta-analysis	Adults	Maintenance	lithium+imipramine	combo	-0.17	0.22	IV (Very Low)	Miura T., 2014 (NMA)	0.17	-0.61	0.26	imp	lit+imp	Relapse, depressive
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	divalproate	Relapse, depressive episode	"eSMD=-0.06 [-0.31, 0.09] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=29.55	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	26	Network meta-analysis	Adults	Maintenance	lithium+divalproate	combo	-0.06	0.1	IV (Very Low)	Miura T., 2014 (NMA)	0.06	-0.31	0.09	div	lit+div	Relapse, depressive
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	lithium	Relapse, depressive episode	"eSMD=-0.05 [-0.32, 0.22] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=35.46	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	26	Network meta-analysis	Adults	Maintenance	lithium+divalproate	combo	-0.05	0.14	IV (Very Low)	Miura T., 2014 (NMA)	0.05	-0.32	0.22	lit	lit+div	Relapse, depressive
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	divalproate	Relapse, depressive episode	"eSMD=-0.02 [-0.21, 0.2] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=88.63	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	26	Network meta-analysis	Adults	Maintenance	lithium	mono	-0.02	0.1	IV (Very Low)	Miura T., 2014 (NMA)	0.02	-0.21	0.2	div	lit	Relapse, depressive
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	imipramine	Relapse, depressive episode	"eSMD=0.02 [-0.36, 0.39] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=88.63	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	26	Network meta-analysis	Adults	Maintenance	lithium	mono	0.02	0.19	IV (Very Low)	Miura T., 2014 (NMA)	-0.02	-0.36	0.39	imp	lit	Relapse, depressive
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	lithium	Relapse, depressive episode	"eSMD=0.03 [-0.17, 0.23] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=59.09	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	26	Network meta-analysis	Adults	Maintenance	olanzapine	mono	0.03	0.1	IV (Very Low)	Miura T., 2014 (NMA)	-0.03	-0.17	0.23	lit	ola	Relapse, depressive
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	lamotrigine	Relapse, depressive episode	"eSMD=0.05 [-0.14, 0.25] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=35.46	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	26	Network meta-analysis	Adults	Maintenance	lithium	mono	0.05	0.1	IV (Very Low)	Miura T., 2014 (NMA)	-0.05	-0.14	0.25	lam	lit	Relapse, depressive
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	aripiprazole+lamotrigine	Relapse, depressive episode	"eSMD=0.12 [-0.23, 0.47] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=14.79	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	26	Network meta-analysis	Adults	Maintenance	lamotrigine	mono	0.12	0.18	IV (Very Low)	Miura T., 2014 (NMA)	-0.12	-0.23	0.47	ari+lam	lam	Relapse, depressive
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	fluoxetine	Relapse, depressive episode	"eSMD=0.27 [-0.05, 0.59] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.6	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	26	Network meta-analysis	Adults	Maintenance	lithium	mono	0.27	0.16	IV (Very Low)	Miura T., 2014 (NMA)	-0.27	-0.05	0.59	fluo	lit	Relapse, depressive
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	olanzapine	Relapse, depressive episode	"eSMD=0.27 [-0.02, 0.56] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.6	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	26	Network meta-analysis	Adults	Maintenance	risperidone LAI	mono	0.27	0.15	IV (Very Low)	Miura T., 2014 (NMA)	-0.27	-0.02	0.56	ola	rispLAI	Relapse, depressive
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	fluoxetine	Relapse, depressive episode	"eSMD=0.42 [0.11, 0.62] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.28	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	26	Network meta-analysis	Adults	Maintenance	placebo	mono	0.42	0.13	II (Moderate)	Miura T., 2014 (NMA)	-0.42	0.11	0.62	fluo	pbo	Relapse, depressive
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	aripiprazole+divalproate	Relapse, depressive episode	"eSMD=0.61 [-0.07, 1.33] <br> <img src=""https://www.linkpicture.com/q/Diapositive17.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	26	Network meta-analysis	Adults	Maintenance	divalproate	mono	0.61	0.36	IV (Very Low)	Miura T., 2014 (NMA)	-0.61	-0.07	1.33	ari+div	div	Relapse, depressive
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2016 (MA)</a>"	risperidone LAI	Relapse, depressive symptoms	"eSMD=-0.1 [-0.33, 0.11] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=17.74	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Maintenance	placebo	mono	-0.1	0.11	II (Moderate)	Kishi T., 2016 (MA)	0.1	-0.33	0.11	rispLAI	pbo	Relapse, depressive (symptoms)
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2019 (MA)</a>"	ramelteon	Relapse, mixed episode	"eSMD=0.03 [-0.55, 0.59] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=59.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Maintenance	placebo	mono	0.03	0.29	III (Low)	Kishi T., 2019 (MA)	-0.03	-0.55	0.59	ram	pbo	Relapse, mixed
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	ziprasidone	Remission	"eSMD=-0.16 [-0.55, 0.23] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=11.1	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	-0.16	0.2	III (Low)	Bahji A., 2020 (NMA)	0.16	-0.55	0.23	zip	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	aripiprazole	Remission	"eSMD=-0.1 [-0.39, 0.19] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=17.74	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	-0.1	0.15	III (Low)	Bahji A., 2020 (NMA)	0.1	-0.39	0.19	ari	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	carbamazepine	Remission	"eSMD=-0.06 [-0.81, 0.69] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=29.55	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	-0.06	0.38	III (Low)	Bahji A., 2020 (NMA)	0.06	-0.81	0.69	cbz	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	gabapentin	Remission	"eSMD=0.02 [-0.83, 0.88] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=88.63	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.02	0.44	III (Low)	Bahji A., 2020 (NMA)	-0.02	-0.83	0.88	gaba	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	paroxetine	Remission	"eSMD=0.09 [-0.28, 0.46] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=19.71	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.09	0.19	III (Low)	Bahji A., 2020 (NMA)	-0.09	-0.28	0.46	par	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	lithium	Remission	"eSMD=0.13 [-0.24, 0.5] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=13.65	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.13	0.19	III (Low)	Bahji A., 2020 (NMA)	-0.13	-0.24	0.5	lit	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	phenelzine	Remission	"eSMD=0.19 [-0.49, 0.88] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=9.36	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.19	0.35	III (Low)	Bahji A., 2020 (NMA)	-0.19	-0.49	0.88	phen	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	lamotrigine	Remission	"eSMD=0.24 [0.04, 0.44] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.42	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.24	0.1	II (Moderate)	Bahji A., 2020 (NMA)	-0.24	0.04	0.44	lam	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	cariprazine	Remission	"eSMD=0.27 [-0.02, 0.56] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.6	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.27	0.15	III (Low)	Bahji A., 2020 (NMA)	-0.27	-0.02	0.56	car	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	olanzapine	Remission	"eSMD=0.28 [0.04, 0.52] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.37	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.28	0.12	II (Moderate)	Bahji A., 2020 (NMA)	-0.28	0.04	0.52	ola	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	lurasidone	Remission	"eSMD=0.32 [0.02, 0.61] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.59	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.32	0.15	II (Moderate)	Bahji A., 2020 (NMA)	-0.32	0.02	0.61	lur	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	quetiapine	Remission	"eSMD=0.36 [0.22, 0.5] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.98	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.36	0.07	III (Low)	Bahji A., 2020 (NMA)	-0.36	0.22	0.5	que	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	divalproate	Remission	"eSMD=0.42 [-0.11, 0.95] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.28	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.42	0.27	III (Low)	Bahji A., 2020 (NMA)	-0.42	-0.11	0.95	div	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	imipramine	Remission	"eSMD=0.44 [-0.07, 0.95] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.44	0.26	III (Low)	Bahji A., 2020 (NMA)	-0.44	-0.07	0.95	imp	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	olanzapine+fluoxetine	Remission	"eSMD=0.46 [0.22, 0.7] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.92	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.46	0.12	II (Moderate)	Bahji A., 2020 (NMA)	-0.46	0.22	0.7	ola+fluo	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	escitalopram	Remission	"eSMD=0.49 [-1.39, 2.42] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.69	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.49	0.97	III (Low)	Bahji A., 2020 (NMA)	-0.49	-1.39	2.42	escit	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	fluoxetine	Remission	"eSMD=0.92 [0.35, 1.5] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.06	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.92	0.29	I (High)	Bahji A., 2020 (NMA)	-0.92	0.35	1.5	fluo	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	fluoxetine	Remission	"eSMD=0.53 [-0.95, 1.93] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.42	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	olanzapine	mono	0.53	0.73	III (Low)	Bahji A., 2020 (NMA)	-0.53	-0.95	1.93	fluo	ola	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	fluoxetine	Remission	"eSMD=0.47 [-1.01, 1.93] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.84	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	olanzapine+fluoxetine	combo	0.47	0.75	III (Low)	Bahji A., 2020 (NMA)	-0.47	-1.01	1.93	fluo	ola+fluo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	fluoxetine	Remission	"eSMD=0.45 [-0.21, 1.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.01	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	imipramine	mono	0.45	0.33	III (Low)	Bahji A., 2020 (NMA)	-0.45	-0.21	1.08	fluo	imp	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	imipramine	Remission	"eSMD=0.17 [-0.55, 0.89] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=10.45	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	phenelzine	mono	0.17	0.37	III (Low)	Bahji A., 2020 (NMA)	-0.17	-0.55	0.89	imp	phen	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	lamotrigine	Remission	"eSMD=-0.16 [-0.55, 0.23] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=11.1	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	olanzapine+fluoxetine	combo	-0.16	0.2	III (Low)	Bahji A., 2020 (NMA)	0.16	-0.55	0.23	lam	ola+fluo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	paroxetine	Remission	"eSMD=-0.23 [-0.63, 0.17] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.74	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	quetiapine	mono	-0.23	0.2	III (Low)	Bahji A., 2020 (NMA)	0.23	-0.63	0.17	par	que	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	lithium	Remission	"eSMD=-0.24 [-0.63, 0.16] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.42	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	quetiapine	mono	-0.24	0.2	III (Low)	Bahji A., 2020 (NMA)	0.24	-0.63	0.16	lit	que	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	imipramine	Remission	"eSMD=-0.28 [-1.27, 0.68] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.37	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	moclobemide	mono	-0.28	0.5	III (Low)	Bahji A., 2020 (NMA)	0.28	-1.27	0.68	imp	moc	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	gabapentin	Remission	"eSMD=-0.33 [-1.27, 0.58] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.42	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	lamotrigine	mono	-0.33	0.47	III (Low)	Bahji A., 2020 (NMA)	0.33	-1.27	0.58	gaba	lam	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	olanzapine	Remission	"eSMD=-0.34 [-0.74, 0.06] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.26	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	olanzapine+fluoxetine	combo	-0.34	0.2	III (Low)	Bahji A., 2020 (NMA)	0.34	-0.74	0.06	ola	ola+fluo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	lithium	Remission	"eSMD=-0.36 [-0.95, 0.24] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.98	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	sertraline	mono	-0.36	0.3	III (Low)	Bahji A., 2020 (NMA)	0.36	-0.95	0.24	lit	sert	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	lithium	Remission	"eSMD=-0.79 [-1.33, -0.21] <br> <img src=""https://www.linkpicture.com/q/Diapositive2.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.36	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	venlafaxine	mono	-0.79	0.29	II (Moderate)	Bahji A., 2020 (NMA)	0.79	-1.33	-0.21	lit	ven	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	imipramine	Remission	"eSMD=-1.17 [-1.93, -0.37] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1.69	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	tranylcypromine	mono	-1.17	0.4	I (High)	Bahji A., 2020 (NMA)	1.17	-1.93	-0.37	imp	tran	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	levetiracetam	Remission	"eSMD=-0.83 [-2.16, 0.38] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.26	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.83	0.65	III (Low)	Bahji A., 2021 (NMA)	0.83	-2.16	0.38	levt	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	minocycline	Remission	"eSMD=-0.63 [-1.77, 0.57] <br> <img src=""https://www.linkpicture.com/q/Diapositive3.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.91	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.63	0.6	III (Low)	Bahji A., 2021 (NMA)	0.63	-1.77	0.57	mino	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	n-acetyl cysteine	Remission	"eSMD=-0.1 [-0.42, 0.23] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=17.74	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.1	0.17	III (Low)	Bahji A., 2021 (NMA)	0.1	-0.42	0.23	nac	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	paroxetine+bupropion	Remission	"eSMD=-0.08 [-0.52, 0.35] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=22.17	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.08	0.22	III (Low)	Bahji A., 2021 (NMA)	0.08	-0.52	0.35	par+bup	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	ziprasidone	Remission	"eSMD=-0.07 [-0.55, 0.4] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=25.33	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.07	0.24	III (Low)	Bahji A., 2021 (NMA)	0.07	-0.55	0.4	zip	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	sAME	Remission	"eSMD=-0.06 [-1.55, 1.39] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=29.55	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.06	0.75	III (Low)	Bahji A., 2021 (NMA)	0.06	-1.55	1.39	sAME	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	agomelatin	Remission	"eSMD=0 [-0.4, 0.4] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0	0.2	III (Low)	Bahji A., 2021 (NMA)	0	-0.4	0.4	ago	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	pioglitazone	Remission	"eSMD=0 [-0.72, 0.74] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0	0.37	III (Low)	Bahji A., 2021 (NMA)	0	-0.72	0.74	pio	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	quetiapine	Remission	"eSMD=0 [-0.7, 0.7] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0	0.36	III (Low)	Bahji A., 2021 (NMA)	0	-0.7	0.7	que	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	pregnenolone	Remission	"eSMD=0.01 [-0.44, 0.45] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=177.25	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.01	0.23	III (Low)	Bahji A., 2021 (NMA)	-0.01	-0.44	0.45	preg	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	vitD3	Remission	"eSMD=0.03 [-0.47, 0.53] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=59.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.03	0.26	III (Low)	Bahji A., 2021 (NMA)	-0.03	-0.47	0.53	vitD3	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	aripiprazole	Remission	"eSMD=0.05 [-0.53, 0.63] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=35.46	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.05	0.3	III (Low)	Bahji A., 2021 (NMA)	-0.05	-0.53	0.63	ari	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	dextromethorphan	Remission	"eSMD=0.08 [-0.34, 0.49] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=22.17	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.08	0.21	III (Low)	Bahji A., 2021 (NMA)	-0.08	-0.34	0.49	dexm	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	citalopram	Remission	"eSMD=0.08 [-0.42, 0.58] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=22.17	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.08	0.26	III (Low)	Bahji A., 2021 (NMA)	-0.08	-0.42	0.58	cit	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	n-acetyl cysteine+acetylsalicylic acid	Remission	"eSMD=0.08 [-0.7, 0.86] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=22.17	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.08	0.4	III (Low)	Bahji A., 2021 (NMA)	-0.08	-0.7	0.86	nac+asa	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	paroxetine	Remission	"eSMD=0.14 [-0.36, 0.65] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=12.68	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.14	0.26	III (Low)	Bahji A., 2021 (NMA)	-0.14	-0.36	0.65	par	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	lurasidone	Remission	"eSMD=0.15 [-0.15, 0.45] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=11.84	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.15	0.15	III (Low)	Bahji A., 2021 (NMA)	-0.15	-0.15	0.45	lur	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	t4 hormone	Remission	"eSMD=0.16 [-0.39, 0.7] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=11.1	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.16	0.28	III (Low)	Bahji A., 2021 (NMA)	-0.16	-0.39	0.7	t4	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	armodafinil	Remission	"eSMD=0.17 [-0.05, 0.37] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=10.45	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.17	0.11	III (Low)	Bahji A., 2021 (NMA)	-0.17	-0.05	0.37	armo	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	inositol	Remission	"eSMD=0.18 [-0.52, 0.89] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=9.87	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.18	0.36	III (Low)	Bahji A., 2021 (NMA)	-0.18	-0.52	0.89	ino	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	bupropion	Remission	"eSMD=0.19 [-1.27, 1.65] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=9.36	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.19	0.74	III (Low)	Bahji A., 2021 (NMA)	-0.19	-1.27	1.65	bup	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	acetylsalicylic acid	Remission	"eSMD=0.2 [-0.38, 0.79] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.89	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.2	0.3	III (Low)	Bahji A., 2021 (NMA)	-0.2	-0.38	0.79	asa	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	omega3	Remission	"eSMD=0.23 [-0.29, 0.74] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.74	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.23	0.26	III (Low)	Bahji A., 2021 (NMA)	-0.23	-0.29	0.74	omega3	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	imipramine	Remission	"eSMD=0.24 [-0.16, 0.63] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.42	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.24	0.2	III (Low)	Bahji A., 2021 (NMA)	-0.24	-0.16	0.63	imp	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	minocycline+acetylsalicylic acid	Remission	"eSMD=0.24 [-0.44, 0.92] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.42	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.24	0.35	III (Low)	Bahji A., 2021 (NMA)	-0.24	-0.44	0.92	mino+asa	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	memantine	Remission	"eSMD=0.25 [-0.25, 0.74] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.13	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.25	0.25	III (Low)	Bahji A., 2021 (NMA)	-0.25	-0.25	0.74	mem	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	fluoxetine	Remission	"eSMD=0.29 [0.03, 0.56] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.15	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.29	0.14	II (Moderate)	Bahji A., 2021 (NMA)	-0.29	0.03	0.56	fluo	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	lisdexamfetamine	Remission	"eSMD=0.36 [-0.32, 1.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.98	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.36	0.34	III (Low)	Bahji A., 2021 (NMA)	-0.36	-0.32	1.01	lisdex	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	t3 hormone	Remission	"eSMD=0.36 [-0.42, 1.12] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.98	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.36	0.39	III (Low)	Bahji A., 2021 (NMA)	-0.36	-0.42	1.12	t3	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	lamotrigine	Remission	"eSMD=0.37 [-0.02, 0.76] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.85	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.37	0.2	III (Low)	Bahji A., 2021 (NMA)	-0.37	-0.02	0.76	lam	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	pindolol	Remission	"eSMD=0.39 [-0.12, 0.89] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.6	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.39	0.26	III (Low)	Bahji A., 2021 (NMA)	-0.39	-0.12	0.89	pin	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	infliximab	Remission	"eSMD=0.45 [-0.1, 1.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.01	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.45	0.28	III (Low)	Bahji A., 2021 (NMA)	-0.45	-0.1	1.01	infx	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	creatine	Remission	"eSMD=0.51 [-0.34, 1.33] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.55	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.51	0.43	III (Low)	Bahji A., 2021 (NMA)	-0.51	-0.34	1.33	creatine	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	coenzyme Q10	Remission	"eSMD=0.56 [-0.72, 1.77] <br> <img src=""https://www.linkpicture.com/q/Diapositive17.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.25	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.56	0.64	III (Low)	Bahji A., 2021 (NMA)	-0.56	-0.72	1.77	coQ10	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	pramipexole	Remission	"eSMD=0.58 [-0.3, 1.47] <br> <img src=""https://www.linkpicture.com/q/Diapositive17.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.14	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.58	0.45	III (Low)	Bahji A., 2021 (NMA)	-0.58	-0.3	1.47	pram	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	celecoxib	Remission	"eSMD=0.66 [0.19, 1.12] <br> <img src=""https://www.linkpicture.com/q/Diapositive18.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.78	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.66	0.24	II (Moderate)	Bahji A., 2021 (NMA)	-0.66	0.19	1.12	cel	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	ketamine	Remission	"eSMD=0.89 [0.03, 1.77] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.12	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.89	0.44	I (High)	Bahji A., 2021 (NMA)	-0.89	0.03	1.77	ket	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	acetylsalicylic acid	Remission	"eSMD=0.98 [-0.2, 2.16] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.95	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	minocycline	aug	0.98	0.6	III (Low)	Bahji A., 2021 (NMA)	-0.98	-0.2	2.16	asa	mino	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	lamotrigine	Remission	"eSMD=0.89 [-0.32, 2.16] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.12	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	risperidone	aug	0.89	0.63	III (Low)	Bahji A., 2021 (NMA)	-0.89	-0.32	2.16	lam	risp	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	inositol	Remission	"eSMD=0.72 [-0.52, 1.93] <br> <img src=""https://www.linkpicture.com/q/Diapositive19.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.57	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	risperidone	aug	0.72	0.63	III (Low)	Bahji A., 2021 (NMA)	-0.72	-0.52	1.93	ino	risp	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	citalopram	Remission	"eSMD=0.38 [-0.33, 1.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.72	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	lamotrigine	aug	0.38	0.36	III (Low)	Bahji A., 2021 (NMA)	-0.38	-0.33	1.08	cit	lam	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	paroxetine	Remission	"eSMD=0.38 [-0.92, 1.65] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.72	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	risperidone	aug	0.38	0.66	III (Low)	Bahji A., 2021 (NMA)	-0.38	-0.92	1.65	par	risp	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	imipramine	Remission	"eSMD=0.32 [-0.19, 0.84] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.59	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	moclobemide	aug	0.32	0.26	III (Low)	Bahji A., 2021 (NMA)	-0.32	-0.19	0.84	imp	moc	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	bupropion	Remission	"eSMD=0.23 [-0.27, 0.72] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.74	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	venlafaxine	aug	0.23	0.25	III (Low)	Bahji A., 2021 (NMA)	-0.23	-0.27	0.72	bup	ven	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	fluoxetine	Remission	"eSMD=0.22 [-0.26, 0.7] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	imipramine	aug	0.22	0.24	III (Low)	Bahji A., 2021 (NMA)	-0.22	-0.26	0.7	fluo	imp	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	sertraline	Remission	"eSMD=0.19 [-0.31, 0.68] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=9.36	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	venlafaxine	aug	0.19	0.25	III (Low)	Bahji A., 2021 (NMA)	-0.19	-0.31	0.68	sert	ven	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	bupropion	Remission	"eSMD=0.12 [-0.61, 0.86] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=14.79	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	topiramate	aug	0.12	0.38	III (Low)	Bahji A., 2021 (NMA)	-0.12	-0.61	0.86	bup	top	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	acetylsalicylic acid	Remission	"eSMD=0.11 [-0.52, 0.74] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=16.13	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	minocycline+acetylsalicylic acid	aug	0.11	0.32	III (Low)	Bahji A., 2021 (NMA)	-0.11	-0.52	0.74	asa	mino+asa	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	fluoxetine	Remission	"eSMD=0.08 [-0.33, 0.48] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=22.17	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	lamotrigine	aug	0.08	0.21	III (Low)	Bahji A., 2021 (NMA)	-0.08	-0.33	0.48	fluo	lam	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	n-acetyl cysteine	Remission	"eSMD=0.06 [-0.74, 0.88] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=29.55	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	n-acetyl cysteine+acetylsalicylic acid	aug	0.06	0.41	III (Low)	Bahji A., 2021 (NMA)	-0.06	-0.74	0.88	nac	nac+asa	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	bupropion	Remission	"eSMD=0.04 [-0.44, 0.52] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=44.32	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	sertraline	aug	0.04	0.24	III (Low)	Bahji A., 2021 (NMA)	-0.04	-0.44	0.52	bup	sert	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	paroxetine	Remission	"eSMD=0 [-0.58, 0.58] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	venlafaxine	aug	0	0.3	III (Low)	Bahji A., 2021 (NMA)	0	-0.58	0.58	par	ven	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	lithium	Remission	"eSMD=-0.02 [-0.63, 0.59] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=88.63	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	paroxetine	aug	-0.02	0.31	III (Low)	Bahji A., 2021 (NMA)	0.02	-0.63	0.59	lit	par	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	imipramine	Remission	"eSMD=-0.05 [-0.55, 0.44] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=35.46	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	paroxetine	aug	-0.05	0.25	III (Low)	Bahji A., 2021 (NMA)	0.05	-0.55	0.44	imp	par	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	bupropion	Remission	"eSMD=-0.07 [-0.63, 0.48] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=25.33	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	desipramine	aug	-0.07	0.28	III (Low)	Bahji A., 2021 (NMA)	0.07	-0.63	0.48	bup	desimp	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	amitriptyline	Remission	"eSMD=-0.14 [-0.68, 0.4] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=12.68	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	l-sulpride	aug	-0.14	0.28	III (Low)	Bahji A., 2021 (NMA)	0.14	-0.68	0.4	amit	l-sulpr	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	inositol	Remission	"eSMD=-0.17 [-0.92, 0.58] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=10.45	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	lamotrigine	aug	-0.17	0.38	III (Low)	Bahji A., 2021 (NMA)	0.17	-0.92	0.58	ino	lam	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	paroxetine	Remission	"eSMD=-0.22 [-1.17, 0.72] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=8.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	risperidone+paroxetine	aug	-0.22	0.48	III (Low)	Bahji A., 2021 (NMA)	0.22	-1.17	0.72	par	risp+par	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	acetylsalicylic acid	Remission	"eSMD=-0.28 [-1.47, 0.89] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.37	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	n-acetyl cysteine+acetylsalicylic acid	aug	-0.28	0.6	III (Low)	Bahji A., 2021 (NMA)	0.28	-1.47	0.89	asa	nac+asa	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	lamotrigine	Remission	"eSMD=-0.33 [-1.08, 0.43] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.42	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	tranylcypromine	aug	-0.33	0.39	III (Low)	Bahji A., 2021 (NMA)	0.33	-1.08	0.43	lam	tran	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	acetylsalicylic acid	Remission	"eSMD=-0.35 [-1.47, 0.81] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.12	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	n-acetyl cysteine	aug	-0.35	0.58	III (Low)	Bahji A., 2021 (NMA)	0.35	-1.47	0.81	asa	nac	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	amitriptyline	Remission	"eSMD=-0.36 [-0.92, 0.19] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.98	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	paroxetine	aug	-0.36	0.28	III (Low)	Bahji A., 2021 (NMA)	0.36	-0.92	0.19	amit	par	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	risperidone	Remission	"eSMD=-0.61 [-1.77, 0.61] <br> <img src=""https://www.linkpicture.com/q/Diapositive4.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	risperidone+paroxetine	aug	-0.61	0.61	III (Low)	Bahji A., 2021 (NMA)	0.61	-1.77	0.61	risp	risp+par	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	minocycline	Remission	"eSMD=-0.89 [-2.16, 0.29] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.12	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	minocycline+acetylsalicylic acid	aug	-0.89	0.63	III (Low)	Bahji A., 2021 (NMA)	0.89	-2.16	0.29	mino	mino+asa	Remission
"<a href='https://doi.org/' target=""_blank"">Bartoli F., 2017 (MA)</a>"	allopurinol	Remission	"eSMD=0.23 [0.1, 0.35] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.74	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	aug	0.23	0.06	III (Low)	Bartoli F., 2017 (MA)	-0.23	0.1	0.35	allopur	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	ziprasidone	Remission	"eSMD=-0.1 [-1.93, 1.78] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=17.74	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.1	0.95	II (Moderate)	Kishi T., 2021 (NMA)	0.1	-1.93	1.78	zip	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	eslicarbazepine	Remission	"eSMD=0.04 [-0.17, 0.26] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=44.32	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.04	0.11	II (Moderate)	Kishi T., 2021 (NMA)	-0.04	-0.17	0.26	eslicbz	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Remission	"eSMD=0.12 [-0.01, 0.26] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=14.79	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.12	0.07	II (Moderate)	Kishi T., 2021 (NMA)	-0.12	-0.01	0.26	div	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Remission	"eSMD=0.13 [0.01, 0.25] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=13.65	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.13	0.06	I (High)	Kishi T., 2021 (NMA)	-0.13	0.01	0.25	lit	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	asenapine	Remission	"eSMD=0.16 [0.03, 0.29] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=11.1	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.16	0.07	I (High)	Kishi T., 2021 (NMA)	-0.16	0.03	0.29	ase	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Remission	"eSMD=0.18 [0.03, 0.33] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=9.87	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.18	0.08	I (High)	Kishi T., 2021 (NMA)	-0.18	0.03	0.33	pal	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Remission	"eSMD=0.2 [0.06, 0.33] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.89	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.2	0.07	I (High)	Kishi T., 2021 (NMA)	-0.2	0.06	0.33	ari	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Remission	"eSMD=0.21 [0.1, 0.33] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.47	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.21	0.06	I (High)	Kishi T., 2021 (NMA)	-0.21	0.1	0.33	hal	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	quetiapine	Remission	"eSMD=0.22 [0.11, 0.33] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.09	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.22	0.06	I (High)	Kishi T., 2021 (NMA)	-0.22	0.11	0.33	que	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Remission	"eSMD=0.24 [0.15, 0.32] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.42	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.24	0.04	I (High)	Kishi T., 2021 (NMA)	-0.24	0.15	0.32	ola	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	cariprazine	Remission	"eSMD=0.25 [0.11, 0.39] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.13	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.25	0.07	I (High)	Kishi T., 2021 (NMA)	-0.25	0.11	0.39	car	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	risperidone	Remission	"eSMD=0.3 [0.13, 0.46] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.95	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.3	0.08	I (High)	Kishi T., 2021 (NMA)	-0.3	0.13	0.46	risp	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	tamoxifen	Remission	"eSMD=1.18 [0.06, 2.29] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.68	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	1.18	0.57	I (High)	Kishi T., 2021 (NMA)	-1.18	0.06	2.29	tamox	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Remission	"eSMD=0.31 [-1.55, 2.18] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.76	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	ziprasidone	mono	0.31	0.95	II (Moderate)	Kishi T., 2021 (NMA)	-0.31	-1.55	2.18	hal	zip	Remission
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Remission	"eSMD=0.07 [-0.09, 0.23] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=25.33	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	0.07	0.08	II (Moderate)	Kishi T., 2021 (NMA)	-0.07	-0.09	0.23	ari	lit	Remission
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Remission	"eSMD=0.06 [-0.14, 0.27] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=29.55	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	oxcarbazepine	mono	0.06	0.1	II (Moderate)	Kishi T., 2021 (NMA)	-0.06	-0.14	0.27	div	oxc	Remission
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Remission	"eSMD=-0.02 [-0.15, 0.12] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=88.63	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	haloperidol	mono	-0.02	0.07	II (Moderate)	Kishi T., 2021 (NMA)	0.02	-0.15	0.12	ari	hal	Remission
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Remission	"eSMD=-0.02 [-0.16, 0.14] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=88.63	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	-0.02	0.08	II (Moderate)	Kishi T., 2021 (NMA)	0.02	-0.16	0.14	hal	que	Remission
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Remission	"eSMD=-0.03 [-0.14, 0.1] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=59.09	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.03	0.06	II (Moderate)	Kishi T., 2021 (NMA)	0.03	-0.14	0.1	hal	ola	Remission
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Remission	"eSMD=-0.04 [-0.2, 0.12] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=44.32	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	-0.04	0.08	II (Moderate)	Kishi T., 2021 (NMA)	0.04	-0.2	0.12	pal	que	Remission
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Remission	"eSMD=-0.06 [-0.23, 0.11] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=29.55	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	risperidone	mono	-0.06	0.09	II (Moderate)	Kishi T., 2021 (NMA)	0.06	-0.23	0.11	ola	risp	Remission
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	asenapine	Remission	"eSMD=-0.08 [-0.2, 0.06] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=22.17	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.08	0.07	II (Moderate)	Kishi T., 2021 (NMA)	0.08	-0.2	0.06	ase	ola	Remission
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Remission	"eSMD=-0.09 [-0.22, 0.04] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=19.71	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	-0.09	0.07	II (Moderate)	Kishi T., 2021 (NMA)	0.09	-0.22	0.04	lit	que	Remission
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Remission	"eSMD=-0.11 [-0.24, 0.02] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=16.13	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.11	0.07	II (Moderate)	Kishi T., 2021 (NMA)	0.11	-0.24	0.02	lit	ola	Remission
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Remission	"eSMD=-0.12 [-0.25, 0.02] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=14.79	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	31	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.12	0.07	II (Moderate)	Kishi T., 2021 (NMA)	0.12	-0.25	0.02	div	ola	Remission
"<a href='https://doi.org/' target=""_blank"">Lam R.W., 2020 (MA)</a>"	bright light therapy	Remission	"eSMD=0.64 [-0.1, 1.39] <br> <img src=""https://www.linkpicture.com/q/Diapositive18.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.86	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Pairwise meta-analysis	Adults	Bipolar Depression	TAU/sham	mono	0.64	0.38	IV (Very Low)	Lam R.W., 2020 (MA)	-0.64	-0.1	1.39	BLT	tau/sham	Remission
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	lithium	Remission	"eSMD=0.42 [0.3, 0.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.28	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Pairwise meta-analysis	Mixed (Children-Adults)	Mania/Mixed	placebo	mono	0.42	0.06	I (High)	McKnight R.F., 2019 (MA)	-0.42	0.3	0.55	lit	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	lithium	Remission	"eSMD=0.14 [-1.22, 1.49] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=12.68	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Mixed (Children-Adults)	Mania/Mixed	risperidone	mono	0.14	0.69	IV (Very Low)	McKnight R.F., 2019 (MA)	-0.14	-1.22	1.49	lit	risp	Remission
"<a href='https://doi.org/' target=""_blank"">Ostacher M., 2018 (NMA)</a>"	ziprasidone	Remission	"eSMD=0.02 [-0.17, 0.18] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=88.63	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	14	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.02	0.09	IV (Very Low)	Ostacher M., 2018 (NMA)	-0.02	-0.17	0.18	zip	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Ostacher M., 2018 (NMA)</a>"	olanzapine	Remission	"eSMD=0.2 [0.05, 0.35] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.89	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	14	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.2	0.08	IV (Very Low)	Ostacher M., 2018 (NMA)	-0.2	0.05	0.35	ola	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Ostacher M., 2018 (NMA)</a>"	quetiapine	Remission	"eSMD=0.38 [0.27, 0.48] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.72	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	14	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.38	0.05	IV (Very Low)	Ostacher M., 2018 (NMA)	-0.38	0.27	0.48	que	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Ostacher M., 2018 (NMA)</a>"	lurasidone	Remission	"eSMD=0.43 [0.17, 0.67] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.19	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	14	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.43	0.13	III (Low)	Ostacher M., 2018 (NMA)	-0.43	0.17	0.67	lur	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Suttajit S., 2014 (MA)</a>"	quetiapine	Remission	"eSMD=0.13 [-0.05, 0.31] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=13.65	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Children & Adolescents	Bipolar Depression	placebo	mono	0.13	0.09	II (Moderate)	Suttajit S., 2014 (MA)	-0.13	-0.05	0.31	que	pbo	Remission
"<a href='https://doi.org/' target=""_blank"">Tee M.M.K., 2020 (MA)</a>"	rTMS	Remission	"eSMD=-1.27 [-2.16, -0.92] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1.59	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	8	Pairwise meta-analysis	Adults	Bipolar Depression	sham	aug	-1.27	0.32	I (High)	Tee M.M.K., 2020 (MA)	1.27	-2.16	-0.92	rTMS	sham	Remission
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	ziprasidone	Response	"eSMD=-0.22 [-0.49, 0.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=8.09	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	-0.22	0.14	II (Moderate)	Bahji A., 2020 (NMA)	0.22	-0.49	0.05	zip	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	gabapentin	Response	"eSMD=-0.14 [-0.72, 0.44] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=12.68	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	-0.14	0.3	II (Moderate)	Bahji A., 2020 (NMA)	0.14	-0.72	0.44	gaba	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	aripiprazole	Response	"eSMD=0.06 [-0.1, 0.22] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=29.55	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.06	0.08	II (Moderate)	Bahji A., 2020 (NMA)	-0.06	-0.1	0.22	ari	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	paroxetine	Response	"eSMD=0.06 [-0.17, 0.29] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=29.55	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.06	0.12	II (Moderate)	Bahji A., 2020 (NMA)	-0.06	-0.17	0.29	par	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	lithium	Response	"eSMD=0.14 [-0.08, 0.36] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=12.68	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.14	0.11	II (Moderate)	Bahji A., 2020 (NMA)	-0.14	-0.08	0.36	lit	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	olanzapine	Response	"eSMD=0.22 [0.1, 0.34] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.09	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.22	0.06	I (High)	Bahji A., 2020 (NMA)	-0.22	0.1	0.34	ola	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	lamotrigine	Response	"eSMD=0.23 [0.11, 0.35] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.74	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.23	0.06	I (High)	Bahji A., 2020 (NMA)	-0.23	0.11	0.35	lam	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	cariprazine	Response	"eSMD=0.25 [0.1, 0.4] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.13	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.25	0.08	I (High)	Bahji A., 2020 (NMA)	-0.25	0.1	0.4	car	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	quetiapine	Response	"eSMD=0.35 [0.27, 0.43] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.12	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.35	0.04	I (High)	Bahji A., 2020 (NMA)	-0.35	0.27	0.43	que	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	carbamazepine	Response	"eSMD=0.38 [-0.15, 0.92] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.72	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.38	0.27	II (Moderate)	Bahji A., 2020 (NMA)	-0.38	-0.15	0.92	cbz	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	phenelzine	Response	"eSMD=0.47 [-0.12, 1.07] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.84	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.47	0.3	II (Moderate)	Bahji A., 2020 (NMA)	-0.47	-0.12	1.07	phen	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	lurasidone	Response	"eSMD=0.51 [0.35, 0.67] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.55	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.51	0.08	I (High)	Bahji A., 2020 (NMA)	-0.51	0.35	0.67	lur	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	olanzapine+fluoxetine	Response	"eSMD=0.52 [0.36, 0.68] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.49	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.52	0.08	I (High)	Bahji A., 2020 (NMA)	-0.52	0.36	0.68	ola+fluo	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	imipramine	Response	"eSMD=0.58 [0.15, 1.02] <br> <img src=""https://www.linkpicture.com/q/Diapositive17.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.14	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.58	0.22	I (High)	Bahji A., 2020 (NMA)	-0.58	0.15	1.02	imp	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	divalproate	Response	"eSMD=0.59 [0.16, 1.03] <br> <img src=""https://www.linkpicture.com/q/Diapositive17.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.09	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.59	0.22	I (High)	Bahji A., 2020 (NMA)	-0.59	0.16	1.03	div	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	escitalopram	Response	"eSMD=0.61 [-0.92, 2.13] <br> <img src=""https://www.linkpicture.com/q/Diapositive17.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.61	0.78	II (Moderate)	Bahji A., 2020 (NMA)	-0.61	-0.92	2.13	escit	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	fluoxetine	Response	"eSMD=0.73 [0.26, 1.21] <br> <img src=""https://www.linkpicture.com/q/Diapositive19.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.54	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.73	0.24	I (High)	Bahji A., 2020 (NMA)	-0.73	0.26	1.21	fluo	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	fluoxetine	Response	"eSMD=0.68 [-0.47, 1.77] <br> <img src=""https://www.linkpicture.com/q/Diapositive18.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.71	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	olanzapine	mono	0.68	0.57	II (Moderate)	Bahji A., 2020 (NMA)	-0.68	-0.47	1.77	fluo	ola	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	imipramine	Response	"eSMD=0.16 [-0.61, 0.95] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=11.1	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	moclobemide	mono	0.16	0.4	II (Moderate)	Bahji A., 2020 (NMA)	-0.16	-0.61	0.95	imp	moc	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	fluoxetine	Response	"eSMD=0.15 [-0.42, 0.72] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=11.84	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	imipramine	mono	0.15	0.29	II (Moderate)	Bahji A., 2020 (NMA)	-0.15	-0.42	0.72	fluo	imp	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	imipramine	Response	"eSMD=0.1 [-0.53, 0.72] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=17.74	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	phenelzine	mono	0.1	0.32	II (Moderate)	Bahji A., 2020 (NMA)	-0.1	-0.53	0.72	imp	phen	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	fluoxetine	Response	"eSMD=0 [-1.08, 1.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	olanzapine+fluoxetine	combo	0	0.55	II (Moderate)	Bahji A., 2020 (NMA)	0	-1.08	1.08	fluo	ola+fluo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	lithium	Response	"eSMD=-0.16 [-0.65, 0.33] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=11.1	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	sertraline	mono	-0.16	0.25	II (Moderate)	Bahji A., 2020 (NMA)	0.16	-0.65	0.33	lit	sert	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	lithium	Response	"eSMD=-0.2 [-0.42, 0.02] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=8.89	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	quetiapine	mono	-0.2	0.11	II (Moderate)	Bahji A., 2020 (NMA)	0.2	-0.42	0.02	lit	que	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	lamotrigine	Response	"eSMD=-0.22 [-0.45, 0.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=8.09	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	olanzapine+fluoxetine	combo	-0.22	0.12	II (Moderate)	Bahji A., 2020 (NMA)	0.22	-0.45	0.01	lam	ola+fluo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	paroxetine	Response	"eSMD=-0.28 [-0.51, -0.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.37	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	quetiapine	mono	-0.28	0.12	I (High)	Bahji A., 2020 (NMA)	0.28	-0.51	-0.05	par	que	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	olanzapine	Response	"eSMD=-0.38 [-0.65, -0.13] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.72	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	olanzapine+fluoxetine	combo	-0.38	0.13	I (High)	Bahji A., 2020 (NMA)	0.38	-0.65	-0.13	ola	ola+fluo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	gabapentin	Response	"eSMD=-0.56 [-1.22, 0.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive4.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.25	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	lamotrigine	mono	-0.56	0.33	II (Moderate)	Bahji A., 2020 (NMA)	0.56	-1.22	0.08	gaba	lam	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	lithium	Response	"eSMD=-0.76 [-1.17, -0.36] <br> <img src=""https://www.linkpicture.com/q/Diapositive2.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.44	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	venlafaxine	mono	-0.76	0.21	I (High)	Bahji A., 2020 (NMA)	0.76	-1.17	-0.36	lit	ven	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	imipramine	Response	"eSMD=-0.98 [-1.55, -0.39] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1.95	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	tranylcypromine	mono	-0.98	0.3	I (High)	Bahji A., 2020 (NMA)	0.98	-1.55	-0.39	imp	tran	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	pindolol	Response	"eSMD=-0.25 [-0.56, 0.06] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.13	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.25	0.16	III (Low)	Bahji A., 2021 (NMA)	0.25	-0.56	0.06	pin	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	aripiprazole	Response	"eSMD=-0.17 [-1.08, 0.75] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=10.45	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.17	0.47	III (Low)	Bahji A., 2021 (NMA)	0.17	-1.08	0.75	ari	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	n-acetyl cysteine	Response	"eSMD=-0.12 [-0.39, 0.16] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=14.79	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.12	0.14	III (Low)	Bahji A., 2021 (NMA)	0.12	-0.39	0.16	nac	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	imipramine	Response	"eSMD=-0.11 [-0.43, 0.2] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=16.13	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.11	0.16	III (Low)	Bahji A., 2021 (NMA)	0.11	-0.43	0.2	imp	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	paroxetine+bupropion	Response	"eSMD=-0.09 [-0.42, 0.24] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=19.71	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.09	0.17	III (Low)	Bahji A., 2021 (NMA)	0.09	-0.42	0.24	par+bup	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	levetiracetam	Response	"eSMD=-0.07 [-0.79, 0.65] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=25.33	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.07	0.37	III (Low)	Bahji A., 2021 (NMA)	0.07	-0.79	0.65	levt	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	ziprasidone	Response	"eSMD=-0.07 [-0.4, 0.26] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=25.33	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.07	0.17	III (Low)	Bahji A., 2021 (NMA)	0.07	-0.4	0.26	zip	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	sAME	Response	"eSMD=-0.06 [-1.55, 1.39] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=29.55	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.06	0.75	III (Low)	Bahji A., 2021 (NMA)	0.06	-1.55	1.39	sAME	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	pregnenolone	Response	"eSMD=-0.05 [-0.43, 0.34] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=35.46	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.05	0.2	III (Low)	Bahji A., 2021 (NMA)	0.05	-0.43	0.34	preg	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	agomelatin	Response	"eSMD=0.01 [-0.29, 0.31] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=177.25	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.01	0.15	III (Low)	Bahji A., 2021 (NMA)	-0.01	-0.29	0.31	ago	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	pioglitazone	Response	"eSMD=0.01 [-0.3, 0.32] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=177.25	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.01	0.16	III (Low)	Bahji A., 2021 (NMA)	-0.01	-0.3	0.32	pio	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	citalopram	Response	"eSMD=0.03 [-0.33, 0.38] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=59.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.03	0.18	III (Low)	Bahji A., 2021 (NMA)	-0.03	-0.33	0.38	cit	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	vitD3	Response	"eSMD=0.03 [-0.38, 0.45] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=59.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.03	0.21	III (Low)	Bahji A., 2021 (NMA)	-0.03	-0.38	0.45	vitD3	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	quetiapine	Response	"eSMD=0.05 [-0.44, 0.53] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=35.46	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.05	0.25	III (Low)	Bahji A., 2021 (NMA)	-0.05	-0.44	0.53	que	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	armodafinil	Response	"eSMD=0.07 [-0.08, 0.22] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=25.33	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.07	0.08	III (Low)	Bahji A., 2021 (NMA)	-0.07	-0.08	0.22	armo	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	dextromethorphan	Response	"eSMD=0.08 [-0.24, 0.4] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=22.17	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.08	0.16	III (Low)	Bahji A., 2021 (NMA)	-0.08	-0.24	0.4	dexm	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	n-acetyl cysteine+acetylsalicylic acid	Response	"eSMD=0.08 [-0.66, 0.84] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=22.17	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.08	0.38	III (Low)	Bahji A., 2021 (NMA)	-0.08	-0.66	0.84	nac+asa	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	lurasidone	Response	"eSMD=0.1 [-0.12, 0.33] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=17.74	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.1	0.11	III (Low)	Bahji A., 2021 (NMA)	-0.1	-0.12	0.33	lur	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	paroxetine	Response	"eSMD=0.11 [-0.28, 0.51] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=16.13	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.11	0.2	III (Low)	Bahji A., 2021 (NMA)	-0.11	-0.28	0.51	par	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	t4 hormone	Response	"eSMD=0.14 [-0.24, 0.52] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=12.68	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.14	0.19	III (Low)	Bahji A., 2021 (NMA)	-0.14	-0.24	0.52	t4	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	minocycline	Response	"eSMD=0.15 [-0.49, 0.79] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=11.84	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.15	0.33	III (Low)	Bahji A., 2021 (NMA)	-0.15	-0.49	0.79	mino	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	bupropion	Response	"eSMD=0.19 [-1.22, 1.65] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=9.36	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.19	0.73	III (Low)	Bahji A., 2021 (NMA)	-0.19	-1.22	1.65	bup	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	celecoxib	Response	"eSMD=0.23 [-0.04, 0.51] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.74	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.23	0.14	III (Low)	Bahji A., 2021 (NMA)	-0.23	-0.04	0.51	cel	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	fluoxetine	Response	"eSMD=0.24 [0.05, 0.43] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.42	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.24	0.1	II (Moderate)	Bahji A., 2021 (NMA)	-0.24	0.05	0.43	fluo	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	memantine	Response	"eSMD=0.24 [-0.19, 0.66] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.42	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.24	0.22	III (Low)	Bahji A., 2021 (NMA)	-0.24	-0.19	0.66	mem	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	lamotrigine	Response	"eSMD=0.25 [-0.02, 0.52] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.13	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.25	0.14	III (Low)	Bahji A., 2021 (NMA)	-0.25	-0.02	0.52	lam	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	omega3	Response	"eSMD=0.26 [-0.12, 0.63] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.86	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.26	0.19	III (Low)	Bahji A., 2021 (NMA)	-0.26	-0.12	0.63	omega3	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	creatine	Response	"eSMD=0.26 [-0.2, 0.7] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.86	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.26	0.23	III (Low)	Bahji A., 2021 (NMA)	-0.26	-0.2	0.7	creatine	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	lisdexamfetamine	Response	"eSMD=0.36 [-0.25, 0.98] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.98	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.36	0.31	III (Low)	Bahji A., 2021 (NMA)	-0.36	-0.25	0.98	lisdex	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	t3 hormone	Response	"eSMD=0.36 [-0.37, 1.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.98	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.36	0.37	III (Low)	Bahji A., 2021 (NMA)	-0.36	-0.37	1.08	t3	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	acetylsalicylic acid	Response	"eSMD=0.39 [-0.1, 0.89] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.6	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.39	0.25	III (Low)	Bahji A., 2021 (NMA)	-0.39	-0.1	0.89	asa	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	infliximab	Response	"eSMD=0.42 [-0.12, 0.98] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.28	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.42	0.28	III (Low)	Bahji A., 2021 (NMA)	-0.42	-0.12	0.98	infx	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	minocycline+acetylsalicylic acid	Response	"eSMD=0.45 [-0.09, 0.98] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.01	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.45	0.27	III (Low)	Bahji A., 2021 (NMA)	-0.45	-0.09	0.98	mino+asa	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	inositol	Response	"eSMD=0.47 [-0.12, 1.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.84	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.47	0.3	III (Low)	Bahji A., 2021 (NMA)	-0.47	-0.12	1.05	ino	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	pramipexole	Response	"eSMD=0.79 [0.15, 1.39] <br> <img src=""https://www.linkpicture.com/q/Diapositive19.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.36	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.79	0.32	II (Moderate)	Bahji A., 2021 (NMA)	-0.79	0.15	1.39	pram	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	coenzyme Q10	Response	"eSMD=0.98 [0.39, 1.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.95	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.98	0.3	I (High)	Bahji A., 2021 (NMA)	-0.98	0.39	1.55	coQ10	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	ketamine	Response	"eSMD=1.39 [0.61, 2.16] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.48	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	1.39	0.4	I (High)	Bahji A., 2021 (NMA)	-1.39	0.61	2.16	ket	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	lamotrigine	Response	"eSMD=0.51 [-0.38, 1.39] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.55	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	risperidone	aug	0.51	0.45	III (Low)	Bahji A., 2021 (NMA)	-0.51	-0.38	1.39	lam	risp	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	inositol	Response	"eSMD=0.45 [-0.44, 1.33] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.01	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	risperidone	aug	0.45	0.45	III (Low)	Bahji A., 2021 (NMA)	-0.45	-0.44	1.33	ino	risp	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	acetylsalicylic acid	Response	"eSMD=0.38 [-0.17, 0.95] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.72	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	minocycline	aug	0.38	0.29	III (Low)	Bahji A., 2021 (NMA)	-0.38	-0.17	0.95	asa	mino	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	citalopram	Response	"eSMD=0.22 [-0.36, 0.81] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	lamotrigine	aug	0.22	0.3	III (Low)	Bahji A., 2021 (NMA)	-0.22	-0.36	0.81	cit	lam	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	imipramine	Response	"eSMD=0.08 [-0.25, 0.43] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=22.17	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	moclobemide	aug	0.08	0.17	III (Low)	Bahji A., 2021 (NMA)	-0.08	-0.25	0.43	imp	moc	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	acetylsalicylic acid	Response	"eSMD=0.08 [-0.35, 0.52] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=22.17	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	minocycline+acetylsalicylic acid	aug	0.08	0.22	III (Low)	Bahji A., 2021 (NMA)	-0.08	-0.35	0.52	asa	mino+asa	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	fluoxetine	Response	"eSMD=0.08 [-0.22, 0.38] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=22.17	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	lamotrigine	aug	0.08	0.15	III (Low)	Bahji A., 2021 (NMA)	-0.08	-0.22	0.38	fluo	lam	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	fluoxetine	Response	"eSMD=0.06 [-0.31, 0.44] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=29.55	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	imipramine	aug	0.06	0.19	III (Low)	Bahji A., 2021 (NMA)	-0.06	-0.31	0.44	fluo	imp	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	n-acetyl cysteine	Response	"eSMD=0.06 [-0.7, 0.83] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=29.55	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	n-acetyl cysteine+acetylsalicylic acid	aug	0.06	0.39	III (Low)	Bahji A., 2021 (NMA)	-0.06	-0.7	0.83	nac	nac+asa	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	sertraline	Response	"eSMD=0.06 [-0.32, 0.44] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=29.55	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	venlafaxine	aug	0.06	0.19	III (Low)	Bahji A., 2021 (NMA)	-0.06	-0.32	0.44	sert	ven	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	bupropion	Response	"eSMD=0.05 [-0.37, 0.48] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=35.46	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	topiramate	aug	0.05	0.22	III (Low)	Bahji A., 2021 (NMA)	-0.05	-0.37	0.48	bup	top	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	risperidone	Response	"eSMD=0 [-0.79, 0.79] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	risperidone+paroxetine	aug	0	0.4	III (Low)	Bahji A., 2021 (NMA)	0	-0.79	0.79	risp	risp+par	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	lithium	Response	"eSMD=-0.02 [-0.58, 0.53] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=88.63	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	paroxetine	aug	-0.02	0.28	III (Low)	Bahji A., 2021 (NMA)	0.02	-0.58	0.53	lit	par	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	paroxetine	Response	"eSMD=-0.05 [-0.48, 0.39] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=35.46	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	venlafaxine	aug	-0.05	0.22	III (Low)	Bahji A., 2021 (NMA)	0.05	-0.48	0.39	par	ven	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	inositol	Response	"eSMD=-0.05 [-0.72, 0.61] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=35.46	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	lamotrigine	aug	-0.05	0.34	III (Low)	Bahji A., 2021 (NMA)	0.05	-0.72	0.61	ino	lam	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	bupropion	Response	"eSMD=-0.06 [-0.45, 0.34] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=29.55	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	venlafaxine	aug	-0.06	0.2	III (Low)	Bahji A., 2021 (NMA)	0.06	-0.45	0.34	bup	ven	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	bupropion	Response	"eSMD=-0.07 [-0.56, 0.42] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=25.33	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	desipramine	aug	-0.07	0.25	III (Low)	Bahji A., 2021 (NMA)	0.07	-0.56	0.42	bup	desimp	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	amitriptyline	Response	"eSMD=-0.08 [-0.42, 0.25] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=22.17	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	l-sulpride	aug	-0.08	0.17	III (Low)	Bahji A., 2021 (NMA)	0.08	-0.42	0.25	amit	l-sulpr	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	bupropion	Response	"eSMD=-0.12 [-0.52, 0.28] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=14.79	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	sertraline	aug	-0.12	0.2	III (Low)	Bahji A., 2021 (NMA)	0.12	-0.52	0.28	bup	sert	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	imipramine	Response	"eSMD=-0.2 [-0.61, 0.21] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=8.89	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	paroxetine	aug	-0.2	0.21	III (Low)	Bahji A., 2021 (NMA)	0.2	-0.61	0.21	imp	par	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	paroxetine	Response	"eSMD=-0.22 [-1.12, 0.68] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=8.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	risperidone	aug	-0.22	0.46	III (Low)	Bahji A., 2021 (NMA)	0.22	-1.12	0.68	par	risp	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	paroxetine	Response	"eSMD=-0.22 [-1.12, 0.68] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=8.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	risperidone+paroxetine	aug	-0.22	0.46	III (Low)	Bahji A., 2021 (NMA)	0.22	-1.12	0.68	par	risp+par	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	acetylsalicylic acid	Response	"eSMD=-0.28 [-1.39, 0.86] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.37	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	n-acetyl cysteine+acetylsalicylic acid	aug	-0.28	0.57	III (Low)	Bahji A., 2021 (NMA)	0.28	-1.39	0.86	asa	nac+asa	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	minocycline	Response	"eSMD=-0.3 [-0.83, 0.26] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.95	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	minocycline+acetylsalicylic acid	aug	-0.3	0.28	III (Low)	Bahji A., 2021 (NMA)	0.3	-0.83	0.26	mino	mino+asa	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	lamotrigine	Response	"eSMD=-0.3 [-0.89, 0.3] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.95	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	tranylcypromine	aug	-0.3	0.3	III (Low)	Bahji A., 2021 (NMA)	0.3	-0.89	0.3	lam	tran	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	acetylsalicylic acid	Response	"eSMD=-0.35 [-1.47, 0.79] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.12	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	n-acetyl cysteine	aug	-0.35	0.58	III (Low)	Bahji A., 2021 (NMA)	0.35	-1.47	0.79	asa	nac	Response
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	amitriptyline	Response	"eSMD=-0.36 [-0.86, 0.13] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.98	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	paroxetine	aug	-0.36	0.25	III (Low)	Bahji A., 2021 (NMA)	0.36	-0.86	0.13	amit	par	Response
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2011 (NMA)</a>"	carbamazapine	Response	"eSMD=0.05 [-0.34, 0.42] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=35.46	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	42	Network meta-analysis	Adults	Mania/Mixed	haloperidol	mono	0.05	0.19	III (Low)	Cipriani A., 2011 (NMA)	-0.05	-0.34	0.42	cbz	hal	Response
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2011 (NMA)</a>"	quetiapine	Response	"eSMD=-0.04 [-0.24, 0.17] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=44.32	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	42	Network meta-analysis	Adults	Mania/Mixed	risperidone	mono	-0.04	0.1	III (Low)	Cipriani A., 2011 (NMA)	0.04	-0.24	0.17	que	risp	Response
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	cariprazine	Response	"eSMD=0.21 [0.09, 0.33] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.47	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	18	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.21	0.06	III (Low)	Kadakia A., 2021 (NMA)	-0.21	0.09	0.33	car	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	topiramate	Response	"eSMD=-0.05 [-0.17, 0.07] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=35.46	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	56	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.05	0.06	III (Low)	Kishi T., 2021 (NMA)	0.05	-0.17	0.07	top	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	eslicarbazepine	Response	"eSMD=0.01 [-0.15, 0.16] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=177.25	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	56	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.01	0.08	III (Low)	Kishi T., 2021 (NMA)	-0.01	-0.15	0.16	eslicbz	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	licarbazepine	Response	"eSMD=0.01 [-0.19, 0.21] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=177.25	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	56	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.01	0.1	III (Low)	Kishi T., 2021 (NMA)	-0.01	-0.19	0.21	licbz	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Response	"eSMD=0.13 [-0.01, 0.26] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=13.65	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	56	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.13	0.07	III (Low)	Kishi T., 2021 (NMA)	-0.13	-0.01	0.26	lam	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	asenapine	Response	"eSMD=0.14 [0.03, 0.25] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=12.68	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	56	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.14	0.06	II (Moderate)	Kishi T., 2021 (NMA)	-0.14	0.03	0.25	ase	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	verapamil	Response	"eSMD=0.15 [-0.76, 1.07] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=11.84	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	56	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.15	0.47	III (Low)	Kishi T., 2021 (NMA)	-0.15	-0.76	1.07	verapamil	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	ziprasidone	Response	"eSMD=0.17 [0.03, 0.3] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=10.45	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	56	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.17	0.07	II (Moderate)	Kishi T., 2021 (NMA)	-0.17	0.03	0.3	zip	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Response	"eSMD=0.18 [0.05, 0.31] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=9.87	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	56	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.18	0.07	II (Moderate)	Kishi T., 2021 (NMA)	-0.18	0.05	0.31	pal	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Response	"eSMD=0.19 [0.1, 0.3] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=9.36	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	56	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.19	0.05	II (Moderate)	Kishi T., 2021 (NMA)	-0.19	0.1	0.3	div	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Response	"eSMD=0.2 [0.13, 0.28] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.89	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	56	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.2	0.04	II (Moderate)	Kishi T., 2021 (NMA)	-0.2	0.13	0.28	lit	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Response	"eSMD=0.23 [0.16, 0.31] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.74	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	56	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.23	0.04	II (Moderate)	Kishi T., 2021 (NMA)	-0.23	0.16	0.31	ari	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	quetiapine	Response	"eSMD=0.24 [0.15, 0.33] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.42	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	56	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.24	0.05	II (Moderate)	Kishi T., 2021 (NMA)	-0.24	0.15	0.33	que	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	cariprazine	Response	"eSMD=0.25 [0.13, 0.36] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.13	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	56	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.25	0.06	II (Moderate)	Kishi T., 2021 (NMA)	-0.25	0.13	0.36	car	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Response	"eSMD=0.26 [0.19, 0.32] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.86	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	56	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.26	0.03	II (Moderate)	Kishi T., 2021 (NMA)	-0.26	0.19	0.32	ola	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Response	"eSMD=0.27 [0.2, 0.35] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.6	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	56	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.27	0.04	II (Moderate)	Kishi T., 2021 (NMA)	-0.27	0.2	0.35	hal	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	risperidone	Response	"eSMD=0.29 [0.19, 0.39] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.15	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	56	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.29	0.05	II (Moderate)	Kishi T., 2021 (NMA)	-0.29	0.19	0.39	risp	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	carbamazepine	Response	"eSMD=0.35 [0.19, 0.52] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.12	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	56	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.35	0.08	II (Moderate)	Kishi T., 2021 (NMA)	-0.35	0.19	0.52	cbz	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	tamoxifen	Response	"eSMD=1.11 [0.35, 1.87] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.76	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	56	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	1.11	0.39	I (High)	Kishi T., 2021 (NMA)	-1.11	0.35	1.87	tamox	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Response	"eSMD=0.26 [0.13, 0.38] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.86	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	56	Network meta-analysis	Adults	Mania/Mixed	topiramate	mono	0.26	0.06	II (Moderate)	Kishi T., 2021 (NMA)	-0.26	0.13	0.38	lit	top	Response
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Response	"eSMD=0.15 [-0.06, 0.36] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=11.84	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	56	Network meta-analysis	Adults	Mania/Mixed	endoxifen	mono	0.15	0.11	III (Low)	Kishi T., 2021 (NMA)	-0.15	-0.06	0.36	div	end	Response
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	carbamazepine	Response	"eSMD=0.15 [-0.03, 0.33] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=11.84	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	56	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	0.15	0.09	III (Low)	Kishi T., 2021 (NMA)	-0.15	-0.03	0.33	cbz	lit	Response
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Response	"eSMD=0.11 [-0.03, 0.25] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=16.13	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	56	Network meta-analysis	Adults	Mania/Mixed	ziprasidone	mono	0.11	0.07	III (Low)	Kishi T., 2021 (NMA)	-0.11	-0.03	0.25	hal	zip	Response
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Response	"eSMD=0.06 [-0.12, 0.25] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=29.55	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	56	Network meta-analysis	Adults	Mania/Mixed	oxcarbazepine	mono	0.06	0.09	III (Low)	Kishi T., 2021 (NMA)	-0.06	-0.12	0.25	div	oxc	Response
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Response	"eSMD=0.03 [-0.08, 0.14] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=59.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	56	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	0.03	0.06	III (Low)	Kishi T., 2021 (NMA)	-0.03	-0.08	0.14	hal	que	Response
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Response	"eSMD=0.03 [-0.07, 0.13] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=59.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	56	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	0.03	0.05	III (Low)	Kishi T., 2021 (NMA)	-0.03	-0.07	0.13	ari	lit	Response
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Response	"eSMD=0.02 [-0.07, 0.11] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=88.63	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	56	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	0.02	0.05	III (Low)	Kishi T., 2021 (NMA)	-0.02	-0.07	0.11	hal	ola	Response
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Response	"eSMD=-0.01 [-0.12, 0.1] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=177.25	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	56	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	-0.01	0.06	III (Low)	Kishi T., 2021 (NMA)	0.01	-0.12	0.1	div	lit	Response
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Response	"eSMD=-0.02 [-0.13, 0.1] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=88.63	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	56	Network meta-analysis	Adults	Mania/Mixed	risperidone	mono	-0.02	0.06	III (Low)	Kishi T., 2021 (NMA)	0.02	-0.13	0.1	hal	risp	Response
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Response	"eSMD=-0.03 [-0.14, 0.07] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=59.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	56	Network meta-analysis	Adults	Mania/Mixed	risperidone	mono	-0.03	0.05	III (Low)	Kishi T., 2021 (NMA)	0.03	-0.14	0.07	ola	risp	Response
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Response	"eSMD=-0.04 [-0.13, 0.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=44.32	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	56	Network meta-analysis	Adults	Mania/Mixed	haloperidol	mono	-0.04	0.05	III (Low)	Kishi T., 2021 (NMA)	0.04	-0.13	0.05	ari	hal	Response
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Response	"eSMD=-0.04 [-0.14, 0.06] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=44.32	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	56	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	-0.04	0.05	III (Low)	Kishi T., 2021 (NMA)	0.04	-0.14	0.06	lit	que	Response
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Response	"eSMD=-0.05 [-0.14, 0.04] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=35.46	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	56	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.05	0.05	III (Low)	Kishi T., 2021 (NMA)	0.05	-0.14	0.04	lit	ola	Response
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Response	"eSMD=-0.06 [-0.16, 0.04] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=29.55	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	56	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.06	0.05	III (Low)	Kishi T., 2021 (NMA)	0.06	-0.16	0.04	div	ola	Response
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Response	"eSMD=-0.06 [-0.2, 0.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=29.55	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	56	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	-0.06	0.07	III (Low)	Kishi T., 2021 (NMA)	0.06	-0.2	0.08	pal	que	Response
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Response	"eSMD=-0.08 [-0.21, 0.06] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=22.17	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	56	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	-0.08	0.07	III (Low)	Kishi T., 2021 (NMA)	0.08	-0.21	0.06	lam	lit	Response
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	asenapine	Response	"eSMD=-0.12 [-0.23, -0.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=14.79	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	56	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.12	0.06	II (Moderate)	Kishi T., 2021 (NMA)	0.12	-0.23	-0.01	ase	ola	Response
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Response	"eSMD=-0.13 [-0.27, 0.02] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=13.65	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	56	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.13	0.07	III (Low)	Kishi T., 2021 (NMA)	0.13	-0.27	0.02	lam	ola	Response
"<a href='https://doi.org/' target=""_blank"">Lam R.W., 2020 (MA)</a>"	bright light therapy	Response	"eSMD=0.46 [0.06, 0.87] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.92	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	6	Pairwise meta-analysis	Adults	Bipolar Depression	TAU/sham	mono	0.46	0.21	III (Low)	Lam R.W., 2020 (MA)	-0.46	0.06	0.87	BLT	tau/sham	Response
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	lithium	Response	"eSMD=0.42 [0.3, 0.53] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.28	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	6	Pairwise meta-analysis	Mixed (Children-Adults)	Mania/Mixed	placebo	mono	0.42	0.06	I (High)	McKnight R.F., 2019 (MA)	-0.42	0.3	0.53	lit	pbo	Response
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	divalproate	Response	"eSMD=-0.11 [-0.29, 0.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=16.13	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Pairwise meta-analysis	Mixed (Children-Adults)	Mania/Mixed	lithium	mono	-0.11	0.09	III (Low)	McKnight R.F., 2019 (MA)	0.11	-0.29	0.08	div	lit	Response
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	lamotrigine	Response	"eSMD=-0.25 [-1.01, 0.49] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.13	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	lithium	mono	-0.25	0.38	III (Low)	McKnight R.F., 2019 (MA)	0.25	-1.01	0.49	lam	lit	Response
"<a href='https://doi.org/' target=""_blank"">Meduri M., 2016 (MA)</a>"	aripiprazole	Response	"eSMD=-0.19 [-0.58, -0.02] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=9.36	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Children & Adolescents	Mania/Mixed	placebo	mono	-0.19	0.14	II (Moderate)	Meduri M., 2016 (MA)	0.19	-0.58	-0.02	ari	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Meduri M., 2016 (MA)</a>"	aripiprazole	Response	"eSMD=0.08 [-0.1, 0.26] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=22.17	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	aug	0.08	0.09	III (Low)	Meduri M., 2016 (MA)	-0.08	-0.1	0.26	ari	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Nguyen T.D., 2021 (MA)</a>"	rTMS bilateral	Response	"eSMD=0.4 [-0.38, 1.17] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.49	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	14	Pairwise meta-analysis	Adults	Bipolar Depression	sham	aug	0.4	0.4	IV (Very Low)	Nguyen T.D., 2021 (MA)	-0.4	-0.38	1.17	rTMS BL	sham	Response
"<a href='https://doi.org/' target=""_blank"">Palacios J., 2019 (MA)</a>"	tamoxifen	Response	"eSMD=0.66 [0.13, 1.18] <br> <img src=""https://www.linkpicture.com/q/Diapositive18.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.78	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	aug	0.66	0.27	II (Moderate)	Palacios J., 2019 (MA)	-0.66	0.13	1.18	tamox	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Poolsup N., 2000 (MA)</a>"	chlorpromazine	Response	"eSMD=-0.37 [-0.72, -0.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.85	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Mixed (Children-Adults)	Mania/Mixed	lithium	mono	-0.37	0.18	III (Low)	Poolsup N., 2000 (MA)	0.37	-0.72	-0.01	chlorp	lit	Response
"<a href='https://doi.org/' target=""_blank"">Rendell J.M., 2010 (MA)</a>"	risperidone	Response	"eSMD=0.17 [0.05, 0.3] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=10.45	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	aug	0.17	0.06	II (Moderate)	Rendell J.M., 2010 (MA)	-0.17	0.05	0.3	risp	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Scherk H., 2007 (MA)</a>"	quetiapine	Response	"eSMD=0.21 [0.11, 0.31] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.47	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	aug	0.21	0.05	II (Moderate)	Scherk H., 2007 (MA)	-0.21	0.11	0.31	que	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Silva M.T., 2013 (MA)</a>"	olanzapine	Response	"eSMD=0.05 [-0.44, 0.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=35.46	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Bipolar Depression	olanzapine+fluoxetine	combo	0.05	0.25	III (Low)	Silva M.T., 2013 (MA)	-0.05	-0.44	0.55	ola	ola+fluo	Response
"<a href='https://doi.org/' target=""_blank"">Taylor D.M., 2014 (NMA)</a>"	ziprasidone	Response	"eSMD=-0.02 [-0.28, 0.26] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=88.63	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.02	0.14	IV (Very Low)	Taylor D.M., 2014 (NMA)	0.02	-0.28	0.26	zip	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Taylor D.M., 2014 (NMA)</a>"	aripiprazole	Response	"eSMD=0.04 [-0.15, 0.2] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=44.32	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.04	0.09	IV (Very Low)	Taylor D.M., 2014 (NMA)	-0.04	-0.15	0.2	ari	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Taylor D.M., 2014 (NMA)</a>"	lithium	Response	"eSMD=0.22 [-0.03, 0.44] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.09	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.22	0.12	IV (Very Low)	Taylor D.M., 2014 (NMA)	-0.22	-0.03	0.44	lit	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Taylor D.M., 2014 (NMA)</a>"	olanzapine	Response	"eSMD=0.23 [0.09, 0.38] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.74	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.23	0.07	IV (Very Low)	Taylor D.M., 2014 (NMA)	-0.23	0.09	0.38	ola	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Taylor D.M., 2014 (NMA)</a>"	lamotrigine	Response	"eSMD=0.26 [0.13, 0.38] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.86	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.26	0.06	IV (Very Low)	Taylor D.M., 2014 (NMA)	-0.26	0.13	0.38	lam	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Taylor D.M., 2014 (NMA)</a>"	quetiapine	Response	"eSMD=0.35 [0.24, 0.47] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.12	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.35	0.06	IV (Very Low)	Taylor D.M., 2014 (NMA)	-0.35	0.24	0.47	que	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Taylor D.M., 2014 (NMA)</a>"	divalproate	Response	"eSMD=0.36 [-0.03, 0.84] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.98	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.36	0.22	IV (Very Low)	Taylor D.M., 2014 (NMA)	-0.36	-0.03	0.84	div	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Taylor D.M., 2014 (NMA)</a>"	olanzapine+fluoxetine	Response	"eSMD=0.51 [0.32, 0.7] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.55	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.51	0.1	III (Low)	Taylor D.M., 2014 (NMA)	-0.51	0.32	0.7	ola+fluo	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Taylor D.M., 2014 (NMA)</a>"	lurasidone	Response	"eSMD=0.52 [0.33, 0.69] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.49	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	0.52	0.09	III (Low)	Taylor D.M., 2014 (NMA)	-0.52	0.33	0.69	lur	pbo	Response
"<a href='https://doi.org/' target=""_blank"">Taylor D.M., 2014 (NMA)</a>"	lithium	Response	"eSMD=-0.13 [-0.38, 0.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=13.65	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Bipolar Depression	quetiapine	mono	-0.13	0.12	IV (Very Low)	Taylor D.M., 2014 (NMA)	0.13	-0.38	0.08	lit	que	Response
"<a href='https://doi.org/' target=""_blank"">Taylor D.M., 2014 (NMA)</a>"	lamotrigine	Response	"eSMD=-0.25 [-0.47, -0.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.13	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Bipolar Depression	olanzapine+fluoxetine	combo	-0.25	0.1	IV (Very Low)	Taylor D.M., 2014 (NMA)	0.25	-0.47	-0.08	lam	ola+fluo	Response
"<a href='https://doi.org/' target=""_blank"">Taylor D.M., 2014 (NMA)</a>"	olanzapine	Response	"eSMD=-0.28 [-0.51, -0.07] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.37	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	29	Network meta-analysis	Adults	Bipolar Depression	olanzapine+fluoxetine	combo	-0.28	0.11	IV (Very Low)	Taylor D.M., 2014 (NMA)	0.28	-0.51	-0.07	ola	ola+fluo	Response
"<a href='https://doi.org/' target=""_blank"">Yildiz A., 2015 (NMA)</a>"	carbamazepine	Response	"eSMD=0.14 [-0.19, 0.45] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=12.68	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	51	Network meta-analysis	Adults	Mania/Mixed	divalproate	mono	0.14	0.16	IV (Very Low)	Yildiz A., 2015 (NMA)	-0.14	-0.19	0.45	cbz	div	Response
"<a href='https://doi.org/' target=""_blank"">Yildiz A., 2015 (NMA)</a>"	divalproate	Response	"eSMD=-0.1 [-0.32, 0.12] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=17.74	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	51	Network meta-analysis	Adults	Mania/Mixed	haloperidol	mono	-0.1	0.11	IV (Very Low)	Yildiz A., 2015 (NMA)	0.1	-0.32	0.12	div	hal	Response
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2019 (MA)</a>"	ramelteon	Sleep scale, PSQI scale	"eSMD=0.04 [-0.74, 0.83] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=44.32	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Maintenance	placebo	mono	0.04	0.4	III (Low)	Kishi T., 2019 (MA)	-0.04	-0.74	0.83	ram	pbo	Sleep, PSQI
"<a href='https://doi.org/' target=""_blank"">Suttajit S., 2014 (MA)</a>"	quetiapine	Sleep scale, PSQI, change frome baseline	"eSMD=2.31 [1.66, 2.95] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.11	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	2.31	0.33	I (High)	Suttajit S., 2014 (MA)	-2.31	1.66	2.95	que	pbo	Sleep, PSQI, change
"<a href='https://doi.org/' target=""_blank"">Chang H., 2017 (MA)</a>"	paliperidone	Suicidal behavior scale, SSI, change from baseline	"eSMD=-0.02 [-0.14, 0.11] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=88.63	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.02	0.06	III (Low)	Chang H., 2017 (MA)	0.02	-0.14	0.11	pal	pbo	Suicidal behavior, SSI, change
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	lithium	Suicide, attempted	"eSMD=0.63 [-1.17, 2.54] <br> <img src=""https://www.linkpicture.com/q/Diapositive18.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.91	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	0.63	0.95	III (Low)	McKnight R.F., 2019 (MA)	-0.63	-1.17	2.54	lit	pbo	Suicide, attempted
"<a href='https://doi.org/' target=""_blank"">Nunez N.A., 2020 (MA)</a>"	armodafinil	Suicide, attempted	"eSMD=-0.01 [-0.58, 0.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=177.25	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	5	Pairwise meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.01	0.29	IV (Very Low)	Nunez N.A., 2020 (MA)	0.01	-0.58	0.55	armo	pbo	Suicide, attempted
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2013 (MA)</a>"	carbamazepine	Suicide, completed	"eSMD=-0.55 [-1.33, 0.23] <br> <img src=""https://www.linkpicture.com/q/Diapositive4.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.3	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Maintenance	lithium	mono	-0.55	0.4	II (Moderate)	Cipriani A., 2013 (MA)	0.55	-1.33	0.23	cbz	lit	Suicide, completed
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Suicide, completed	"eSMD=0.3 [-1.01, 1.65] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.95	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	25	Network meta-analysis	Adults	Maintenance	placebo	mono	0.3	0.68	III (Low)	Kishi T., 2021 (NMA)	-0.3	-1.01	1.65	div	pbo	Suicide, completed
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Suicide, completed	"eSMD=0.21 [-0.47, 0.89] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.47	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	25	Network meta-analysis	Adults	Maintenance	placebo	mono	0.21	0.35	III (Low)	Kishi T., 2021 (NMA)	-0.21	-0.47	0.89	lit	pbo	Suicide, completed
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Suicide, completed	"eSMD=0.1 [-0.92, 1.12] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=17.74	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	25	Network meta-analysis	Adults	Maintenance	placebo	mono	0.1	0.52	III (Low)	Kishi T., 2021 (NMA)	-0.1	-0.92	1.12	lam	pbo	Suicide, completed
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	quetiapine	Suicide, completed	"eSMD=0.08 [-1.33, 1.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=22.17	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	25	Network meta-analysis	Adults	Maintenance	placebo	mono	0.08	0.73	III (Low)	Kishi T., 2021 (NMA)	-0.08	-1.33	1.55	que	pbo	Suicide, completed
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole LAI	Suicide, completed	"eSMD=-0.01 [-2.16, 2.16] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=177.25	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	25	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.01	1.1	III (Low)	Kishi T., 2021 (NMA)	0.01	-2.16	2.16	ariLAI	pbo	Suicide, completed
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	asenapine	Suicide, completed	"eSMD=-0.01 [-2.16, 2.16] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=177.25	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	25	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.01	1.1	III (Low)	Kishi T., 2021 (NMA)	0.01	-2.16	2.16	ase	pbo	Suicide, completed
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	risperidone LAI	Suicide, completed	"eSMD=-0.02 [-1.47, 1.47] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=88.63	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	25	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.02	0.75	III (Low)	Kishi T., 2021 (NMA)	0.02	-1.47	1.47	rispLAI	pbo	Suicide, completed
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Suicide, completed	"eSMD=-0.03 [-2.16, 2.16] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=59.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	25	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.03	1.1	III (Low)	Kishi T., 2021 (NMA)	0.03	-2.16	2.16	ari	pbo	Suicide, completed
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Suicide, completed	"eSMD=-0.09 [-1.27, 1.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=19.71	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	25	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.09	0.6	III (Low)	Kishi T., 2021 (NMA)	0.09	-1.27	1.08	ola	pbo	Suicide, completed
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Suicide, completed	"eSMD=-0.59 [-2.54, 1.17] <br> <img src=""https://www.linkpicture.com/q/Diapositive4.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	25	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.59	0.95	III (Low)	Kishi T., 2021 (NMA)	0.59	-2.54	1.17	pal	pbo	Suicide, completed
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	cariprazine	Suicide, completed	"eSMD=-0.4 [-1.55, 0.74] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.49	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	25	Network meta-analysis	Adults	Maintenance	lithium	mono	-0.4	0.58	III (Low)	Kishi T., 2021 (NMA)	0.4	-1.55	0.74	car	lit	Suicide, completed
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Suicide, completed	"eSMD=-0.12 [-1.22, 1.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=14.79	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	25	Network meta-analysis	Adults	Maintenance	lithium	mono	-0.12	0.57	III (Low)	Kishi T., 2021 (NMA)	0.12	-1.22	1.01	lam	lit	Suicide, completed
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Suicide, completed	"eSMD=-0.07 [-1.77, 1.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=25.33	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	25	Network meta-analysis	Adults	Maintenance	risperidone LAI	mono	-0.07	0.85	III (Low)	Kishi T., 2021 (NMA)	0.07	-1.77	1.55	ola	rispLAI	Suicide, completed
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Suicide, completed	"eSMD=-0.05 [-1.93, 1.93] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=35.46	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	25	Network meta-analysis	Adults	Maintenance	lithium+divalproate	combo	-0.05	0.98	III (Low)	Kishi T., 2021 (NMA)	0.05	-1.93	1.93	lit	lit+div	Suicide, completed
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole+lamotrigine	Suicide, completed	"eSMD=0.02 [-2.16, 2.16] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=88.63	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	25	Network meta-analysis	Adults	Maintenance	lamotrigine	mono	0.02	1.1	III (Low)	Kishi T., 2021 (NMA)	-0.02	-2.16	2.16	ari+lam	lam	Suicide, completed
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Suicide, completed	"eSMD=0.05 [-1.93, 2.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=35.46	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	25	Network meta-analysis	Adults	Maintenance	lithium+divalproate	combo	0.05	1.01	III (Low)	Kishi T., 2021 (NMA)	-0.05	-1.93	2.01	div	lit+div	Suicide, completed
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Suicide, completed	"eSMD=0.09 [-1.12, 1.29] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=19.71	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	25	Network meta-analysis	Adults	Maintenance	lithium	mono	0.09	0.61	III (Low)	Kishi T., 2021 (NMA)	-0.09	-1.12	1.29	div	lit	Suicide, completed
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Suicide, completed	"eSMD=0.14 [-1.33, 1.65] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=12.68	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	25	Network meta-analysis	Adults	Maintenance	quetiapine	mono	0.14	0.76	III (Low)	Kishi T., 2021 (NMA)	-0.14	-1.33	1.65	lit	que	Suicide, completed
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Suicide, completed	"eSMD=0.3 [-0.92, 1.47] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.95	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	25	Network meta-analysis	Adults	Maintenance	olanzapine	mono	0.3	0.61	III (Low)	Kishi T., 2021 (NMA)	-0.3	-0.92	1.47	lit	ola	Suicide, completed
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (MA)</a>"	ketamine	Suicide, ideation	"eSMD=1.04 [0.46, 2.5] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.86	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Bipolar Depression	placebo/midazolam	aug	1.04	0.52	IV (Very Low)	Bahji A., 2021 (MA)	-1.04	0.46	2.5	ket	pbo/mid	Suicide, ideation
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	escitalopram	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.28 [-1.47, 1.93] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.37	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.28	0.87	II (Moderate)	Bahji A., 2020 (NMA)	-0.28	-1.47	1.93	escit	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	fluoxetine	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.17 [-0.65, 1.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=10.45	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.17	0.42	II (Moderate)	Bahji A., 2020 (NMA)	-0.17	-0.65	1.01	fluo	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	ziprasidone	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.14 [-0.66, 0.95] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=12.68	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.14	0.41	II (Moderate)	Bahji A., 2020 (NMA)	-0.14	-0.66	0.95	zip	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	divalproate	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.06 [-0.52, 0.65] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=29.55	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.06	0.3	II (Moderate)	Bahji A., 2020 (NMA)	-0.06	-0.52	0.65	div	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	lurasidone	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.02 [-0.43, 0.48] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=88.63	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	0.02	0.23	II (Moderate)	Bahji A., 2020 (NMA)	-0.02	-0.43	0.48	lur	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	carbamazepine	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.01 [-1.39, 1.39] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=177.25	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	-0.01	0.71	II (Moderate)	Bahji A., 2020 (NMA)	0.01	-1.39	1.39	cbz	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	gabapentin	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.04 [-1.39, 1.33] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=44.32	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	-0.04	0.69	II (Moderate)	Bahji A., 2020 (NMA)	0.04	-1.39	1.33	gaba	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	cariprazine	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.07 [-0.45, 0.31] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=25.33	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	-0.07	0.19	II (Moderate)	Bahji A., 2020 (NMA)	0.07	-0.45	0.31	car	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	lamotrigine	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.08 [-0.42, 0.26] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=22.17	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	-0.08	0.17	II (Moderate)	Bahji A., 2020 (NMA)	0.08	-0.42	0.26	lam	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	lithium	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.12 [-0.58, 0.35] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=14.79	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	-0.12	0.24	II (Moderate)	Bahji A., 2020 (NMA)	0.12	-0.58	0.35	lit	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	olanzapine+fluoxetine	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.13 [-0.51, 0.25] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=13.65	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	-0.13	0.19	II (Moderate)	Bahji A., 2020 (NMA)	0.13	-0.51	0.25	ola+fluo	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	olanzapine	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.22 [-0.52, 0.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=8.09	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	-0.22	0.15	II (Moderate)	Bahji A., 2020 (NMA)	0.22	-0.52	0.08	ola	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	phenelzine	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.25 [-1.65, 1.17] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.13	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	-0.25	0.72	II (Moderate)	Bahji A., 2020 (NMA)	0.25	-1.65	1.17	phen	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	quetiapine	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.32 [-0.52, -0.13] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.59	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	-0.32	0.1	I (High)	Bahji A., 2020 (NMA)	0.32	-0.52	-0.13	que	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	paroxetine	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.37 [-0.81, 0.09] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.85	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	-0.37	0.23	II (Moderate)	Bahji A., 2020 (NMA)	0.37	-0.81	0.09	par	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	aripiprazole	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.45 [-0.81, -0.09] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.01	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	-0.45	0.18	I (High)	Bahji A., 2020 (NMA)	0.45	-0.81	-0.09	ari	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	imipramine	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.63 [-1.33, 0.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive3.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.91	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	placebo	mono	-0.63	0.36	II (Moderate)	Bahji A., 2020 (NMA)	0.63	-1.33	0.08	imp	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	imipramine	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.95 [-1.77, -0.12] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.01	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	tranylcypromine	mono	-0.95	0.42	I (High)	Bahji A., 2020 (NMA)	0.95	-1.77	-0.12	imp	tran	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	lithium	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.79 [-1.77, 0.15] <br> <img src=""https://www.linkpicture.com/q/Diapositive2.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.36	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	sertraline	mono	-0.79	0.49	II (Moderate)	Bahji A., 2020 (NMA)	0.79	-1.77	0.15	lit	sert	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	olanzapine	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.61 [-1.39, 0.14] <br> <img src=""https://www.linkpicture.com/q/Diapositive4.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	olanzapine+fluoxetine	combo	-0.61	0.39	II (Moderate)	Bahji A., 2020 (NMA)	0.61	-1.39	0.14	ola	ola+fluo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	paroxetine	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.09 [-0.55, 0.37] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=19.71	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	quetiapine	mono	-0.09	0.23	II (Moderate)	Bahji A., 2020 (NMA)	0.09	-0.55	0.37	par	que	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	imipramine	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.07 [-1.65, 1.53] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=25.33	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	moclobemide	mono	-0.07	0.81	II (Moderate)	Bahji A., 2020 (NMA)	0.07	-1.65	1.53	imp	moc	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	fluoxetine	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.07 [-1.77, 1.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=25.33	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	olanzapine	mono	-0.07	0.85	II (Moderate)	Bahji A., 2020 (NMA)	0.07	-1.77	1.55	fluo	ola	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	imipramine	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.05 [-1.65, 1.54] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=35.46	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	phenelzine	mono	-0.05	0.81	II (Moderate)	Bahji A., 2020 (NMA)	0.05	-1.65	1.54	imp	phen	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	lithium	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.01 [-1.55, 1.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=177.25	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	venlafaxine	mono	-0.01	0.79	II (Moderate)	Bahji A., 2020 (NMA)	0.01	-1.55	1.55	lit	ven	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	fluoxetine	Discontinuation, due to adverse events (Tolerability)	"eSMD=0 [-1.65, 1.65] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	olanzapine+fluoxetine	combo	0	0.84	II (Moderate)	Bahji A., 2020 (NMA)	0	-1.65	1.65	fluo	ola+fluo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	gabapentin	Discontinuation, due to adverse events (Tolerability)	"eSMD=0 [-1.55, 1.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	lamotrigine	mono	0	0.79	II (Moderate)	Bahji A., 2020 (NMA)	0	-1.55	1.55	gaba	lam	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	lamotrigine	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.04 [-0.47, 0.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=44.32	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	olanzapine+fluoxetine	combo	0.04	0.26	II (Moderate)	Bahji A., 2020 (NMA)	-0.04	-0.47	0.55	lam	ola+fluo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	lithium	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.17 [-0.31, 0.65] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=10.45	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	quetiapine	mono	0.17	0.24	II (Moderate)	Bahji A., 2020 (NMA)	-0.17	-0.31	0.65	lit	que	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2020 (NMA)</a>"	fluoxetine	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.98 [0.03, 1.93] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.95	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	46	Network meta-analysis	Mixed (Children-Adults)	Bipolar Depression	imipramine	mono	0.98	0.48	I (High)	Bahji A., 2020 (NMA)	-0.98	0.03	1.93	fluo	imp	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (MA)</a>"	ketamine	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.22 [-0.63, 1.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.09	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Bipolar Depression	placebo/midazolam	aug	0.22	0.44	IV (Very Low)	Bahji A., 2021 (MA)	-0.22	-0.63	1.08	ket	pbo/mid	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	paroxetine	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.74 [-0.42, 1.93] <br> <img src=""https://www.linkpicture.com/q/Diapositive19.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.5	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.74	0.6	II (Moderate)	Bahji A., 2021 (NMA)	-0.74	-0.42	1.93	par	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	citalopram	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.48 [-0.24, 1.22] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.76	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.48	0.37	II (Moderate)	Bahji A., 2021 (NMA)	-0.48	-0.24	1.22	cit	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	dextromethorphan	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.45 [-0.18, 1.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive16.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.01	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.45	0.32	II (Moderate)	Bahji A., 2021 (NMA)	-0.45	-0.18	1.08	dexm	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	t3 hormone	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.33 [-1.08, 1.77] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.42	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.33	0.73	II (Moderate)	Bahji A., 2021 (NMA)	-0.33	-1.08	1.77	t3	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	inositol	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.25 [-0.7, 1.17] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.13	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.25	0.48	II (Moderate)	Bahji A., 2021 (NMA)	-0.25	-0.7	1.17	ino	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	aripiprazole	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.17 [-0.7, 1.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=10.45	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.17	0.45	II (Moderate)	Bahji A., 2021 (NMA)	-0.17	-0.7	1.05	ari	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	ketamine	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.16 [-0.61, 0.95] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=11.1	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.16	0.4	II (Moderate)	Bahji A., 2021 (NMA)	-0.16	-0.61	0.95	ket	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	memantine	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.14 [-0.65, 0.92] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=12.68	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.14	0.4	II (Moderate)	Bahji A., 2021 (NMA)	-0.14	-0.65	0.92	mem	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	sAME	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.06 [-1.39, 1.47] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=29.55	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.06	0.73	II (Moderate)	Bahji A., 2021 (NMA)	-0.06	-1.39	1.47	sAME	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	pramipexole	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.02 [-1.01, 1.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=88.63	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.02	0.53	II (Moderate)	Bahji A., 2021 (NMA)	-0.02	-1.01	1.05	pram	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	minocycline+acetylsalicylic acid	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.02 [-1.47, 1.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=88.63	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0.02	0.77	II (Moderate)	Bahji A., 2021 (NMA)	-0.02	-1.47	1.55	mino+asa	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	creatine	Discontinuation, due to adverse events (Tolerability)	"eSMD=0 [-1.47, 1.47] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0	0.75	II (Moderate)	Bahji A., 2021 (NMA)	0	-1.47	1.47	creatine	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	pindolol	Discontinuation, due to adverse events (Tolerability)	"eSMD=0 [-1.05, 1.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	0	0.54	II (Moderate)	Bahji A., 2021 (NMA)	0	-1.05	1.05	pin	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	pioglitazone	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.03 [-1.08, 1.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=59.09	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.03	0.53	II (Moderate)	Bahji A., 2021 (NMA)	0.03	-1.08	1.01	pio	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	vitD3	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.03 [-1.55, 1.47] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=59.09	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.03	0.77	II (Moderate)	Bahji A., 2021 (NMA)	0.03	-1.55	1.47	vitD3	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	fluoxetine	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.05 [-0.43, 0.33] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=35.46	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.05	0.19	II (Moderate)	Bahji A., 2021 (NMA)	0.05	-0.43	0.33	fluo	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	lurasidone	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.05 [-0.39, 0.29] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=35.46	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.05	0.17	II (Moderate)	Bahji A., 2021 (NMA)	0.05	-0.39	0.29	lur	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	armodafinil	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.05 [-0.24, 0.14] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=35.46	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.05	0.1	II (Moderate)	Bahji A., 2021 (NMA)	0.05	-0.24	0.14	armo	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	lamotrigine	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.1 [-0.49, 0.28] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=17.74	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.1	0.2	II (Moderate)	Bahji A., 2021 (NMA)	0.1	-0.49	0.28	lam	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	pregnenolone	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.12 [-0.89, 0.66] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=14.79	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.12	0.4	II (Moderate)	Bahji A., 2021 (NMA)	0.12	-0.89	0.66	preg	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	lisdexamfetamine	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.13 [-1.55, 1.33] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=13.65	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.13	0.73	II (Moderate)	Bahji A., 2021 (NMA)	0.13	-1.55	1.33	lisdex	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	omega3	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.14 [-0.59, 0.31] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=12.68	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.14	0.23	II (Moderate)	Bahji A., 2021 (NMA)	0.14	-0.59	0.31	omega3	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	paroxetine+bupropion	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.17 [-0.49, 0.17] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=10.45	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.17	0.17	II (Moderate)	Bahji A., 2021 (NMA)	0.17	-0.49	0.17	par+bup	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	agomelatin	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.17 [-0.66, 0.31] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=10.45	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.17	0.25	II (Moderate)	Bahji A., 2021 (NMA)	0.17	-0.66	0.31	ago	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	bupropion	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.19 [-1.55, 1.22] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=9.36	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.19	0.71	II (Moderate)	Bahji A., 2021 (NMA)	0.19	-1.55	1.22	bup	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	celecoxib	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.24 [-1.22, 0.72] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.42	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.24	0.49	II (Moderate)	Bahji A., 2021 (NMA)	0.24	-1.22	0.72	cel	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	n-acetyl cysteine+acetylsalicylic acid	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.25 [-1.65, 1.22] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.13	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.25	0.73	II (Moderate)	Bahji A., 2021 (NMA)	0.25	-1.65	1.22	nac+asa	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	minocycline	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.25 [-1.77, 1.27] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.13	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.25	0.78	II (Moderate)	Bahji A., 2021 (NMA)	0.25	-1.77	1.27	mino	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	n-acetyl cysteine	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.25 [-0.65, 0.14] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.13	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.25	0.2	II (Moderate)	Bahji A., 2021 (NMA)	0.25	-0.65	0.14	nac	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	t4 hormone	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.3 [-1.22, 0.63] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.95	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.3	0.47	II (Moderate)	Bahji A., 2021 (NMA)	0.3	-1.22	0.63	t4	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	levetiracetam	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.31 [-1.17, 0.55] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.76	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.31	0.44	II (Moderate)	Bahji A., 2021 (NMA)	0.31	-1.17	0.55	levt	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	coenzyme Q10	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.33 [-1.65, 0.98] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.42	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.33	0.67	II (Moderate)	Bahji A., 2021 (NMA)	0.33	-1.65	0.98	coQ10	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	ziprasidone	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.33 [-0.66, 0.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.42	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.33	0.17	II (Moderate)	Bahji A., 2021 (NMA)	0.33	-0.66	0.01	zip	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	acetylsalicylic acid	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.42 [-1.47, 0.61] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.28	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.42	0.53	II (Moderate)	Bahji A., 2021 (NMA)	0.42	-1.47	0.61	asa	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	infliximab	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.55 [-1.39, 0.32] <br> <img src=""https://www.linkpicture.com/q/Diapositive4.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.3	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.55	0.44	II (Moderate)	Bahji A., 2021 (NMA)	0.55	-1.39	0.32	infx	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	imipramine	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.56 [-0.98, -0.14] <br> <img src=""https://www.linkpicture.com/q/Diapositive4.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.25	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-0.56	0.21	I (High)	Bahji A., 2021 (NMA)	0.56	-0.98	-0.14	imp	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	quetiapine	Discontinuation, due to adverse events (Tolerability)	"eSMD=-1.12 [-2.16, -0.02] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1.75	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	placebo	aug	-1.12	0.55	I (High)	Bahji A., 2021 (NMA)	1.12	-2.16	-0.02	que	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	imipramine	Discontinuation, due to adverse events (Tolerability)	"eSMD=-1.27 [-2.54, -0.18] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1.59	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	paroxetine	aug	-1.27	0.6	II (Moderate)	Bahji A., 2021 (NMA)	1.27	-2.54	-0.18	imp	par	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	citalopram	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.38 [-1.65, 0.86] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.72	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	lamotrigine	aug	-0.38	0.64	II (Moderate)	Bahji A., 2021 (NMA)	0.38	-1.65	0.86	cit	lam	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	acetylsalicylic acid	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.32 [-1.77, 1.08] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.59	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	n-acetyl cysteine+acetylsalicylic acid	aug	-0.32	0.73	II (Moderate)	Bahji A., 2021 (NMA)	0.32	-1.77	1.08	asa	nac+asa	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	acetylsalicylic acid	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.27 [-1.77, 1.23] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.6	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	minocycline+acetylsalicylic acid	aug	-0.27	0.77	II (Moderate)	Bahji A., 2021 (NMA)	0.27	-1.77	1.23	asa	mino+asa	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	minocycline	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.27 [-1.77, 1.23] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.6	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	minocycline+acetylsalicylic acid	aug	-0.27	0.77	II (Moderate)	Bahji A., 2021 (NMA)	0.27	-1.77	1.23	mino	mino+asa	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	acetylsalicylic acid	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.26 [-1.65, 1.14] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.86	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	n-acetyl cysteine	aug	-0.26	0.71	II (Moderate)	Bahji A., 2021 (NMA)	0.26	-1.65	1.14	asa	nac	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	bupropion	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.07 [-0.81, 0.66] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=25.33	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	sertraline	aug	-0.07	0.38	II (Moderate)	Bahji A., 2021 (NMA)	0.07	-0.81	0.66	bup	sert	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	fluoxetine	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.07 [-0.44, 0.3] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=25.33	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	lamotrigine	aug	-0.07	0.19	II (Moderate)	Bahji A., 2021 (NMA)	0.07	-0.44	0.3	fluo	lam	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	n-acetyl cysteine	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.06 [-1.47, 1.39] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=29.55	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	n-acetyl cysteine+acetylsalicylic acid	aug	-0.06	0.73	II (Moderate)	Bahji A., 2021 (NMA)	0.06	-1.47	1.39	nac	nac+asa	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	lamotrigine	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.05 [-0.89, 0.8] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=35.46	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	tranylcypromine	aug	-0.05	0.43	II (Moderate)	Bahji A., 2021 (NMA)	0.05	-0.89	0.8	lam	tran	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	amitriptyline	Discontinuation, due to adverse events (Tolerability)	"eSMD=0 [-1.47, 1.47] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	l-sulpride	aug	0	0.75	II (Moderate)	Bahji A., 2021 (NMA)	0	-1.47	1.47	amit	l-sulpr	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	lamotrigine	Discontinuation, due to adverse events (Tolerability)	"eSMD=0 [-0.53, 0.53] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	risperidone	aug	0	0.27	II (Moderate)	Bahji A., 2021 (NMA)	0	-0.53	0.53	lam	risp	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	acetylsalicylic acid	Discontinuation, due to adverse events (Tolerability)	"eSMD=0 [-1.47, 1.49] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	minocycline	aug	0	0.76	II (Moderate)	Bahji A., 2021 (NMA)	0	-1.47	1.49	asa	mino	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	paroxetine	Discontinuation, due to adverse events (Tolerability)	"eSMD=0 [-1.47, 1.47] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	risperidone	aug	0	0.75	II (Moderate)	Bahji A., 2021 (NMA)	0	-1.47	1.47	par	risp	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	paroxetine	Discontinuation, due to adverse events (Tolerability)	"eSMD=0 [-1.47, 1.47] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=Inf	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	venlafaxine	aug	0	0.75	II (Moderate)	Bahji A., 2021 (NMA)	0	-1.47	1.47	par	ven	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	imipramine	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.02 [-0.48, 0.52] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=88.63	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	moclobemide	aug	0.02	0.26	II (Moderate)	Bahji A., 2021 (NMA)	-0.02	-0.48	0.52	imp	moc	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	bupropion	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.07 [-1.33, 1.47] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=25.33	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	desipramine	aug	0.07	0.71	II (Moderate)	Bahji A., 2021 (NMA)	-0.07	-1.33	1.47	bup	desimp	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	lithium	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.2 [-1.27, 1.65] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.89	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	paroxetine	aug	0.2	0.74	II (Moderate)	Bahji A., 2021 (NMA)	-0.2	-1.27	1.65	lit	par	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	bupropion	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.22 [-0.37, 0.81] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.09	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	topiramate	aug	0.22	0.3	II (Moderate)	Bahji A., 2021 (NMA)	-0.22	-0.37	0.81	bup	top	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	inositol	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.27 [-0.34, 0.89] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.6	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	risperidone	aug	0.27	0.31	II (Moderate)	Bahji A., 2021 (NMA)	-0.27	-0.34	0.89	ino	risp	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	inositol	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.27 [-0.34, 0.89] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.6	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	lamotrigine	aug	0.27	0.31	II (Moderate)	Bahji A., 2021 (NMA)	-0.27	-0.34	0.89	ino	lam	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	amitriptyline	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.33 [-0.59, 1.27] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.42	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	paroxetine	aug	0.33	0.47	II (Moderate)	Bahji A., 2021 (NMA)	-0.33	-0.59	1.27	amit	par	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	paroxetine	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.61 [-0.55, 1.77] <br> <img src=""https://www.linkpicture.com/q/Diapositive17.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	risperidone+paroxetine	aug	0.61	0.59	II (Moderate)	Bahji A., 2021 (NMA)	-0.61	-0.55	1.77	par	risp+par	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	risperidone	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.61 [-0.55, 1.77] <br> <img src=""https://www.linkpicture.com/q/Diapositive17.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	risperidone+paroxetine	aug	0.61	0.59	II (Moderate)	Bahji A., 2021 (NMA)	-0.61	-0.55	1.77	risp	risp+par	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	bupropion	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.76 [0.2, 1.33] <br> <img src=""https://www.linkpicture.com/q/Diapositive19.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.44	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	venlafaxine	aug	0.76	0.29	II (Moderate)	Bahji A., 2021 (NMA)	-0.76	0.2	1.33	bup	ven	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	fluoxetine	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.84 [0.03, 1.65] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.23	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	imipramine	aug	0.84	0.41	II (Moderate)	Bahji A., 2021 (NMA)	-0.84	0.03	1.65	fluo	imp	Tolerability
"<a href='https://doi.org/' target=""_blank"">Bahji A., 2021 (NMA)</a>"	sertraline	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.84 [0.26, 1.39] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.23	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	70	Network meta-analysis	Adults	Bipolar Depression	venlafaxine	aug	0.84	0.29	I (High)	Bahji A., 2021 (NMA)	-0.84	0.26	1.39	sert	ven	Tolerability
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2006 (MA)</a>"	carbamazapine	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.4 [-0.38, 1.2] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.49	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	haloperidol	mono	0.4	0.4	II (Moderate)	Cipriani A., 2006 (MA)	-0.4	-0.38	1.2	cbz	hal	Tolerability
"<a href='https://doi.org/' target=""_blank"">Cipriani A., 2013 (MA)</a>"	divalproate	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.22 [0.04, 0.39] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.09	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Low	4	Pairwise meta-analysis	Mixed (Children-Adults)	Maintenance	lithium	mono	0.22	0.09	I (High)	Cipriani A., 2013 (MA)	-0.22	0.04	0.39	div	lit	Tolerability
"<a href='https://doi.org/' target=""_blank"">Jochim J., 2019 (MA)</a>"	divalproate	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.13 [-0.89, 0.65] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=13.65	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Children & Adolescents	Mania/Mixed	placebo	mono	-0.13	0.39	III (Low)	Jochim J., 2019 (MA)	0.13	-0.89	0.65	div	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Jochim J., 2019 (MA)</a>"	divalproate	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.18 [-0.95, 0.58] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=9.87	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Children & Adolescents	Mania/Mixed	risperidone	mono	-0.18	0.39	III (Low)	Jochim J., 2019 (MA)	0.18	-0.95	0.58	div	risp	Tolerability
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	lurasidone	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.06 [-0.56, 0.56] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=29.55	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	18	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.06	0.29	III (Low)	Kadakia A., 2021 (NMA)	0.06	-0.56	0.56	lur	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	olanzapine	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.2 [-0.52, 0.21] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=8.89	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	18	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.2	0.19	III (Low)	Kadakia A., 2021 (NMA)	0.2	-0.52	0.21	ola	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	cariprazine	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.22 [-0.53, 0.11] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=8.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	18	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.22	0.16	III (Low)	Kadakia A., 2021 (NMA)	0.22	-0.53	0.11	car	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	ziprasidone	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.24 [-0.56, 0.15] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.42	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	18	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.24	0.18	III (Low)	Kadakia A., 2021 (NMA)	0.24	-0.56	0.15	zip	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	quetiapine	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.49 [-0.72, -0.25] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.69	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	18	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.49	0.12	II (Moderate)	Kadakia A., 2021 (NMA)	0.49	-0.72	-0.25	que	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Kadakia A., 2021 (NMA)</a>"	aripiprazole	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.51 [-0.89, -0.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.55	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	18	Network meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.51	0.21	II (Moderate)	Kadakia A., 2021 (NMA)	0.51	-0.89	-0.05	ari	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2019 (MA)</a>"	ramelteon	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.06 [-0.14, 0.26] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=29.55	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Adults	Maintenance	placebo	mono	0.06	0.1	III (Low)	Kishi T., 2019 (MA)	-0.06	-0.14	0.26	ram	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	asenapine	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.56 [0.11, 1.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive17.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3.25	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	21	Network meta-analysis	Adults	Maintenance	placebo	mono	0.56	0.23	II (Moderate)	Kishi T., 2021 (NMA)	-0.56	0.11	1.01	ase	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	quetiapine	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.34 [-0.05, 0.72] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.26	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	52	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.34	0.2	III (Low)	Kishi T., 2021 (NMA)	-0.34	-0.05	0.72	que	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	brexpiprazole	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.07 [-0.47, 0.61] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=25.33	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	52	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	0.07	0.28	III (Low)	Kishi T., 2021 (NMA)	-0.07	-0.47	0.61	brex	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	topiramate	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.01 [-0.43, 0.42] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=177.25	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	52	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.01	0.22	III (Low)	Kishi T., 2021 (NMA)	0.01	-0.43	0.42	top	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.05 [-0.28, 0.19] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=35.46	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	52	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.05	0.12	III (Low)	Kishi T., 2021 (NMA)	0.05	-0.28	0.19	ola	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.1 [-0.3, 0.09] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=17.74	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	52	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.1	0.1	III (Low)	Kishi T., 2021 (NMA)	0.1	-0.3	0.09	ari	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.11 [-0.42, 0.2] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=16.13	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	52	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.11	0.16	III (Low)	Kishi T., 2021 (NMA)	0.11	-0.42	0.2	div	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.12 [-0.55, 0.3] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=14.79	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	52	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.12	0.22	III (Low)	Kishi T., 2021 (NMA)	0.12	-0.55	0.3	pal	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	ziprasidone	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.13 [-0.52, 0.26] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=13.65	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	52	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.13	0.2	III (Low)	Kishi T., 2021 (NMA)	0.13	-0.52	0.26	zip	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	risperidone	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.2 [-0.52, 0.12] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=8.89	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	52	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.2	0.16	III (Low)	Kishi T., 2021 (NMA)	0.2	-0.52	0.12	risp	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	valnoctamide	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.26 [-1.22, 0.66] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.86	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	52	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.26	0.48	III (Low)	Kishi T., 2021 (NMA)	0.26	-1.22	0.66	valnoctamide	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	cariprazine	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.28 [-0.59, 0.03] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.37	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	52	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.28	0.16	III (Low)	Kishi T., 2021 (NMA)	0.28	-0.59	0.03	car	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.32 [-0.59, -0.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.59	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	52	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.32	0.14	II (Moderate)	Kishi T., 2021 (NMA)	0.32	-0.59	-0.05	lit	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.35 [-0.56, -0.12] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.12	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	52	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.35	0.11	II (Moderate)	Kishi T., 2021 (NMA)	0.35	-0.56	-0.12	hal	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	asenapine	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.35 [-0.65, -0.06] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.12	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	52	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.35	0.15	II (Moderate)	Kishi T., 2021 (NMA)	0.35	-0.65	-0.06	ase	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	carbamazepine	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.37 [-0.81, 0.07] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.85	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	52	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.37	0.22	III (Low)	Kishi T., 2021 (NMA)	0.37	-0.81	0.07	cbz	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.37 [-0.86, 0.11] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.85	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	52	Network meta-analysis	Adults	Mania/Mixed	placebo	mono	-0.37	0.25	III (Low)	Kishi T., 2021 (NMA)	0.37	-0.86	0.11	lam	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole LAI	Discontinuation, due to adverse events (Tolerability)	"eSMD=-1.08 [-2.16, 0.09] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1.8	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	21	Network meta-analysis	Adults	Maintenance	placebo	mono	-1.08	0.57	IV (Very Low)	Kishi T., 2021 (NMA)	1.08	-2.16	0.09	ariLAI	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.68 [-1.08, -0.26] <br> <img src=""https://www.linkpicture.com/q/Diapositive3.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.71	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	52	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	-0.68	0.21	II (Moderate)	Kishi T., 2021 (NMA)	0.68	-1.08	-0.26	hal	que	Tolerability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.66 [-1.12, -0.2] <br> <img src=""https://www.linkpicture.com/q/Diapositive3.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.78	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	52	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	-0.66	0.23	II (Moderate)	Kishi T., 2021 (NMA)	0.66	-1.12	-0.2	lit	que	Tolerability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	paliperidone	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.47 [-0.98, 0.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.84	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	52	Network meta-analysis	Adults	Mania/Mixed	quetiapine	mono	-0.47	0.26	III (Low)	Kishi T., 2021 (NMA)	0.47	-0.98	0.05	pal	que	Tolerability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	quetiapine+lithium/divalproate	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.42 [-1.22, 0.4] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.28	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	6	Network meta-analysis	Adults	Maintenance	placebo+lithium/divalproate	combo	-0.42	0.41	IV (Very Low)	Kishi T., 2021 (NMA)	0.42	-1.22	0.4	que+lit/div	pbo+lit/div	Tolerability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.33 [-0.86, 0.2] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.42	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	52	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.33	0.27	III (Low)	Kishi T., 2021 (NMA)	0.33	-0.86	0.2	lam	ola	Tolerability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.31 [-0.74, 0.12] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.76	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	52	Network meta-analysis	Adults	Mania/Mixed	topiramate	mono	-0.31	0.22	III (Low)	Kishi T., 2021 (NMA)	0.31	-0.74	0.12	lit	top	Tolerability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	asenapine	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.31 [-0.63, 0.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.76	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	52	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.31	0.16	III (Low)	Kishi T., 2021 (NMA)	0.31	-0.63	0.01	ase	ola	Tolerability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.3 [-0.56, -0.03] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.95	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	52	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.3	0.14	II (Moderate)	Kishi T., 2021 (NMA)	0.3	-0.56	-0.03	hal	ola	Tolerability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lithium	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.27 [-0.61, 0.06] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=6.6	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	52	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.27	0.17	III (Low)	Kishi T., 2021 (NMA)	0.27	-0.61	0.06	lit	ola	Tolerability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.21 [-0.59, 0.17] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=8.47	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	52	Network meta-analysis	Adults	Mania/Mixed	ziprasidone	mono	-0.21	0.19	III (Low)	Kishi T., 2021 (NMA)	0.21	-0.59	0.17	hal	zip	Tolerability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	haloperidol	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.14 [-0.51, 0.22] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=12.68	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	52	Network meta-analysis	Adults	Mania/Mixed	risperidone	mono	-0.14	0.19	III (Low)	Kishi T., 2021 (NMA)	0.14	-0.51	0.22	hal	risp	Tolerability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole+lithium/divalproate	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.13 [-1.27, 0.98] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=13.65	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	6	Network meta-analysis	Adults	Maintenance	placebo+lithium/divalproate	combo	-0.13	0.57	IV (Very Low)	Kishi T., 2021 (NMA)	0.13	-1.27	0.98	ari+lit/div	pbo+lit/div	Tolerability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	cariprazine	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.12 [-0.7, 0.45] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=14.79	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	21	Network meta-analysis	Adults	Maintenance	lithium	mono	-0.12	0.29	IV (Very Low)	Kishi T., 2021 (NMA)	0.12	-0.7	0.45	car	lit	Tolerability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.06 [-0.35, 0.23] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=29.55	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	52	Network meta-analysis	Adults	Mania/Mixed	olanzapine	mono	-0.06	0.15	III (Low)	Kishi T., 2021 (NMA)	0.06	-0.35	0.23	div	ola	Tolerability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lamotrigine	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.06 [-0.55, 0.43] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=29.55	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	52	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	-0.06	0.25	III (Low)	Kishi T., 2021 (NMA)	0.06	-0.55	0.43	lam	lit	Tolerability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	lurasidone+lithium/divalproate	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.01 [-1.22, 1.22] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=177.25	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	6	Network meta-analysis	Adults	Maintenance	placebo+lithium/divalproate	combo	0.01	0.62	IV (Very Low)	Kishi T., 2021 (NMA)	-0.01	-1.22	1.22	lur+lit/div	pbo+lit/div	Tolerability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	risperidone	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.07 [-0.89, 1.01] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=25.33	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	52	Network meta-analysis	Adults	Mania/Mixed	valnoctamide	mono	0.07	0.48	III (Low)	Kishi T., 2021 (NMA)	-0.07	-0.89	1.01	risp	valnoctamide	Tolerability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.15 [-0.2, 0.51] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=11.84	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	52	Network meta-analysis	Adults	Mania/Mixed	risperidone	mono	0.15	0.18	III (Low)	Kishi T., 2021 (NMA)	-0.15	-0.2	0.51	ola	risp	Tolerability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.21 [-0.09, 0.52] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.47	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	52	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	0.21	0.16	III (Low)	Kishi T., 2021 (NMA)	-0.21	-0.09	0.52	ari	lit	Tolerability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.22 [-1.12, 1.54] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	52	Network meta-analysis	Adults	Mania/Mixed	endoxifen	mono	0.22	0.68	III (Low)	Kishi T., 2021 (NMA)	-0.22	-1.12	1.54	div	end	Tolerability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	divalproate	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.21 [-0.17, 0.59] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.47	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	52	Network meta-analysis	Adults	Mania/Mixed	lithium	mono	0.21	0.19	III (Low)	Kishi T., 2021 (NMA)	-0.21	-0.17	0.59	div	lit	Tolerability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	aripiprazole	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.24 [-0.01, 0.49] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.42	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	High	52	Network meta-analysis	Adults	Mania/Mixed	haloperidol	mono	0.24	0.13	III (Low)	Kishi T., 2021 (NMA)	-0.24	-0.01	0.49	ari	hal	Tolerability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	ziprasidone+lithium/divalproate	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.24 [-0.89, 1.39] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.42	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	6	Network meta-analysis	Adults	Maintenance	placebo+lithium/divalproate	combo	0.24	0.58	IV (Very Low)	Kishi T., 2021 (NMA)	-0.24	-0.89	1.39	zip+lit/div	pbo+lit/div	Tolerability
"<a href='https://doi.org/' target=""_blank"">Kishi T., 2021 (NMA)</a>"	olanzapine+lithium/divalproate	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.29 [-0.92, 1.47] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.15	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	6	Network meta-analysis	Adults	Maintenance	placebo+lithium/divalproate	combo	0.29	0.61	IV (Very Low)	Kishi T., 2021 (NMA)	-0.29	-0.92	1.47	ola+lit/div	pbo+lit/div	Tolerability
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	lithium	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.05 [-0.29, 0.38] <br> <img src=""https://www.linkpicture.com/q/Diapositive11.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=35.46	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	6	Pairwise meta-analysis	Mixed (Children-Adults)	Mania/Mixed	placebo	mono	0.05	0.17	III (Low)	McKnight R.F., 2019 (MA)	-0.05	-0.29	0.38	lit	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	lamotrigine	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.2 [-0.47, 0.86] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=8.89	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	23	Network meta-analysis	Adults	Maintenance	placebo	mono	0.2	0.34	IV (Very Low)	Miura T., 2014 (NMA)	-0.2	-0.47	0.86	lam	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	paliperidone	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.09 [-0.95, 0.74] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=19.71	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	23	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.09	0.43	IV (Very Low)	Miura T., 2014 (NMA)	0.09	-0.95	0.74	pal	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	quetiapine	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.12 [-0.55, 0.31] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=14.79	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	23	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.12	0.22	IV (Very Low)	Miura T., 2014 (NMA)	0.12	-0.55	0.31	que	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	risperidone LAI	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.32 [-1.01, 0.34] <br> <img src=""https://www.linkpicture.com/q/Diapositive7.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=5.59	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	23	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.32	0.34	IV (Very Low)	Miura T., 2014 (NMA)	0.32	-1.01	0.34	rispLAI	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	olanzapine	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.43 [-1.01, 0.03] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.19	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	23	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.43	0.27	IV (Very Low)	Miura T., 2014 (NMA)	0.43	-1.01	0.03	ola	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	lithium	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.52 [-0.92, -0.16] <br> <img src=""https://www.linkpicture.com/q/Diapositive5.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=3.49	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	23	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.52	0.19	II (Moderate)	Miura T., 2014 (NMA)	0.52	-0.92	-0.16	lit	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	aripiprazole	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.86 [-1.93, 0.25] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.19	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	23	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.86	0.56	IV (Very Low)	Miura T., 2014 (NMA)	0.86	-1.93	0.25	ari	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	lamotrigine	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.89 [-2.54, 0.92] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=2.12	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	23	Network meta-analysis	Adults	Maintenance	lamotrigine+divalproate	combo	-0.89	0.88	IV (Very Low)	Miura T., 2014 (NMA)	0.89	-2.54	0.92	lam	lam+div	Tolerability
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	lithium	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.4 [-0.92, 0.07] <br> <img src=""https://www.linkpicture.com/q/Diapositive6.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=4.49	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	23	Network meta-analysis	Adults	Maintenance	quetiapine	mono	-0.4	0.25	IV (Very Low)	Miura T., 2014 (NMA)	0.4	-0.92	0.07	lit	que	Tolerability
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	aripiprazole+lamotrigine	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.23 [-0.92, 0.42] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=7.74	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	23	Network meta-analysis	Adults	Maintenance	lamotrigine	mono	-0.23	0.34	IV (Very Low)	Miura T., 2014 (NMA)	0.23	-0.92	0.42	ari+lam	lam	Tolerability
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	fluoxetine	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.22 [-1.39, 0.95] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=8.09	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	23	Network meta-analysis	Adults	Maintenance	placebo	mono	-0.22	0.6	IV (Very Low)	Miura T., 2014 (NMA)	0.22	-1.39	0.95	fluo	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	olanzapine	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.11 [-0.83, 0.56] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=16.13	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	23	Network meta-analysis	Adults	Maintenance	risperidone LAI	mono	-0.11	0.35	IV (Very Low)	Miura T., 2014 (NMA)	0.11	-0.83	0.56	ola	rispLAI	Tolerability
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	lithium	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.1 [-0.51, 0.43] <br> <img src=""https://www.linkpicture.com/q/Diapositive9.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=17.74	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	23	Network meta-analysis	Adults	Maintenance	olanzapine	mono	-0.1	0.24	IV (Very Low)	Miura T., 2014 (NMA)	0.1	-0.51	0.43	lit	ola	Tolerability
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	imipramine	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.05 [-2.16, 2.2] <br> <img src=""https://www.linkpicture.com/q/Diapositive10.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=35.46	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	23	Network meta-analysis	Adults	Maintenance	lithium	mono	-0.05	1.11	IV (Very Low)	Miura T., 2014 (NMA)	0.05	-2.16	2.2	imp	lit	Tolerability
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	lithium	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.24 [-0.74, 1.22] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.42	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	23	Network meta-analysis	Adults	Maintenance	lithium+oxcarbazepine	combo	0.24	0.5	IV (Very Low)	Miura T., 2014 (NMA)	-0.24	-0.74	1.22	lit	lit+oxc	Tolerability
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	lithium	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.25 [-0.44, 0.93] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=7.13	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	23	Network meta-analysis	Adults	Maintenance	lithium+divalproate	combo	0.25	0.35	IV (Very Low)	Miura T., 2014 (NMA)	-0.25	-0.44	0.93	lit	lit+div	Tolerability
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	fluoxetine	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.3 [-0.89, 1.49] <br> <img src=""https://www.linkpicture.com/q/Diapositive14.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=5.95	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	23	Network meta-analysis	Adults	Maintenance	lithium	mono	0.3	0.61	IV (Very Low)	Miura T., 2014 (NMA)	-0.3	-0.89	1.49	fluo	lit	Tolerability
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	divalproate	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.36 [-0.28, 1.02] <br> <img src=""https://www.linkpicture.com/q/Diapositive15.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=4.98	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	23	Network meta-analysis	Adults	Maintenance	lithium	mono	0.36	0.33	IV (Very Low)	Miura T., 2014 (NMA)	-0.36	-0.28	1.02	div	lit	Tolerability
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	divalproate	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.61 [-0.1, 1.33] <br> <img src=""https://www.linkpicture.com/q/Diapositive17.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=3	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	23	Network meta-analysis	Adults	Maintenance	lithium+divalproate	combo	0.61	0.36	IV (Very Low)	Miura T., 2014 (NMA)	-0.61	-0.1	1.33	div	lit+div	Tolerability
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	imipramine	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.63 [-1.27, 2.45] <br> <img src=""https://www.linkpicture.com/q/Diapositive18.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.91	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	23	Network meta-analysis	Adults	Maintenance	lithium+imipramine	combo	0.63	0.95	IV (Very Low)	Miura T., 2014 (NMA)	-0.63	-1.27	2.45	imp	lit+imp	Tolerability
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	lithium	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.68 [-1.17, 2.48] <br> <img src=""https://www.linkpicture.com/q/Diapositive18.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.71	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	23	Network meta-analysis	Adults	Maintenance	lithium+imipramine	combo	0.68	0.93	IV (Very Low)	Miura T., 2014 (NMA)	-0.68	-1.17	2.48	lit	lit+imp	Tolerability
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	carbamazepine	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.73 [0.07, 1.4] <br> <img src=""https://www.linkpicture.com/q/Diapositive19.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.54	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	23	Network meta-analysis	Adults	Maintenance	lithium	mono	0.73	0.34	II (Moderate)	Miura T., 2014 (NMA)	-0.73	0.07	1.4	cbz	lit	Tolerability
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	lamotrigine	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.73 [0.07, 1.4] <br> <img src=""https://www.linkpicture.com/q/Diapositive19.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=2.54	"Moderate <br> <img src=""https://www.linkpicture.com/q/Diapositive2_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	23	Network meta-analysis	Adults	Maintenance	lithium	mono	0.73	0.34	II (Moderate)	Miura T., 2014 (NMA)	-0.73	0.07	1.4	lam	lit	Tolerability
"<a href='https://doi.org/' target=""_blank"">Miura T., 2014 (NMA)</a>"	aripiprazole+divalproate	Discontinuation, due to adverse events (Tolerability)	"eSMD=1.17 [-0.48, 2.54] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.69	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	23	Network meta-analysis	Adults	Maintenance	divalproate	mono	1.17	0.77	IV (Very Low)	Miura T., 2014 (NMA)	-1.17	-0.48	2.54	ari+div	div	Tolerability
"<a href='https://doi.org/' target=""_blank"">Scherk H., 2007 (MA)</a>"	risperidone	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.26 [-0.55, 1.05] <br> <img src=""https://www.linkpicture.com/q/Diapositive13.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=6.86	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	aug	0.26	0.41	IV (Very Low)	Scherk H., 2007 (MA)	-0.26	-0.55	1.05	risp	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Scherk H., 2007 (MA)</a>"	quetiapine	Discontinuation, due to adverse events (Tolerability)	"eSMD=0.1 [-0.33, 0.52] <br> <img src=""https://www.linkpicture.com/q/Diapositive12.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=17.74	"Very Low <br> <img src=""https://www.linkpicture.com/q/Diapositive4_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	aug	0.1	0.22	IV (Very Low)	Scherk H., 2007 (MA)	-0.1	-0.33	0.52	que	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">Smith L.A., 2010 (MA)</a>"	divalproate	Discontinuation, due to adverse events (Tolerability)	"eSMD=-0.22 [-1.22, 0.74] <br> <img src=""https://www.linkpicture.com/q/Diapositive8.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=8.09	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	4	Pairwise meta-analysis	Adults	Bipolar Depression	placebo	mono	-0.22	0.5	III (Low)	Smith L.A., 2010 (MA)	0.22	-1.22	0.74	div	pbo	Tolerability
"<a href='https://doi.org/' target=""_blank"">McKnight R.F., 2019 (MA)</a>"	carbamazepine	Mean duration of treatment, weeks	"eSMD=-2 [-16.88, 12.88] <br> <img src=""https://www.linkpicture.com/q/Diapositive1.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNH=1.19	"Low <br> <img src=""https://www.linkpicture.com/q/Diapositive3_1.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	3	Pairwise meta-analysis	Mixed (Children-Adults)	Mania/Mixed	lithium	mono	-2	7.59	III (Low)	McKnight R.F., 2019 (MA)	2	-16.88	12.88	cbz	lit	Treatment duration, weeks
"<a href='https://doi.org/' target=""_blank"">Rendell J.M., 2010 (MA)</a>"	risperidone	Mean duration of treatment, weeks	"eSMD=2 [1.06, 2.94] <br> <img src=""https://www.linkpicture.com/q/Diapositive20.png"" height=""30"" width=""60%"" data-toggle=""tooltip"" data-placement=""right""></img>"	eNNT=1.19	"High <br> <img src=""https://www.linkpicture.com/q/Diapositive1_2.png"" height=""30"" data-toggle=""tooltip"" data-placement=""right""""></img>"	Critically Low	2	Pairwise meta-analysis	Adults	Mania/Mixed	placebo	mono	2	0.48	I (High)	Rendell J.M., 2010 (MA)	-2	1.06	2.94	risp	pbo	Treatment duration, weeks
